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ABSTRACT 
Radiotherapy is prescribed to more than 50% of cancer patients during their treatment 
schedule. Due to intrinsic factors, individual variation in response exists, which will result 
in side effects or toxicity in a number of patients. Therefore, development of an assay or 
biomarker for the prediction and assessment of radiosensitivity among cancer patients 
undergoing radiotherapy would be beneficial. Such an assay would limit toxicities and 
facilitate dose-escalation for those patients who require it.  
Assays for predicting intrinsic cellular radiosensitivity remains as the established G2 
chromosomal radiosensitivity and most promising, γH2AX foci assay. They can be 
applied to blood samples from donors and are sensitive enough to detect individual 
radiosensitivity. Therefore, both assays were applied to normal control cohorts compared 
to ‘radiosensitive’ cells to assess their efficacy as potential predictive assays for the clinic. 
Different low doses and energies of Linac radiation was applied to cells to assess their 
impact on patient intrinsic radiosensitivity and the most radiosensitive dose was 
confirmed at 0.5Gy (6MV photon beam) Linac radiation in cells. In addition to this, 
intrinsic radiosensitivity which could be measured at initial diagnosis and treatment 
planning stages for patients was investigated. The assays were applied to patients sampled 
at various time-points throughout a course of their radiotherapy treatment. The time-
points included pre-treatment, post hormone treatment, last day of radiotherapy and the 2 
and 8 month follow ups. Both assays were capable of depicting a dose response and 
differences between treatment visits. 
The DNA damage based assays indicated that cell cycle regulation through the DNA 
damage response (DDR) activated by radiation was central to the underlying mechanistic 
response. Therefore, the molecular mechanisms of radiosensitivity were studied with an 
 
emphasis of genes related to the cell cycle and DDR.  Furthermore, genetic targets that 
emerged from this work could potentially be biomarkers of radiosensitivity that could 
also be incorporated into the clinic. 
Following from the emergence of cell cycle and DDR genes, potential biomarkers for 
predicting radiosensitivity was analysed in a collaboration with Public Health England. 
This was done using the most sensitive genes which were found from bio dosimetry 
microarray studies carried out by the group (P21, PCNA, SESN1 and FDXR). Again this 
work was done on blood from healthy controls, prostate cancer patients and radiosensitive 
cells from Ataxia Telangiectasia donors. The genes in combination were able to depict a 
clear difference in the cohorts analysed in which expression was collectively highest in 
the healthy controls, less expression was observed in the Prostate cancer cohort and the 
least expression was observed in the radiosensitive cells from Ataxia Telangiectasia 
donors.  
Finally, investigation of the miRNA composition of exosomes in healthy cells and cells 
from Ataxia telangiectasia donors was done to identify novel biomarkers for 
radiosensitivity prediction, in a collaboration with Trinity College Dublin. A subgroup of 
the let-7 family of miRNA’s was among the top 88 expressed miRNA’s in this chapter. 
Additionally, most miRNA’s were not as highly expressed in radiosensitive cells 
compared to normal healthy cells.  This work forms the basis for future work on prostate 
cancer patient samples. 
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1. THESIS INTRODUCTION 
1.1. Clinical radiotherapy  
Radiotherapy (RT) is one of the three most prescribed treatment modalities for cancer 
including chemotherapy and/or surgery and RT remains the most cost effective cancer 
treatment modality globally1. More than 50% of cancer patients will experience RT as 
part of their treatment plan and it accounts for 40% of the curative treatment for cancer2. 
RT can be used to control the spread of malignant tumours after surgery, cure, and for 
palliative treatment to alleviate symptoms in elderly patients. According to the world 
health organisation (WHO), Prostate cancer (PCa) is the second most commonly 
diagnosed cancer in males and 4th most common cancer (gender combined) worldwide3.  
RT is used for a number of reasons but mainly to cure or control metastasis and it can be 
used in conjunction with surgery as a neo-adjuvant treatment (before) or adjuvant 
treatment (after).  The most common type of radiation therapy is external beam RT 
(EBRT) (outside the body) and internal brachytherapy (small radioactive rods placed 
inside the body in close proximity of the tumour)4. Within EBRT, treatment can be either 
conformal RT (CRT) or intensity modulated RT (IMRT) which varies dose across the 
region of the tumour, proven to reduce long term side effects5. Radiation treatment allows 
for cure (considerable levels of local tumour control if treated in the early stages of 
disease) and palliative care (relief of symptoms by controlling the tumour size, and pain 
relief). Although in its curative and palliative effects, radiation treatment causes unwanted 
side effects, similar to many curative drug treatments.  
Development of clinical radiation treatment and planning has progressed considerably 
during the past century. The  discovery of X – rays by Rontgen6 was followed by the 
finding of natural radioactivity by Becquerel7 and isolation of radium by Curie8 from 
1895 – 1898 which all paved the way for development of two of the main RT techniques 
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still used today; EBRT and Brachytherapy. Gastric and basal cell carcinoma were the first 
tumours treated with RT in 18969 and harmful effects of radiation were discovered soon 
after.  
Two factors became apparent in early clinical radiation treatment planning; (1) to aim for 
as close to 100% dose delivery per target volume and (2) to reduce the risk of harmful 
radiation damage in healthy surrounding tissue. Only successful treatment of superficial 
tumours or highly radiosensitive tumours was done with the use of kilovoltage (KV) 
energies between 1900 – 194010 as higher energy beams in the megavoltage range were 
developed. Around this time, 3 fundamental areas to advance RT  were discovered; (1) 
the law of radiosensitivity by Bergonie and Tribondeau who were the first to describe the 
“susceptibility” of cells to ionizing radiation11, (2) The use of fractionated radiotherapy 
with 2Gy fractions by Coutard who showed greater normal tissue recovery by delivering 
small fractions of radiation dosage12, and (3) development of the International 
Commission on Radiological Protection (ICRP) agency in 1928 which would set out and 
monitor guidelines, usage and practises of radiation use throughout the world13.  
Early in the megavoltage (MV) era, the first Cobalt 60 (60Co) teletherapy unit was 
installed in Hamilton in Canada, with a higher radiation photon beam of 1.2 MeV (Mega 
electron Volt) energy14. This allowed for treatment of deep seated tumours (such as 
prostate, bladder, bowel, brain) and cases of Hodgkin Lymphoma. As 60Co teletherapy 
units required much maintenance especially for the disposal of radioactive 60Co at the end 
of its half-life, a new clinical radiation source was introduced as the first linear accelerator 
(Linac) in 194815. 
The development of the Linac allowed for delivery of MV energies with much higher 
absorbed (total amount of radiation absorbed in the tissue of interest) doses of 60 – 70Gy 
without exceeding the tolerance dose (i.e. the dose at which the patient can receive before 
increase in normal tissue complications) and could also deliver electron beam RT for 
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superficial tumours within the one machine unit16. Computer assisted RT joined with 60Co 
Teletherapy and Linac RT from 1996 to the present day and have 3 main modalities; (1) 
Intensity modulated RT (IMRT) which is a method of EBRT that uses shaping of the 
beam to achieve a high tumour dose while sparing healthy surrounding tissue17, (2) 
Stereotactic RT for medically inoperable tumours18 and (3) 4 dimensional computed 
tomography (4D CT) RT which is a type of stereotactic RT used for example in lung 
cancer which provides CT images for better treatment dose planning, taking into account 
the motion of the lungs during respiration19. These developments have revolutionised 
modern RT practices which allow for better RT control and incorporate the shaping of 
photon beams, image guidance and patient movements20.   
Current plans for future development of RT involve particle therapy such as proton 
therapy, carbon ion therapy and hyper-fractionation. Proton therapy is a promising type 
of RT as the proton beam allows for a spread out Bragg Peak (i.e. a dose-depth 
measurement which peaks at its highest dose in a depth of tissue). The spread out of the 
Bragg peak allows for a high dose in a larger volume with little to no dosage in normal 
healthy tissue and is very promising for its future use21. Carbon ion therapy is also a type 
of particle therapy, with the same spread out Bragg Peak properties as proton therapy, 
however some differences in beam penumbra, linear energy transfer (LET) and overall 
better relative biological effectiveness gives credibility to more investigation using 
carbon ion therapy22. In 2013 a report by Fujii et al  compared patient outcome between 
proton and carbon ion therapy, and although there was no significant differences in 3 year 
survival rates, progression free survival and local tumour control were observed and a 
slightly higher percentage in each of the measures were found after carbon ion therapy22. 
Therefore, particle ion therapy looks promising for future routine clinical use. Hyper 
fractionation allows for more fractions of slightly reduced fraction dose, more often 
(usually twice a week instead of once) resulting in the same overall dose. Sapkota et al  
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conducted a randomized trial in 2013 which showed significantly better tumour response 
in the hyper fractionated treatment group23. It is also clear that advances in RT treatment 
devices along with experimental radiobiological data will help pave the way for 
improvement of future radio therapeutic approaches for individual patients suffering from 
different cancer types. The relationship between clinical radiobiology and radiotherapy is 
associated with the 5 R’s. The 5 R’s of RT are key to how experimental radiobiology 
leads to adjustment of treatment regimes.  
1.2. Clinical radiobiology – the 5 R’s 
One of the first most important milestones to influence RT with experimentation was the 
therapeutic treatment of a hairy mole by Leopold Freund in 189624. In the early 1900’s, 
Regaud et al   found that sterilisation of a rams testes was not possible using only a single 
dose of radiation but rather multiple doses over a period of weeks was required for 
minimal skin reaction and successful sterilisation 25. This is the theory of fractionation, 
which is still used today and relates to redistribution which is one of the 5 R’s of 
radiobiology and explained below.  
 
1.2.1. Repair 
Sub-lethal and lethal damage results from deoxyribonucleic acid (DNA) being traversed 
by radiation tracks. The effect of this collision can be direct – where the structure of DNA 
is physically damaged from the DNA-radiation collision. Or the effect can lead to indirect 
interaction of ionized particles with water molecules, leading to the formation of highly 
reactive oxygen radicals. RT utilises the cells molecular repair mechanisms for 
appropriate cell killing of cancerous tissue and repair of sub-lethal damage in healthy 
tissue as discussed in later sections. As normal cells are well oxygenated, healthy tissue 
should repair within a few hours of radiation treatment, whereas hypoxic tumours should 
ultimately die. Repair of healthy tissue after RT is dependent on the correct and efficient 
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functioning of DNA damage and repair response which is often not the case in many 
cancer patients. 
1.2.2. Redistribution 
When irradiation occurs, cells are distributed in different parts of the cell cycle. Those 
cells which are in the most sensitive phases (G2 and M) are more likely to go through cell 
death pathways. Fractionation allows time for redistribution of more resistant cells within 
the cell cycle to move to a more sensitive phase on the next round of treatment. This 
revolutionary theory came from Claudius Regauds work in 1911, who figured that a ram’s 
testes could be sterilized if three separate irradiations were delivered 15 days apart 25. 
1.2.3. Repopulation 
Evidence suggests that after a course of radiation treatment, cell death and damage may 
induce an increased rate of cell proliferation. Originally described in the 1970s, Muneyasu 
et al  reported that tumour cells exhibited a rapid proliferation after irradiation which was 
followed by a growth delay26.  This gives promise to the theory of accelerated therapy, 
where less fractions but a higher dose is given during RT. Ciervide et al found this to be 
advantageous when breast cancer patients were recruited in two groups in 2012 for 2.8Gy 
delivered in 15 fractions and 2.7Gy in 15 fractions compared to 2Gy in 25 fractions for 
each group, and they reported no invasive recurrence within a 5 year follow up period 27. 
This area is still under intense investigation, and is most certainly affected by patient 
radiosensitivity. 
1.2.4. Reoxygenation 
In order for a tumour to grow and develop, an efficient vasculature network is needed to 
bring an adequate supply of nutrients and oxygen and this is first supplied by the host. 
The rapid rate of growth of abnormal cells soon requires the tumours own vasculature 
system which is developed through angiogenesis and is far from normal. Vessels are 
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primitive in nature with a loss of basement membranes, no pericytes and lack of smooth 
muscle which all contributes to the glucose and energy deprivation, high lactate and 
oxygen deficiency observed in these tumours28.  Tumours are naturally hypoxic, but 
heterogeneity in cellular oxygenation can be a problem and is influenced by tumour size 
and site29 as tumours are said to fluctuate between hypoxia (reduced oxygen levels) and 
normoxia (normal oxygen levels). A recent article by Bayer et al describes how over- 
simplified reoxygenation has been portrayed over these past decades and how it has 
affected radiosensitivity. For example, at oxygen concentrations of <0.1% and during 
fluctuation of hypoxia-normoxia, malignant cells can still undergo permanent genomic 
and epigenetic modifications which could lead to aggressive survival strategies for the 
abnormal cell30. 
1.2.5. Radiosensitivity 
Defined by Bergonie and Tribondeau in 1959 as the “susceptibility of cells to the effects 
of ionizing radiation,” radiosensitivity has been the subject of intense investigation for 
decades11. Varying levels of sensitivity are found in different cell types. Rapidly dividing 
cells (such as benign and malignant tumours but not exclusive) have higher radiation 
sensitivity than those cell types which do not rapidly divide (e.g. nerve cells). The more 
rapidly dividing the cell, the more times the cell will move through the cell cycle and 
therefore the higher the probability of detection of damage. This is an example of how a 
radiobiological investigation was advantageous for RT. Giving multiple fractions over a 
period of time allows for the death of cancerous cells while repair in healthy cells takes 
place by the cells repair mechanisms. Mechanisms of radiosensitivity come from 
molecular functional studies on genes which control DNA Damage Response (DDR) 
mechanisms. Most genes which are affected in this response correspond to disorders 
which all possess a highly radiosensitive phenotype (Ataxia Telangiectasia, Fanconi’s 
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Anaemia, Blooms Syndrome, Xeroderma Pigmentosa, Severe Combined Immuno 
Deficiency and AT-Like Disorder). 
1.3. Radiosensitive Phenotypes 
Radiosensitive cohorts of patients suffering from neurodegenerative disorders have 
factors in common; mutation and defects in DNA damage repair genes, an increased 
sensitivity to the effects of ionizing radiation, and predisposition to cancer. The following 
examples of radiosensitive cohorts have been a major focus in different radiosensitivity 
studies worldwide which describe defective DNA damage or repair mechanisms due to 
specific mutated genes. Important radiosensitive cohorts which have been under intense 
investigation include Ataxia telangiectasia (AT) and ATLD, Fanconi Anaemia (FA), 
Xeroderma pigmentosa (XP), Blooms Syndrome (BS) and Severe combined 
immunodeficiency disorder (SCID). They are described briefly below, but of most 
relevance to this work are Ataxia Telangiectasia (AT) described below and Prostate 
cancer cohorts described in Chapter 3, section 3.1. 
AT was one of the first radiosensitive patient cohorts to be described clinically in the 
literature with first reports dating back to 1920’s but not clinopathologically defined until 
196731. Boder et al  described the clinical causes of death in 1975 from a series of 9 
autopsies to be persistent Sino pulmonary infection and lymphoreticular malignancy as 
the first and second most common causes of death for AT31. AT is phenotypically 
characterised by a neurodegenerative immune disorder with  uncontrolled cerebellar 
motor control32. ATM (Mutated AT gene) is considered the central transducer of damage 
from ionizing radiation induced double strand breaks (DSB’s) in the DDR which controls 
phosphorylation and activation of downstream DDR events activating cell cycle arrest. 
Mutations of the ATM gene result in AT, with other mutations including decreased 
amounts of the ATM protein or reduced kinase activity which results in a milder form of 
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the disease32. The ATM gene was cloned in 199533 and was  mapped to chromosome 
11q22-23 (Figure 1.1) and represents 69 exons spread across approximately 150kilobases 
of DNA, from a 12 kilobase transcript34. ATM is part of the Phosphoinositide 13 and 14 
(P13/P14) kinase family which is involved in phosphorylation and regulator of 
downstream that control cell cycle progression, such as tumour protein (p53), breast 
cancer associated gene (BRCA1), checkpoint kinase 2 (CHK2) and Nibrin 1 (NBS1)35. 
As mentioned later, PI kinases under regulation of phosphatase enzymes can 
autophosphorylate and/or phosphorylate other substrates such as effectors in the DDR. 
AT is an autosomal recessive disorder, in which both parents of the affected offspring 
would have carried one functional and one mutated copy of the ATM gene in 
heterozygous form and therefore the offspring inherited each of the mutated copies in 
homozygous form. The disorder was first described as a pleiotrophic phenotype originally 
in 1926 by Syllaba and Henner36, but not clinically described until years later by 
Sedgwick and Boder37. It was not long after that the abnormally high sensitivity to 
radiation was observed and increased predisposition to cancer was reported using cultured 
skin fibroblasts as an in vitro model33,38,39. 
 
 
. 
 
 
Figure 1.1 Genomic location of the ATM gene which is highlighted by the red dash. The ATM gene is 
located as a cytogenetic band at 11q22.3 and is comprised of 146,619 bases. Image and information taken 
from GeneCards35 
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Attempts have been made to use the ATM gene to predict individual radiosensitivity in 
patients with promising outcomes. Cesaretti et al  showed that ATM sequence variants 
could correlate well and predict adverse reactions of prostate tumours to RT40. The group 
suggest that gene sequence variants (not only ATM) are involved in radiosensitivity and 
could potentially be used as a predictor of radiosensitivity. Such genes include 
transforming growth factor beta (TGFβ), X-Ray Cross Complementing protein 1 and 2, 
(XRCC1 and 2) and superoxide dismutase (SOD) 40. 
AT-Like Disorder (ATLD) is similar in clinical presentation to that of AT and is a result 
of a mutation in the meiotic recombination homolog 11 (hMRE11) gene. This gene is an 
important constituent of the MRN complex alongside DNA repair protein (RAD51) and 
NBS41. As the components responsible for AT and Nijmegen Breakage Syndrome (NBS) 
are within the same complex, it would be automatically presumed that patients with these 
syndromes would present with similar clinical symptoms, however this is not the case. 
One similar presentation is radiosensitivity and an increased predisposition to cancer. 
ATLD is similar to AT disorder, in that patients present with ocular apraxia, slurred 
speech and increased incidence of respiratory infections, but patients do not have 
immunodeficiency as in AT or NBS. In NBS, symptoms include microcephaly, growth 
retardation and immunodeficiency41. Cells from AT, ATLD and SCID are virtually 
indistinguishable in their response to ionizing radiation, as all show an increased in 
radiosensitivity involving different genes, but differences in their clinical presentation 
outline the need for further investigation to observe if other co – factors are involved42. 
FA is a rare genetic condition which is characterised clinically by defects in normal 
development, bone marrow failure, hyper-radiosensitivity and increased cancer 
predisposition, with 15 genetic subtypes of the disorder reported43. A high frequency of 
mutations have been found in patients with FA (most recently FANC-A, -C, -G and -
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D2)44 which proves difficult to find a comprehensive diagnostic test for all FA patients 
and incredibly most often produces false positives while testing45. Cells from FA patients 
have been found to be hypersensitive to chromosomal breaks and a classical chromosomal 
breakage test was done in combination with multiplex ligation- dependant probe 
amplification (MLDP)46 on patients directly for diagnosis of the condition. However, 
more  recently whole exome sequencing of the FANCA gene is used45. 
XP was first described in the 1800’s by Hebra47, and is an inherited autosomal disorder 
classified clinically by pigment disorders, photosensitivity, increased susceptibility to 
tumour development as a result of defects in DNA repair processes48. Reviewed in a case 
series by Butt et al  in 201048, XP has 8 genetic sub variants, 7 of which result from 
defects in the nucleotide excision pathway of repair (NER) in response to ultraviolet (UV) 
induced DNA damage49.  
BS also targets defects in repair pathways. This is a genetic autosomal recessive disorder 
which is characterised clinically by a photosensitive rash, short stature and a 
predisposition to cancer, which results from excessive homologous recombination (HR) 
repair and possesses one of the strongest correlations between chromosomal 
radiosensitivity and cancer predisposition50. The disorder, which is a result of a mutation 
in the Blooms Syndrome (BLM) gene, encodes DNA helicases that are important in DNA 
stability and  helicase activities within the replication fork during homologous 
recombination51. 
SCID syndrome is a result of defects in the non-homologous end joining (NHEJ) 
pathway. In cases of SCID associated with radiosensitivity, proteins with mutations that 
interact to re-join DSB’s (including DNA cross link repair protein (ARTEMIS), non-
homologous end joining factor 1 (XLF) and DNA ligase IV, as well as DNA – PKcs) are 
mutated, with ARTEMIS mutations the most common in SCID patients and the knockout 
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of all of these proteins resulted in lethality in mice52. Patients lack a fully functioning 
immune system and therefore lack of helper T cells in the immune response. This results 
in SCID patients being reported as highly radiosensitive and vulnerable to normal every 
day infectious agents53.  
1.3.1. Cancer 
Healthy cells can repair and adapt in response to a number of cellular stresses such as 
fluctuations in calcium levels, nutrient deprivation, and oxygen status. In response to 
DNA damage from ionizing radiation, the cell can cease dividing completely. Cellular 
stress causing DNA damage is accurately monitored by cell cycle control, repair and cell 
fate mechanisms to ensure correct repair or disposal of a faulty cell. Cancer cells in 
general tend to have mutations in genes associated within the control mechanism steps. 
One of the most extensively studied is p53 because of its multifunctional role in cellular 
mechanisms leading it to be considered as ‘the guardian of the genome’ if subjected to 
any type of damage. P53 is a tumour suppressor gene and is the most commonly mutated 
in most cancer types54. Recent evidence suggests that even though loss of function TP53 
could result in carcinogenesis, mutated TP53 with gain of function results in more 
aggressive cancer types using mouse models55. This was shown to influence the correct 
homeostasis of tissues, and allows for tumour growth and spread.  
Due to increased proliferation rate, tumour cells tend to be more radiosensitive than 
normal cells (if they remain normoxic)30. This is due to the high rate of passage through 
the cell cycle. Therefore, samples from cancer cohorts are generally more radiosensitive 
than those from healthy donors. For example, the majority of PCa cases show mutated 
P53 (a crucial tumour suppressor gene) which results in the accumulation of inactive 
P5356. P53 is therefore crucial in regulating radiosensitivity, and reinstatement of mutated 
P53 to wild type P53 in tumours could potentially increase radiosensitivity and sensitize 
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cells to radiation57. The crucial role of P53 in radiosensitive cohorts will be investigated 
later in this thesis.  
Targeting cellular sensitivity or resistance are key radiobiological mechanisms which are 
manipulated for therapeutic gain.  
1.4. Cellular Sensitivity to radiation 
Cellular radiosensitivity is affected by many factors which can be subdivided into 
individual intrinsic genetic differences (radiosensitive phenotypes described previously) 
as well as experimental test model and conditions. In 1989, Sanford et al  reported a 
number of experimental conditions that affected the in vitro radiosensitivity of human 
skin fibroblast cultures which included pH and temperature, cell culture medium batch, 
cell density of cultures used and bacterial contamination58. Although the molecular 
mechanisms of individual intrinsic radiosensitivity are currently still poorly understood, 
it is known that gender, environmental and lifestyle factors such as diet and exercise can 
play a huge role59. 
1.4.1. Types of DNA damaging agents 
Up to 10,000 natural errors in DNA replication can happen in mammalian cells each 
day60. Cells are also continually exposed to different exogenous agents that can further 
compromise the genome. To cope with such a high rate of DNA damage, the cell has its 
own comprehensive DNA repair system which responds to various endogenous and 
exogenous DNA damage each day. The cell is able to cope with exogenous damage 
(which causes single strand break (SSB) and DSB) by using the highly specialised repair 
systems for SSB repair and DSB repair processes (discussed more later). The list of 
damaging agents is much larger than what is described in this section. The main types of 
DNA damage with relevance to disease and mutagenesis include chemical agents, UV 
and ionizing radiation (IR) insults. Figure 1.2 shows examples of DNA damaging agents 
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with lesion types, cell checkpoint control by checkpoints and the array of downstream 
cellular changes that can occur due to damage. 
 
 
  
Figure 1.2 Examples of DNA damaging agents. Base modifications, adducts, Double strand breaks (DSB) 
and cyclobutane pyrimidine dimers (CPD) are defects caused by Reactive oxygen species (ROS), alkylating 
agents, ionizing radiation (IR) and ultraviolet (UV) irradiation. The cell has a DNA damage and repair 
system (DDR) capable of detecting and repairing the damages mentioned, or changes the cells fate. 
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DNA can be damaged through Reactive oxygen species (ROS) as a result of metabolism 
of oxygen within the cell. Normally, ROS is a natural part of oxygen metabolism within 
the cell, but when an accumulation of ROS results from e.g. IR, homeostasis of the cell 
is disrupted and ROS can affect the DNA structure, as well as react with amino acids and 
other enzymes within the cell. These type of highly reactive molecules can cause DNA 
damage by modifying DNA bases, producing inter-and intra–strand crosslinks, protein-
DNA crosslinks and SSB’s and DSB’s respectively61. ROS can be produced through the 
indirect interaction of radiation particle tracks with water molecules. Reduction of oxygen 
can produce superoxide, which serves as a precursor for other reactive species. A three 
step pathway converting hydroxyl radical to hydrogen peroxide, superoxide and 
ultimately back to oxygen takes place62. 
The most notable alkylating agents which cause DNA damage are well established anti-
cancer drugs, which are mostly methylating agents forming adducts at the N and O atoms 
in DNA bases63. More commonly used anti-cancer drugs like chlorambucil are 
bifunctional alkylating agents which produce more complicated DNA lesions and require 
a more robust DNA repair mechanism. The primary adducts are repaired through methyl-
guanine DNA methyl transferase (MGMT) but secondary adducts like inter-strand 
crosslinks require nuclear excision repair (NER) factors, DNA repair endonuclease 
(XPF), FA and HR64. 
The effects of DNA damage through UV and its influence in skin cancer are well studied. 
Direct or indirect irradiation of DNA through UVB range (230nm – 320nm) or artificial 
UVC (254nm) range causes dimerization of pyrimidines which leads to the formation of 
cis-syn cyclobutane pyrimidine dimers (CPD’s) and pyrimidine pyrimidone 
photoproducts65. UVA and UVB can also cause the formation of oxidised bases such as 
8-oxo-7, 8-dihydro-2’-deoxyguanosine (8-oxodG)66. The formation of 8-oxodG is rapidly 
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repaired by the cells repair systems, but CPD’s are more persistent DNA lesions and can 
potentially lead to mutagenesis67. These lesions are commonly attributed to the mutagenic 
causes of melanoma.  
The most relevant DNA damage causing agent in this thesis is IR at both the clinical 
radiobiological and radio therapeutic level. Damaging effects of IR come from its ability 
to ionise or eject electrons from molecules within the cell68. The ejected electrons can 
then set of a chain of ionizing events causing further damage within the traversal track of 
irradiation and causing clusters of DNA damage69. Therefore, DNA damage from IR can 
be either direct or indirect (Figure 1.3). Direct damage to DNA is caused when photons 
interact directly with the DNA structure, causing damage to the sugar-phosphate 
backbone and strand breaks. Although the cell has specialised repair processes to repair 
DNA damage, clustered strand breaks which are induced by IR are more difficult to 
repair. Evidence from early work by Warters and Hofer in 1977 show that DNA is the 
critical target of IR induced cell killing as they used alpha particles produced by small 
polonium needles to irradiate only the plasma membranes and cytoplasm of the cell but 
not the nucleus where DNA is housed, and the cell was able to recover and survive70. 
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Figure 1.3 Illustration depicting the direct effect of ionizing radiation and the indirect effect on the DNA 
double helix structure and interaction with water molecules respectively. Image taken from Montoro et al 
71. 
 
Non targeted effects of radiation include radiation induced bystander effects (RIBE) and 
genomic instability (GI). Abscopal and bystander mediated adaptive response (AR) are 
subdivisions of bystander effects72 which although are of extreme importance are beyond 
the scope of this body of work.  
1.4.2. Types of DNA damage  
As already discussed in the previous section, DNA is damaged and repaired daily in 
mammalian cells. Table 1.1 shows examples of the main DNA damage insults in terms 
of rate of occurrences of each. In the United States of America, 90% of lung cancer cases 
are attributed to smoking73. For example, a β-unsaturated aldehyde called Acrolein is 
thought to be the most important factor of cigarette smoke which can easily penetrate 
through the cell membrane and bind to the N2 amine of deoxyguanine (dG) which is then 
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followed by cyclization of N1 which forms DNA adducts α -hydroxyl-1, N2-propano-
2’deoxyguanine (α-HOPdG) which is a major DNA damage type responsible for 
mutagenesis of cells caused by smoking74. This is of relevance for this work as smoking 
has been included in the analysis from donors in chapter 2. 
 
Table 1.1 Examples of rate of DNA damaging agents and rate of occurrences daily in human cells. Adapted 
from Bernstein and Prasad60. 
 
DNA Damages Reported Rate of Occurances 
Oxidative 10 - 11500 per cell per day in humans 
Specific oxidative damage products: 8-
hydroxyguanine, 8-
hydroxydeoxyguanosine, 5-
(hydroxymethyl) uracil 
2,800 per cell per day in Humans 
Depurinations 10,000 per cell per day 
Depyrimidinations Up to 700 per cell per day 
Single Strand Breaks 55,200 per cell per day 
Double Strand Breaks up to 50 per cell cycle in Humans 
O6 Methylguanine 3120 per cell per day 
Cytosine Deamination 192 per cell per day 
 
 
Of the types of DNA damage mentioned, the most relevant is SSB and DSB which are 
caused by IR. The SSB is the most common form of DNA damage occurring from 
endogenous (replication errors) and exogenous agents (Chemotherapeutic drugs, UV), 
with upwards of 55,000 events per cell per day (Table 1.1). This form of DNA damage is 
not as serious in terms of cellular fate, as the SSB repair (SSBR) system deals with the 
insult quite efficiently using the non-damaged DNA strand as a template for repair 
(discussed more later).   
However, the DSB is more fatal as it involves breakage of both DNA strands and can lead 
to genomic instability. The DSB is mostly formed by exogenous sources like IR (most 
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relevant to this thesis) or endogenous enzymatic processing of collapsed replication forks 
or inter/intra-strand crosslinks (usually in S phase)75. This one ended DSB which is 
caused in S phase, is usually repaired by HR with the Fanconi Anemia proteins and ATR 
pathways76,77. In response to DSB damage the cell has two major mechanisms built to 
attempt to repair the DSB, namely HR and NHEJ pathways.  
1.4.3. Damage Recognition and signal propagation 
The initial events which follow a DSB have been under intense investigation for many 
years, with conflicting theories. It has now been recognised that the very earliest event 
(even before recruitment of sensor proteins to the site of damage) is relaxation of the 
chromatin, which through acetylation of histone H4 would allow for the recruitment of 
DNA damage sensor and repair proteins and allow for checkpoint functions78. Figure 1.4 
shows a schematic of events which happen in the basal state. In normal conditions, histone 
H4 is kept inactive through deacetylation by a protein called males-absent on the first 
(MOF) and another 60kda tat interacting protein (TIP60) (histone acetylases). Levels of 
ATM are kept at a relatively low level through the action of dephosphorylation and 
downregulation of TIP60 and activating transcription factor 2 (ATF2).   
Figure 1.4 Interplay of factors in the basal state before DSB occurrence. Histone H4 (H4) is kept inactive through 
deacetylation by 60 kDa interacting protein (TIP60) and males absent on the first (MOF). Ataxia telangiectasia 
mutated (ATM) levels are kept low through TIP60 and Activating transcription factor 2 (ATF2).  
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Proteins involved in all cellular pathways undergo conformational changes when 
switched ON or OFF, through phosphorylation or dephosphorylation by kinases or 
phosphatases respectively. This allows for highly efficient and rapid cellular 
mechanisms79.  
When a DSB occurs through IR, increase in H4 acetylation occurs which allows 
relaxation and mobilisation of heterochromatin protein 1 (HP1) bound to H3 (required by 
phosphorylation). Schematic of events are demonstrated in figure 1.5. Much like thread 
wrapped around a spool, cellular DNA is tightly bound to core histone proteins (H2A, 
H2B, H3 and H4) and linker (H1 and H5) histone proteins, which are subject to chemical 
modifications primarily through phosphorylation, methylation and acetylation but also 
ubiquitylation, SUMOlyation and ribosylation (reviewed by Rothbart and Strahl80). Tip60 
becomes activated when bound to unmasked H3 which is recruited into foci requiring the 
MRN complex. Poly ADP ribose polymerase (PARP) 1 and 2 are activated upon binding 
to SSB or DSB’s and this allows for phosphorylation of ATM, collaboration of PARP 
with Ku and DNA protein kinases (DNA PK’s). The recruitment of amplified in liver 
cancer 1 (ALC1) and nucleosome remodelling deacetylase (NURD) allow for chromatin 
remodelling81. ATM can be phosphorylated at very distant sites away from the DSB, 
through phosphorylation or autophosphorylation, which can then in turn phosphorylate 
the well-known histone H2AX (H2AX) becoming γH2AX. Phosphorylation and 
activation of H2AX is one event of many which happens in response to DNA damage 
“sensor” activity. A large recruitment of proteins and protein complexes to the site of SSB 
or DSB are most commonly grouped into 3 pathways; 1) MRN – ATM protein pathway, 
2) DNA – protein kinases (PKcs) – KU pathway and–  3) ATR - ATR interacting protein 
(ATRIP) pathways. 
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1.4.3.1. ATM - MRN 
The first and most studied sensor pathway is the ATM – MRN pathway. The MRN 
complex is recruited to ATM, (through Tip60/ATF2 as previously mentioned) and 
consists of DSB repair proteins in a complex MRE11, RAD50 and NBS1. NSB1 has a 
key role of directly binding to ATM and takes it to the site of the DSB. The gene of the 
NBS protein was found to be mutated in Nijmegen Breakage Syndrome, and patients 
show similar symptoms to that of ATM patients82. Defects in DSB repair, radiosensitivity 
and immuno – compromise are some of the symptoms. Therefore, when NBS is mutated, 
defective or inactivated, the individual is found to be radiosensitive and lacks the 
appropriate DNA repair machinery required for efficient DNA damage sensing and 
repair. The MRN complex is important in sensing damage to DNA and recruiting ATM, 
but evidence suggests that it is also important in processing the DSB. It does this through 
digestion of incompatible ends of broken DNA that cannot be ligated. ATM is present in 
Figure 1.5 Sequence of signalling events after a DSB occurs. Histone H4 (H4) is acetylated which allows for 
chromatin relaxation and mobilisation of Histone protein 1 (HP1) bound to Histone H3 (H3). This allows for 
association of H3 with 60 kDa interacting protein (TIP60). H3 and TIP60 then become incorporated into the MRN 
complex (which consists of MRE11, RAD50 and NBS1) and this allows for recruitment of Ataxia telangiectasia 
mutated (ATM) and phosphorylation of Histone H2 A (H2AX). Recruitment of MDC1 allows for signal spread and 
propagation to distant sites. 
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every cell in its inactive form and becomes activated when it comes in contact with the 
DSB, brought by the MRN complex, which in turn causes the phosphorylation of 
signalling proteins such as H2AX. H2AX can be described as an “amplifier,” as this 
signal can spread over a relatively large area of chromatin in both directions of the DSB 
with the help of the MDC1 protein. This signal “spread” allows for recruitment of other 
repair machinery to become activated within the cell and localisation around the DSB83. 
How ATM is inactivated or why it is activated in response to non – DNA damaging events 
such as osmotic shock and chloroquine is not yet known, but reiterates that ATM is a core 
protein responsible for many functions of which are not yet known83. There are also 
reports of how ATM could be activated in three forms, ATM S367A, ATM S1893A and ATM 
S1981A corresponding to the serine phosphorylation sites on ATM, and evidence suggests 
that after IR, not all 3 forms are activated together (ATM S1983 is less responsive to IR), 
suggesting yet further roles for ATM within the cellular response to irradiation84. 
The importance of ATM in DNA damage checkpoints was clearly outlined with the 
discovery of ATM gene in ATM deficient patients. Without this protein, patients exhibit 
symptoms such as poor immunity, increased risk of cancer, and poor motor control of 
muscles. This showed that not only was the ATM checkpoint important in regulating the 
cell cycle and stalling cells, it was also important in the interaction between other 
checkpoints or proteins separate from the cell cycle 85. AT patients exhibit symptoms of 
elevated radiosensitivity to the damaging effects of ionizing radiation. 
1.4.3.2. DNA – PKcs - KU 
When ATM is inhibited, it has been shown that limited DNA repair can take place through 
an alternate pathway. This pathway, known as the DNA dependant protein kinase 
catalytic subunit (DNA – PKcs) interacts with Ku heterodimers to also activate a pathway 
which allows for phosphorylation of H2AX. The pathway is involved in DSB detection 
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and repair through the non- homologous end joining (NHEJ) pathway and is structurally 
similar to ATM. It has a similar role to the ATM pathway, and needs to recruit a further 
complex to “sense” damage. It does this through the Ku70/Ku80 complex which on 
binding to DSB ends allows recruitment of DNA – PKcs and phosphorylation of H2AX86. 
1.4.3.3. ATR - ATRIP 
ATR – ATRIP is the third known kinase which is able to phosphorylate H2AX. So far it 
has not been implicated into the direct pathway associated with DSB, but it has been 
known to become activated in response to other forms of DNA damage, such as SSB and 
replication fork errors. When DNA polymerase enzymes stall in response to strand 
damage, replication continues along the single strand of DNA, a single strand binding 
protein replication protein A (RPA) binds to the DNA and recruits the ATR – ATRIP 
complex, which interacts in response to loading of proliferating cell nuclear antigen 
(PCNA) related 911 by cell cycle checkpoint protein RAD17 clamp loader83. ATR - 
ATRIP acts as the sensor of damage. Although not known to act in the earlier events of 
DSB, ATR is known to become activated with the MRN (MRE11/RAD/NBS1) 
processing of broken incompatible DNA ends. Therefore, ATM can activate ATR in a 
downstream pathway which can phosphorylate various other proteins to act in the DDR. 
ATR has also been shown to activate components of effector pathways and cell cycle 
checkpoints, therefore these actions are dependent on ATR activity83. Sensors such as 
MRN, PARP detect the damage at the damage site, and the signal is further propagated 
by transducers (to include ATM, DNA PK’s, ATR-ATRIP, BRCA etc.). When the signals 
of damage are propagated, effector proteins (XRCC4, RPA, retinoblastoma binding 
protein 8 (Ctip)) are phosphorylated to determine activation of effector pathways, whether 
it be cell cycle checkpoint activation, cell death or repair (Figure 1.6).   
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Figure 1.6 Overview of DSB signalling with a timescale of events which occur in the DDR cascade. Sensor 
proteins such as PARP recognise the DSB immediately, while the MRN complex is recruited and causes 
phosphorylation of ATM and γH2AX. The signal is propagated to cause activation of cell cycle checkpoints 
and a decision is made for which type of repair will take place (either HR or NHEJ) which is influenced by 
many factors including cell cycle stage etc. (discussed in text later). Image taken from Vignard et al 87.  A-
H outlines the process in terms of seconds to minutes and then hours. 
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1.4.4. Cell Cycle Checkpoints 
The DDR works by sensing and transducing signals of damage effectively to halt the cell 
cycle and allow for the appropriate repair mechanisms to occur. The cell cycle consists 
of 4 distinct phases (Figure 1.7). DNA is replicated during S phase, condensed into 
chromosomes in late G2 phase and then undergoes division in M phase. The S phase is 
sensitive to a DNA damage checkpoint, under the control of ATM/ATR, Chk1/2, cyclin 
dependent kinase inhibitor 1 (P21) and P53 (Figure 1.7). Two gap phases (G1 and G2) 
are present to prepare for both S and M phase respectively. During G1 phase, the cell 
grows and prepares proteins essential for DNA synthesis in S phase. In response to DNA 
damage, ATM/R is activated to phosphorylate p53 and activate p21 which inhibits the 
progression of the cell in the cell cycle through cyclin D – cyclin dependent kinase 
(CDK4) action. In G2 phase, the cell also grows and prepares for cell division in mitosis, 
when threshold levels of cyclinB1/CDK1 have been reached. There are two checkpoints 
associated with G2 – M cycle entry, an early and a late checkpoint. 
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There is also a quiescent phase G0, in which cells can exit the cell cycle and stay in this 
phase until resuming their proliferating capacity. Some cells may permanently stay in G0 
phase of the cell cycle until they or the organism dies.  Of a 24hr cell cycle, interphase 
occupies 23/24hrs, while mitosis lasts approximately 1hr 88.  
The cell cycle is controlled by extracellular signals and the external environment of the 
cell. If conditions are favourable and the appropriate signals are in place, the cell will 
progress through the cell cycle. Cell cycle checkpoints are located in G1/S, intra S phase 
and G2/M phases of the cell cycle (figure 1.7). At each checkpoint, complexes of cyclin 
Figure 1.7 Overview of cell cycle checkpoints in response to various cellular stresses. The spindle 
assembly checkpoint, chromosome segregation, DNA damage, and DNA replication checkpoints are 
shown. Image taken from Makoto et al381. 
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proteins and partner cyclin dependant kinases (CDK’s) are involved in maintaining and 
regulating the progression of a cell through each phase of the cell cycle. 
The G1 phase checkpoint functions to facilitate the activation of checkpoints and 
progression of the cell through the G1 to S phase of the cell cycle and is brought about 
by the control of E2F transcription factor by the retinoblastoma protein (RB). The process 
begins through phosphorylation events of RB by G1 cyclin – CDK’s. After irradiation, 
this can be prevented by ATM activity. ATM can activate p53, which can in turn up-
regulate the gene CDK1 p21 (CDKN1A). This inhibits cyclin – CDK complexes in G1 
phase, preventing phosphorylation of RB and therefore preventing the activation of E2F, 
which will in turn stop the cell at this checkpoint and phase in the cell cycle. Therefore, 
the cell will have delayed entry into S phase until repair and normal conditions are 
stabilised.  
The S phase checkpoints are regulated by checkpoint genes CHK2 and CHK1. These can 
be activated by phosphorylation by ATM and ATR respectively. To prevent cells from 
progressing to G2 after S phase, the CDK2 kinase must be dephosphorylated. This is 
regulated by a protein known as cell division cycle 25A (CDC25A) and CDC25C 
phosphatases. CHK1 and CHK2 become activated and can phosphorylate CDC25A and 
CDC25CC which leads to degradation of CHK1 and CHK2. When activated by ATM 
and ATR, an increase in CDK2 follows and this slows progression from S to G2 phase. 
Other proteins have been implicated into this response, including the well-known BRCA1 
and BRCA2. ATM/ATR checkpoint regulation was recently reviewed by Reinhardt and 
Yaffe, 200989, who describe an emerging third effector pathway that involves MAPK-
activated protein kinase 2 (MK2) and shares substrate homology with CHK1/2 to arrest 
the cell cycle.  
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There are two G2 phase checkpoints; the early and late G2 checkpoints. The early G2 
checkpoint is related to cells that are irradiated in the G2 phase of the cell cycle and can 
be activated by even low doses of irradiation. This results in a G2 block. It works through 
ATM – CHK2-CDC25A/C signalling and targets mitotic cyclin B – CDK1 complex. This 
complex must be dephosphorylated to become activated. This checkpoint stops 
progression of cells in G2 phase into mitosis and therefore explains why there is a drop 
in mitotic cells shortly after periods of irradiation90. The late G2 checkpoint (also known 
as the Sinclair checkpoint, after Warren Sinclair91) is a longer delay checkpoint and it 
applies to those cells which may have been irradiated in G1 or S phase that managed to 
progress in the cell cycle. These cells have a prolonged delay before mitotic entry and are 
a result of higher doses of irradiation92. In addition to higher doses of irradiation causing 
G2 inhibition, G2 block has been observed in cells irradiated with high LET irradiation. 
One of the earliest reports of prolonged G2 arrest following high LET irradiation was by 
Lücke–Huhle et al  in 1979 who showed a much more perturbed cell cycle progression 
after high energy, high LET irradiation compared to x-ray irradiation93. This checkpoint 
is also ATM independent and utilises ATR – CHK1 – CDC25C signalling.  
1.4.5. Cell Fate after DNA damage  
The fate of a damaged cell has various endpoints in response to radiation. A number of 
repair pathways are in place to help repair the damaged DNA when the cell cycle has 
been stopped by the appropriate checkpoint. These pathways include SSB repair 
mechanisms which include mismatch repair (MMR), base excision repair (BER), NER 
and DSB repair mechanisms which include NHEJ, HR, FA pathway (in response to intra 
strand crosslinking) and repair of bulky adducts using trans-lesion synthesis (TS) in 
response to production of thymidine dimers caused by UV irradiation. If the cell is too 
badly damaged and the correct repair mechanisms are not faulty, the cell will commit to 
a programmed cell death pathway such as apoptosis. Other forms of cell death include 
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Necrosis, Apoptosis, Mitotic catastrophe, autophagy and replicative senescence. If 
mutations exist in the repair or cell death machinery, problems such as genomic instability 
and carcinogenesis arise. Each cell fate pathway will be discussed in the following sub-
sections. 
1.4.5.1. DNA Repair processes 
As explained previously, there are a number of specialised repair mechanisms in place to 
repair the damaged cell and these mechanisms are specific to the different types of DNA 
lesions. The repair mechanisms employed for SSB are BER, MMR and NER. On 
recognition of chemically modified bases, the NER pathway involves glycosylases which 
can catalyse the cleavage of the base-sugar bond creating an apurinic/apyrimidinic (AP) 
site on the DNA structure to release the damaged base, and proceeds to repair either 
through short or long patch repair 94. After DNA replication, MMR corrects mismatched 
bases on the newly synthesised strand by recognising strand specific “nicks” on the 
damaged site, which are recognised by the Mutator S (MutS) protein and form a complex 
with the MutL protein, further recruiting MutH forming a DNA loop, which allows for 
the excision of the incorrectly matched base along with several other bases and synthesis 
of a new strand by DNA polymerase and ligation95. NER is a specialised repair pathway 
capable of repairing damage which is caused by UV irradiation. CPD lesions (as 
described in previous sections) are firstly recognised by damage specific DNA binding 
protein 1 and 2 (DDB1 and 2), xeroderma pigmentosum complementation group c (XPC)  
and repair can take place via two pathways; global genomic repair (GGR) and 
transcription coupled repair (TCR) through the action of 4 RNA polymerases which 
ultimately protects the genome from carcinogenesis from UV damage  to an extent96. 
Of primary relevance in this thesis with regard to DSB repair after IR, are two pathways; 
HR and NHEJ. Although figure 1.8 demonstrates the prime differences between NHEJ 
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and HR, it is important to note that there may be interplay between these pathways. It 
should not be assumed that all simple DSB are repaired by NHEJ and all complex damage 
is repaired by HR. Complex damage can be clustered (two or more lesions formed within 
two helical turns of the DNA by a single radiation track) or complex DSB (additional 
lesions close to the ends of the DSB)97,98.  
 
 
 
Figure 1.8 Non homologous end joining (NHEJ) and Homologous Recombination (HR) pathways. NHEJ 
is a rapid process, involving DNA protein kinases (DNA PKcs) and recruitment of factors such as XRCC4, 
Cernunnos and Artemis. The process ends with direct ligation of the two broken strands. HR is a more 
accurate pathway involving a base homology search on a sister chromatid through strand invasion and DNA 
synthesis of a new strand for repair. Image taken from Renodon-Cornière et al99. 
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Using a homologous sister chromatid as a template strand, HR can synthesise a new strand 
and ligate strands together to restore genomic stability, a process which is slower but 
much more accurate than NHEJ (Figure 1.8). In mammals, the process begins with 
sensing of the break by MRN and coating of the exposed single strand DNA (ssDNA) 
with RPA and recombination mediator proteins (RMP’s) such as BRCA2, which allows 
for Rad51 to form a nucleoprotein filament on ssDNA, performing a base homology 
search and initiates strand invasion on sister chromatids100. After resection from 5’ to 3’ 
takes place by exonucleases, strand invasion, or a “D – loop” forms, and synthesis of a 
new strand takes place by DNA polymerases, identical to the sister chromatid sequence, 
and formation of a “holiday junction.” How this holiday junction is resolved or cut is not 
fully known, but recent evidence suggests that BLM binds in a complex with 
topoisomerase III alpha ( TopIIIa) and BLM associated protein of 75kDa (BLAP75), 
which allows the complex to push the entangled holiday junction strands closer together 
and untangles DNA by TopIIIa, leaving only a small crossover region of DNA and 
ligation of broken ends are resolved by ligase1101.  
NHEJ is a more rapid technique yet less accurate as there are no homology requirements 
and broken DSB ends are literally bound together (Figure 1.8). The choice of whether to 
use NHEJ rather than HR is still under intense investigation; however, the most plausible 
reason why NHEJ would be preferred is if a homolog is not available for HR to take place. 
It is known that HR is the preferred pathway for DSB repair in lower eukaryotes including 
yeast, but NHEJ is the preferred pathway in higher eukaryotes such as mammalian 
cells102. When NHEJ responds to a DSB, the initial event is the binding of Ku heterodimer 
and this (Ku70/80) is thought to bind to DSB ends within milliseconds after irradiation 
with a huge binding affinity for DNA ends103. When Ku is anchored to DSB ends, it serves 
as a scaffold for loading of DNA-PKc’s X-ray cross complementing protein 4 (XRCC4), 
DNA ligase IV, XLF, aprataxin and PNK like factor (APLF)104. Evidence suggests that 
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in order for this Ku – DNA-PKc complex to become activated, it requires the presence of 
DNA and cannot be activated without DNA binding105. Non-specific processing of DNA 
DSB ends is protected also by Ku70/80 which is important as this could lead to 
chromosomal aberrations and genomic instability if allowed to proceed. A filament is 
created using XRCC4 and XLF which bridges the two ends of the DSB for stability and 
docking of further substrates106. After stabilisation occurs, the ends of DNA need to be 
stuck together and this is done with various enzymes depending on how much damage is 
caused. Factors that are recruited include artemis, PNKP, APF, Polymerases μ and λ, 
Werner, Aprataxin and Ku104. Complexes of Artemis, Werners Syndrome gene (WRN) 
and APLF resect the DNA DSB ends which may require the phosphorylation of ATM 
and DNA PKc’s by Artemis107. Finally, ligase IV can ligate the broken ends by becoming 
adenylated by XRCC4 which promotes ligase IV activity108. 
1.4.5.2. Cell Death mechanisms 
If cell damage is substantial, cell death via a number of pathways can occur. Cell death 
pathways associated with various forms of cellular stress include Necrosis, Apoptosis, 
Mitotic catastrophe, autophagy and replicative senescence.   
Necrosis is a more chaotic form of cell death, usually in response to cellular trauma which 
results in autolysis. Usually, necrosis results from extreme conditions, such as extreme 
temperature increase or decrease (frostbite), or exposure to extreme doses of IR radiation. 
At these high levels of IR, the damage is irreversible and often fatal109.  
First noted by Hayflick in early 1960’s using human fibroblasts, cellular senescence is a 
type of cell “ageing” described as an inability of proliferation regardless of nutrient 
abundance110. This is known as the Hayflick limit, in which cells reach their proliferative 
capacity through serial shortening of telomeres and either die through apoptosis or enter 
a senescent state, which is a protective mechanism against tumourigenesis111. Premature 
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senescence on the other hand can be induced by a variety of cellular stresses, such as 
ROS, IR and UV irradiation, which ultimately acts as a tumour suppressor mechanisms 
to prevent cellular damage from being carried through the progeny of cells112. It is thought 
that in response to DNA damage, two pathways can be activated to arrest cells in a 
senescent state; the first is the p53/p21 pathway and the second involves p16/pRB113.  
Mitotic catastrophe should not be misinterpreted as a failure of the cell to complete 
mitosis, it is more likely a result of aberrant chromosome segregation or DNA damage 
during mitosis and it is most commonly associated with IR induced cell death114. 3 models 
of mitotic catastrophe have been presented; the first abnormalities in mitosis allows for 
increase of cyclin B1 levels and cell death machinery before the cell has exited mitosis, 
the second model allows for the cell to exit mitosis and then die in interphase of the next 
cell cycle (which can happen quickly or delayed, such like the radio-induced cell death 
years after RT), and finally the third model demonstrates activation of senescence  
irreversibly inactivating the damaged cell115. Mitotic catastrophe has been manipulated 
for therapeutic gain from the use of anticancer agents (such as taxanes and alkaloids) 
which bind to tubulin and disrupt the mitotic spindle116. The process aims to effectively 
disable or eliminate cells with aberrant chromosomal structures, thus preventing 
oncogenesis.  
Autophagy is a metabolic process which functions in the destruction of cells within the 
body. The process is capable of regulating cellular homeostasis through recycling of 
proteins in the degradation process. Recently, a study demonstrating inhibition of 
autophagy showed a downscale of proteins involved in the homologous recombination 
and non-homologous end joining DNA repair pathways in response to nuclear 
irradiation117.  
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Finally, apoptosis is the last mentioned form of cellular death and is the most studied with 
relation to radiobiology and cancer research. P53 is a central player in initiating apoptosis, 
as it is regulated by mouse double minute homolog (MDM2). P53 is continually 
synthesised but degraded by ubiquitylation by the proteasome. When ATM is activated 
in response to DNA damage, P53-MDM2 is phosphorylated and stabilised. P53 can then 
up-regulate pro-apoptotic genes such as BCL2 associated X protein (BAX) and P53 
upregulator of apoptosis (PUMA). Two pathways were originally described for the 
activation of apoptosis. First, the extrinsic pathway (binding of death ligands such as 
tumour necrosis factor receptor superfamily (FAS), tumour necrosis factor (TNF) and 
others to the death receptor is mediated through the death inducing signalling complex 
(DISC) and initiator caspase 8 activation to execute apoptosis by executioner Caspase 3.  
The second, ‘intrinsic pathway’ is initiated by a variety of toxicants including IR where 
the mitochondria are the direct target.  Cytochrome C is released from the mitochondria 
which interacts with Apaf1 and initiator caspase 9 to form the Apoptosome complex 
which activates executioner caspase 3 for apoptosis. More recently, a third pathway called 
the Perforin granzyme pathway has been explained which involves a caspase-dependent 
and –independent pathway - primarily with the immune response118. Both pathways are 
outlined in figure 1.9. 
The extrinsic pathway involves binding of an extracellular ligand to a transmembrane 
death receptor which is a member of the TNF superfamily. The most common and well 
characterised ligand which can bind and activate these receptors are FasL, TNF-alpha, 
Apoliprotein (Apo) 3L and Apo2L to corresponding receptors FasR, TNFR1, Death 
receptor 3 (DR3) and DR4/5 respectively119–121. Upon binding of pro-apoptotic ligands to 
the corresponding death receptor, aggregation of receptors and recruitment of the Fas-
associated death domain (FADD) occurs122. Assembly of the DISC complex and further  
cleavage and activation of initiator pro – caspases (8 and 10) follows which causes a 
 34 
 
caspase cascade of events resulting in digestion of DNA by caspase activated DNase 
(CAD) and proteolytic degradation of cellular proteins by executioner caspases 3 and 7123.  
 
 
 
 
The intrinsic pathway is initiated by signalling from various stress factors such as IR, 
which target the mitochondria and responds by releasing many apoptotic factors such as 
cytochrome c, apoptosis inducing factor (AIF), second mitochondria-derived activator of 
Figure 1.9 Simplified schematic of the intrinsic and extrinsic pathways of apoptosis. In response to 
intracellular stress (including Ionising radiation), release of apoptotic factors from the mitochondria which 
leads to formation of the apoptosome and cell death.  The extrinsic pathway involves binding of an 
extracellular ligand such as TNF-α, FAS, Apoliprotein (APOE). Following assembly of the death inducing 
signalling complex (DISC) and activation of procaspases, cell death occurs. Interplay between the two 
pathways has been studied. Image taken from Favoloro et al382. 
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caspases (Smac) from the mitochondrial intra-membrane space122. The pathway is 
dependent on the release of cytochrome C under the control of pro-apoptotic proteins 
BCL2, BCL2-associated – X protein (BAX) and Bcl2 homologous antagonist/killer 
protein (BAK) which operate in synergy with anti - apoptotic proteins Bcl2 and Bcl xl. 
Pro-apoptotic proteins initiate the release of cytochrome c from the mitochondria which 
binds to Apoptotic protease activating factor1 (APAF1) and pro – caspase 9 to produce 
the apoptosome (often referred to as the wheel of death). Caspase-3 is activated through 
the cytochrome-c/Apaf1/caspase-9 apoptosome complex122. Smac/DIABLO are 
antagonist proteins, released from the mitochondria in combination with cytochrome c 
and they promote caspase activation through inhibitory effects of IAPs by binding to 
inhibitors of apoptosis (IAP’s) such as XIAP123. 
In addition to the extrinsic and intrinsic pathways, a third pathway, the Perforin Granzyme 
pathway has been explained, which eliminates toxic cells by rapidly transporting perforin 
out of the cell to signal and deliver the pro apoptotic protease Granzyme into the cell to 
cause apoptosis118. The three pathways converge on the same terminal for the execution 
of apoptosis. One of the two subtypes of perforin-granzyme pathway; the granzyme B 
pathway is activated on cleavage of caspase 3, which results in DNA fragmentation, 
degradation of proteins, protein crosslinking, and expression of ligands for phagocyte 
uptake121. The granzyme A pathway has been shown to work independently from caspase 
activity, by nicking the DNA through DNase nucleotide diphosphate kinase (NM23-H1). 
NM23-H1 is important in immune surveillance which induces apoptosis therefore it is a 
tumour suppressor gene, which usually remains inhibited by the proto-oncogene SET. 
Granzyme A cleaves SET, which removes this inhibitory effect and leads to apoptosis 
through DNA fragmentation121.  
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Another apoptotic pathway was recently described that involves the endoplasmic 
reticulum (ER)  responding to stresses such as pharmacological agents that block protein 
transports from ER to Golgi and inhibition of calcium uptake through 
sarcoplasmic/endoplasmic Ca2+ -ATPase124. Although poorly understood, one example 
of how this pathway regulates cell death is through the action of C/EBP homolog  
(CHOP)/ growth arrest and DNA damage (GADD)153 which can downregulate BCL2 
and activate GADD34 and endoplasmic reticulum oxidoreductin (ERO)1α encoding ER 
oxidase125. This stress can lead to the proteolytic cleavage of caspase 4 in human cells to 
activate apoptosis and evidence suggests crosstalk between this pathway and the 
mitochondria126, which would not be unusual due to the involvement of Ca2+127. 
1.4.5.3. Genomic Instability and Carcinogenesis 
Genomic instability (GI) is a hallmark of carcinogenesis which refers to the relative 
increase of genetic alterations or mutations within the cell lineage128. GI is subdivided 
into three categories, namely chromosomal, nucleotide, and microsatellite instability.  
Most cancers display a form of genomic instability called ‘Chromosomal instability’ 
(CIN) which refers to the high rate of structural and numerical changes over time in cancer 
cells compared to normal cells. These changes were observed in cancer cells over 100 
years ago129. CIN changes were sometimes found in all cells of a tumour, but not in all 
cells of other tumours, suggesting that the instability arises from one single unstable cell 
which acquires abnormalities over time130. 90% of human cancers exhibit CIN and 
aneuploidy, and are characterized by amplifications, deletions, loss of heterozygosity, 
translocations and inversions131. CIN develops early in cases of cancer, displays complex 
levels of heterogeneity among cell types and between individuals, and is associated with 
chemotherapeutic drug resistance which makes early detection of CIN important132. The 
molecular mechanisms of CIN are still poorly understood, as a large amount of instability 
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from a combination of genes within DNA damage and repair, chromosomal segregation 
and telomere maintenance can give rise to sporadic cancers.  
Nucleotide instability (NIN) occurs as a result of replication errors and defects in the NER 
and BER DNA repair pathways. This type of instability is less common, and although 
subtle sequence changes in one or a few nucleotides (such as insertions and deletions) can 
occur, they can lead to a more drastic phenotype for e.g. Xeroderma pigmentosa which 
predisposes the individual to skin cancer133. Figure 1.10a demonstrates an example of 
NIN alongside Microsatellite instability (MIN) (Figure 1.10b).  
MIN is a result of defects in the DNA MMR pathway which is responsible for correcting 
mismatched DNA bases. Cells with defects in this pathway are not able to carry out repair 
properly and therefore accumulate DNA matching errors. With accumulation of 
mismatched base errors, microsatellites are formed, which are short repetitive DNA 
sequences consisting of 1-6bp, scattered throughout the genome134. Microsatellites are 
most often GT/ CA repeats, and lengths are highly variable between individuals135. Figure 
1.10b shows an example of expansion or contraction of microsatellites. 
 
 
Figure 1.10 Example of a) Nucleotide instability (NIN) showing a GC variant encoding an amino acid 
change (Gly – Arg) and b) first contraction of a microsatellite sequence and expansion of the sequence 
which arise from defects in mismatch repair (MMR). Image taken from Pikor et al 136. 
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A combination of mutation in DNA sequences that transcribe DNA damage sensing and 
repair genes, pro-apoptotic genes, cell cycle genes and other signalling substrates that 
alert the cell to defects in DNA repair contribute to genomic instability. Defects in spindle 
formation contribute largely to abnormal chromosome number and complement. All of 
the above mentioned cellular mechanisms in the DNA DDR function to eliminate 
damaged cells so that defects will not be continued in the progeny of irradiated cells. 
Much work has been done to find “driver” genes in genomic instability which could be 
targeted for therapeutics; some driver genes in relation to chromosome aberrations 
involve Birc5, BCL2 and the Androgen receptor which results in trisomy 17, gain of 17q 
gain of 20q11.21 and Trisomy X respectively137. Predictive biomarkers of radiosensitivity 
and cancer predisposition are still under intense investigation and the area warrants 
further research. 
1.5. Predictive Biomarkers of radiosensitivity 
As physical models used for RT treatment planning are not accurate measurements for 
biological outcome, radiobiological based assays have been developed for prediction of 
biological outcome. Over the years many attempts for predicting response have been 
made based on the advancement of techniques from cell to molecular based 
radiobiological assay, with the later focusing on DNA damage and repair. 
1.5.1. Cell based assays 
 The first gold standard technique for measuring radiosensitivity was the in vitro 
clonogenic assay. West and colleagues used the clonogenic assay to predict patient 
outcome in 1993, and extended follow up time to 2 years, but poor growth of specimens 
for clonogenic analysis was observed and the group encouraged the development of other 
assays for a more successful prediction of radiosensitivity138. West et al  also ruled out 
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correlation of patient age, grade and stage with radiosensitivity in cervical carcinomas 139 
and when using lymphocytes they showed that survival fractions on peripheral blood 
lymphocytes from patients before receiving therapy was a good prognostic factor in 
predicting late tissue outcomes 140. Tam et al  took a step further in comparing the 
clonogenic assay with the adenosine tri-phosphate (ATP) Cell viability assay and showed 
no significant difference in survival fraction between both assays, and therefore suggested 
the use of the alternate assay to be a more representative measure of patient tumour 
response with high reproducibility141. However, limitations of these in vitro assays 
include how they are laborious and time consuming for routine clinical use on patient 
samples. The clonogenic assay is still used in many in vitro radiobiological assays on cell 
lines it requires approximately 2 weeks for colonies to form to obtain data. Many other 
attempts have therefore been made to develop a more rapid, accurate assay for 
radiosensitivity prediction using high throughput viability assays. Plate based assays such 
as (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) (MTT) and Alamar 
Blue have largely replaced clonogenic assays due to the rapid output. In the past decade, 
combinational plate assays such as the ApoTox™ triplex assay have taken over due to 
multi endpoint measures. For each well, three endpoints (cell viability, cytotoxicity and 
caspase activation) are measured in one, which reduces cost and experiment time.  
1.5.2. Cytogenetics Based Assays  
The most researched cytogenetic based assays involve the micronucleus test (MN), the 
G2 chromosomal radiosensitivity assay and more recently fluorescent in situ 
hybridisation (FISH) analysis on chromosomes. Others include premature chromosome 
condensation, G0 and G1 chromosomal assays and other sub forms of FISH, but the 
primary 3 are mentioned as they are of most relevance to this work. 
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The Micronucleus (MN) test is another good reliable predictive assay of radiosensitivity. 
Developed and adapted for use by Heddle and colleagues142, the assay was further 
improved by Fenech et al143 and it is used to detect bi nucleated cells scored as 
extranuclear bodies within the cell. As formation of extranuclear bodies is associated with 
defective DNA repair or replication, a link between radiosensitivity and the formation of 
micronuclei has been found. Vral et al  observed high variability using the micronucleus 
assay in 2002, reporting that at one sampling time a person was considered to be 
radiosensitive, and when the assay was repeated was not considered radiosensitive144. 
This is not unusual as an individual’s intrinsic radiosensitivity is said to fluctuate. The 
amount of extranuclear bodies is said to increase with radiation dose and thus is a reliable 
measure of radiosensitivity145, Encheva et al  used the micronucleus assay to test 
radiosensitivity in cervical carcinoma patients and concluded that at doses > 1.5Gy 
difference between their tested control and cervical cancer cohort did not differ 
significantly, and they reported high inter individual variation values with outliers 
showing no side effects but a high micronucleus content146. These data are complicated 
and such confusion between sensitive and non-sensitive donors would not form basis for 
a reliable predictive assay to be used in the clinic. Further adding to this, early in 1999 
Scott et al  found the G2 chromosomal radiosensitivity assay to be more sensitive to 
detecting radiosensitivity of Breast cancer patients compared to the micronucleus test, as 
40% were shown to be radiosensitive using the G2 assay vs 25% using the micronucleus 
test, however different molecular mechanisms are at work in both assays so it is important 
not to rule out any assay as it is dependent on the particular research endpoint147.  
One of the most used predictive cytogenetic based assays to date is the G2 chromosomal 
radiosensitivity assay. The assay is a reliable predictor of radiosensitivity and correlates 
well with cancer predisposition148.  All reports in the literature provide evidence of the 
predictive ability of the G2 chromosomal radiosensitivity assay, along with the different 
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donor control and patient cohorts. For example, Roberts et al  used blood samples from 
healthy controls and breast cancer patients in 1999 to show inter and intra variation of 
7%147. Baria et al  used blood samples from healthy donors in comparison to breast, 
cervix, colorectal and lung carcinoma patients and found inter and intravariations of 15% 
and 10% respectively148. These reports are described in more detail in chapter 2 and 3 of 
this thesis. The previous assays mentioned are deemed to be time consuming with 
significant inter assay and cohort variability. In contrast, the G2 chromosomal 
radiosensitivity assay takes 3- 5 days to complete and shows good assay reproducibility 
between different cohorts. Therefore, the G2 chromosomal radiosensitivity assay has 
been shown to be a quick, reliable and reproducible marker of radiosensitivity and has 
the potential for use as a routine clinical test for predicting patient outcome before 
receiving RT.  
The G2 chromosomal radiosensitivity assay is a cytogenetic based assay which can be 
used on patient blood samples and has been shown to be reliable for predicting patient 
radiosensitivity. The G2 chromosomal assay has been used for many years now in studies 
for validating prediction of radiation response in control and cancer cohorts and has 
proved to be a reliable and reproducible assay.  Shadley and Wolff in 1987 first reported 
increased aberration yield in blood samples after radiation149. This initial concept formed 
the basis of the G2 assay that was later developed by Sanford and Parshad in 198958 and 
was  further adapted by Scott et al  in 2003150. Early studies linking radiosensitivity and 
cancer predisposition showed increased chromosomal aberration yield using the G2 assay 
in those patients suffering from genetic instability syndromes, (as per section 1.3) such as 
Bloom Syndrome and FA58,151, Ataxia Telangiectasia individuals152 and immunodeficient 
individuals153,154.  These reports all observed an increase in chromosomal aberration yield 
after radiation, and increased sensitivity in those radiosensitive populations which found 
the ATM gene to be the main key player in radiation response and radiosensitivity. Other 
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G2 studies have been complete using cancer cohorts such as; head and neck cancer 
cohorts155, retinoblastoma cases156, melanoma157, prostate158, breast cancer150,159–167, and 
general cancer studies148,168–171. Each report shows an increase in chromosomal aberration 
yields (more breaks, gaps and abnormalities) in cancer samples compared to healthy 
controls, and shows an extensive link between chromosomal radiosensitivity and cancer 
predisposition. A few reports have assessed reproducibility for the G2 assay by observing 
levels of variation in donor cohorts. In 1999 Scott et al  reported inter variation (variation 
of G2 chromosomal radiosensitivity scores between individuals in a cohort) of between 
15%-20%147, as did Baria et al  in 2001 and 2002148,168. Smart et al  reported no significant 
variation between donors170 and Vral et al  in 2004 reported very high variation values of 
above 39%164. A workshop held by Bryant et al  in 2002 discussed experimental factors 
which affected G2 assay reproducibility169 . These factors included regulation of 
temperature, pH and source of media for blood cultures. As published in a technical report 
by Bryant et al , variability in G2 aberration yield was associated with higher temperatures 
than 4˚C, different media and serum batches, use of blood samples at more than 24hrs 
after extraction etc169. Although slight variability has been observed between laboratories 
(medium batch, FBS, usage of antibiotics within media58), the G2 assay is still a key 
radiobiological assay for predicting and monitoring radioresponse in patients cohorts.  
Fluorescent in situ hybridisation (FISH) is also a cytogenetic based assay in which 
chromosomes are tagged with fluorescent probes which correspond to specific DNA 
sequences. FISH is a highly specialised medical technique in which genetic conditions 
such as Leukaemia and Downs syndrome are detected. Recently, FISH has been used to 
detect varying qualities of radiation which produce different complex chromosomal 
aberrations and rearrangements that would not otherwise have been able to be observed 
or analysed using classical m-Banding techniques172. Additionally, selected 
chromosomes can be probed using FISH to analyse specific rearrangements such as re-
 43 
 
joined chromosomal breaks, as Ritter et al  detected distinct differences in chromosomal 
aberrations between low and high LET using FISH173. This technique is useful for 
detecting translocations of chromosomal material, which would not be identified fully 
using other cytogenetic techniques. Early in 1992, Lucas et al successfully detected 
higher levels of translocation frequency in chromosomes extracted from lymphocytes 
from atomic bomb survivors, decades after exposure. The results from both in vitro assays 
including dicentric frequency (using standard cytogenetic analysis) and translocation 
frequency (using FISH) were in excellent agreement174. There are a variety of probes 
available for FISH analysis, however the most relevant and used for this work include 
CEPX, ATM-TP53 and IGH (Table 1.2). FISH is a useful technique which can be 
interpreted directly and quickly without specialised training, as presented in Table 1.2. 
Presence of two green probes in a metaphase spread for CEPX indicates a karyotype of 
XX, which represents a female gender. Also, this can be easily and quickly observed in 
the interphase form. Dual colour probe ATM-TP53 is represented by two red copies 
(TP53) and two green copies (ATM) in normal karyotypes. In abnormal, a loss of one or 
both can be easily observed. Additionally, this can be quickly analysed using interphase 
FISH. Metaphase IGH break apart probe were also used to identify loss of or duplications 
of the probe. In normal karyotypes, two red dots in close proximity within the same 
chromosome are observed (Table 1.2). In abnormal cells, loss of one or duplication of 
this probe represents translocation or abnormality within the cells analysed. The FISH 
probes used for this work were of great benefit and show potential as an important 
biomarker of response (for e.g. patient response after radiotherapy). Use of the probes 
requires minimal training and processing time as abnormalities can be quantified quickly.  
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Table 1.2 FISH probes used for chapter 4 of this thesis. CEP X and ATM-TP53 probes were used in 
interphase and metaphase spreads. The IGH break apart probe was used only for interphase.  
Name of Probe 
Used 
Details  Example 
Metaphase CEPX 
Probe directed to the X 
chromosome for 
identification of the 
individual’s sex 
 
Interphase CEPX Same as above, only in 
interphase 
 
Metaphase ATM-TP53 
Probe directed for 
identification of ATM 
and TP53 in metaphase 
spreads 
 
Interphase ATM-TP53 
Same as metaphase 
probe, only directed for 
use with interphase cells 
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Metaphase IGH 
Detection of IGH break 
apart probe in metaphase 
spreads 
 
 
1.5.3. DNA Damage Markers 
DNA damage assays have been used to predict radiosensitivity. The most commonly used 
foci assay is the γH2AX foci assay, which targets phosphorylated H2AX after radiation 
exposure by means of fluorescent labelling by confocal and flow cytometry analysis. One 
of the most central and important processes that occurs rapidly after DNA damage is the 
localisation and phosphorylation of histone H2AX (as explained in previous sections). 
Andrievski and Wilkins used the γ-H2AX assay on blood lymphocytes exposed between 
0Gy – 10Gy of Caesium – 137 to detect foci by means of flow cytometry, reporting that 
although the assay provides good detection of foci in all lymphocyte subpopulations 
(CD19+ more so than CD4+ and CD8+), the assay could only be used as an indicator of 
exposure to ionizing radiation due to large inter variation between donors175. The 
importance of phosphorylation in the DDR was further outlined in knock out experiments 
of H2AX which results in increased radiosensitivity and genomic instability in mice, 
presenting with growth retardation and immunodeficiency 176. In 2009 Redon et al used 
blood lymphocytes and fibroblasts exposed to 0.2 – 5Gy of γ-irradiation to show a linear 
dose –response pattern of γH2AX at 24hrs and 48hrs after radiation exposure177 which 
demonstrated good reproducibility and consistency of the assay. It was therefore 
suggested as a potential predictive assay of radiosensitivity or an assay of radiation 
exposure (reviewed by Scully and Xie, 2013178). Most recently, Bourton et al used a small 
number of 12 cancer patients (Pituitary, Thyroid, Larynx, Breast, Colorectal, Prostate and 
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Cervix) to show that flow cytometric analysis of prolonged γH2AX correlated well with 
those patients experiencing acute and chronic tissue toxicity after radiotherapy. Although 
this study shows excellent potential for distinguishing those patients with toxicity 
compared to normal patient reactions, the assay was not sensitive enough to distinguish 
those patients with extreme sensitivity nor those patients with moderate severity of 
toxicity179. 
The comet assay is another beneficial marker of DNA damage and potential marker of 
radiation response. Also known as ‘single cell gel electrophoresis,’ the method was first 
developed in 1984 by Östling & Johansson who suspended irradiated cells in melted 
agarose and cast on to microscope slides which were then lysed by detergent and 
electrophoresed180. After fluorescent staining, analysis reveals fragmented regions of 
DNA which form a comet shape, and is representative of the extent of DNA damage 
breaks. The intensity of the ‘comet’ tail in comparison to the head reveals how much 
DNA damage has occurred. Sophisticated automation of the assay and imaging 
techniques have propelled the comet assay to the forefront of DNA damage research 
(Figure 1.11). In this figure, many factors of measurement using the comet assay are 
shown, to include the most often used ‘tail moment’ and ‘tail length.’ 
The alkaline comet assay (ACA) is the most sensitive method for detecting SSB. It has 
been shown in early 1990’s to detect DNA damage after clinically relevant doses of 
radiation181 and Jones’ et al’s group has also recently shown the ACA method beneficial 
for predicting bladder carcinoma cell sensitivity to irradiation182. However, in the original 
report by Östling & Johansson, a minimum dose of 0.5Gy is used and they explain how 
loss of sensitivity of the assay occurs at doses lower than this point. Therefore, the comet 
assay would be of no relevance to this work, as doses of 0.5Gy and lower are used 
throughout.  
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1.5.4. Genomic markers of radiation exposure 
Recent work by Badie et al  in 2011183 suggest that using a new gene expression screening 
analysis technique could be a good predictor of individual radiation sensitivity because it 
was used to identify specific biomarkers of radiosensitivity. Of a panel of 800 genes 
simultaneously analysed, 5 key genes were selected to be key in the radiation response, 
these were phosphohistidine phosphatase (PHPT1), PUMA, cyclin G1 (CCNG1), DDB2 
and MDM2 detected on an nCounter analysis system and Multiplex Quantitive Real Time 
PCR (MQRT-PCR). The nCounter technique was ideal for analysing 800 genes as it 
provides information on modification of a large number of genes without the need for 
enzymatic amplification of RNA prior to analysis, whereas the MQRT – PCR technique 
could only analyse a maximum of 6 genes. However, further work is required to 
investigate why different genes are radioresponsive at different times, and why radio 
responsive genes could be altered depending on the tissue sampling area; i.e. saliva, 
blood, tissue biopsy etc. 
 
Figure 1.11 Informative results from comet assay analysis. Original reports analysed tail 
intensity to gain information about DNA damage. However more informative information 
is now given through automated software as described above. Image taken from Lucia 
Cytogenetics383.  
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1.5.5. Single nucleotide polymorphisms (SNP’s) 
Abbreviated to SNP’s, single nucleotide polymorphisms are small alterations in 
nucleotide sequences in DNA that can account for 80% of individual variation in the 
population184. Relatively new for the prediction of radiosensitivity, it is thought that 
assays monitoring SNP’s have the potential for routine use.   SNPs are currently used for 
predicting human immunodeficiency virus (HIV) patient response to drugs such as 
Abacavir, in which SNP screening reduced the risk of hypersensitivity reaction to the 
drug185, but no current radio-toxic SNP’s have been identified for radiosensitivity analysis 
and much more work needs to be done to verify this186. Many attempts have been made 
at analysing SNP variants in genome wide association studies (GWAS) to pick up 
common genetic variants between samples but a limitation of this system is that it may 
not detect rare genetic variants. As these methods are relatively new, further work needs 
to be done to validate and standardise the use of SNPs for detecting radiosensitivity 
1.5.6. Histone Modifications 
Modification to histone proteins can alter the expression of genes in response to radiation 
by altering the overall structure and compaction of the chromatin. The most common 
alteration is the phosphorylation of histone H2AX, which has been described for its use 
in predictive assays in section 1.5.3. It is known that the alteration of histone 
modifications can be dose and time dependant after radiation insults due to the action of 
histone acetyl transferases (HAT’s) and histone deacetyl transferases (HDAC’s) but this 
is not fully understood187. 
DNA methylation involves the addition of a methyl group to a cytosine residue on a CpG 
dinucleotide in the DNA sequence. These changes can be hereditary, and are termed the 
“epigenetic code.” Changes most often lead to transcriptional repression, which can be a 
problem if a tumour suppressor gene (TSG) is repressed and would ultimately lead to a 
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mutation and genomic instability. Previous studies state that currently DNA methylation 
is not a good choice for radiosensitivity prediction because not enough studies have been 
done (especially in the low dose region) that elucidate all the mechanisms behind DNA 
methylation. Also much variability in methylation patterns has been noted in cohorts of 
individuals, which would also generate confusing results187. 
1.5.7. Micro RNA’s Exosomes 
Recently, the role of exosomal trafficking of functional micro RNA’s (miRNA’s) has 
gained increasing interest in cancer research and cell biology. The involvement of miRNA 
in the radiation induced DDR is a new and emerging field of investigation. miRNA’s are 
small, non-coding RNA’s capable of altering gene expression at the pre and post 
transcription level, through many mechanisms which are unclear and have not been fully 
outlined, but provide interesting insights into how aberrant DDR in tumorigenesis can be 
manipulated or controlled. In summary, miRNAs are formed via two pathways, intergenic 
(formed separate from genes with own transcriptional unit) and intronic/extronic (formed 
together with host genes). Figure 1.12 illustrates the biogenesis of miRNA from Pri-
miRNA.  Pri – miRNAs are recognised in the nucleus and cleaved by ribonuclease type 
iii (Drosha) – DiGeorge syndrome chromosomal region 8 (DGCR8) complex, generating 
a hairpin – like structure, and forming pre – miRNA. This hairpin pre –miRNA is exported 
from the nucleus in a Ras-related nuclear protein (RAN)–Guanosine triphosphate (GTP) 
dependant manner by Exportin 5. Dicer – Tar RNA binding protein (RBP) complex then 
cleaves the pre –miRNA to form a duplex, mature miRNA, which can then associate with 
Argonaute and RNA induced silencing complex (RISC), which can alter gene expression 
(reviewed by Wan et al  2011188, Metheetrairut and slack 2013189). A number of miRNA’s 
have been discovered, with anticipation of discovering more. It has recently come to light 
that miRNA’s can alter genes central in the DDR, one well known example is the tumour 
suppressor P53. miR -504 and miR-125b have recently been shown to negatively regulate 
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P53 and promote tumorigenicity of cells in vivo190. Another target, ATM has been shown 
to be inhibited by miR -421, which binds to ATM mRNA and leads to altered S phase 
cell cycle checkpoint and increased radiosensitivity191. 
 
 
Figure 1.12 Biogenesis of miRNA and functions. Firstly, Pri-MIRNAs are cleaved in the nucleus by 
DROSHA-DGCR8. A hairpin pre-miRNA is formed and transported from the nucleus via a RAN-GTPase 
dependent manner by Exportin-5. The pre-miRNA is cleaved by DICER and TRBP to form a duplex, 
mature miRNA. Association of the duplex miRNA with Argonaute and RISC complex allows for the 
miRNA to interact with mRNA and leads to translational repression of many genes. Image taken from 
Winter et al192.  
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1.6.  Novel tools for predicting radiosensitivity 
As physical models used for RT treatment planning are not accurate measurements for 
biological outcome, radiobiological based assays have been developed for the prediction 
of biological outcome. Some of the original in vitro assays are too time consuming for 
routine clinical use and require invasive cellular extraction methods on patients such as 
biopsy extraction for laboratory testing. Many assays which involve less invasive cell 
extraction from blood have been developed and optimised for measuring patient 
radiosensitivity by modern genetic and/or molecular methods. However, limitations exist 
on all current assays and in some cases further experimentation is required to validate 
other methods (as described previously). Many other attempts have therefore been made 
to develop a more rapid, accurate measure of radiosensitivity prediction in patients. This 
includes the use of spectroscopy. Most non-biological methods of prediction of 
drug/therapy response use computational analysis which is based on data taken from 
biological endpoints. For example, Frank Emmert-Strieb et al  were able to use 
agglomerative hierarchical clustering to assign haematuria patients into 5 subtypes based 
on the heterogeneity of the biomarker data, which was done on multiple biological 
measures previously taken from the urine of haematuria patients193. 
1.6.1. Raman Spectroscopy  
At our RESC laboratory in DIT, we are currently testing the hypothesis that Raman 
Spectroscopy may be a novel rapid method of predicting individual patient 
radiosensitivity. The Raman Effect, which is a term used to describe the inelastic 
scattering of photons from a material in response to a laser, was first described by CV 
Raman in 1930194. The method is based on measuring the vibrational profile of chemicals 
and substances in a sample. Raman spectroscopy does not alter or damage the biological 
material should it need to be used again. The process allows for the output of a 
biochemical profile, almost like a fingerprint, unique to the individual sample, where 
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peaks on the output graph represent a particular protein or molecule. Not only does the 
peak represent a particular protein or molecule, it also represents the content of protein 
present in the sample.  
Raman spectroscopy has been successfully used to detect non cancer samples from 
cancerous samples in a variety of cancer types; Nijssen et al  analysed skin cancer biopsy 
samples195, de Jong analysed bladder cancer tissue samples196 and Tollefson et al  used 
Raman spectroscopy to investigate whether Gleeson 7 prostate samples could be used to 
detect those patients who would progress to metastatic disease197.  As it has been 
successful in distinguishing between cancer and non-cancer, it would be of interest to 
observe if Raman spectroscopy could predict individual radiosensitivity.  
The RESC has recently used Raman Spectroscopy for cervical smear screening. Lyng et 
al  carried out an investigation in 2007 using Raman spectroscopy to distinguish between 
normal and abnormal cervical smear samples by screening macromolecules such as 
proteins, lipids, nucleic acids and carbohydrates198. The study validated the use of the 
Raman technique for screening different grades of smears in CIN. Raman spectroscopy 
has branched out to other fields, but with many factors still to be resolved (in house review 
on sample preparation considerations by Meade et al  2010 where the same fixation/ 
preservative of samples and sample desiccation is required199, and problems associated 
with high background in measurements from samples which can be adjusted by biological 
means and not only mathematical manipulation of the data by Bonnier et al200). Meade et 
al  conducted a study in 2007 using human keratinocytes which outlined the correlation 
between spectroscopic and biochemical analysis and identified the sensitivity and 
potential of use of Raman spectroscopy when used with appropriate spectroscopic 
substrates201. Raman spectroscopy was not carried out directly in the work for this PhD 
thesis. Raman studies were conducted by a colleague (Dr. Adrian Maguire) in parallel 
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with this work to validate the method of using Raman Spectroscopy for measuring 
radiosensitivity in individual donor samples. 
1.7 Aims and objectives of Thesis; 
The primary aim of this project was to investigate if there was a reliable predictive method 
or biomarker to measure cellular radiosensitivity in blood samples from normal donors 
or patients. This work was carried out in parallel with Raman spectroscopic studies so 
that standard in vitro radiosensitivity measurements could be taken and compared to 
Raman data for validation and optimisation of Raman spectroscopy as a potential clinical 
predictive tool. Although biological validation was conducted for parallel analysis with 
Raman Spectroscopy, Raman data is not featured in this thesis. 
 
Individual aims 
1. To optimize and validate the G2 chromosomal radiosensitivity assay for 
correlation with other methods of radiosensitivity prediction in donor and patient 
samples in parallel with Raman Spectroscopy conducted by Dr. Adrian Maguire 
2. To investigate the effects of low doses of ionizing radiation of different radiation 
energies on whole blood cultures from healthy donors 
3. To investigate changes in radiosensitivity levels in Prostate cancer patients 
throughout their radiotherapy plan; at baseline, post hormone treatment, post 
radiotherapy, 2month and 8month follow up 
4. Further explore biomarkers involved in radiosensitivity driven by mechanisms of 
ATM 
5. To identify any potential genetic Biomarkers of radiosensitivity in normal, AT 
cells and prostate cancer cells which could be further explored 
6. Attempt to find novel miRNA’s in cell and exosome extracts from normal and AT 
Lymphoblastoid cell lines which could explain the mechanisms of radiosensitivity 
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2. OPTIMISATION AND VALIDATION OF THE G2 CHROMOSOMAL 
RADIOSENSITIVITY ASSAY ON HEALTHY DONOR BLOOD SAMPLES 
 
2.1 Introduction 
 
Conventional radiotherapy dose limits are based on the reaction of the most sensitive 
patients (those who develop acute severe reactions) and are prescribed to keep radiation 
response in all patients to a tolerable level16.  If patient response could be predicted before 
radiotherapy, it would allow for a better individualised treatment plan, which would allow 
for dose escalation in radio resistant patients and dose alteration for radiosensitive 
patients. These problems could be addressed if an accurate individualised predictive assay 
was developed, and should ultimately be non – invasive, non – labour intensive, and time-
efficient to deliver results after diagnosis during the therapy planning stage.  
 
As described in section 1.5, attempts have been made to develop such an assay which 
include the clonogenic assay202, Micronucleus (MN) test143 , γ– H2AX foci assay. One of 
the most extensively studied assays with clinical potential for predictive testing of 
radiosensitivity is the G2 chromosomal radiosensitivity assay. The G2 assay is used as a 
reliable predictor of in vitro radiosensitivity and has been optimised and validated for its 
efficacy by many groups (discussed more later). It is a cytogenetic based assay where 
donor/patient whole blood samples are cultured and synchronised in their cell cycle and 
irradiated at the G2 phase. Chromosomes are then extracted and fixed from the leucocyte 
population for microscopic analysis of radiation-induced chromatid damage that incurred 
in vitro in the G2 phase of the cell cycle as it is known to be the most sensitive phase 
before M phase and therefore ideal for measuring radiosensitivity11.  
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The assay was developed in 1989 by Sanford and Parshad58 who used the assay on skin 
fibroblasts from radiosensitive patients (as described in chapter 1). The G2 assay was 
deemed to be a reliable assay for the prediction of individual radiosensitivity, but over 
many years the assay has been improved to reduce variability.  
In the original studies by Sanford and Parshad the assay was carried out at room 
temperature and this was later adapted by Scott et al 152 who reduced temperatures to 0-
4˚C to prevent DNA damage repair mechanisms occurring during the cytogenetic 
preparation of chromosomes. A media change to the whole blood cultures was also 
performed 1 hr before irradiation but this was adapted by Howe et al  to carry out the 
media change at least 24 hrs before irradiation, to allow whole blood cultures to settle 
before irradiation165. It is well known that strict conditions are needed for the successful 
use of this assay, with variations such as temperature and pH reported between different 
groups. The strict assay conditions were demonstrated by Sanford et al  who showed an 
increased chromatid aberration yield in response to lowering the temperature and 
increasing the pH to pH 8 in the time immediately after X irradiation to 1Gy58. In a 
technical report published in 2002, Bryant et al 169  describes factors which do or do not 
influence G2 chromosomal radiosensitivity. The factors that do not appear to influence 
aberration yield are blood storage (once used within 24 hrs post extraction) and type of 
phytohaemagluttinin, PHA – M and PHA – P. Factors that do affect aberration yield 
include temperature, transport of blood samples and cultures (which is thought to depend 
on temperature fluctuations), types of irradiations and doses (with reduced mitotic index 
at doses over 0.5Gy), and serum batch in which the authors concluded that an 
experimental series using the G2 chromosomal radiosensitivity assay should be planned 
around using one batch of serum169,170.  
In addition to experimental factors which cause variation, biological effects differ 
depending on cell and tissue type, dose and linear energy transfer (LET)68. LET represents 
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the energy transferred to the material by ionising radiation per unit track. Generally, 
higher relative biological effectiveness (RBE) is observed with increasing LET173,203–206, 
but at very high LET, the RBE begins to change, as shown by Barendsen et al  comparing 
normal tissues, cultured cells and tumour samples207. Many studies have compared DNA 
double strand breaks, reproductive cell death and chromosome aberrations in cells 
irradiated in vitro with sparsely ionizing radiation of low LET or densely ionizing 
radiation of higher LET208–213. A number of radiobiological studies have also shown an 
increase in RBE with decreasing energy for low LET radiations, electrons and photons 
(reviewed214–216). 
Chromosome damage has been reported in the literature as an effective endpoint for 
assessing radiation damage. The first study which demonstrated radiation damage to 
chromosomes using Trudescantia microspores, also showed a lower RBE of  60Co gamma 
radiation compared to 250 kVp X – rays217, most likely as a result of a slightly higher 
RBE of 250 kVp X – rays as shown by Fowler 218. Subsequent studies on human 
lymphocytes have shown that relatively high energy low LET radiation, such as gamma 
radiation, is several times less effective than relatively low energy low LET radiation, 
such as low energy X radiation215,219–223.   Despite evidence from in vitro radiobiological 
data that the RBE of high energy low LET radiation is less than that of low energy low 
LET radiation, there is limited epidemiological data to show that cancer risk decreases as 
radiation energy increases for low LET radiations (reviewed215). Despite the 
radiobiological data suggesting that low LET radiations of different energy show different 
RBE, for radiation protection, the ICRP 2007 recommendations retain a weighting factor 
of 1 for all low LET radiations224. However an ICRU 1978 report states that absorbed 
dose values for 100-300 kV X-rays should be multiplied by 1.18, and not 1, when 
comparing effects to MV X- rays 225. A recent study showed cluster patterns of energy 
deposition sites to differ up to 15% between low photon energy brachytherapy sources 
 57 
 
(103Pd and 125I with mean photon energies of 0.021 and 0.028 MeV) and less than 2% for 
the high photon energy (192Ir and 137Cs with mean photon energies of 0.36 and 0.615 
MeV) brachytherapy sources with respect to 60Co 69 which correlated with reported RBE 
values for double strand break yields 226.  
This is of importance, as samples from the healthy control (HC) cohort of donors used to 
validate our assay were irradiated using γ-irradiation from a 60Co source which has been 
decommissioned from the hospital and our use. A linear accelerator (Linac) which 
delivers x-ray irradiation will be used on future cohorts, therefore it must be investigated 
if beam energy/source conveys additional radiobiological variation using the G2 assay. 
To validate the G2 chromosomal radiosensitivity assay as a reliable predictor assay of 
individual radiosensitivity many studies describe a healthy donor control study prior to 
or in parallel with patient studies. Healthy control donor studies use mitotic index (mitotic 
inhibition) and G2 scoring to assess the inter- and intra- individual variation values 
between donor samples to ensure consistency within the assay.  
The first measurement performed using the assay includes mitotic index. This is a quick 
measure of cell cycle checkpoint efficiency. Calculated by analysing the ratio of cells in 
metaphase to total cells, the mitotic index allows for a % checkpoint value to be assigned 
to each donor in response to that given dose of irradiation. The donors’ mitotic inhibition 
is usually calculated and used for analysis (% mitotic index at 0Gy is subtracted from the 
% mitotic index at each radiation dose). The significance of this value is based on the 
mechanisms of cell cycle checkpoints in response to irradiation. When the donor cells are 
irradiated, the cell cycle checkpoints should function to halt the cell cycle to allow repair 
processes to occur before progressing to mitosis, and therefore would give a lower mitotic 
index value (or a higher mitotic inhibition value) during a cytogenetic analysis. Mitotic 
index and inhibition values were obtained in earlier G2 assay reports to analyse 
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checkpoint response in healthy controls, radiosensitivity populations such as Ataxia 
telangiectasia, Bloom’s Syndrome, Fanconi’s Anaemia or cancer patients. For example, 
in 1994 Scott et al reported mitotic index values in a range of 4-5% for healthy controls 
and 3% for Ataxia telangiectasia patients using 0.5Gy  x-irradiation152. Howe et al found 
much lower mitotic indices (<1%) in irradiated blood samples of benign prostate 
hyperplasia and prostate cancer patients using 0.5Gy  γ – irradiation158. This value is 
important for measuring donor checkpoint efficiency but also for validating the use of the 
assay on different donor cohorts to compare with previous reports in the literature. 
G2 radiosensitivity scores form the basis of the G2 chromosomal radiosensitivity assay 
in donor samples. All chromatid aberrations (Figure 2.1) including gaps, breaks, 
fragments, deletions and dicentrics were totalled per 100 metaphase spreads analysed on 
each slide (0Gy, 0.05Gy and 0.5Gy). The spontaneous aberration yield at 0Gy is 
subtracted from the aberration yield at each dose to give a radiation induced G2 score. It 
is already well outlined that blood samples from patients with genetic disorders such as 
ataxia telangiectasia152, Bloom’s syndrome50, Fanconi anaemia227, severe combined 
immunodeficiency syndrome53 and patients with cancer show increased G2 chromatid 
aberration yield compared to healthy control samples (Table 2.1).  
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Figure 2.1 Chromatid type aberrations according to criteria 2 of the Radiation Biology Centre, 
Kyoto Japan. Chromatid gaps (ctg), chromatid breaks (ctb), chromatid exchanges (cte) and 
isochromatid gaps and breaks (csg and csb) are shown384.  
 60 
 
Radiosensitivity cut off values represents another benchmark for the optimisation and 
validation of the G2 assay which express the data in terms of radiosensitive and non – 
radiosensitive patients. The G2 radiosensitivity cut off value is represented by calculating 
a 90th percentile from the range of radiation induced G2 scores in a number of donor 
control cohorts and it was first described by Scott et al  in 1999147. The 90th percentile is 
the value at which 90% of the sampled population will fall below and be deemed normal 
or radio resistant. The upper 10% represents donors/patients who are considered to be 
radiosensitive. The 90% percentile value has been used in most of the G2 chromosomal 
radiosensitivity studies reported in the literature to date (discussed below and table 2.1). 
Individual G2 chromosomal radiosensitivity values are recorded as the total number of 
aberrations per 100 metaphases (written X abs/100 metaphases), and can vary between 
research groups from 80 to <200 aberrations per 100 metaphases for healthy donors. The 
90th percentile is calculated from all of the G2 values from the healthy donor cohort. The 
radiosensitivity cut off value would generally rise if a cohort is based on cancer patients 
as these generally have higher G2 scores due to higher levels of intrinsic radiosensitivity. 
Published reports show slight variation in radiosensitivity cut off values using an array of 
cohort types, such as healthy controls, radiosensitive disorders and cancer cohorts with a 
minimum of 87 aberrations per 100 metaphases and a maximum of 175 aberrations per 
100 metaphases (Table 2.1).  
When the G2 radiosensitivity scores and radiosensitivity cut off values are determined, 
inter and intra-individual variation values can be obtained to compare control donor and 
cancer patient radiosensitivity by searching and obtaining values from the literature. This 
was deemed to be an important part of validating the G2 chromosomal radiosensitivity 
assay within our laboratory with new users. Inter variation is a measure of the variability 
in the G2 chromosomal radiosensitivity scores between a group of normal donors and 
intra – variation is a measure of the variability of the G2 chromosomal radiosensitivity 
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scores for the same donor sampled at multiple times. Many authors have reported 
validation of the G2 assay through inter–variability and intra–variability values (table 
2.2). Using healthy control donors, the original published report was by David Scott and 
colleagues at the Patterson Institute of Cancer Research (PICR) in Manchester147. 
 
 
 
Author Date 
Donor & Sample 
Type 
Radiation 
Type 
Dose 
(Gy) 
Cut off Ref 
Scott et al  1999 Bca X - Rays 0.5 110  147 
Roberts et al  1999 HC and BCa X - Rays 0.5 110  160 
Riches et al  2001 BCa γ-Rays 0.4 80  161 
Baria et al  2001 
HC, BCa, CCa, 
CRCa, LCa  X - Rays 0.5 100  148 
Baeyens et al  2002 BCa γ-Rays 0.4 120  162 
Thierens et al  2002 Radiation workers γ-Rays 0.4 130  228 
Vral et al  2002 HC γ-Rays 0.4 135  144 
Baria et al  2002 Young Donors X - Rays 0.5 87  168 
Smart et al  2003 HC X - Rays 0.5 95  170 
Vral et al  2004 HC γ-Rays 0.4 129  164 
De Ruyck et 
al  2005 Cca γ-Rays 0.4 139  229 
Howe et al  2005 BCa γ-Rays 0.5 110  165 
Howe et al  2005 HC, BPH and PCa γ-Rays 0.5 110  158 
Howe et al  2009 HC and CRCa  γ-Rays 0.5 
105 (HC) - 164 
(CRC)  230 
De Ruyck et 
al  2008 HC and HNCa γ-Rays 0.4 133  231 
Borgmann et 
al  2010 Twins and PCa  X - Rays 0.5 
164 (HC) and 172 
(PCa)  232 
Brzozowska et 
al  2012 HC & PCa  γ-Rays 0.5-1 
<70 (HC) and 150 
(PCa)  233 
 
 
Table 2.1 Summary of radiosensitivity cut off values, radiation type and doses used from previous reports in the 
literature. Cases of healthy controls (HC), breast cancer (BCa), Cervical cancer (CCa), colorectal cancer (CRCa), 
Lung cancer (LCa), benign prostate hyperplasia (BPH), prostate cancer (PCa), and head and neck cancer (HNCa) 
are presented. 
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Levels of inter and intra variation differ significantly between laboratories which 
emphasises the importance of assay validation by each new group adopting the assay for 
different cohorts. The assay has been validated through inter- and intra-variation values 
in numerous healthy donor cohorts and cancer cohorts showing inter individual values of 
between 7%-31% and intra individual values of between 1%-26% (Table 2.2). These 
authors used the G2 chromosomal radiosensitivity assay on either lymphocytes or whole 
blood samples from normal and/or patient donors and this specific experimental protocol 
(using whole blood) was adopted for the G2 studies described in this thesis. Variation 
could be attributed to the different radiation doses and types used, which varied between 
all studies. Most reports used a dose of 0.4 – 0.5Gy and either x or γ-irradiation with the 
odd report using either much lower doses (<0.1 Gy) or much higher doses (3Gy – 6Gy) 
(Table 2.2).  
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Author Date 
Donor & 
Sample 
Type 
Radiation 
Type 
Dose 
(Gy) 
Inter 
variation 
Intra 
Variation REF 
Scott et al  1999 BCa X - Rays 0.5 20 7  147 
Roberts et al  1999 HCA and Bca X - Rays 0.5 7 7  160 
Riches et al  2001 BCa γ-Rays 0.4 19 8 161  
Baria et al  2001 
HC, BCa, 
CCa, CRCa, 
LCa  X - Rays 0.5 15.1 10.3  148 
Baeyens et al  2002 BCa γ-Rays 0.4 20 15  162 
Thierens et al  2002 
Radiation 
workers γ-Rays 0.4 20 9  228 
Vral et al  2002 HC γ-Rays 0.4 17 
2 donors 
14 and 16  144 
Baria et al  2002 
Young 
Donors X-Rays 0.5 19.2 18.6  168 
Smart et al  2003 HC X-Rays 0.5   0.5 - 26  170 
Vral et al  2004 HC γ-Rays 0.4 20 3 to 22  164 
Howe et al  2005 BCa γ-Rays 0.5 30.5 4.6 to 5.1  165 
Howe et al  2005 
HC, BPH and 
PCa γ-Rays 0.5 30.5  4.6 to 5.1    
Borgmann et 
al  2007 HC X-Rays 0.5 31 NONE  234 
Borgmann et 
al  2008 BCa X-Rays 
3 or 
6 17 NONE  235 
 
 
 
Intra-variation is also assessed to validate the G2 assay and ensure consistency in the 
experimental conditions (Table 2.2). It was reported that checkpoint response and G2 
radiosensitivity levels vary between individuals particularly at higher radiation doses, as 
reported in the technical meeting in 2002169. The groups here reported good assay 
reproducibility with regard to their achieved intra–individual values which ranged from 
4.6% to 15%. The range (1%-30%) in intra-variation values were proposed to be due to 
G2 assay experimental conditions but specific donor cases pointed to the fact that repeated 
Table 2.2 Summary of inter-individual and intra-individual variation values by author. Radiation type 
and doses differ between cohorts used. Healthy control (HC), Breast cancer (BCa), Cervical Cancer 
(CCa), Colorectal Cancer (CRCa), Lung cancer (LCa), Benign prostate hyperplasia (BPH) and Prostate 
Cancer (PCa) cases are presented.  
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sampling at different times affected radiosensitivity  possibly due to immune status, 
medication, hormone status and other intrinsic conditions  and more studies examining 
these factors were encouraged164.   
The main objective of this chapter was to optimise and validate the G2 chromosomal 
radiosensitivity assay using the experimental parameters and criteria reported in the 
published studies for radiosensitivity cut off values and variation values, in addition to 
investigating the factors which may influence donor radiosensitivity such as blood 
culturing techniques, smoking status, season of blood sample extraction and radiation 
type (i.e. γ or x ray irradiation). 
The desired aims of this study was to obtain inter-variation values which lie in the range 
of other published work to validate the use of the assay in our laboratory (between 7%-
30.5% and intra-variation between 4.6%-15% with a G2 radiosensitivity cut off 90% 
percentile value ranging from 80-135 aberrations/100 metaphases) in a healthy donor 
control sample cohort. Once these parameters were obtained to prove validity of the G2 
chromosomal radiosensitivity assay, then the same G2 radiosensitivity values could be 
adopted for a parallel study validating and testing Raman Spectroscopy as a potential 
predictive tool of radiosensitivity236. 
Furthermore, because blood samples from cohorts were being obtained, several subtypes 
of cells from whole blood could also be extracted and further investigated for their 
radiobiological response specifically related to immunity. Whole blood is made up of 
erythrocytes (red blood cells), leucocytes (white blood cells) and plasma.  Erythrocytes 
are the most abundant cell type in whole blood (approximately making up 40 – 45% of 
all cell subtypes), which are biconcave in structure and contain haemoglobin which is 
responsible for the physiological functioning of oxygen transport throughout the body. 
As erythrocytes do not possess a nucleus, this cell type is not of importance within our 
studies and was eliminated through haemolysis using potassium chloride (KCl) early in 
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the G2 chromosomal assay. White blood cells (WBC’s) however, delineate into a number 
of cellular subtypes involved in an immune response elicited by DNA damage. The most 
abundant white blood cell (WBC) type are the neutrophils, which make up approximately 
60% of the white cell content, but only survive between 6 – 10 hrs,  the next most 
abundant WBC subtype are lymphocytes (30%) (which are currently used for the assay) 
and monocytes which incorporate only 5% of the white cell content237. Lymphocytes can 
be further subdivided into T and B cells, with T cells even further divided into helper, 
cytotoxic, regulatory, natural killer subtypes. In response to cellular stress or injury, these 
cells are part of a coordinated immune response which respond to the invasion of foreign 
material or cellular damage. The chromosomes analysed in the G2 chromosomal 
radiosensitivity assay are of lymphocyte origin, and are easily obtained through blood 
sampling from the individual. These are separated out from the whole blood in the G2 
assay protocol. However, sub-population of lymphocytes were also extracted from a ficoll 
gradient (using Histopaque) and analysed for both G2 and Raman studies in parallel. 
Whole blood was used for the G2 chromosomal radiosensitivity assay as this is the best 
method which incorporates all elements of the blood sample. However, the abundance of 
contaminating RBC’s made Raman spectroscopic analysis difficult as the WBC 
population of lymphocytes could not be directly analysed which is the cell type of interest 
in this work. Steps were taken to remove RBC’s but pre-extraction of lymphocytes from 
whole blood was deemed to be the best option. Therefore, optimisation of this technique 
to ensure no major differences between whole blood and pre-extracted lymphocytes from 
3 donors was done using the G2 chromosomal radiosensitivity assay. To come to the 
conclusion of using extracted lymphocytes for Raman studies, optimisation was done 
using whole blood vs extracted lymphocytes with different doses of radiation. The 
methods are described here as part of the blood processing protocol for donor and cancer 
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patient samples (discussed later in chapter 3), but the results specifically on Raman 
spectroscopy are outlined in another PhD thesis at our Institute by Dr. A Maguire236.   
2.2 Materials & Methods 
 
2.2.1. Blood samples and Ethics 
 
Blood samples were donated from 42 volunteers at our Institute (Dublin Institute of 
Technology, Kevin St, Dublin). 19 donors were male and 23 were female, with an age 
range from 21- 64 and 6 of the donors were smokers.  20 ml of circulating peripheral 
blood was extracted from donors and placed into heparinised vacutainers (Sarstedt). 
Ethical approval for this study was granted by the DIT Research Ethics Committee.  
 
2.2.2 Whole blood cultures 
 
Whole blood cultures were set up using 2 ml of whole blood and 18 ml of pre–warmed 
(37˚C) pre–gassed (5% CO₂) RPMI medium (Sigma) supplemented with 12.5% FBS 
(Sigma), 2 mM L-glutamine (Sigma) and 0.2 ml (45mg Phytohaemagglutinin (PHA) 
PAA Laboratories). Cultures were incubated at 37oC with 5% CO2 for 72 hours prior to 
radiation exposure. Whole blood cultures were stimulated with the mitogen PHA to 
induce and synchronise cultured lymphocytes into a cell cycle. 24hrs prior to irradiation, 
15mls of media was removed from each culture and replaced with fresh pre- warmed and 
pre-gassed RPMI media supplemented as described above.    
2.2.3 Histopaque Lymphocyte Isolation 
 
3 mL of whole blood was layered on to 3ml of Histopaque-1077 in a 15ml conical 
centrifuge tube and centrifuged at 400g for 30mins at room temperature with the brake 
off. After centrifugation, a plastic Pasteur pipette was used to carefully remove the opaque 
interface containing mononuclear cells which were transferred to a clean conical 
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centrifuge tube and washed 3 times with 10mls of PBS. The cell pellet was resuspended 
5 mL of RPMI (Sigma) and cultures were incubated for 72hrs. After 24hrs of incubation, 
media with lymphocytes were removed and placed in a fresh flask, while monocytes 
(adhered to the bottom of the flask) were removed by scraping, were then centrifuged and 
cultured in separate flasks.  
2.2.4 Irradiation procedure 
 
At 72 hours, whole blood cultures were irradiated in G2 phase of the cell cycle at 0.05 
Gy and 0.5 Gy using linac 6MV Photons. The dosimetry was performed with Gafchromic 
film to ensure that each flask was irradiated with the actual dose required238. The film was 
calibrated against a Farmer type ionization chamber using the triple channel dosimetry 
method and the film was scanned using the single scan protocol 239 on an Epson 
Expression 10000 XL scanner using the recommended scanning resolution of 72 dpi in a 
48-bit RGB format in a single scan240. Glass was placed over the calibration and test film 
during scanning to minimize ringing artefacts. The film was analysed using FilmQAe Pro 
(Ashland Inc.). This calibration technique was needed to ensure that all flasks for the 
study were irradiated at the exact doses required, and that each flask (all 42 donors with 
6 flasks each) was irradiated in exactly the same conditions.  
For investigation of radiobiological responses in cells between radiation sources, three 
sets of cultures were set up per donor with 20 donors investigated in total. The first set 
were irradiated using γ irradiation from the 60Co Teletherapy unit (Theratron 780 E, MDS 
Canada). The second set was exposed to a 6 MV x-ray photon beam and the third set to a 
12 MeV electron beam on an Elekta Precise Linac.  Irradiation procedures were set up as 
per figure 2.2. 
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Figure 2.2 Irradiation procedure set up. Figure (a) 6MV Photon 
irradiation set-up, (b) Cell Flask Irradiation Phantom, (c) 12 MeV 
Electron irradiation set-up 
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2.2.5 Post irradiation Cytogenetics 
 
After irradiation, cultures were incubated for 30 mins and then incubated with 200µl of 
colcemid (1µg/ml stock) (Gibco) at 37˚C with 5% CO2 for 60mins to arrest cells in 
metaphase.  Samples were centrifuged at 1200rpm for 10mins at 0˚C and an ice cold 
hypotonic solution was added (5mls of 0.075mM KCL) to lyse red blood cells. Samples 
were incubated on ice for 20mins to prevent chromatid damage repair. All further 
centrifugation steps were carried out at 0˚C at 1200rpm for 10 minutes. The extracted 
chromosomes were fixed with 3:1 methanol: acetic acid twice and then stored at 4˚C until 
slide preparation 
For slide preparation, slides were pre-cleaned in methanol 24hrs prior to use and stored 
in deionised water until needed. Cell suspensions were centrifuged at 1200rpm for 10mins 
and resuspended in 1ml of fixative. Cell suspension was dropped on to 3 slides per dose 
and per donor. Slides were gently flamed over a Bunsen burner to fix cells onto the slide 
and were left to cool. Slides were then stained with 3% Giemsa (Gibco) prepared in pH 
6.8 buffer (BDH Chemicals) for 15mins. All slides were then mounted in DPX.   
Microscopy was carried out to obtain mitotic indices and G2 radiosensitivity scores. The 
mitotic index was calculated by counting the ratio of metaphase spreads among interphase 
cells from a total number of 1000 cells. G2 radiosensitivity was determined by analysing 
100 clear metaphase spreads at x 100 magnification for chromatid aberrations which 
mainly consisted of chromosome breaks and gaps. Chromosomes were also counted for 
any numerical abnormality (e.g. alteration in chromosome number from 46). Figure 2.1 
outlines examples of the types of aberrations analysed. Most metaphase aberrations 
included chromatid gaps or breaks, little to no exchanges (cte) or complex aberrations 
were observed in the healthy control donor cohort.  
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The data was recorded for all slides of the same donor (0Gy, 0.05Gy and 0.5Gy). 
Aberrations found in the 0Gy control are known to be spontaneous aberrations and a G2 
score was calculated for the number of aberrations per 100 metaphases scored and this 
acted as the control for the set of samples per donor. These control G2 scores were 
subtracted from the G2 scores recorded at the different radiation doses 0.05Gy and 0.5Gy 
and are recorded as radiation-induced G2 scores for a particular dose per donor.  
2.2.6 Statistical Analysis 
All statistical analysis was carried out using Microsoft Excel 2010 and GraphPad Prism 
5241. Coefficient of variation (CV) was calculated by dividing the mean by the standard 
deviation and multiplying by 100 to obtain a % variation value. The 90th percentile was 
calculated on each dose by using the “percentile” function in Microsoft Excel in the 
following formula; =percentile (A1:A42, 0.9) where A1 – A42 represent the excel cells 
with each donor value at that dose and 0.9 represents the 90th percentile.  
Non-parametric statistics were used as no assumptions were made about the sampling 
population distribution and how many donors would need to be sampled. This analysis 
was carried out using Graphpad prism 5. Analysis of variance (ANOVA) was used to 
compare donors and doses to the control.  
 
 
2.3 Results 
The mitotic index and G2 radiosensitivity scores were calculated per donor to obtain 
radiation induced mitotic inhibition (MIn) and radiation induced G2 scores (RIG2). These 
values were then used to obtain inter- and intra-individual variation and 90th percentiles 
to assess assay reproducibility and validity. Brief details of optimisation of blood 
culturing and conclusion of techniques chosen for analysis are provided.  
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2.3.1 Mitotic index 
The mitotic index is the ratio of cells in metaphase to all other cells present on the slide 
and it was calculated from each dose (0, 0.05 and 0.5Gy) per donor. Analysis from 42 
healthy control donor samples revealed a decrease in mitotic index value with increasing 
dose (Figure 2.3). The highest mitotic index value was found to be 4.4% at 0.05Gy from 
HC41, and the lowest value was 0.1% at 0.5Gy from donor HC37. A large distribution in 
mitotic index was observed across all donors. 
Cell cycle checkpoint response was assessed by calculating a mitotic inhibition value 
(MIn), which is the mitotic index at each dose (0.05 and 0.5Gy) subtracted from the 
control (0Gy) mitotic index value. An increase in mitotic inhibition (decrease of mitotic 
index) was observed in all donors and values lay below 5%. Comparison of MIn values 
between 0.05Gy and 0.5Gy compared to the control was significantly different (p < 0.001) 
demonstrating efficient checkpoint response after ionizing radiation. Comparison of MIn 
between 0.05Gy and 0.5Gy were also significantly different (p ≥ 0.002) showing a dose 
response. The largest MIn (difference between irradiated and non-irradiated) was found 
to be a difference of 2.8% from donor HC22 at 0.5Gy, and the smallest MIn was found 
to be 0.1% from donor HC25 at 0.05Gy.  
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Figure 2.3 Distribution of mitotic index values from 42 healthy donors. Non-irradiated, 0Gy control 
samples are presented in blue, 0.05Gy samples in red and 0.5Gy samples in green.  
 
2.3.2 G2 chromosomal radiosensitivity scores 
The G2 chromosomal radiosensitivity score was derived from calculating the total 
number of structural aberrations (chromatid breaks and gaps) in 100 metaphase cells per 
dose per donor (Figure 2.4).  This ranged from a minimum of 0 at 0Gy in a number of 
donors to a maximum of 218 at 0.5Gy from donor HC18.  
A radiation-induced G2 chromosomal radiosensitivity score was calculated by 
subtracting the 0Gy control (non- irradiated spontaneous aberrations) from the irradiated 
(0.05Gy or 0.5Gy) G2 scores per donor. The distribution of G2 radiosensitivity scores for 
all 42 healthy donors per dose (0, 0.05 and 0.5Gy) were varied (Figure 2.4). It was evident 
that G2 scores were dependent on dose based on the discrimination between the values 
per dose and donor in Figure 2.4.  
A significant increase in G2 scoring at 0.05Gy and 0.5Gy samples was observed 
compared to the non-irradiated control (p<0.001). Also, a significant increase in G2 
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scoring from 0.05Gy to 0.5Gy was observed (p<0.001) with scores doubling or more 
between dose indicating a dose dependent response.  
 
 
 
 
2.3.3 Validation of the assay – Variation and Radiosensitivity Cut off  
The blood samples from 42 normal individuals were obtained for irradiation at two doses 
(0.05Gy and 0.5Gy) and a sham-irradiated control (0Gy). The mean (μ), standard 
deviation (SD), and coefficient of variation (CV) were calculated per dose per group 
(n=42) (Table 2.3).  Using all 42 donors, inter- individual variation values were calculated 
(CV as described in methods section) as a measure of assay reproducibility from the 
radiation induced G2 scores assigned per donor. An inter-variation value of 34% was 
obtained for 0.05Gy and a value of 22% was obtained at 0.5Gy. Intra–individual variation 
was calculated using 3 donors, sampled at multiple times over the course of 4 years (table 
-100
-50
0
50
100
150
200
250
0 5 10 15 20 25 30 35 40 45G
2
 R
ad
io
se
n
si
ti
vi
ty
 S
co
re
/1
0
0
 M
et
ap
h
as
es
Healthy Donor
0Gy 0.05Gy 0.5Gy
Figure 2.4 Distribution of individual G2 radiosensitivity scores from 42 healthy donors. 0Gy non irradiated 
controls are presented in blue, 0.05Gy represented in red and 0.5Gy represented in green. Error bars have 
been added to those donors which were sampled more than once.  
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2.3). From table 2.3, the mitotic index and G2 radiosensitivity score is given for the 3 
donors coded HC3, HC8 and HC38. Intra- variation fell below a value of 30% at 0.05Gy 
and below a value of 26% for 0.5Gy. All values in the present study were comparable, 
but slightly higher than previous studies which report ranges of 4%-15% for intra-
variation (explained in table 2.2)144,148,158,234. 
 
 
 
 
Table 2.3 Intra individual variation values for three healthy donors who consented for multiple samples 
over a period of 4 years. Raw G2 Radiosensitivity scores are presented. The intra variation at 0.5Gy is 
highlighted as this measurement is routinely used at a dose of between 0.1-0.5Gy. 
 
  Mitotic Index G2 Radiosensitivity Score 
  0Gy 0.05Gy 0.5Gy 0Gy 0.05Gy 0.5Gy 
Sample No. HC3 
1 2.5 2 1.3 4 60 156 
2 1.6 1.7 0.7 4 40 116 
3 2.7 1.9 0.4 4 32 132 
4 2 1.1 1.1 4 32 134 
5 3.6 2.7 1.6 0 32 126 
6 3.6 2 0.7 4 36 124 
Intra-variation    49% 30% 10% 
  HC8 
1 2.1 1.4 0.9 8 64 116 
2 1.2 0.5 0.1 0 44 170 
3 2.8 2.1 1 12 28 138 
4 1.6 0.4 0.4 8 56 188 
5 1.5 1.4 0.7 8 44 156 
Intra-variation    60% 29% 18% 
  HC38 
1 2.5 0.4 1.4 4 36 116 
2 3.6 1.7 0.6 4 32 122 
3 1.7 1.5 0.8 16 44 208 
4 4 4.4 2.2 4 48 160 
5 3.9 2.9 4.2 4 28 128 
Intra-variation    84% 22% 26% 
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A radiosensitivity cut off value was defined by calculating the 90th percentile of each 
group at each dose (Table 2.4). This value represents a threshold of which 90% of the 
donor population fall below. The radiosensitivity cut off value can also be represented 
graphically, as shown in figure 2.5. Donors who lie to the left of this dashed line (which 
represents a radiosensitivity cut off) are considered normal while those donors who lie to 
the right of the line are considered slightly radiosensitive. As 0.5Gy is considered the 
most radiosensitive dose, 7 donors were considered radiosensitive as their G2 values lay 
above the cut off for 0.5Gy.  
 
 
 0.05Gy 0.5Gy 
Mean 35 aberrations/100 metaphases 124 aberrations/ 100 metaphases 
St. Dev 12 27 
90th Percentile 51 152 
C.V (%) 34% 22% 
Table 2.4 Summary of statistics from G2 scoring of 42 healthy controls. The radiosensitivity cut off 
values are represented by the 90th percentile values.  
 
 76 
 
 
 
 
No significant difference was observed in radiosensitivity scores between male and 
female samples at any dose (P> 0.17). A higher aberration frequency was observed in all 
of the donors who smoked compared to non-smokers except for one pair of donors which 
showed the opposite, only at 0.05Gy (Figure 2.6) (p=0.019).  
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Figure 2.5 Range of radiosensitivity scores from 42 healthy donors at 0.05Gy (a) and 0.5Gy 
(b). Radiosensitivity cut offs are represented by a dashed line on each graph for each dose. 
Spontaneous aberrations from the control were subtracted from each dose to give radiation 
induced G2 sensitivity scores. 
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2.3.4 Correlations  
Investigation of links between MIn and radiation induced G2 scoring in addition to age, 
and season of blood sampling was done (Figure 2.7). A small significant (P = 0.049) (R 
=-0.31) negative correlation was found at 0.05Gy between age and MIn. As age increased, 
the MIn decreased. This was not significant at 0.5Gy (P = 0.054) (R = -0.3).  
A significant negative correlation was found with age and radiation induced G2 scores at 
0.05Gy (Figure 2.7). As age increased, radiosensitivity score decreased significantly (P = 
0.0009) (R = -0.5). This was not significant at 0.5Gy (P = 0.42) (R = -0.13).    
No significant correlation of MIn and radiosensitivity score was observed at 0.05Gy 
(Figure 2.8) (P = 0.4) (R = 0.13). However, a significant negative correlation was 
observed between MIn and radiosensitivity score at 0.5Gy (Figure 2.8) (P = 0.0077) (R = 
-0.41).  
A significant correlation between season of blood sampling and mitotic index was 
observed at 0Gy (P = 0.0065) (R = -0.4285) and 0.5Gy (P = 0.0001) (R = -0.5760) but 
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Figure 2.6 Differences in G2 chromosomal radiosensitivity between smoker and non-
smoking donors. Donors were sex matched before statistical analysis.  
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not at 0.05Gy (P = 0.3881) (R = -0.142). The mitotic index was lower toward December, 
and highest in January.  
Additionally, a significant correlation was found between season of blood sampling and 
G2 radiosensitivity scoring of donors at 0.05Gy (P = 0.0428) (R = -0.3260) but not at 0Gy 
(P = 0.3) (R = -0.1711) or 0.5Gy (P = 0.9) (R = -0.020). With the significant correlation 
at 0.05Gy, G2 scores were slightly higher in January and lower toward the following 
December. 
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Figure 2.7 Pearson R correlation of age with mitotic inhibition (MIn) and Radiosensitivity score.  
Correlation of age with MIn at 0.05Gy and 0.5Gy are presented in the top panel. Values at each dose have 
been subtracted from the 0Gy non-irradiated control. Correlations of Age with Radiosensitivity score at 
0.05Gy and 0.5Gy are presented in the bottom panel. The 0Gy non-irradiated control has been subtracted 
from both doses.  
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Figure 2.8 Pearson R correlation of Mitotic inhibition (MIn) with Radiosensitivity 
score. The top panel represents no correlation at 0.05Gy, and the bottom panel 
represents a negative correlation with MIn and Radiosensitivity Score.  
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Figure 2.9 Correlations between month of blood sampling from healthy donors and Mitotic Index values 
(left panel) and G2 radiosensitivity Scores (Right panel). * Denotes significant correlation i.e. P ≤ 0.05.   
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2.3.5 Culturing Effects 
 
A slight but not significant difference in G2 scores between whole blood and pre-
extracted lymphocytes was observed in 3 donors (Figure 2.10) (p=0.6531 at 0.05Gy and 
p=0.2 at 0.5Gy). Doses of 2Gy were also investigated using the G2 radiosensitivity assay 
(Raw Data, appendix 10.4) and high aberration frequency along with high inhibition was 
observed. Aberrations were in excess of >300 per 100 metaphases.  
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Figure 2.10 Comparison of radiation induced G2 scores from whole blood vs pre extracted 
lymphocytes. Blue bars represent values obtained at 0.05Gy and orange represent 0.5Gy. 
Spontaneous aberration yield at 0Gy was subtracted from each dose. 
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2.3.6 Beam energy effect 
Cell cycle checkpoint response was assessed by calculating a radiation induced mitotic 
inhibition value (MIn) (explained in section 2.3.1). MIn values per dose and radiation 
type are shown in figure 2.11.  
Comparison of means showed that inhibition was observed in all donors as MIn values 
fell below 5%. MIn values between control and irradiated samples were significantly 
different (P<0.001). MIn values were compared between radiation source (Co-60, Linac 
Photon and Linac Electron) by using ANOVA. Inhibition was observed in all donors 
across all sources, but no statistically significant difference was observed between sources 
(p= 0.8835). Considerable inter – individual variation of mitotic index was observed 
within the donor group, but consistent across radiation source for each donor (Table 2.5). 
 
 
Table 2.5 Summary of statistics for radiation induced G2 scores for all beam sources at 0.05Gy and 0.5Gy. 
Mean, standard deviation (St. Dev), coefficient of variation (CV) and radiosensitivity cut offs (90th 
percentile) are shown 
    Co60 Photon Linac Photon Linac Electron 
0.05Gy Mean (μ) 32.6 32.8 34.5 
  SEM 1.45 1.682 1.857 
  CV (%) 20.01% 22.93% 21.54% 
  90th Percentile 40 44 42 
0.5Gy Mean (μ) 124.6 113.3 116.4 
  SEM 5.016 3.937 5.742 
  CV (%) 18% 15.54% 19.74% 
  90th Percentile 147 132 144 
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A 
Figure 2.11 Checkpoint response as calculated from radiation induced mitotic inhibition 
at a) 0.05Gy and b) 0.5Gy. Mitotic index values for each dose point were subtracted 
from the 0Gy control to give a mitotic inhibition value. Data from 6MV photons (Linac) 
and 12MeV electrons (Linac) are presented compared to Cobalt 60. Error bars represent 
upper and lower values.  
B 
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Distribution of G2 radiosensitivity scores are illustrated as boxplots in Figure 2.12 for 
each dose and each source. No statistically significant difference between radiation 
sources (60Co, linac photon and linac electron) was observed (P=0.2305).  
A significant difference in G2 score between 0Gy control and irradiated (0.05Gy and 
0.5Gy) samples was observed (p < 0.001). In addition, a significant difference between 
each dose (0.05Gy and 0.5Gy) was observed (p < 0.001) with G2 scores increasing at 
least three fold. Comparison of G2 scores between radiation sources was performed using 
ANOVA. No statistically significant difference in G2 scores between sources was 
observed (p > 0.05). 
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Figure 2.12 G2 Chromosomal radiosensitivity at low doses from clinical sources (Linac 
photon 6MV and Linac electron 12MeV). Boxplots show G2 radiosensitivity scores from 
blood samples taken from 20 Healthy control donors irradiated to a) 0.05Gy and b) 0.5Gy. 
The spontaneous aberration yield from the 0Gy control was subtracted from each dose to 
give a radiation induced G2 radiosensitivity score. Error bars represent upper and lower 
values. 
A 
B 
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2.4 Discussion 
2.4.1 Checkpoint Response 
Mitotic index is a measure of individual checkpoint response, which should respond 
quickly and effectively to radiation insults. Significant drops in mitotic index were 
observed in control donors as shown with a decrease in mitotic cells (from a maximum 
of 4.4% to a minimum of 0.1%) indicating good cell cycle checkpoint efficacy. The 
mitotic inhibition is derived from subtracting the mitotic index at each dose from the 
control, non-irradiated sample value. A significant increase in mitotic inhibition was 
observed in irradiated samples (both 0.05Gy and 0.5Gy) compared to control samples. 
There was also significant mitotic inhibition between 0.05Gy and 0.5Gy. It was expected 
that mitotic inhibition would increase following ionizing radiation exposure in a 
molecular DNA damage response to radiation. This suggests an inhibition of cyclin-CDK 
complex (cyclin B – CDC2), which prevents the cell from progressing into mitosis. 
Therefore, blood lymphocytes exposed to radiation (0.05 and 0.5Gy) through the G2 
chromosomal radiosensitivity assay would have a reduced number of cells in mitosis 
compared to the control (0Gy). For very low doses of 0.05Gy this has not been done 
previously, and for 0.5Gy values of up to 15% were obtained in some early reports152,242.  
This increase in mitotic inhibition was discovered in early reports in response to 
irradiation and lower mitotic inhibition was observed in a cohort of breast cancer 
patients150. A reduced mitotic inhibition is expected in samples from cancer cohorts, as 
mutations in the tumour suppressor genes (such as P53) controlling cell cycle progression 
are key factors in carcinogenesis. In 2005, another report using blood samples from 
healthy controls and prostate cancer patients demonstrated a lower mitotic inhibition in 
response to irradiation in the cancer cohort158. The response to irradiation described here 
suggests a contribution of the two G2 phase checkpoints. The ATM independent and dose 
dependent checkpoint which is thought to be activated in response to doses of 0.5Gy and 
 87 
 
responds to accumulation of cells damaged in G1/S. This checkpoint inhibits progression 
in the cell cycle in response to doses between 1Gy and 10Gy. In normal conditions, the 
G2 checkpoint involves activation and stabilisation of CDC25 which inhibits CDC2 and 
allows progression as normal in the cell cycle. However, in response to activation of 
CHK1 by ATM, Wee1 is phosphorylated, activated and stabilised which inhibits CDC25 
activity and therefore cannot associate with CDC2 and prevents progression of the cell in 
the cell cycle through a stable G2 arrest243. The ATM dependent and dose independent 
checkpoint, causes upregulation of p21which inhibits CDK1 – cyclin B complex and 
therefore results in G2 arrest244. It is well known that radiosensitive populations exhibit a 
delayed mitotic inhibition, with reports dating back to 1994. Those reports used skin 
fibroblasts from AT patients to demonstrate an increased G2 chromosomal 
radiosensitivity concluding that there is a defective G2 checkpoint in AT patients152. This 
defect, is rather described now as a “delayed” checkpoint in AT patients relating back to 
the absence of ATM and cell cycle inhibition by other checkpoints (CDC2 – CDC25)245. 
This is now well documented and ATM is known to be a key player in the DNA damage 
response which transduces the damage from radiation exposure so that CDK1 – Cyclin B 
is inhibited and cell cycle progression is halted. 
2.4.2 G2 Chromosomal Radiosensitivity 
G2 aberration analysis involves recording the amount of chromatid aberrations in 100 
metaphase cells in each sample, at each dose, and assigning a G2 score to each individual. 
The G2 score is indicative of individual radiosensitivity, and varies between doses. Here, 
spontaneous aberration yields in samples from healthy controls were minimal at under 20 
aberrations/100 metaphases analysed. This was a little higher than previous reports, 
which is most likely due to the subjectivity of G2 aberration scoring, as the radiosensitive 
cut off values in this study were slightly higher than previous reports150,165. A significant 
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increase in aberration yield between 0.05Gy and 0.5Gy was observed, as well as 
significant differences between doses and controls (P <0.002). Again, a higher aberration 
yield was expected in response to radiation. A natural variation in aberration yield was 
observed between the 42 healthy donors, which represents variation in intrinsic 
radiosensitivity in the individual donors.  
After obtaining a range of G2 radiosensitivity scores for the 42 healthy controls, a 90th 
percentile was calculated which represents the radiosensitivity cut off value within the 
cohort. This was done for 0.05Gy and 0.5Gy, and a cut off value of 51 and 152 was found 
for each dose respectively. The value at 0.5Gy was used as this represents the most 
sensitive dose for the G2 assay150,158,246. This value represents a cut off for radiosensitive 
donors, samples with values that fall above this point are considered radiosensitive (figure 
2.3b). From the data generated 7 donors were deemed radiosensitive, but surprisingly 
were not the same 7 donors for each dose i.e. those who are considered radiosensitive at 
0.05Gy may not be radiosensitive at 0.5Gy and vice versa). This could suggest that 
different molecular mechanisms are initiated at each dose. The 7 donors’ samples 
considered radiosensitive would be candidates for further investigation, if variation 
induced by extrinsic factors were ruled out (e.g. smoking, hormone status, age). This is 
consistent with a recent radiobiological report conducted in our laboratory that 
demonstrated a significant upregulation of critical apoptotic genes at the lower dose of 
0.05Gy compared to 0.5Gy and therefore different mechanisms of arrest, repair or cell 
death in biological systems is possible for low doses of radiation247. This response at 
lower doses was further shown in a recent report that showed differing cellular response 
pathways at low doses of radiation concluding that directly irradiated cells undergo 
apoptotic, necrotic and some mitotic cell death compared to bystander cells which 
predominantly undergo mitotic cell death248. Furthermore, Beels et al  recently showed a 
hyper sensitivity response at lower doses (<0.5Gy) using whole blood and isolated T 
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lymphocytes, in response to x-irradiation, in which the hypersensitivity response at lower 
doses was not observed after γ-irradiation at low doses249. The radiosensitive cut off value 
obtained in this healthy control cohort is of importance in chapter 4 using cancer and AT 
cohorts as it provides a radiosensitivity benchmark to report which patients are considered 
more radiosensitive in response to radiotherapy. 
2.4.3 Correlation Analysis 
Previous reports have suggested a correlation between mitotic inhibition and G2 
radiosensitivity158.  It was expected that radiosensitive patients who have a higher 
aberration yield (G2 radiosensitivity score) would also have a higher mitotic inhibition. 
A Pearson’s Rank correlation was performed between checkpoint response (MIn) and 
radiation induced G2 chromosomal radiosensitivity.  A slight, significant negative 
correlation between MIn and G2 scoring was observed (p = 0.0077) (R = -0.41). This 
result is surprising, as it is expected that an increase of radiation induced damage would 
cause a more pronounced MIn checkpoint response. In previous cancer patient reports a 
correlation was found between mitotic inhibition and G2 radiosensitivity using a prostate 
cancer cohort158. The correlation may not be as evident in normal healthy donors 
compared to more radiosensitive cancer populations. In 1994, Scott et al  reported 
significant mitotic delay in radiosensitive subpopulations by describing a highly variable 
mitotic inhibition in AT patients in comparison to controls152.  
 
A significant correlation was observed with age and MIn at 0.05Gy. As age increases, 
MIn decreases. In early reports, Scott et al  also showed a reduced mitotic inhibition with 
increasing age152. Altered mitotic inhibition values represent defects in cell cycle 
checkpoint control and efficiency. The effect of age on cell cycle could be a result of 
telomere shortening which is known to be associated with the ageing process and involved 
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in genomic instability. A significant correlation of age and G2 radiosensitivity was also 
observed at 0.5Gy, which showed a reduced aberration yield with increasing age. The 
opposite was observed in an early study by Ramsey et al in 1995 who showed an increase 
in aberration yield with increasing age using chromosomal painting techniques. But in 
this report, variables such as exposure to asbestos, diet/intake of sweeteners, suffering 
from a major illness and smoking were recorded, which would contribute to accumulation 
of cytogenetic damage250. The variables examined in the mentioned report were not 
recorded in this work, and there are limited reports within the literature therefore more 
investigation of factors affecting individual radiosensitivity are encouraged.  
A correlation of MIn and G2 radiosensitivity was also previously shown by Howe et al  
in 2005158 using control and prostate cancer and benign prostate hyperplasia patients. A 
small positive correlation was found between mitotic inhibition values and radiation 
induced G2 scores in the prostate cancer patient cohort, but no significant correlation 
between the endpoints was found in control or benign prostate hyperplasia patients.  
In the data presented, a small significant correlation with MIn and season of blood 
sampling was found at 0Gy and 0.5Gy. The MIn reduced toward December and was at 
its highest in January. There has been no reference to this finding in other reports, but it 
has been suggested that diet can affect cell cycle kinetics, such as caffeine intake. For e.g. 
an early study by Lau et al showed that caffeine in combination with DNA damaging 
agents increased the potency of the drug and therefore induced a more pronounced cell 
cycle inhibition.    
 
2.4.4 Assay Validation 
Two measures used to validate the assay successfully were inter individual variation and 
intra- variation. Previous reports have calculated inter-individual variation values in 
cohorts of various donors/patients of 15% - 39% (Chapter 2 section 2.2). The inter-
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individual variation values were calculated from the radiation-induced G2 scores for both 
dose points 0.05Gy and 0.5Gy in this study were 34% and 22% respectively. These results 
fall within the acceptable range according to the literature. It is of interest that higher 
variation was observed at the lower doses, further adding speculation about the different 
molecular events that possibly occur at very low doses. It has been reported that female 
hormonal status has an effect on G2 scoring with increased variation in female donors251. 
There have been other physiological conditions attributed to variation such as smoking, 
medication, immune and hormonal status251 although in this work only a significant 
difference in smoker vs non-smoker at 0.05Gy was found, with no differences between 
male and female donors. Significantly lower aberrations were observed in the non-
smoking donors compared to smokers’ which is not surprising as these cells would have 
more DNA damage occurring daily in response to carcinogen exposures, therefore 
leading to a higher damage rate. The intra - variation values (samples obtained 5or 6 
times) per individual for each dose 0.05Gy and 0.5Gy, fall below values of 29% and 10% 
respectively, which is also comparable with the literature for 0.5Gy. Inter-individual 
differences in samples are expected and are what makes a radiosensitive assay successful 
as a patient’s radiosensitivity status should be determined based on the measurement 
taken directly that day and date in the clinic. Due to fluctuations in the intra-variation of 
patient sampling it was previously suggested by Smart et al 170 that more than one sample 
should be taken if the G2 assay is incorporated for use within the clinic.   
2.4.5 Beam Energy Effect 
Another factor which was previously described to affect G2 radiosensitivity was radiation 
beam energy. Although most reports described differences between low and high LET, it 
was not known if little differences in beam energy of similar LET but delivered from 
different sources would be observed. In the current work, the distribution of G2 scores 
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and mitotic index values between sources showed similar minimum and maximum values 
and overlapping error bars which demonstrates no significant difference in G2 
radiosensitivity or mitotic inhibition between sources. Therefore, regardless of beam 
source, the same effect was observed. To the best of the authors knowledge, no previous 
reports investigating this exist.  
2.5 Aims of chapter and conclusions 
To summarise, the G2 chromosomal radiosensitivity assay was optimised and validated 
at our laboratory for further use on patient cohorts, with good assay reproducibility and 
reliability. The values obtained in the current work were in accordance with other 
published studies in the area. This was confirmed by expected levels of mitotic indices 
representing G2 checkpoint efficacy, G2 scores and 90% percentile for the donor control 
study consisting of 42 donors. Furthermore, variation was assessed between donors for 
inter-variation of all 42 donors and intra-variation of 3 donors sampled 5/6 times. This 
was also in accordance with published studies. Additionally, our study shows no 
significant difference in radiobiological response with beam energy as measured by 
chromosomal radiosensitivity. This data therefore allowed for the progression of work 
using a linear accelerator for irradiation of samples instead of the 60Co unit which was 
used for the current healthy control cohort. The 60Co unit was decommissioned so the 
subsequent experiments were completed using a linear accelerator.  
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3. CYTOGENETIC ANALYSIS OF RADIOSENSITIVITY OF PROSTATE 
CANCER PATIENTS THROUGHOUT THEIR RADIOTHERAPY REGIME 
AND FOLLOW UP 
 
3.1 Introduction 
The work described in this chapter is part of an on-going All-Ireland Cooperative 
Oncology Research Group (ICORG) clinical trial, ICORG08-17. The mission of ICORG 
is to bring early access of new cancer treatments to Irish cancer patients. So far, 
approximately 340 research protocols have been opened to allow research treatments to 
more than 14,000 cancer patients since ICORG was established in 1996, encompassing 
95% of Ireland’s oncology consultants as members. ICORG08-17, A Prospective Phase 
II Dose Escalation Study using IMRT for High Risk N0M0 Prostate Cancer, is a 
prospective, phase II non-randomised controlled clinical study where the primary 
endpoint is to determine if dose escalation up to 81 Gy using IMRT for high risk localised 
prostate cancer can provide prostate specific antigen (PSA) relapse-free survival.  The 
associated translational study described in this chapter was funded by Science Foundation 
Ireland and the FP7 Network of Excellence, Low Dose Research toward Multidisciplinary 
Integration (DoReMi). This programme investigates effects of radiation in multiple areas 
which spans biology, chemistry and physics, to examine non targeted effects of radiation, 
low dose effects, cancer-dose risks, dosimetry, individual variation in radiation 
sensitivity, radiation quality and non-cancer effects.  
Enrolment for the ICORG08-17 translational study involved recruiting patients from the 
St Luke’s Radiation Oncology Network of St Luke’s, The Beacon, St. James’ and 
Beaumont hospital. The first patient sample for DIT was collected in August 2014. In 
brief, patients with newly diagnosed PCa of Gleason score >8, Prostate Specific Antigen 
(PSA) levels of >20ng/ml and Karnofsky Performance Status (KPS) greater than or equal 
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to 60 were chosen for participation in the trial (full details of inclusion and exclusion 
criteria are detailed in appendix 10.1). KPS is a measure of the ability of the patient to do 
everyday tasks and ranges from 1-100. The estimated primary completion date is 2017 
with a complete study end date of September 2026 and with an estimated overall 
enrolment of 190 PCa patients. Clinical details, including PSA levels, are being recorded 
prior to treatment and at follow up.  KPS and toxicity, using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading system, 
version 3.0, are being recorded prior to treatment, weekly during treatment and at follow 
up. Patients are being followed up regularly at 2 months’ post radiation therapy (RT), 8 
months’ post RT and at 6 monthly intervals until Year 9. Radiotherapy volume/dose 
metrics are being recorded for planning target volumes (PTVs) and organs at risk (OARs) 
together with details on duration of treatment, treatment breaks etc. Details regarding 
medications (disease / trial-related) are captured on an on-going basis.   The aim of this 
chapter was to investigate radiosensitivity in PCa patients recruited to the ICORG08-17 
translational study throughout their radiotherapy treatment, i.e. at baseline (before RT), 
post hormone treatment, last day of radiotherapy, 2 month follow up and 8 month follow 
up.  
3.1.1 Prostate Cancer detection, diagnosis and staging 
PCa is the second most commonly diagnosed cancer in Ireland, with over 150,000 new 
cases each year (National Cancer Registry Ireland)252. Risk factors for PCa include 
increasing age, ethnicity (African men with high Gleason score presenting with a higher 
PSA level than Caucasian men with the same Gleason score)253 and heredity, with 
doubling of risk if a first line relative was previously diagnosed 254.  
On presentation of symptoms, (urinary frequency, painful urination and blood in urine or 
semen), a full digital rectal examination (DRE) and blood sampling is performed to 
 95 
 
determine abnormality within the prostate or detection of prostate specific antigen (PSA) 
in the individual’s blood. Usually an elevated PSA (>4ng/mL) is considered abnormal 
but could indicate non-malignant disorders such as prostatitis and benign prostate 
hyperplasia (BPH) (National Cancer Institute (NIH)255). The PSA value has been under 
intense investigation, as it is not unusual but uncommon if a patient with PCa presents 
with levels of PSA lower than 4ng/mL256. However, PSA detection is still deemed to be 
the most clinically effective predictor of PCa.  
If abnormality is detected in the DRE or PSA test, further investigation is warranted via 
biopsy. Ultrasound-guided trans-rectal biopsy is the method of preference for prostate 
biopsy257 followed by histopathological staging using the Gleason Score. The system was 
first described by Dr. Gleason258 in which he described 5 pathological patterns; pattern 1 
showing well differentiated, normal tissue with a range up to pattern 5 which shows 
poorly differentiated abnormal tissue. Figure 3.1 shows the original illustration by Donald 
Gleason depicting the 5 different histological patterns that are used to derive a Gleason 
Score. This is a histological score deduced by adding the primary pattern throughout the 
sample (primary grade pattern) and the second most common pattern throughout the 
sample (secondary grade pattern) to give a score between 2 and 10. Sometimes, a third or 
tertiary grade pattern is included in histological analysis but not thoroughly used 
worldwide259. The specimen is analysed for tumour/node/ metastasis (TNM) status which 
evaluates the size of the tumour, if there is any nodal involvement or if there are any 
distant metastasis evident. Table 3.1 displays the TNM system which groups the 
histological outcome into one of 3 stages, localised, locally invasive or metastatic and 
these outcomes determine the type of treatment available for the individual 260. TX to T2C 
represents evaluation of the tumour itself, size, location and if both lobes of the prostate 
are involved. T3a to T4 represents if the tumour locally extends to immediate structures 
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close to the prostate gland, and N1 to M1 represents the involvement of lymph nodes, and 
metastatic disease. 
 
 
Table 3.1 Tumour, node, metastasis (TNM) staging system. Localised disease is denoted as Tx to T2c, local 
extension is T3a to T4 and Metastatic disease is represented by N1 for nodal involvement and M1 for distant 
metastasis. Table adapted from the AJCC Cancer Staging manual, Edge et al 260. 
 
Localized Disease   
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically apparent tumour neither palpable nor visible by imaging 
T1a Tumour incidental histologic finding in ≤5% of resected tissue 
T1b Tumour incidental histologic finding in ≥5% of resected tissue 
T1c Tumour identified by needle biopsy (e.g., because of elevated PSA level 
T2 Tumour confined within prostate 
T2a Tumour involves one-half of one lobe or less 
T2b Tumour involves more than one-half of one lobe but not both lobes 
T2c Tumour involves both lobes 
Local extension   
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumour invades seminal vesicles 
T4 
Bladder invasion, fixed to pelvic side wall, or invasion of adjacent 
structures 
Metastatic 
disease   
N1 Positive regional lymph nodes 
M1 Distant metastasis 
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3.1.2 Types of therapy for PCa and outcomes 
Therapy for PCa is dependent on grade and stage of the tumour. To determine the type of 
treatment for an individual the stage and grade of the tumour is considered and the patient 
is classified into low, intermediate and high risk groups. Options for treatment include 
the following, which can be stand-alone treatment options or combined depending on the 
extent of tumour progression; 
 
Figure 3.1 Gleason histological staging drawn by D.F. Gleason, 
illustrating grades 1 to 5. Image taken from P. Humphrey259. 
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i. Deferred treatment – watchful waiting or active surveillance  
Deferred treatment or “watchful waiting” is an older approach which is used while 
waiting until local or systemic progression of the PCa occurs261. Sometimes hormone 
therapy or radiation therapy were used as a palliative treatment for metastasis. A more 
recent (post 1990) approach has been adopted which is to actively decide not to treat the 
PCa but to keep a close follow up to deduce if the PCa is progressing and this is termed 
active surveillance.  If treatment is needed with active surveillance, then it is with a 
curative intent. The purpose of deferred treatment is to avoid unnecessary overtreatment 
of localised PCa, it is most often prescribed to older patients who have a shorter life 
expectancy or less aggressive tumour. Often, increasing grade/stage correlate with lower 
disease specific survival with a deferred treatment approach262. Low Gleason scores of 
<7, confined PCa (T1-T2), and PSA levels of <20ng/ml are some of the criteria which are 
used to select patients for an active surveillance treatment approach263. During active 
surveillance, other criteria are used to define a cancer “progression” such as PSA doubling 
between 2 and 4 years and progression of Gleason score >7 in less than 4 years263. For T3 
– M0, deferred treatment is rare as patients with locally advanced PCa are candidates for 
hormone deprivation therapy.  For metastatic PCa treatment is usually only deferred if 
the patient feels strongly against it, as median survival with metastatic PCa is less than 2 
years261.   
ii. Radical Prostatectomy 
This surgical method involves complete removal of the prostate gland and seminal 
vesicles, often with assessment of pelvic lymph nodes and sometimes removal of the 
lymph nodes. This is an advantageous treatment option for localised PCa in patients with 
a predicted survival of >10 years264. Two surgical methods were originally used in the 
beginning of the 20th century; Young used a perineal approach (between anus and 
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scrotum)265 while Memmelar and Millin used a retropubic approach (incision in the 
abdomen)266. The latter method is more commonly used to limit faecal incontinence, 
whereas the perineal approach leads to a faster recovery time and limited loss of blood 
during surgery compared to the retropubic approach267. Radical prostatectomy through 
the retropubic approach is favoured as more minimally invasive laparoscopic radical 
prostatectomy (LRP) and robot assisted radical prostatectomy (RARP) have been 
developed. No evidence in the literature suggests that one technique is superior to the 
other when used alone, and more work is needed to determine which is best. However 
both LRP and RARP have been described as the superior techniques for radical 
prostatectomy in localised PCa as lymph nodes can be checked during the surgery, it 
requires less operative time and surgical ‘skill,’ less mean blood loss through surgery, and 
a hospital stay of 24hrs in more than 96% of patients268. Intermediate risk PCa patients 
(T1-3) are counselled and guided toward a radical prostatectomy approach. If any lymph 
node involvement is found with intermediate risk and often with high risk patients, 
surgery alone is not sufficient to provide disease control and survival and often multiple 
modalities are  necessary261. With lymph node involvement, extended lymph node 
dissection (eLND) should be done if the estimated risk of positive lymph node 
involvement exceeds more than 7%, which is often the case in intermediate risk and high 
risk PCa patients269. Neoadjuvant hormonal therapy and radical prostatectomy has been 
used and no overall significant improvement in disease free survival was observed, but 
adjuvant hormonal therapy after radical prostatectomy has been reported as favourable 
for disease free survival, although not significant261.  
Most often, radical prostatectomy can be done with limited side effects. Mortality rate for 
this procedure remains low at 0-1.5%270 with urinary incontinence the most common side 
effect which affects 7% of patients undergoing radical prostatectomy271. 
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The combination of, timing of and exact types of treatment needed for PCa differs 
between individuals and often expertise from a multidisciplinary team of urologists, 
histopathologists, radiologists and oncologists is needed to decide the treatment plan best 
suited for the individual. 
iii. Definitive radiation therapy 
External Beam Radiotherapy (EBRT) specifically Image Guided Intensity Modulated RT 
(IMRT) and 3 dimensional conformal radiotherapy (3D-CRT) are the most standard form 
of Radiotherapy (RT) for treatment of PCa worldwide261.  
Image guided radiotherapy (IGRT) is the most used form of RT as it allows for planar 
images of the patient to be taken on a daily basis prior to RT at each session, as a linear 
accelerator is equipped with an on board imaging system (OBI). A sophisticated form of 
IGRT is cone beam RT which rotates the OBI to obtain volumetric images of the patient 
for better control of treatment272.  
3D-CRT is based on image guidance through computed tomography scanning and 
provides a 3D image of the internal anatomy of the patient and tumour site. Highly 
advanced computer software has been developed to shape and contour radiation beams to 
deliver a high dose of radiation to the target volume of the tumour, while allowing 
margins which spare normal healthy tissue19. Intensity modulated RT (IMRT) is vastly 
becoming the most used type of 3D-CRT for PCa, as use of a multileaf collimator allows 
for intensity of radiation to be controlled (increased or decreased) while treating a 
particular tumour.  Early reports using patients with clinically localized PCa demonstrate 
the safe use of high dose IMRT for treatment, which also decreased the incidence of rectal 
bleeding up to 8 years to <2%273. In PCa trial studies, evidence suggests that disease free 
survival is significantly higher in cases where >72Gy are used compared to those with 
less than 72Gy of irradiation in localised (T1-2c, N0, M0) PCa274. With intermediate risk 
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(T1c-T3) PCa, dose escalation was shown to provide a better 5 year biological outcome 
without hormonal therapy275,276. With a high risk (T2c, Gleason Score>7) PCa, dose 
escalation that is predominantly used as phase III trials have shown an overall better 
disease free survival compared to lower doses277. Additionally, determined by phase III 
clinical trials, neoadjuvant hormonal therapy (6 months of ADT) resulted in a 13% 
improvement on survival of high risk PCa patients276. 
Innovative techniques for the treatment of PCa with RT involving IMRT have 
predominantly attempted to escalate doses of up to 86Gy aimed homogeneously to the 
target volume of tumour. The ICORG clinical trial aims of this chapter are based on the 
work by the Memorial Sloan-Kettering Cancer Centre. In the first cohort using >500 PCa 
patients, use of 81Gy resulted in PSA relapse free survival rates of 85%, 76% and 72% 
in the favourable, intermediate and unfavourable risk groups respectively278. Later, using 
478 PCa patients, doses of up to 86Gy were used to show PSA relapse free survival rates 
of 98%, 85% and 70% for the low, intermediate and high risk groups respectively279. The 
ICORG08-17 study aims to investigate the overall survival and disease free survival of 
patients treated with a maximum dose escalation of up to 81Gy and report the toxicity 
data associated with such dose escalation methods. 
Low risk PCa patients can be effectively treated with low dose rate brachytherapy. Small 
radioactive seeds are implanted into the tumour and left for weeks – months to allow slow 
release of irradiation to the prostate280.  High dose rate brachytherapy (HDR) is usually 
combined with EBRT or neoadjuvant hormonal therapy to treat higher risk PCa 
patients281. In patients with organ confined PCa, a significant increase in disease free 
survival was reported when HDR brachytherapy in combination with EBRT was used 
compared to EBRT alone282. 
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For extracapsular invasion in pT3, NO and MO, post-operative (after RP) EBRT is a 
recommended option. If EBRT is used after surgery before PSA levels rise again, more 
than 60% of patients achieve a progression free rate of 80% at 5 years after therapy261, 262.  
iv. Locally Advanced PCa (Hormone Therapy)  
Incidence rates of advanced PCa are decreasing due to the vast screening of PSA in 
individuals with symptoms. In patients with advanced disease, EBRT alone provides poor 
prognosis285,286 due to the dependence of hormones from PCa tumours. Therefore ADT 
(hormonal therapy) is used in combination with RT to reduce progression of the disease 
and metastasis as well as reducing local recurrances287. Trials have been completed using 
hormone treatment in combination with EBRT such as neoadjuvant ADT (hormone 
treatment for a period of time before RT), neoadjuvant and concomitant ADT (hormone 
treatment before RT and during), concomitant and adjuvant (during RT and after) and 
long term adjuvant ADT (hormone treatment for a long period of time after RT). With 
neoadjuvant (2 months prior to RT) and concomitant hormonal therapy, a higher (but not 
significant) 10 year overall survival was shown in EBRT + ADT compared to ADT 
alone288. Using concomitant and long-term adjuvant therapy and comparing to EBRT 
alone, the combined ADT and EBRT demonstrated significant survival compared to 
EBRT alone289. Furthermore, long term adjuvant therapy in combination with EBRT has 
also shown a significantly higher 10 year survival rate in the adjuvant therapy group 
compared to standalone EBRT290.  In one trial using neoadjuvant, concomitant and long 
term adjuvant treatment, significant improvements were demonstrated such as local 
control and disease free survival in the long term treatment compared to short term ADT, 
but a lower 10 year overall survival was found in the long term ADT patients291. 
Moreover, comparison of short term adjuvant ADT with long term adjuvant ADT 
demonstrated a lower survival rate with short term adjuvant ADT292. As previously 
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mentioned in the Memorial Sloan-Kettering Cancer Centre report, dose escalation in 
combination with hormonal therapy has proved significantly advantageous. Although the 
main aim of the study was directly on dose escalation and not comparing any type of 
ADT, it still provides an opportunity for investigating the effect of dose escalation in 
combination with ADT, yielding a higher survival rate in patients receiving 86Gy 
compared to 81Gy273. Again, this work forms the basis of the ICORG 08-17 study in this 
chapter.  
3.1.3  Patient toxicity and side effects 
Although radiation treatment for early stage tumours is effective, it is not without 
unwanted side effects or toxicity. Toxicity grading is categorised depending on Patients 
with acute toxicity of > Grade 2 represents about 5-10%  and about 35% of those patients 
will continue to have toxicity at 10 years after radiotherapy278. With radical 
prostatectomy, side effects vary depending on which surgical approach is adopted. As 
explained in section 3.1.2, the retropubic approach reduces faecal incontinence, but less 
blood is lost during the actual surgery of  a perineal approach268. According to the Irish 
Cancer Society, normal and common side effects related to RT include tiredness, 
nausea/vomiting, hair loss, constipation and/or bouts of diarrhoea293. Specifically, for 
PCa, side effects recorded in the demographics of our study include urinary 
frequency/retention/pain, rectal bleeding, cystitis, proctitis, nocturia, diarrhoea or 
constipation and hot flushes. Acute toxicity such as those described can be damaging to 
quality of life for the patient, but could potentially predict occurrence of late toxicity278. 
In this study, toxicity is recorded using the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI-CTCAE) grading system, version 3.0, 
prior to treatment, weekly during treatment and at follow up.  
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3.1.4 Assays for measuring PCa Patient Toxicity 
As explained in the general introduction of this thesis in section 1.5, attempts have been 
made to predict patient response to irradiation specifically in PCa cohorts. In 2009 
Mitchell et al tried to predict patient response through radiotherapy regimes in PCa 
patients by measuring excreted exosomes in patient urine. They found a decrease in 
exosomes following hormone therapy, but only a clear decline through all hospital visits 
in one of eight patients, and the number of and quality of exosome purification was highly 
variable294. Additionally, Schnarr et al  found lower apoptotic responses in lymphocytes 
from PCa patients with late toxicity compared to those who had no toxicity after therapy, 
using an apoptotic assay in response to much higher in vitro doses (8Gy)295. Most 
recently, Brzozowska et al investigated the predictive capacity of γH2AX induction, G2 
chromosomal radiosensitivity and apoptosis by annexin V assay to distinguish between 
PCa patients with and without severe acute side effects, and found no significant 
correlations between toxicity and each endpoint. Although they found a marked increase 
in aberration induction in PCa patients compared to age and sex matched controls, they 
conclude that the predictive capacity of each endpoint for severe toxicity is doubtfull233. 
It is well known that dicentric chromosomes are formed in response to irradiation and are 
therefore a good predictor for biodosimetry296. It is also known that a higher baseline level 
of dicentrics are present in PCa patients and could potentially be an indicator of 
radiosensitivity297. Similar to this work, in 2010 Hille et al conducted a study 
investigating dicentric occurrence before, in the middle, at the end and at 1 year follow 
up after radiation therapy. They found a high level of baseline dicentrics at first sampling 
from patients, which persisted up to 1 year after therapy indicating high genomic 
instability in those patients298. Therefore, in addition to γH2AX induction and G2 
chromosomal radiosensitivity, dicentrics could provide an insight into toxicity in PCa 
during and after radiotherapy.  
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To date, there are still no accurate predictive tests for measuring patient toxicity response 
to their radiotherapy treatment. This would be beneficial at the treatment planning stage 
so that treatment regimens could be individualised according to the patient’s response and 
needs. Chapter 2 described the standardisation and validation of the G2 chromosomal 
radiosensitivity assay using patient blood samples as a potential predictive test. 
Furthermore, this work was carried out in parallel with a Raman Spectroscopy study 
which has the potential to be a predictive tool of response in the clinic. The G2 
chromosomal radiosensitivity assay was applied to prostate cancer patient samples taken 
at baseline (V1), post hormone treatment (V2), last day of radiotherapy (V3), 2 month 
(V4) and 8 month follow up (V5) stages of their radiotherapy treatment. In vitro 
irradiation was performed to low doses of 0.05Gy and 0.5Gy. No study has currently used 
multiple sampling times to investigate patient sensitivity throughout a treatment regime 
using low doses of irradiation.  
An additional set of patients who experienced long term grade 2+ toxicity (>2years after 
treatment) were recruited toward the end of this study. Only 3 patients were recruited 
while this thesis chapter was written, along with controls who experienced no long term 
toxicity, grade 0, but who received radiotherapy at the same time as those patients who 
experienced long term toxicity. This recruitment and investigation is currently ongoing 
in RESC, DIT.  
The novelty in this work lies in the investigation of individual radiosensitivity in patient 
blood samples using low doses of ionizing radiation. To the best of the author’s 
knowledge this is the first report investigating individual sensitivity using low doses at 
each sampling point (V1 – V5) with chromosomal radiosensitivity endpoints. 
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3.2 Methods 
Radiosensitivity was analysed in 22 PCa patients and compared to a subset of 19 male 
healthy controls from the previous healthy control cohort presented in chapter 2. Blood 
samples were collected from a total of 22 Prostate Cancer patients who were sampled at 
1-5 different visits; 22 at baseline (V1), 15 at post hormone treatment (V2), 10 at the last 
day of irradiation (V3), 7 at the two month follow up (V4) and 3 at the eighth month 
follow up (V5). On each visit, 20 ml of circulating peripheral blood was extracted into 
heparinised vacutainers (Sarstedt). Ethical approval for the acquisition of whole blood for 
the ICORG 08-17 translational study was granted by the research ethics committees of St 
Luke’s, St. James’ and Beaumont hospitals (DIT Ethics Ref. 15-32).   
3.2.1 Blood culture set up 
Whole blood cultures were set up as per section 2.2.2 of this thesis. 
 
3.2.2 Histopaque Lymphocyte Isolation 
The methodology for the isolation of lymphocytes was described in chapter 2, section 
2.2.3. These cultures were used for Raman spectroscopy 
3.2.3 Irradiation Conditions 
At 72 hrs, whole blood cultures and lymphocyte cultures were irradiated in G2 phase of 
the cell cycle at 0.05 Gy and 0.5 Gy using a 6 MV photon beam on an Elekta Precise 
Linac. Irradiation conditions and calibration from section 2.2.4 were used.  
3.2.4 G2 chromosomal radiosensitivity assay 
The assay was carried out as previously described in chapter 2 section 2.2.5 of this thesis. 
Microscopy was carried out to obtain mitotic index and G2 radiosensitivity scores as 
described in chapter 2.2.5.  
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3.2.5 Statistical Analysis 
Statistical comparison of mitotic index between doses was done using the non-parametric 
Kruskal-Wallis test in Graphpad Prism 6. G2 radiosensitivity scores which were obtained 
through totalling the number of aberrations per 100 metaphases on each slide per dose 
per donor were also compared between doses using the Kruskal-Wallis test. Comparison 
of radiation doses per donor for checkpoint response, radiosensitivity scoring and γH2AX 
were done using a grouped two-way ANOVA on GraphPad Prism 6 to determine any 
significant changes between all doses or different endpoints. Analysis of donor and dose 
for each hospital visit (V1 pre hormonal, V2 post hormone treatment, V3 last day of RT, 
V4 2 month follow up and V5 8month follow up) for each endpoint was also done using 
a two-way ANOVA. A p value was derived and a significance level of 0.05 was used. 
This was done using Microsoft Excel 2016 and is explained in detail in chapter 2 of this 
thesis. Radiosensitivity cut offs calculated from a male subset of the healthy control 
cohort in chapter 2 were used to determine radiosensitive individuals. 
3.3 Results 
Radiosensitivity was analysed in 22 PCa patients and compared to a subset of 19 male 
healthy controls from the previous healthy control cohort in chapter 2. Additionally, 
radiosensitivity was investigated in PCa patients throughout their radiotherapy treatment 
regime – V1 represents baseline, V2 after hormone treatment, V3 last day of radiotherapy, 
V4 2month follow up and V5 8month follow up. G2 Checkpoint response and G2 
chromosomal radiosensitivity were analysed. 
3.3.1 G2 Checkpoint response 
Mitotic index was obtained by counting the ratio of cells in metaphase (on each slide at 
each dose per donor) compared to all other cells on the slide (interphase). No significant 
difference in non-irradiated, baseline values from PCa and healthy controls was observed 
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at both dose points (p>0.1) The mitotic index value at each dose was then subtracted from 
each individual’s non irradiated control value to obtain a radiation induced mitotic 
inhibition value (MIn). This is a value representative of the individual’s response to each 
particular dose of irradiation. Figures 3.2-3.4 show the G2 checkpoint response data in 
healthy controls (figure 3.2), pre-therapy/baseline PCa (figure 3.3) and all 5 visits for 3 
PCa patients at 0.05Gy compared to 0.5Gy (figure 3.4). 
A significant increase in MIn was observed in the subset of male healthy controls at 0.5Gy 
(p=0.0004) (figure 3.2) as was observed in the PCa patients (P=0.02) (figure 3.3). A drop 
in mitotic inhibition at both doses was observed after hormone treatment (V2) (Figure 
3.4) which then increased significantly after last day of radiotherapy (V3) and 8month 
follow up (V5). There was little to no inhibition at the 2month follow up. At 0.5Gy, little 
change was observed after V2, with only a significant drop from V1 to V2 from 3% to 
1% (P=0.048) (Figure 3.5).  
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Figure 3.2 Checkpoint response from the male subset of a healthy control donor cohort 
as represented by Mitotic Inhibition (MIn) at 0.05Gy and 0.5Gy. P =0.0004. 
Figure 3.3 Baseline (V1) checkpoint response in Prostate Cancer (PCa) donors as 
represented by mitotic inhibition (MIn) values. The MIn value was obtained by 
subtracting the mitotic index for each dose from the individuals non irradiated control. 
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Figure 3.4 Checkpoint response as represented by mitotic inhibition (MIn) from 3 PCa 
donors for all 5 hospital visits. V1 represents baseline, V2 after hormone treatment, V3 
last day of RT, V4 2month follow up and V5 8month follow up. 
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Figure 3.5 Checkpoint response as represented by mitotic inhibition (MIn) from 3 PCa 
donors for 4 hospital visits. V1 represents baseline, V2 after hormone treatment, V3 
last day of RT, V4 2month follow up. 
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3.3.2 G2 Chromosomal Radiosensitivity 
G2 chromosomal radiosensitivity was analysed in PCa patients for all types of structural 
and numerical aberrations (described previously in the methods section and examples 
shown in figure 3.6). 100 metaphase spreads were analysed per dose, per donor and a G2 
score was assigned to each donor.  
 
 
 
 
The radiation induced G2 score was calculated by subtracting spontaneous aberrations in 
the non-irradiated control away from the dose points. A radiosensitive cut-off value was 
used from a male subset of the healthy donor cohort which was validated in chapter 2. 
This cut-off represents a point where 90% of the sampled population lie, and donors above 
this point are considered to be radiosensitive. This was previously used in a number of 
chromosomal radiosensitivity studies. For this thesis, the radiosensitive cut-off was 159 
aberrations/100 metaphases as derived from the validation study in chapter 2 using the 
healthy control cohort. Figures 3.7 – 3.12 represent G2 radiosensitivity data of HC, PCa 
and comparison of hospital visits for PCa patients. Figure 3.7 represents ranges of G2 
Figure 3.6 Examples of chromosomal aberrations recorded by microscopy in this chapter. The first image 
represents endoreduplication, the second tetraploidy, and the third shows an example of a break.  
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scores at 0.5Gy from donors in each category; a subset of 19 male healthy donors from 
the 42 healthy control donor cohort in chapter 2 and V1 baseline G2 scores from 22 PCa 
patients. The radiosensitivity cut off has been routinely used to identify radiosensitive 
subgroups in previous studies (chapter 2).  
 
 
 
 
A significant increase in aberration yield was observed between spontaneous aberrations 
in the controls compared to aberration yields at 0.05Gy and 0.5Gy in both HC and PCa 
patients (Figure 3.8) (P<0.001). Additionally, a significant increase in aberration yields 
was observed in PCa compared to HC at 0Gy and 0.5Gy (P = 0.002), but not at 0.05Gy 
where aberration yields were slightly higher in HC (P>0.01).  
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Figure 3.7 Range of Healthy controls (HC’s) and Prostate Cancer (PCa) patients in 
each category of G2 scores at 0.5Gy. Radiosensitivity cut-off is represented with a solid 
dark line at 159 aberrations/100 metaphases. 
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For 3 donors at all 5 follow ups, a trend was observed in aberration yields between follow 
up visits, with a significant drop in radiosensitivity scores between visit 2 and visit 3 (p = 
0.038) (Figure 3.9). A drop in aberration yield was observed from baseline until last day 
of radiotherapy, but by 2 month follow up the aberration yield had increased, with more 
aberrations observed by the 8 month follow up at 0.05Gy (Figure 3.9).  
At 0.5Gy a significant trend was observed in radiosensitivity through follow up visits 
(Figure 3.10). A drop in aberration yield was observed between baseline and post 
hormone treatment, but an increase in aberration yield followed at last day of 
radiotherapy, which dropped again at the 2 month follow up only to increase at 8 month 
follow up (Figure 3.9) (P=0.0428). The same was observed for four visits with 13 donors. 
 
 
Figure 3.8 G2 Radiosensitivity in Healthy controls (HC) compared to Prostate Cancer 
patients (PCa) at 0Gy, 0.05Gy and 0.5Gy 
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Figure 3.9 Radiosensitivity scores at 0.05Gy for Prostate Cancer (PCa) patients 
through their radiotherapy regimes. V1 represents baseline, V2 after hormone 
treatment, V3 last day of Radiotherapy, V4 2month follow up and V5 8month follow 
up. 
 
Figure 3.10. Radiosensitivity scores from Prostate Cancer (PCa) patient blood samples 
irradiated at 0.5Gy throughout radiotherapy visits. V1 – V5 corresponding to hospital 
visits as described previously. Spontaneous aberration yield was subtracted from each 
dose. 
 115 
 
As more patients were recruited for sampling in 4 out of 5 follow ups, those 13 patients 
were analysed to determine the trend over pre-therapy (V1), post-hormone treatment 
(V2), last day of radiotherapy (V3) and 2 month follow up (V4). Similar trends were 
observed as per Figure 3.8 and 3.9 and no significant change between any follow up was 
observed at both dose points (P >0.056). Additionally, no significant change in aberration 
yield was observed between the first two follow ups in 13 donors (pre therapy and post 
hormone therapy) at both dose points (P > 0.5).  
3.3.3 Radiosensitivity and Toxicity 
From the subset of PCa patients (N=22), no donor showed extreme radiosensitivity as 
compared to other radiosensitive disorders using the assays mentioned. Therefore, 
patients with long-term side effects were recruited as part of the study. These individuals 
were sampled at 2 years after radiotherapy with side effects (grade 2 late toxicity) and 
compared to control patients who received radiotherapy at the same time as those 
individuals but did not display long term side effects. 3 of those patients were used in this 
study, as patient recruitment and sampling is currently ongoing for an extension of this 
study. No significant change in checkpoint response or radiosensitivity was observed, 
apart from one of the 3 patients who had an abnormally low G2 radiosensitivity score at 
0.5Gy at 85 aberrations/100 metaphases compared to healthy controls and other prostate 
cancer patients.  
Using the Spearmann – Rank correlation test, correlations were done using each endpoint 
– MIn, RIG2 and Toxicity grading at each dose and each visit. The correlation was 
performed in Graphpad Prism 6 by sorting values in ascending order. The test gave a 
correlation coefficient of between 0 and 1 as an output, with values closer to 1 
representing a positive correlation. All the mentioned endpoints were analysed together 
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to observe if any correlations existed, but no significant correlation was found between 
all the experimental endpoints (R>0.2 for all).  
3.4 Discussion 
G2 checkpoint response and radiation induced G2 chromosomal aberrations data are 
discussed with reference to dose, patient visit and toxicity gathered from the ICORG 
clinical trial (explained in section 3.1). 
Significant checkpoint inhibition was observed at 0.5Gy but not 0.05Gy for both the 
subset of male HC’s and PCa patients. This was expected as it represents efficient 
checkpoint activation in response to the doses of radiation used. A radiosensitivity score 
was assigned to all donors throughout their radiotherapy visits (as previously explained). 
PCa patients showed a significantly greater level of aberrations per 100 metaphases 
compared to a subset of male healthy controls as expected.  This was found to be true in 
a number of other studies on G2 radiosensitivity of PCa and BPH patients, for example 
Howe et al  found a significant increase in aberration yield in both PCa and BPH patients 
compared to healthy controls158. A radiosensitivity cut off of 159 aberrations per 100 
metaphases was derived by the 90th percentile calculation of healthy controls in chapter 
2 of this thesis. A significant proportion of PCa donors (represented in blue) are to the 
right of this cut off, which represents that this subset of donors is considered 
radiosensitive. Similar work was shown by Howe et al  using PCa and BPH patients158, 
and again using breast cancer165 and colorectal carcinoma cohorts230. In this prostate 
study, a higher aberration yield was observed at 0.5Gy compared to 0.05Gy at all 
radiotherapy hospital visits (V1-5) which is not unusual. The highest aberration yield was 
observed at baseline. A significantly higher level of aberrations was observed in PCa 
donors at 0.5Gy compared to male healthy controls, and although not significant but 
interestingly, the opposite pattern was observed at 0.05Gy, which suggests that 
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aberrations are produced through differing molecular mechanisms at the lower dose point 
as discussed in chapter 2299. At 0.05Gy, the lowest aberration yield is after radiation 
therapy (V3), and aberration yield increases at 2 months and 8 month follow up. This may 
be due to cell death mechanisms after radiotherapy. At 0.5Gy, the opposite is observed, 
with the highest level of aberrations shown after radiotherapy at V3. Baseline levels (V1), 
after radiotherapy (V3) and 8 month follow up (v5) aberration yields are all similar, with 
a drop in aberrations after hormone treatment and at 2 month follow up. This could be 
due to hormonal effects in response to hormone therapy at V2, and possibly redistribution 
of cells in the cell cycle after radiotherapy. Recently, a long term follow up in PCa patients 
who received radiotherapy showed that even from 2 years to 15 years after radiotherapy, 
side effects such as urinary leakage, bowel problems and erectile dysfunction still exists  
therefore an increased aberration yield at 8 month follow up in the data compared to the 
2 month follow up presented here could possibly predict future side effects or 
complications300. 
18 patients were recruited as part of the study who exhibited grade 2 toxicity up to 2 years 
after radiation treatment. Using 3 of these donors, no significant change in checkpoint 
response or radiosensitivity was observed compared to controls, apart from one of the 
three donors who showed extremely low levels of aberrations at 85/100 metaphases at the 
higher dose point. No differences in toxicity using G2 chromosomal radiosensitivity is 
not unusual, as Brzozowska et al found exactly the same results using lymphocytes from 
PCa patients with and without acute side effects after 0.5Gy or 1Gy of ex vivo 
irradiation233. Cesaretti et al found that ATM sequence variants could predict adverse 
reaction to brachytherapy in PCa patients, so further exploration of ATM and target genes 
could provide more information for identifying a biomarker panel for toxicity testing40. 
In their findings, many more patients were tested (>2000) over a 15 year period for 20 
ATM variants and they found that those patients with a variant substitution were 
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candidates for further investigation as they tended to be more prone to developing toxicity 
after treatment with brachytherapy.  
 
3.5 Chapter Conclusions and Summary 
To the best of the author’s knowledge, this is the first piece of work which investigates 
prostate cancer patient radiosensitivity using a chromosomal aberration approach at the 
low doses used at 5 different stages of radiotherapy treatment.  The data presented in this 
chapter supports the idea of potentially using the G2 chromosomal radiosensitivity assay 
as an accurate predictor of radiotherapy response. This is evident by the response 
presented in this chapter at the doses of 0.05Gy and 0.5Gy compared to 0Gy control. 
Although the picture is complicated at 0.05Gy for all techniques, using this dose was able 
to show higher aberration frequency in Grade 0/1 toxicity compared to Grade 2 toxicity 
in 2 PCa donors. However, further work is needed with a larger number of patients and 
toxicity data to draw any conclusions from this. 
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4. FURTHER EXPLORATION OF BIOMARKERS OF RADIOSENSITIVITY 
DRIVEN BY CELLULAR MECHANISMS  
 
4.1 Introduction 
Ataxia Telangiectasia (AT) is an inherited autosomal recessive disorder in which carriers 
(AT heterozygotes) constitute approximately 1% of the population160. It is the most 
thoroughly studied radiosensitive phenotype and was first described clinically in 1926 by 
Syllaba et al  who reported the clinical observations of AT (then known as Louis-Barr 
syndrome)36. These observations were ocular telangiectasia, cerebellar ataxia, chorea, 
cerebellar atrophy and thinning of the cerebellum and slurred speech. The name Louis-
Barr comes from Madame Louis-Barr who reported a case of AT in a nine year old boy 
in 1941, who presented with cerebellar ataxia and cutaneous telangiectasias301. There 
were no further reports until the late 1950’s when AT was then established as a disease 
entity after a study of eight unrelated cases of AT and six familial cases by Boder and 
Sedgwick, who termed the disease Ataxia Telangectasia37.   
Symptoms of the disease develop in children before the age of 6 with the most common 
symptom reported as slurred speech and loss of balance and then progressive 
neurodegeneration leads to wheelchair confinement before the age of 10 years32. The 
median survival rate ranges from 19 – 25 years of age302. Chronic lung disease is the most 
frequent cause of death among AT patients due to recurrent sino-pulmonary infections 
and immune disorders32. AT patients demonstrate characteristic cellular features of 
immunodeficiency, radiosensitivity and present a high predisposition to cancer (most 
often leukaemia’s or breast cancer). These characteristics are all common cellular features 
of a variety of radiosensitive syndromes described in section 1.3 of this thesis.  These 
syndromes are caused by an underlying genetic mechanism most often associated with 
the DNA damage and repair response.  
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In addition to the clinical features of AT, patients have diminished cellular immunity with 
little to no immunoglobulin A (IgA)303. Additionally, Waldmann and McIntire reported a 
higher level of alpha feto-protein specific to AT patients and not in patients from other 
immunodeficient syndromes. Interestingly, it was found  to be elevated in pregnant 
women, the molecular link of which is not yet known304. Other elevated blood proteins in 
AT patients include cancer antigen 125 (CA125) which is also a marker of ovarian cancer 
and is used to help diagnose AT305. AT patients are monitored periodically due to their 
diminishing lung function. Recently, an association between elevated interleukin-6 (IL-
6) levels and lower forced vital capacity (FVC) has helped to monitor AT patients within 
the clinic306. Additionally, significantly increased levels of copper and decreased levels 
of zinc were identified in the blood from AT patients compared to control donor blood 
copper and zinc levels using mass spectrometry307.  
Chromosomal radiosensitivity was one of the first cellular features described in AT 
patients. Higurashi et al  found a higher level of chromosomal aberrations in AT patients 
and other associated immunodeficient syndromes in response to 0.1-1Gy of γ-rays 
delivered to leukocytes308. Taylor et al  further described higher chromosomal 
radiosensitivity of cells from AT patients compared to controls and fluctuations of 
radiosensitivity in AT cells through the stages of the cell cycle309. They also described 
how histone modifications prevented AT cells from repairing DNA damage, as healthy 
cells readily utilised histone remodelling to promote DNA repair in response to DNA 
damage289, 290. Bender et al 312 and Parshad et al 151  also described higher aberration 
frequencies in LCLs and fibroblasts from AT patients and AT heterozygotes compared to 
age matched controls. These observations came before identification and mapping of the 
ATM gene. 
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In 1988, Gatti et al  mapped the gene responsible for AT to chromosome 11 on the q arm 
and position 22-2334. This was later identified by Savitsky et al  who identified the gene 
as ataxia telangiectasia mutated (ATM)33. The ATM gene is a member of the 
phosphatidylinositol-3-kinase (PI3K) family of kinases and is 150kb which comprises 69 
exons encoding a protein of 3056 amino acids313. Kinases catalyse the addition of 
phosphates to other proteins in the process of phosphorylation. This can activate or 
deactivate other proteins and operates in tandem with dephosphorylation (removal of a 
phosphate). 
Several mutations have been associated with AT with the most common being truncating 
mutations, resulting in the total absence of ATM kinase activity. In contrast, Missense or 
splice site mutations of ATM result in limited kinase activity314. According to the Ataxia 
Telangiectasia Mutations database website, 459 unique DNA sequence variants  have 
been discovered as of 15 Feb 2016315. Over 33 allelic variants of ATM mutations have 
been found. For example, Savitsky et al observed a loss of serine 152 resulting from a 
deletion of 3 base pairs in one allele in a case of AT complement A in a Dutch family. 
They went on to describe two siblings diagnosed with AT complement group E and found 
both were homozygous for a deletion of 9 base pairs resulting in a loss of amino acids 
1198-1200 in the gene product. On analysis of the ATM gene in two AT patients with 
English/Indian ancestry, a complementation group D was defined showing a deletion of 
6bp in one allele resulting in deletion of 2 amino acids in the gene product33. Whether 
truncating, splice or missense mutations, mutations in ATM result in loss of amino acids 
leading to diminished or altered ATM levels and perturbed response to DNA damage and 
repair. 
The role of ATM is to coordinate a cascade of molecular events by phosphorylation 
mechanisms in the DNA damage response (DDR)316. ATM is the central coordinator in 
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the DNA damage response for recognition and transduction of signals so that the cell 
cycle is halted to allow for repair mechanisms to occur. The cell does this via two 
pathways, namely ataxia telangiectasia rad 3 related (ATR) and ATM. Single strand 
breaks (SSB’s) caused by replication errors in DNA synthesis activate ATR which in turn 
inhibits cell cycle progression at G2/M through CHK1. Double strand breaks (DSB’s) are 
the most common break associated with ionizing radiation induced damage. DSB’s are 
sensed by ATM and downstream signalling causes the activation of CHK2 and G1/S 
checkpoint arrest. ATM signalling is described in detail in section 1.4.3. 
The radiosensitivity phenotype of AT cell lines along with the characterised molecular 
role of ATM in the DNA damage response to radiation has been adopted by many 
radiobiologists as the best biological model for studying cellular radiosensitivity. The 
work described in this chapter aims to investigate cellular radiosensitivity and the role of 
ATM in lymphoblastoid cell lines (LCL’s) from healthy controls versus AT patients. The 
cell lines were established from lymphocytes taken from healthy controls (2139 and 2145) 
and AT patients (AT2Bi and AT3Bi) and immortalised with the Epstein Barr virus. This 
allowed for multiple experiments and replicates to be conducted which was in contrast 
with the studies done on whole blood cells directly from donors.   
The normal cell lines were established before 1990 using healthy controls and 
characterised as normal for AT comparison analysis based on cell survival, cell cycle 
analysis and ATM gene expression317. The AT2Bi cell line was established from a 19-
year-old Caucasian female affected by AT who exhibited increased chromosomal 
radiation sensitivity and increased chromosome breakage induced by bleomycin. From 
the repository of Coriell Institute of Medical Research, genetic characterisation of AT2Bi 
showed one allele which carries an insertion of TT at nucleoside 6404 (6404insTT) in 
exon 46 which leads to a frameshift beginning at codon 2073 and a truncation at codon 
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2135 (L2073fsX2135)318. AT3Bi cell line was collected and established from a donor 
affected with AT. No other genetic information was supplied or found for this cell line 
but it was characterised as radiosensitive among other radiosensitive syndromes using 
cell survival as an endpoint319. 
Characterisation of the normal and AT cells was performed to investigate if a molecular 
cytogenetic probe could distinguish AT from the healthy control cell lines and be potential 
cytogenetic biomarkers for cellular radiosensitivity. The target probes employed were 
ATM, CEPX (for centromere), TP53, and immunoglobulin heavy chain (IGH). The ATM 
and TP53 probes were used to determine any gene deletions in the AT cells. CEPX was 
a chromosomal marker used to determine the sex of the donor and IGH was used to 
determine any rearrangements in chromosome 14 due to its association with blood based 
cancers i.e.: Leukaemia. IGH rearrangements have been associated with a wide range of 
leukaemias and lymphomas including non-Hodgkin’s lymphomas (NHL), chronic 
lymphocytic leukaemia, Multiple Myeloma and acute lymphoblastic leukaemia (ALL) 
which AT patient have been known to be susceptible to.  
The aim of this chapter was to investigate the normal cellular response to irradiation using 
healthy cells and cells lacking in ATM using an array of radiobiological assays, doses, 
time-points and endpoints. These included cell survival, viability, cytotoxicity, γH2AX 
induction, cytogenetics (to include chromosomal aberration analysis, G-Banding and 
fluorescent in situ hybridisation).  
4.2 Methods 
4.2.1 Cell lines and Cell culture and Irradiation setup  
LCL’s generated from lymphocytes taken from two healthy donors (2145 and 2139) were 
donated from Dr Janet Hall at the Institute d’ Curie, Paris, France. LCL’s from donors 
with confirmed Ataxia telangiectasia (AT) (AT2Bi and AT3Bi) were donated from 
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Professor Malcolm Taylor from the University of Birmingham. These lymphocytes were 
immortalised with Epstein-Barr virus. LCL’s are cells which grow in suspension and do 
not attach to surfaces of their environment. They were maintained in standard RPMI 
medium (Sigma) supplemented with 10% Foetal bovine serum (FBS), L-Glutamine and 
incubated at 37°C with 5% CO2. Each cell line was kept at a density of 1x10
5/ml and split 
by 1:5 dilutions every 24-48 hrs. Prior to irradiation, 5 mls of cells at a density of 
1x106cells/ml were seeded per flask, per cell line and per dose for each of the biological 
endpoints described below. Flasks were irradiated at 0 Gy, 0.05Gy, 0.5Gy and 2Gy using 
a Linear Accelerator (setup and dosimetry described in Chapter 2).   
4.2.2 Cell viability and Cytotoxicity 
Cell viability, cytotoxicity and caspase activation was analysed 1 hr and 24 hrs post 
irradiation using the ApoTox – Glo Triplex assay (Promega). To determine viability and 
cytotoxicity, two differential protease biomarkers were measured by the addition of a 
non-lytic reagent with two peptide substrates. The live cell portion was analysed for 
viability with a fluorogenic cell permanent peptide substrate (GF-AFC substrate) which 
restricted uptake of the dye into live intact cells only. A second, non-permanent 
fluorogenic peptide substrate (bis-AAF-R110) was used simultaneously to measure dead 
cell protease activity which was released from cells with ruptured membranes.  
  
4.2.3 Cell Survival 
Cells were plated at a density of 1x106 cells/ml for each cell line. After irradiation the 
cells were incubated for 72 hrs. Cell counts were conducted from suspensions taken at 72 
hrs post irradiation using a Coulter Counter. The data collected was used from three 
independent experiments which were carried out for cell survival analysis. 
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4.2.4 DNA Damage 
Twenty-four hours prior to irradiation, LCL’s were seeded into T25 flasks at a density of 
1x106cells/ml. 1 hr and 72 hrs post irradiation, cells were fixed with 70% ethanol (Sigma, 
Laboratory Grade). 
4.2.5 Cytogenetics and Microscopic analysis 
The G2 Chromosomal radiosensitivity assay as described previously in Chapter 2 section 
2.2. was also conducted to measure cell cycle checkpoint response by mitotic indices and 
radiation-induced mitotic inhibition, as well as G2 chromosomal radiosensitivity. The 
mitotic index was calculated by counting the ratio of cells in metaphase to all cells on the 
slide up to 1000 cells in total for each dose and cell line. Mitotic inhibition was calculated 
by subtracting the mitotic index at each dose away from the control. A G2 radiosensitivity 
score was assigned to each of the cell lines and per irradiation dose by calculating the 
total number of aberrations in each. All numerical aberrations 
(aneuploidy/polyploidy/endoreduplication) and structural (gaps/breaks/terminal 
deletions/fragments/dicentrics etc.) were totalled for each dose per 100 metaphase cells. 
The spontaneous aberration yield in the non-irradiated control (0Gy) for each cell line 
was subtracted from each dose (0.05Gy and 0.5Gy) to calculate a radiation induced G2 
radiosensitivity score.  For LCL’s, incubation of colcemid was increased from 1hr to 2hrs 
for chromosome harvest. Low chromosome harvest was observed compared to whole 
blood cultures used previously.  
4.2.6 G-Banding 
After metaphase preparation on glass slides, slides were aged for 1 minute in the UV box.  
They were then placed on the slide rack and covered with 30% hydrogen peroxide 
solution for one minute. After rinsing with 0.9% NaCl solution the slides were placed in 
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trypsin solution for the 2 mins. Slides were rinsed with Gurr buffer and were then stained 
in 1ml of 1:2 Leishmann: Gurr buffer mix for 1min.  After 1 minute, slides were rinsed 
with Gurr buffer and immediately with distilled water. The excess water was drained from 
the slide on to tissue and the slide was placed on to a slide to allow the surface to dry 
thoroughly. The slides were then mounted with DPX with air bubbles removed. Each 
slide was evaluated under the microscope set up for bright-field use, noting conditions of 
under or over banding or staining. 25 metaphases were analysed under the microscope 
for G-Banding and karyotyping. 
4.2.7 Fluorescent In Situ Hybridisation (FISH) cytogenetics 
Slides were soaked in sodium chloride and sodium citrate buffer (SCC) for 2mins at 37°C, 
before being soaked in protease solution for 30-40 seconds at 37°C. Slides were then 
washed in 1xPBS at room temperature. Slides were dehydrated in an ethanol series (70%, 
85% and 100%) for 2 minutes each at RT and air dried before hybridisation. Hybridisation 
probes were used to identify deletions or rearrangements in ATM-TP53 (Cytocell), CEPX 
(Abbott) and IGH (Abbott). Probes for ATM-TP53 were used to show if ATM was 
deleted in the AT cells. CEPX is a probe for the X chromosome and was used to identify 
the sex of the donor of each cell line. IGH break apart probes were used to detect breakage 
of IGH, which is observed in the t(14;14) (q11;q32) translocation (or in(14)(q11q32) 
rearrangement) and is usually found in T-cell leukaemia associated with AT. IGH Break 
Apart Probes are designed to detect the translocation involving the immunoglobulin 
heavy chain (IGH) locus on chromosome 14q32. In normal situations, two colours 
represent the 3’ and 5’ ends of IGH. In disease break apart of the probe colours represent 
duplications or deletions of one or more colours of the probe indicating abnormality. 
Probes were mixed according to the manufacturers protocol (Appendix 3) and the 
required amount was added to each slide. Slides were transferred to a Hybrite machine 
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which was programmed to 37°C. Hybridisation program 1 was selected (75°C for 2 min, 
37°C for 20 hours). On removal from the Hybrite, coverslips were removed and slides 
were immersed in wash solution (0.4xSSC/0.3% NP 40, Appendix 3) for 2 minutes. 
Slides were then transferred into a solution of 2xSSC/0.1% NP40 for a minimum of 1 
minute and excess liquid was removed from each slide. 20μl of DAPI stain and then 
coverslips were added to the slide preparations. For FISH microscopy 25 metaphases 
were recorded.  
4.2.8 Statistical Analysis 
Statistical analysis was completed using Graphpad Prism 6 for all cellular assays. For 
each assay, ANOVA was done for all doses (0Gy, 0.05Gy, 0.5Gy and 2Gy) and cell lines 
(normal 2145 and 2139, and radiosensitive AT2Bi and AT3Bi). A significance level of 
0.05 was assigned for each output. Coefficient of variation (%) for cytogenetic results 
was calculated using Microsoft Excel and was described in chapter 2 section 2.2. This 
formula was as follows; Variation = (standard deviation of the mean/mean) x 100.  
4.3 Results 
4.3.1 Cell Growth and DNA Damage Post Irradiation 
Relative growth of cells after irradiation was measured by cell counts at 72 hrs post 
irradiation. No significant difference was observed with dose using the normal 2145 cell 
line, however a dose response effect was observed with the control cell line 2139 and 
both AT cell lines (Figure 4.1) (p<0.05). A higher cell survival (between 50,000 and 
100,000 cells) was observed with the 2139 and both AT cell lines compared to the 2145 
cell line which showed low levels of cell survival (less than 50,000 cells) and no 
differences between any dose. A higher level of variation of triplicates was observed for 
the non-irradiated control in AT2Bi, and a higher cell survival was observed at the lower 
dose point (0.05Gy) with this cell line compared to all other cell lines and doses.  
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4.3.2 Cell viability and Cytotoxicity 
Figures 4.2 and 4.3 represent cell viability and cytotoxicity which was measured using 
the ApoTox -ProGlo™ triplex assay kit from Promega at 1 hr and 24 hrs following 
irradiation. There was no significant change in viability between cell line, dose or time 
point. However, a large difference in viability was observed in AT2Bi for the 3 doses at 
Figure 4.1 Survival after irradiation of LCL’s measured by their relative growth at 72hrs 
post irradiation. Cell survival for normal cell lines (2145 and 2139) were compared to AT 
cell lines (AT2Bi and AT3Bi) N=3.   
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24 hours indicating a varied response compared to the other cells lines (Figure 4.2) (p 
>0.05).  
For cytotoxicity, little difference was observed across dose or time point for the control 
cell lines, except for 2Gy at 24 hrs for the 2139 cell line (Figure 4.3). A significant 
increase in cytotoxicity was observed at 24 hrs post irradiation in AT2Bi compared to 1 
hr, as well as a significant increase in cytotoxicity at 1 hr for AT3BI compared to 24 hrs 
for the irradiated cells only (p=0.04).  With deficient ATM, AT cells cannot recognise 
DNA damage or inhibit cell cycle progression for repair. AT cells undergo aberrant repair 
despite lacking ATM, but this is chaotic and involves lowering the threshold of p53 
activation due to spontaneous DNA damage (not involving ATM). This could be why the 
AT2Bi cell line here showed an immediate spike in cellular cytotoxicity (immediate 
recognition of damage not involving ATM) and also why AT3Bi showed a delayed 
response (delay until p53 is activated). Both cell lines differ due to their heterogeneity 
(separate individuals) and therefore would be predicted to show differences in 
radioresponse.  
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Figure 4.2 Cell viability as a percentage of the non-irradiated control. Cells from Ataxia Telangiectasia 
individuals (AT2BI and AT3BI) in comparison to cells from normal healthy donors (2145 and 2139) 
(N=2).  
 
Figure 4.3 Cytotoxicity at 1hr and 24hrs post irradiation. Values for each dose and cell line were 
expressed as a percentage of the non-irradiated control. n=2 
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4.3.3 DNA Damage  
DNA damage was investigated by means of γH2AX. This was performed using flow 
cytometry (mean fluorescence intensity (MFI)) and foci induction using confocal 
microscopy. Using flow cytometry, MFI was plotted for each of the doses as a percentage 
of their control for 1 hr post irradiation (figure 4.4) and 72 hrs post irradiation (figure 
4.5). At 1 hr, the two control cell lines are very different at the lower dose point (0.05Gy) 
and the higher dose point (2Gy) as a higher level of γH2AX is observed in the 2139 cell 
line for both of these doses compared to a much lower level in the 2145 cell line. The 
highest overall intensity of γH2AX was observed at 2Gy in the normal cell line 2139. 
Both AT cell lines show a similar response apart from a much higher baseline γH2AX 
induction in the non-irradiated control of AT3Bi, which indicates a level of damage 
present before irradiation exposure. Additionally, large variation was observed at 2Gy 
with the AT3Bi cell line, indicated by large overlapping error bars. 
An overall reduced response of γH2AX induction was observed at 72 hrs (Figure 4.5). A 
lower level of γH2AX was observed at 0.05Gy and 2Gy in the normal 2145 cell line, 
compared to little or no γH2AX in the irradiated samples of 2139. No γH2AX was 
observed at 0.5Gy and 2Gy in the AT2Bi cell line, compared to a much higher level of 
γH2AX at 0.05Gy and 2Gy with the AT3Bi cell line. A large variation in γH2AX 
induction was observed in AT3Bi at 2Gy again, represented by large error bars. 
There was an overall reduced response of γH2AX at 72 hrs post irradiation compared to 
1 hr, which highlighted that γH2AX foci are presented instantly in the DNA damage 
response and that cell cycle response and DNA repair mechanisms are central to this 
response so that damage foci would indeed be reduced by 72 hours. A reduced expression 
of γH2AX was observed in the 2145 cell line at the lower dose points at 72 hrs, compared 
to the high level at 1 hr.  
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Figure 4.4 Mean fluorescence intensity (MFI) of γH2AX at 1hr after irradiation for each of 
the cell lines and doses. n=2 
 
 
 
 
Figure 4.5 Mean fluorescence intensity (MFI) of γH2AX at 72hrs after irradiation for each 
cell line and dose. n=2 
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Using confocal microscopy, average foci per cell were calculated for each of the cell lines 
and doses at 1 hr and 72 hrs. This was done to observe if measuring another endpoint in 
parallel for γH2AX could confirm results of flow cytometry induction of γH2AX or 
obtain additional information to distinguish radiosensitivities of each cell line per dose 
and time point. A dose response was observed in all cell lines, between each dose for 1 
hr (Figure 4.6) (not distinguishable for the lower dose points with AT3BI cell line). At 72 
hrs the average number of foci per cell had dramatically decreased at the higher dose 
points (Figure 4.7). This most likely represents a reduction of γH2AX foci around the site 
of DNA damage break as the damage has had time to repair. A dose response was 
observed in 2139, and AT3Bi, and a higher level of foci observed at 0.5Gy for AT2Bi 
(p<0.05). Similar levels of γH2AX foci remained from 1hr to 72hrs for the lower dose 
points (0.05Gy and 0.5Gy) and a reduction was observed from 1hr to 72hrs for the higher 
dose of 2Gy. A high level of background foci was observed in the non- irradiated controls 
for both flow cytometry and confocal microscopy γH2AX endpoints. 
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Figure 4.6 Average foci per cell of normal (2139 and 2145) cell lines compared to 
AT (AT2BI and AT3BI) cell lines. n=1 
Figure 4.7 Average foci per cell observed in normal (2145/2139) vs AT (AT2Bi and 
AT3Bi) cell lines. n=3  
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4.3.4 G2 Chromosomal Radiosensitivity 
Checkpoint and G2 radiosensitivity analysis was performed by measuring the mitotic 
index and G2 radiosensitivity scoring respectively as described in the methods of Chapter 
2 and 3.  
4.3.4.1 Radiation induced Mitotic Inhibition and G2 Radiosensitivity 
A higher cell cycle checkpoint radiation-induced mitotic inhibition was observed in the 
2145 and 2139 cell lines at each dose (except for 2Gy in the 2145 cell line which was 
lower than at 0.5Gy) compared to the AT cell lines, indicating that the cell cycle 
checkpoint response was functioning normally in the underlying DNA damage response. 
No inhibition was observed at the lowest dose point for both AT cell lines, (represented 
by negative inhibition in Figure 4.8). A lower inhibition was observed in all other doses 
in each of the AT cell lines (figure 4.8).  Mitotic inhibition represents checkpoint response 
to the given dose of irradiation. Inhibition is the result of activation of ATM which in turn 
regulates inhibition of cell cycle progression through CHK1 and CHK2. Therefore, more 
inhibition represents a delay in progression of cells in the cell cycle to allow for DNA 
damage repair in the normal DDR. The normal cell lines were expected to show more 
checkpoint inhibition and more sensitivity to radiation because the DDR is working 
normally. However, if ATM was depleted, an alteration in checkpoint response (mitotic 
inhibition) would be expected and was observed in the AT cells 
A significant increase in radiation induced G2 chromosomal aberration frequency was 
observed with increasing dose in all cell lines (Figure 4.9) with a significant change 
observed in all doses compared to the control, and between each dose (p<0.05). No 
significant difference was observed between control cell lines and AT cell lines at any 
dose point. Therefore, all cells showed similar chromosome damage induced by the same 
low doses of radiation. 
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Figure 4.8 Mitotic inhibition was calculated by subtracting the mitotic index value at 
each dose point from the value at the respective cell line’s 0Gy control value. This is 
represented as a percentage for each of the cell lines. n=3 
 
Figure 4.9 Radiation induced G2 score was calculated by subtracting the spontaneous 
aberration score in the 0Gy controls for each cell line from the dose value in each cell line. 
n=3  
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4.3.4.2 LCL variation in radiosensitivity response 
Coefficient of variation was calculated on the healthy control cohort from chapter 2 for 
optimisation and validation of the G2 chromosomal radiosensitivity assay. From the 
variation results in chapter 2, it was clear that less inter variation is observed with 
increasing radiation dose (chapter 2, section 2.3.3). Here, variation was calculated 
between normal healthy cells (HC) (2145 and 2139) and compared to AT cells (AT2Bi 
and AT3Bi) since all cells were derived from individual donors and similar to the inter 
variation analysis performed on donor and patient blood cohorts. A higher variation was 
observed with dose in the healthy control cells and compared to the AT cells (Figure 
4.10). The highest variation (38%) was observed at the dose of 0.5Gy for both healthy 
and AT cell lines, indicating that there were different radiation responses between the 
healthy and AT cell lines at the most radiosensitive dose, but surprisingly that some 
underlying factor was responsible for radiosensitivity observed in the healthy controls. In 
contrast, minimal difference between the healthy controls and AT cell lines was observed 
at 0Gy highlighting that radiation exposure was a critical instigator of the DNA damage 
response in all cell lines and that the DNA damage response involving ATM was a key 
player. Although a difference was observed between the doses and cell lines, this was not 
significant due to the high levels of variation (P=0.08 for cell lines and P=0.111 for dose).  
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4.3.5 G-Banding  
For cytogenetic characterisation and analysis, G-Banding was completed on the 4 
lymphoblastoid cell lines. This work was carried out in collaboration with Dr Natasha 
Coen at the Crumlin Hospital Genetics Department. The cell line 2145 repeatedly failed 
to produce any metaphase to carry out a G-band analysis and therefore no conclusive 
results were given and experiments continued with the 2139 control cells for comparison.  
Clonal or recurrent aberrations are a hallmark of carcinogenesis found in nearly all cancer 
types. Clonal chromosomal aberrations are defined as follows; a chromosomal aberration 
which can be detected at least twice within 20 to 40 randomly examined mitotic figures320. 
Figure 4.10. Coefficient of variation (%) was calculated by dividing the standard 
deviation of the mean by the mean for the Healthy cells (HC) (2145 and 2139) 
and the AT cell lines (AT2Bi and AT3Bi).  
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Therefore, the frequency of detecting a clonal aberration should be above 10 – 15%, and 
the frequency of detecting a non-clonal aberration should be below 5%.  
Non clonal aberrations were first considered as genetic noise and spontaneous aberrations 
which are not induced by outside factors. More recent reports suggest however that non-
clonal aberrations are a main feature of heterogeneity and most of the aberrations detected 
after chemo or radio therapy are non-clonal and unbalanced (>75%)320. Therefore, these 
types of aberrations can serve as an indicator of genomic instability and were 
characterised in the cytogenetic G-banding analysis. 
The cytogenetic analysis on 2139 cells surprisingly showed a loss of a sex chromosome 
in all of cells analysed (Table 4.1/ Figure 4.11 for karyotype). There was no other single 
cell or non-recurrent aberrations detected (Table 4.2). The loss of a sex chromosome is 
associated with the constitutional diagnosis of Turners syndrome in females. FISH 
analysis using ATM (11q22)/TP53 (17p13.1) probe set showed no deletions or numerical 
aberrations involving these loci in the 100 cells analysed (Table 4.3).  Cytogenetic 
analysis of the AT2B1 cell line detected loss of chromosome X (monosomy X) in 9 out 
of the 50 cells examined and so demonstrating that it was clonal (Table 4.1/ Figure 4.12 
for karyotype). There were non-clonal aberrations detected in 4 out of the 50 metaphases 
examined (Table 4.2). 2 out of these cells showed a marker chromosome of unknown 
origin which were seen in both the normal clone and the clone with the monosomy X, this 
marker was not clonal as it was different in both cells. The 3rd  cell showed a complex 
hyper-diploid (chromosome number 51-65 ) karyotype containing both numerical and 
structural aberrations including addition of material of unidentifiable origin to the long 
arms of both chromosome 1 homologues and to chromosome 2 (there was an additional 
chromosome 1 containing  additional material on unidentifiable origin on the long q arm 
but at a different breakpoint) and there were also gains of numerous chromosomes 
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including chromosomes 4, 6, 11, 13, 14, 15, 18, 19, 20 and 21. The 4th cell showed an 
apparently balanced translocation between the short arms of chromosomes 12 and 19.  
 
 
 
 
Cell 
Line 
Karyotype Comments 
2145 Fail Failed to produce 
metaphases for G-
banding 
2139 45,X[50] Loss of a sex 
chromosome in all 
cells (Turners 
Syndrome) 
AT2B1 45,X,-X[9]/46,XX[39] Monosomy X in 9 out 
of 50 cells 
AT3B1 46,XX,add(14)(q32),add(15)(p13)[25]/46,XX[14] Addition of material of 
unknown origin to the 
long arm of 
chromosome 14 and to 
the short arm of 
chromosome 15 
 
 
Table 4.1 Results of the G-band analysis of each of the cell lines showing recurrent and clonal cytogenetic 
aberration. Addition denoted by (add). 
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Figure 4.11 G-Banding of the 2139 cell line showing an abnormal karyotype. Loss of X chromosome was 
found in all 50 metaphases analysed. 
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Cell Line Karyotype 
2139 None Found 
AT2B1 47,XX,+mar 
 46,X,-X,+mar 
 56,X,-X,del(1)(q12q42)x2,+add(1)(q44),+add(2)(q37)x2,-
3,+4,+4,+4,+6,+6,-7,-8,-9,+11,+13,+14,+15,-16,16,-
17,+18,+19,+20,+21,+2mar 
 46,XX,t(12;19)(p13;p12) 
AT3B1 46,X,add(X)(p11.2) 
 46,X,del(X)(q21q26) 
 39,XX,-4,-7,+8,-9,-10,-12,-13,-16,-16,dic(19;?)(q13;?) 
 44,XX,-10,-11,dic(19;?)(q13.3;?) 
 46,XX,add(11)(q25) 
 43,XX,del(1)(q12),-3,-5,-5,-16,+mar 
 45,XX,del(1)(q11q44),del(5)(q11.2q35),add(6)(q13),add(14)(q32),add(1
5)(p13), 
add(16)(q11.2),add(20)(q11.1) 
Table 4.2 Non-clonal aberrations that were detected by G-band analysis. Note that normal cell line 2145 did 
not yield enough metaphases for analysis and no aberrations were found in the 2139 karyotype. Deletion (Del), 
marker (mar), addition (add) 
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The cytogenetic analysis of the AT3B1 cell line showed addition of material of 
unidentifiable origin to the long arm of chromosome 14 and to the short arm of 
chromosome 15 in 25 out of the 50 metaphases analysed (Figure 4.13 for cell line 
karyotype). There were 7 metaphases found with non-clonal aberrations out of the 50 
metaphases. These included 2 cells found with aberrations involving the X chromosome, 
the first had addition of material of unknown origin to the short arm and the second had 
an interstitial deletion in the long arm. There were 2 cells found containing a dicentric 
chromosome 19 where breakage and reunion occurred between the long arm of 
chromosome 19 and a chromosome of unidentifiable origin, both these aberrations were 
different in morphology and the breakpoints were also different, and therefore they were 
classified as non-clonal. There was a cell found containing an aberration in the long arm 
of chromosome 11. The final 2 cells contained deletions in the long arm of chromosome 
1 but with different breakpoints, the first of these cells also contained loss of 
chromosomes 3, 5 and 16 as well as a marker chromosome. The second cell also contained 
numerous other structural aberrations including a deletion in the long arm of chromosome 
5 and addition of material of unidentifiable origin to the long arms of chromosomes 6, 16 
and 20 as well as the clonal add(14q) and add(15p) previously described.   
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Figure 4.12 G-Banding and karyotype of AT2Bi showing loss of X chromosome. This was found in 9 out 
of 50 cells analysed. 
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Figure 4.13 G-Banding and karyotype of AT3Bi showing numerous addition and deletions of 
chromosomal material on/from the wrong chromosomes. 
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4.3.6 Fluorescent in situ Hybridisation (FISH) 
FISH analysis using the ATM (11q22)/TP53 (17p13.1) probe set showed no deletions or 
numerical aberrations involving these loci in the 100 cells analysed (Table 4.3). Further 
FISH with centromere specific probe (CEPX) to chromosome X showed a low level loss 
in 14 out of 100 cells examined and thus confirming the G-band finding of monosomy X 
for 2139 cells (Table 4.1).  
 
Cell Line FISH Probe Karyotype 
2139 TP53/ATM .nuc ish (ATM,TP53)x2[100] 
AT2B1 TP53/ATM .nuc ish(ATM,TP53)x2[100] 
 CEPX .nuc ish(DXZ1x1)[14/100] 
AT3B1 TP53/ATM  .nuc ish(ATM,TP53)[100] 
 IGH (Break 
apart) 
.ish add(14)(q32)(5’IGH +,3’IGH-,5’IGH+)[10] 
 
 
 
 
In normal cells, break apart probes depict two colours which represent the 3’ and 5’ end 
of the IGH locus on chromosome14q32.  Further metaphase FISH with an IGH (14q32) 
break apart probe showed a population of cells with loss of the 3’IGH and a duplication 
Table 4.3 FISH analysis of each of the cell lines to include probes for CEPX, IGH, TP53 and ATM. Note normal 
cell line 2145 did not yield enough metaphases for a conclusive analysis. Addition is denoted by ‘add,’. Nuclear 
in situ hybridisation denoted as (Nuc ish). 
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of the 5’IGH end of the probe that has been shown to be on the derivative chromosome 
14 by metaphase FISH (Figure 4.15). This result would represent a rearrangement of the 
IGH locus with the 5’IGH promotor region been retained on the critical chromosome 14 
and loss of the 3’IGH region. Unfortunately, interphase FISH was not possible due to the 
high level of FITC (green) background making it difficult to read the signals in the nuclei. 
There was a t(14;14) aberration that is classical to AT patients but the aberration observed 
was different as it showed foreign chromosomal material and the orientation of the second 
5’IGH is proximal to the native 5’IGH. This indicated a duplication of the 5’IGH region 
post translocation of the IGH locus.  There was also a more complex rearrangement 
present that involved another unidentifiable chromosome resulting in loss of the 3’IGH.   
 
 
Figure 4.14 FISH analysis using the ATM probe set for AT3Bi cell line showing loss of the 3 IGH and 
duplication of the 5 IGH end of probe. 
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Interphase FISH was done on each cell line with a probe used for detection of ATM and 
TP53 presence or absence. Both ATM and TP53 were observed in all cell lines in two 
copies (Figure 4.15). 
 
 
 
Figure 4.15 Interphase FISH using dual ATM-TP53 probe. A normal ATM and TP53 presence is indicated 
here by two red dots (TP53) and two green dots (ATM).  
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4.4 Discussion 
Epstein Barr virus immortalised lymphoblastoid cell lines from normal (2145 and 2139) 
and AT (AT2Bi and AT3Bi) were used as radiobiological models to investigate extreme 
cellular radiosensitivity and the underlying genetic mechanisms incorporating ATM and 
the DNA damage response.   
Overall with cell survival, viability, cytotoxicity and caspase activation, a small 
difference was observed between normal cell lines and AT cell lines. For γH2AX there 
was a marked response at 1 hr which was dramatically reduced by 72 hrs, which indicates 
that repair mechanisms are still in place for up to 72 hrs after irradiation. These results 
confirm findings by Porcedda et al  who also found residual γH2AX foci present in AT 
cells up to 72hrs after 2Gy of irradiation321.   
It was expected that a different radio-response would be observed in the normal cell lines 
compared to the AT cell lines which was cited by a number of groups using cell survival 
assays for AT radiosensitivity32. Results for the 2139 cell line were surprising as they 
responded quite similarly to the AT cell lines with cell survival experiments. There was 
a large variation within the control cell lines and AT cell lines, which is not unusual as 
they were extracted at one stage from human donors and cells were cultured and 
immortalized. This in addition to the variation of responses in healthy controls at 0.5Gy 
emphasise the underlying genetic mechanisms and factors which may be involved.  
Due to conflicting results between assays, the 4 cell lines were sent to the Cytogenetics 
Department in Crumlin Hospital, Dublin for cytogenetic characterisation by G banding 
and FISH analysis using several selected probes.  Of huge interest was the “normal” cell 
line 2139 which was found to have a loss of X chromosome in all cells analysed, and 
therefore characterised as Turners syndrome. Although, it can only be confirmed as 
Turners syndrome if the results are not a consequence of culturing techniques, which have 
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acquired instability over rigorous culturing and time. A radiosensitivity study conducted 
in 2012 using two groups of Turners syndrome patients, each with different variants (45 
X complement and 46 XX gonadal dysgenesis) and compared to age and sex matched 
controls demonstrated significantly higher levels of chromosomal radiosensitivity after 
3Gy of irradiation322. Therefore, the conflicting data which was obtained with the 
radiobiological assays specifically between the two control cell lines is in agreement with 
previous groups findings. The 2139 cell line in the cellular survival studies shows the 
exact delayed dose response as recorded for the AT cells compared to the normal cellular 
response in the normal 2145 cell line.  
Additionally, G2 aberration scoring from the G2 chromosomal radiosensitivity assay 
demonstrated a higher (although not significant) aberration frequency in the 2139 cell line 
compared to the control 2145 cell line. However, a huge difference in radiosensitivity 
between normal and radiosensitive cell lines was not observed. This is not unusual, as 
Bender et al explained in 1985 reports that no difference was observed in sensitivity 
between normal peripheral blood lymphocytes and peripheral blood lymphocytes from 
AT patients312. It could be worth using fresh whole blood for future experiments, however 
as AT is so rare (<1% of the population) this could be difficult to obtain sufficient 
numbers of donors for analysis. In addition, ATM sequence variants play a huge role in 
heterogeneity and could be one of many factors affecting results in this work. As 
discussed in the previous chapter, Cesaretti et al found over 20 ATM sequence variants 
that contributed to toxicity after brachytherapy for prostate cancer40. As the immortalised 
cell lines were extracted from different donors, the lack of determination of 
radiosensitivity between the cell lines in this work could be attributed to donor 
heterogeneity.  
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Although the cytogenetic findings were in excellent agreement with the data presented 
for cell survival and G2 radiosensitivity, the remaining normal cell line 2145 failed to 
produce enough metaphases for conclusive karyotyping. This cell line (2145) had an 
extremely slow doubling time (approx. 64 hrs) which proved difficult in synchronising 
the experiments with the short doubling time of the three other cell lines (all <20hrs). This 
also indicated that the 2145 cell line had reached its Hayflick limit and was in replicative 
senescence.  
The cytogenetic analysis using G-Banding and FISH clearly indicated that 2139, AT2Bi 
and AT3Bi were genetically unstable cell lines.  A high level of clonal and non- clonal 
aberrations was found in the AT cell lines, and additional chromosomal material from 
unidentifiable origin were found on a number of chromosomes (specifically on 
chromosome 14). In the initial chromosomal reports (pre ATM mapping) on cells from 
AT patients, chromosome 14 rearrangements were often identified and mapped to the q 
arm of the chromosome between area 31-32303.   FISH probing showed a number of cells 
with loss of the 3’IGH end of the probe and duplication of the 5’IGH end of the probe, 
which confirms genetic instability associated with radiosensitive syndromes. As a 
common breakpoint for chromosomes in patients with AT (14q32), this represents an 
increased risk (38%) for neoplasia, and young AT children have been described to be 
prone to acute lymphoblastic leukaemia and older AT patients  at risk of T cell 
leukaemia323. 
Interphase FISH probes were particularly useful for detecting presence or absence of 
ATM-TP53. These could possibly be used in a clinical setting as they require very little 
training to analyse results, and do not take a lot of time for conclusive results.  
The cytogenetic probes which were used here yielded more information about the cell 
lines used than the radiobiological assays showed. The data presented confirms the crucial 
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central role of ATM in the DNA damage response as deduced from the different cell cycle 
(mitotic inhibition) response. As previously explained, cell cycle checkpoints are 
activated by ionising radiation and are under control of ATM thus altered ATM in AT 
cells would be expected to result in higher mitotic inhibition. This was observed from the 
mitotic inhibition data for the normal cell lines but not for the AT cell lines which showed 
a reduction in mitotic inhibition. Although one of the ‘normal’ cell lines (2139) showed 
a normal cell cycle response in terms of inhibition, it is important to remember that this 
donor’s ATM was not mutated and the radiosensitivity of those cells are due to different 
underlying genetic mechanisms than those which cause radiosensitivity in the two AT 
cells. No deletion in ATM or TP53 was shown in the normal cell line 2139 or both AT 
cell lines. However, loss of the 3’ end of the IGH break apart probes and duplication of 
the 5’ IGH in chromosome 14q32 which is associated with radiosensitive syndromes and 
a t(14q14) which is a classical AT aberration303 was found here.  
4.5 Chapter Conclusions and Summary 
In Summary, ATM is the key gene involved in coordinating the cellular response to 
ionising radiation. It is responsible for downstream signalling and activation of cell cycle 
checkpoints to inhibit progression of damaged cells in the cell cycle and to promote DNA 
repair. In summary, it is clear that ATM, the cell cycle and DNA repair mechanisms in 
the DDR are key genetic mechanisms underlying radiosensitivity and should be 
considered for investigating potential biomarkers for radiosensitivity prediction. 
Additionally, the cytogenetic probes used (TP53, ATM, CEPX and IGH) were useful 
indicators of abnormalities, therefore would be useful as potential biomarkers of 
radiosensitivity. The IGH break-apart probe was particularly useful and easy to examine 
samples quickly. 
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5. POTENTIAL OF A FOUR-GENE SIGNATURE FOR THE PREDICTION 
OF RADIOSENSITIVITY IN HEALTHY DONOR AND PROSTATE 
CANCER PATIENTS COMPARED TO ATAXIA TELANGIECTASIA 
SAMPLES 
 
5.1 Introduction  
Intrinsic individual variation is a key aspect involved in the prediction of radiosensitivity. 
Factors affecting radiosensitivity include sex, age, tissue type, medication, smoking or 
alcohol intake and hormones59 (described in section 2.1). It is thought that the mentioned 
factors do not account for all factors which influence radiosensitivity, and genetic and 
epigenetic mechanisms play a major role324. In addition to the factors mentioned, target 
dose, anatomical variation, tumour or tissue volume treated and field size may account 
for inter individual differences in radiosensitivity variation after radiation treatment325. 
Although the many factors mentioned have been suggested to play a role in inter and intra 
individual variability in radiosensitivity, evidence suggests involvement of a more 
profound underlying biological mechanism. This evidence points toward a genetic 
underlying cause of radiosensitivity and comes from early studies showing that first 
degree relatives of those suffering breast cancer (BCa) showed a higher level of 
radiosensitivity compared to healthy controls using a micronucleus assay approach326.  
Genetic alterations associated with radiosensitivity have been further investigated in 
depth through the finding of radiosensitive syndromes such as Ataxia Telangiectasia 
(AT), Nijmegen Breakage Syndrome (NBS) and Bloom’s syndrome (BS) in which all 
patients suffer cellular and clinical radiosensitivity due to mutations in DNA damage and 
repair response genes327.  
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Furthermore, large intra individual variations within radiosensitivity genes have been 
attributed to single nucleotide polymorphisms (SNP’s) that make up approximately 90% 
of naturally occurring sequence variations328. Hall et al  outlined in a review that 
polymorphisms in DNA damage and repair response genes such as ATM, XRCC1, 
hHR21 and TGF-β are positively associated with increased late tissue reactions, with one 
ATM polymorphism showing a radioprotective effect329.  
As the genetic basis of radiosensitivity is still unfolding, more complex gene expression 
studies in the form of micro-arrays are being investigated to identify more accurate 
predictors of radioresponse. Genome wide association studies are currently ongoing; for 
example the Gene-PARE project (Genetic predictors of adverse radiotherapy effects) 
utilizes large scale population cohorts to identify genetic signatures and sequence 
variations in radio-responsive genes which could be of use in radiosensitivity 
monitoring330.  
In 2010, Kabacik et al  successfully identified radio-responsive genes for dose estimation 
and individual radio-response, in which peripheral blood lymphocytes from healthy 
controls were exposed to either 2Gy or 4Gy of x-irradiation using a multiplex quantitative 
real time polymerase chain reaction (MQRT-PCR) method331. After micro-array analysis 
of over 800 genes, key genes such as sestrin 1 (SESN1), cyclin-dependent kinase inhibitor 
1 a (CDKN1A) (also known as p21), ferredoxin reductase (FDXR) and proliferating cell 
nuclear antigen (PCNA) were among the key radio responsive genes upregulated at 2 hr 
and 24 hrs after irradiation. CDKN1a and SESN1 were upregulated for a longer time after 
irradiation (up to 48 hrs).  
Using a multiplex polymerase chain reaction (PCR) approach, multiple gene targets can 
be used within one reaction tube allowing for the analysis of several genes of interest in 
one reaction and greatly minimizing costs and time needed for gene analysis.  As multiple 
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healthy donors and prostate cancer patient samples as well as AT specific lymphoblastoid 
cell lines were used for the radiosensitivity studies described previously, this multiplex 
PCR approach was adopted to assess radiosensitivity gene candidates from all of the 
different cellular samples. 
Four specific genes are of interest in this work. Figure 5.1 outlines the main functions and 
interactions of each gene with the others. The first, p21 (CDKN1A) is a Cyclin Dependent 
Kinase Inhibitor which binds to and inhibits cyclin – CDK1, CDK2 and CDK4/6 
complexes to regulate or halt cell cycle progression at G1 and S phase332.  This is done 
through p21 regulation of p53 which up-regulates ATM and activates the cell cycle 
checkpoints in response to ionizing radiation. In addition to the role of p21 within the cell 
cycle, it has also been found to possess a strong affinity for binding with Proliferating 
Cell Nuclear Antigen (PCNA), another of the genes found to be highly radioresponsive332. 
PCNA is a DNA clamp that helps binding of DNA polymerase δ in eukaryotic cells and 
is essential for replication. PCNA also has a direct role in the DNA damage response 
(DDR) as it is placed at replication forks and coordinates DNA replication and DNA 
repair. It also acts as a loading clamp for additional DDR proteins to recruit to the site of 
DNA damage and bind333.   P21 is also highly expressed in senescent cells, and inhibition 
of p21 has been found to increase radiosensitivity in prostate cancer cells334. The 
interaction of p21 with PCNA was also of interest because this interaction and binding 
facilitates the inhibition of DNA synthesis in response to irradiation. This promotes cell 
checkpoint arrest until DNA repair is complete through trans lesion synthesis, promoting 
genetic stability335. Additionally, the interaction of p21 and PCNA causes G1 and G2 cell 
cycle arrest in the absence of p53 in human colon cancer cells336.   
 
 
 156 
 
 
 
 
SESN1 has been identified as a p53-dependent target gene (solely activated by p53) 
which functions to regenerate over oxidized peroxiredoxins in response to ionizing 
radiation among other members of the sestrin family such as SESN2337. SESN1 and 
SESN2 has also been found to negatively regulate mTOR and its signalling, in which 
mTOR functions to promote tumorigenesis through proliferation and chemoresistance338.  
 
 
Figure 5.1 Overview of the 4 genes used in this chapter for radiosensitivity prediction. The first, 
CDKN1A (P21) regulates P53 inhibition of CDK complexes for cell cycle inhibition in response to 
stress. PCNA is a DNA synthesis clamp which facilitates loading of factors for DNA replication, but 
also loading of DDR genes in the event of a DSB. SESN1 is regulated by p53 for metabolism of 
peroxiredoxins, but the SESN family are important negative regulators of MTOR which promotes 
tumorigenesis. SESN1 can also regulate ROS levels in response to ionising radiation. FDXR is also 
regulated by p53 in response to ROS production, but favours an apoptotic approach as a fate to cellular 
stress.   
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FDXR was of interest to these studies because it was found to be highly responsive to 
radiation and useful for bio dosimetry, but has also recently shown evidence of a 
heritability factor for its expression. Correa and Cheung demonstrated a higher variability 
in FDXR and p21 expression among a number of twin pairs as opposed to within 
individual twin pairs339. Therefore genetic stability and radiosensitivity are strongly 
linked in the stress response to ionizing radiation through the actions of p21, PCNA, 
SESN1 and FDXR which have been highly expressed in previous studies331. Furthermore, 
given that p21 and SESN1 are linked to critical regulators of the cell cycle, they are of 
interest in the present work to investigate if they are potential biomarkers of 
radiosensitivity using healthy donors compared to prostate cancer patients and cell lines 
from AT patients.  
From the original 800 gene studies by Kabacik et al, genes involved in metabolism have 
surfaced331. Of the four genes used for this study both SESN1 and FDXR are involved in 
regulating cellular fate after oxidative stress. It is known from previous work that 
repression of the SESN family of genes (SESN1, 2 and 3) leads to an upregulation of 
ROS through the action of RAS, which can lead to genomic instability and is of 
importance in research for cancer therapy340. In addition, FDXR is known to regulate 
normal metabolism and mitochondrial function but has been found to be transcriptionally 
regulated by p53 in response to ROS production, favouring an apoptotic pathway 
approach341. Therefore, as these two genes have important roles in metabolism related to 
ROS and ionising radiation produces a large amount of ROS within the cellular 
microenvironment, they could be useful biomarkers for radiosensitivity prediction.  
The aim of the current chapter was to use a panel of genes in multiplex (P21, PCNA, 
SESN1 and FDXR) to determine if they would be suitable predictive biomarkers or 
indicators of patient radiosensitivity. The current work aimed to investigate levels of 
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radiosensitivity in a cohort of healthy donors and prostate cancer patients which are of 
unknown and variable levels of radiosensitivity, and compare the gene expression to that 
obtained from a cellular radiosensitivity phenotype in Ataxia telangiectasia patients 
which are known to display extreme radiosensitivity. The work presented in this chapter 
was carried out in collaboration with Public Health England (PHE) who has expertise in 
the bio dosimetry field for monitoring and prediction of radiation exposure. The group 
have used genome wide association studies to elucidate key radio-responsive genes and 
have refined the nCounter and MQRT-PCR techniques for radiation bio dosimetry 
applications183. Therefore, four of the highly expressed radio-responsive genes found 
through their genome wide studies on healthy cohorts were used here as a possible panel 
of genes for prediction of individual radiosensitivity among healthy controls and prostate 
cancer patients with reference to LCLs from AT patients. 
 
5.2 Methods 
5.2.1 Samples and Cell Culture 
Blood samples were used from the healthy control (HC) cohort described in Chapter 2 
and the Prostate Cancer (PCa) cohort in chapter 3 of this thesis. 15 HC’s were used for 
MQRT-PCR analysis and 6 PCa patients were used. For investigation of effect of 
hormone therapy on gene expression, 6 PCa patients were used at visit 1 (baseline) and 
visit 2 (post androgen deprivation therapy (ADT)). A larger cohort of PCa samples could 
not be analysed as they were not available at the time. Whole blood was obtained from 
healthy control donors and prostate cancer patients and cultured as per section 2.2.2. 
Whole blood cultures were irradiated at 0.05Gy and 0.5Gy compared to a non-irradiated 
control (section 2.2.4).   
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Lymphoblastoid cell lines (LCL’s) obtained from 2 clinically characterised Ataxia 
telangiectasia (AT) patients from chapter 4 were used for this study and were coded 
AT2Bi and AT2BI. The cells were kindly donated from the University of Birmingham. 
Culturing and maintenance described in section 4.2. For experimental set up, 1x106/ml 
cells for each cell line were seeded into T25 flasks per dose (at doses of 0Gy, 0.05Gy, 
0.5Gy and 2Gy) and (Irradiation procedures and set up as described in section 2.2).  
 
5.2.2 RNA extraction and Quantification 
At 1 hr post irradiation (1 hr and 24 hrs for AT cells), samples were centrifuged at 300g 
for 5 mins and pellets were resuspended in 1ml of TriReagent (Sigma) (supplemented 
with 3N Acetic Acid) for RNA extraction. 200µl of Chloroform (Sigma) was added to 
each sample for 10 – 15 seconds with shaking and allowed to stand for 5 mins at room 
temperature. After centrifugation at 12,000 rpm for 15mins at 4°C, the upper aqueous 
phase containing RNA was collected and transferred to a clean Eppendorf tube with 500µl 
of isopropanol (Sigma) and stored for 5-10 mins at room temperature. Samples were then 
centrifuged at 12,000g for 10 mins at 4°C. After centrifugation, the RNA pellet was 
washed with Ethanol (Sigma) and centrifuged at 7,500g for 5 mins at 4°C. Ethanol was 
removed and RNA pellets were air dried for 10 mins and then resuspended in 30µl of 
RNase free water (Ambion). Samples were stored at -80°C until reverse transcription and 
real time PCR.  
RNA was quantified on a Nanodrop spectrophotometer and 1µg of RNA with RNase free 
water and loading buffer was loaded on to 1.2% agarose (Sigma) gels with 4µl of GelRed 
(Sigma) for quality analysis. Gel electrophoresis was set up for 30 mins at 80 volts and 
gels were subsequently visualized using the SynGene G: BOX chemi XX6 
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transilluminator system. Only samples with complete intact 18s and 28s RNA bands were 
used for cDNA synthesis and MQRT-PCR analysis. 
5.2.3 CDNA Synthesis 
Reverse transcription reactions were performed using High Capacity cDNA Reverse 
transcription kit, (Applied Bio- systems, Foster City, CA, USA) according to the 
manufacturer’s protocol with 700ng of total RNA and as previously described by 
Manning et al 183. 
5.2.4 Multiplex Quantative Real Time PCR 
Real-time PCR was performed using Rotor-Gene Q (Qiagen, Hilden, Germany). 
Reactions were run in triplicate using PerfeCTa ® MultiPlex qPCR SuperMix (Quanta 
Biosciences, Inc. Gaithersburg, MD, USA) with primer and probe sets for each of the 
target genes at 300 nM concentration each and 2.5 μl of cDNA in 30 μl reaction volume 
(Table 5.1). 3 ′ 6-Carboxy fluorescein (FAM), 6-Hexachloro fluorescein (HEX), Texas 
Red and CY5 (Eurogentec Ltd, Fawley, Hampshire, UK) were used as fluorochrome 
reporters for the hydrolysis probes analysed in multiplexed reactions between the 5 genes 
(p21, PCNA, SESN1 and FDXR in combination with the housekeeping gene HPRT1) per 
run. Cycling parameters were 2 min at 95 ° C, then 45 cycles of 10 secs at 95 ° C and 60 
secs at 60 ° C. Data was collected and analysed by Rotor-Gene Q Series Software. Gene 
target Ct (cycle threshold) values were normalized to a Hypoxanthine-Guanine 
phosphoribosyl transferase 1 (HPRT1) internal control. Ct values were converted to 
transcript quantity using standard curves obtained by serial dilution of PCR-amplified 
DNA fragments of each gene. The linear dynamic range of the standard curves covering 
six orders of magnitude (serial dilution from 3.2 x 10-4 to 8.2 x 10-10) gave PCR 
efficiencies between 91% and 103% for each gene with an efficiency score of R2 >0.998 
(PCR efficiency graphs can be found in appendix 10.4). Fold change in gene expression 
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levels are presented. Raw data was entered into a pre-programmed Microsoft Excel 
worksheet which calculated average gene expression per triplicate wells and normalized 
each gene expression to the housekeeping gene and 0Gy non-irradiated control. Statistical 
analysis and graphical outputs were carried out using ANOVA on Graphpad Prism 5.  
 
 
Table 5.1 Primer and probe sequences used in this work for genes analysed with MQRT-PCR. The primers 
were designed within Public Health England specifically for use with MQRT-PCR for bio dosimetry and 
as per Kabacik et al 331. 
Gene PCR Primers, Fwd., Rev Probes 
HPRT1 TCAGGCAGTATAATCCAAAGATGG 
AGTCTGGCTTATATCCAACACTTCGT 
CGCAAGCTTGCTGGTGAAAAGGACCC 
P21 GCAGACCAGCATGACAG 
TAGGGCTTCCTCTTGGA 
TTTCTACCACTCCAAACGCCGGCT 
FDXR GTACAACGGGCTTCCTGAGA 
CTCAGGTGGGGTCAGTAGGA 
CGGGCCACGTCCAGAGCCA 
PCNA  CTCAAGGACCTCATCAACGA CCGCTGCGACCGCAACCTGG  
GGACATACTGGTGAGGTTCA 
SESN1 GCTGTCTTGTGCATTACTTGTG 
CTGCGCAGCAGTCTACAG 
ACATGTCCCACAACTTTGGTGCTGG 
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5.3 Results 
5.3.1 Healthy Controls 
Higher expression levels of all genes analysed was observed after 0.5Gy compared to 
0.05Gy. Considerable inter individual variation between the healthy controls was 
observed at both doses, but most notably at 0.5Gy (Figure 5.2). Significant fold increases 
were observed in only a small number of donors (if fold change was > 2). A gene 
expression fold change of 2 was considered significant when using a small donor cohort 
(as with the present work) and with considerable PCR triplicate variation of gene 
expression.  
 163 
 
 
 
 
 
 
 
 
Figure 5.2. Combined relative gene expression in healthy controls (HC) compared to Prostate Cancer (PCa) patients. The top panel represents HC's and the bottom PCa patients at each 
dose at 1hr post irradiation. Gene expressions were normalized to a housekeeping gene and to a non-irradiated control. Note that all genes except SESN1 for the HC’s were not above 2-
fold change in gene expression. 
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All genes were analysed to observe if they differed significantly according to dose. 
Overall, a significantly higher expression was observed after 0.5Gy compared to 0.05Gy 
for SESN1 only (P=0.0028). The remaining three genes were not significantly changed 
in response to irradiation; PCNA (P=0.0564), FDXR (P= 0.1057) or P21 (P= 0.1354).  
Gene expression of PCNA, FDXR, P21 and SESN1 were analysed relative to a 
housekeeping internal control and to a non-irradiated control (0Gy) for each of the healthy 
control (HC) donors. Inter variation was calculated for each gene and dose, by dividing 
the standard deviation of gene expression for all donors at each dose by the mean and 
multiplying by 100 to get a percentage variation value.  This ranged between 14%-40% 
at 0.05Gy and 22%-54% at 0.5Gy (Table 5.2).  
 
Table 5.2 Inter individual variation in Healthy controls. 0Gy is not displayed as the 0Gy control is used to 
normalize gene expression data for overall fold changes in gene expression at each dose. The inter 
individual variation was calculated for each gene at each dose for a cohort of healthy controls. The variation 
was calculated by dividing the standard deviation by the mean and multiplying by 100 to get a percentage 
variation level. 
 Healthy Control Inter Individual Variation (%)  
  PCNA FDXR P21 SESN1 
0.05Gy 14.14 29.86 39.90 26.26 
0.5Gy 22.68 38.36 41.32 53.28 
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5.3.2 Prostate Cancer 
Expression of four genes (PCNA, FDXR, P21 and SESN1) were analysed relative to a 
non-irradiated control (Figure 5.3). Few significant fold change in gene expression (of >2 
fold) were observed, so gene expressions were analysed according to dose. No significant 
change in gene expression between 0.05Gy and 0.5Gy was observed for PCNA (P= 
0.4848), FDXR (P= 1), P21 (P= 1) or SESN1 (P= 0.1320). Significantly higher inter 
individual variation was observed at 0.5Gy compared to 0.05Gy (Table 5.3) over the 
range of all genes, indicating a more varied gene response at the most radiosensitive dose 
and as expected. 
 
 
Table 5.3 Inter individual variation of gene expression in 6 Prostate cancer patients. Each value represents 
a percentage variation. Variation was calculated for each gene at each dose by dividing the standard 
deviation by the mean and multiplying by 100 to get a percentage variation value. Gene expressions were 
normalized to a control housekeeping gene (HPRT1) and normalized to the non-irradiated control.  
Prostate Cancer Inter Individual Variation (%) 
  PCNA FDXR P21 SESN1 
0.05Gy 9.9487 28.01354 38.77959 32.55822 
0.5Gy 10.93878 51.91584 61.19946 39.72864 
 
 
5.3.3 Cells from Ataxia Telangiectasia Donors 
The AT2Bi and AT3Bi cell lines were used for comparison to HC’s and PCa as they are 
known to show extreme radiosensitivity in biological assays (Chapter 4). However, no 
significant fold change in gene expression was observed for any of the genes (Figure 5.3) 
(fold change >2). A higher dose point and additional time-point for AT cells was then 
used for a further investigation as more LCL cells were available for analysis compared 
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to the limited availability of whole blood (only 0.05Gy and 0.5Gy were used compared 
to a 0Gy control). No significant change in gene expression was observed between doses 
at 0.05Gy, 0.5Gy and 2Gy at 1 hr (P= 0.8473) but gene expression had significantly 
increased at each dose for the 24 hr time-point (P= 0.0158). This was interesting as it 
demonstrated that time was a critical factor for the underlying genetic response to 
radiation. 
 
5.3.4 Combined Cohort Analysis 
Only SESN1 was sensitive enough using HC’s to be “significantly” up-regulated (> 2-
fold change compared to control) (Figure 5.3). However, to analyse if a dose effect was 
observed using the combination of genes investigated, a significant change in expression 
was evident between 0.05Gy and 0.5Gy for HC’s (P< 0.0001), but not for PCa donors 
(P= 0.2821) or AT cell lines (P= 0.8473). Investigation of all genes between donors was 
carried out to conclude if radiosensitivity in the cohort type could be determined by the 
panel of MQRT-PCR genes analysed. When all cohort types were investigated together 
using a two-way ANOVA in Graphpad Prism, a significant change in radiosensitivity 
between HC, PCa and AT was observed at 0.5Gy (P= 0.0297) but not after 0.05Gy (P= 
0.7114). This again was expected since 0.5Gy is known to be the most radiosensitive 
dose.
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Figure 5.3 Gene expression in two AT cell lines. The top panel represents one AT cell line at 1hr and 24hrs after radiation exposure, and the bottom panel represents 
expression in the other AT cell line at 1hr and 24 hrs after exposure. (Details of AT cell lines in section 4.2) 
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A. 
B. 
Figure 5.4. Differential gene expression between Healthy controls (HC), prostate cancer (PCa) and 
Ataxia Telangiectasia (AT) cell lines at 0.05Gy and 0.5Gy at 1hr post radiation exposure. 
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As an additional time point of 24 hrs was used for AT cells, this was compared between 
donor cohorts (Figure 5.4). A more pronounced gene expression was observed across all 
genes analysed for AT at 24 hrs however these were not significantly different from gene 
expression in HC or PCa patients as was observed in figure 5.3.  
5.3.5 Use of MQRT-PCR panel through PCa treatment visits 
Further investigation of the 6 PCa donors through hospital visits (and as described in 
chapter 3) was carried out to observe if any change in gene expression correlated with 
PCa donors before hormone and after hormone treatment. Relating back to chapter 3, V1 
represents first sampling of PCa donor blood, and V2 is after hormone therapy, pre 
radiotherapy. Similar levels of gene expression were observed at both doses, but again no 
significant fold change in gene expression (> 2 fold) was observed in any particular 
gene/dose or visit (Figure 5.6). No significant change of expression in any gene analysed 
was observed between doses for either visit (Figure 5.6) (P>0.3). However, the sample 
number was small for this analysis. 
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Figure 5.5. Gene expression in healthy controls (HC), prostate cancer (PCa) patients and cells from 
Ataxia Telangiectasia (AT) donors for 0.05Gy and 0.5Gy. AT cells at 24hrs post irradiation. Gene 
expression was normalized to a housekeeping gene (HPRT1) and a 0Gy non-irradiated control.  
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Figure 5.6. Gene expression in Prostate Cancer (PCa) patients pre and post hormonal androgen 
deprivation therapy (ADT) treatment. Gene expression levels after 0.05Gy and 0.5Gy are represented.  
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5.4 Discussion 
The aim of the current chapter was to investigate the underlying genetic response of 
radiosensitivity and discover any potential genetic biomarkers of radiosensitivity that 
could be incorporated into future predictive testing using HC’s, PCa patient samples and 
cells from AT patients. 
In all cohorts; healthy controls, prostate cancer and Ataxia Telangiectasia a higher 
variation of gene expression was observed at 0.5Gy at 1 hour for all genes p21, PCNA, 
SESN1 and FDXR. This was as expected, as 0.5Gy is the most radiosensitive dose (as 
this dose is sufficient to induce DNA repair244).   Cells were analysed at 1 hr because G2 
chromosomal radiosensitivity studies were performed at this time-point in parallel. LCLs 
could be tested at many doses and time-points because they are immortalized cell lines 
and plentiful, therefore 2 Gy and 24 hr were also incorporated as an additional dose and 
time-point to the study. However, 2Gy did not show significant results (only 0.5Gy as it 
is considered most radiosensitive like the variation above) but the later time point of 24 
hrs showed a higher gene expression (although not significant) indicating that the genetic 
radiosensitivity response may be later than 1 hour for particular genes and donor types.  
Kabacik et al  and Manning et al  found the current genes used in this work (p21, FDXR, 
PCNA and SESN1) to be highly radioresponsive to doses of >1Gy as they are key 
regulators in the response to irradiation164, 316. P21 is a key Cyclin Dependent Kinase 
Inhibitor which is under tight regulation of p53 to control progression of damaged cells 
within the cell cycle through CDK1/CDK2 and CDK4/6 activity. Previous evidence 
suggests a threshold which would need to be reached before this inhibition could occur, 
for example Marples et al  described how the early G2 checkpoint is activated in response 
to irradiation immediately, dependent on ATM and requires an activation threshold (doses 
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>1Gy)244. It is possible that, from this data complete activation of p21 was not observed 
as a high enough dose was not used.  
PCNA’s interaction with p21 was of interest as the high binding affinity of p21 for PCNA 
in response to irradiation has been shown to inhibit DNA synthesis. The two genes 
interact to inhibit cell cycle progression at G1 and G2 phase in response to DNA damage 
therefore would be of interest for radiosensitivity analysis. No correlation was observed 
between both genes in the current work, but again more doses and time-points would 
determine the use of either or both genes as a radiosensitivity predictor. PCNA shows 
potential for prediction of radio-response as it has been shown to be involved in an array 
of processes including (but not limited to) DNA replication, repair, chromosome 
segregation and cell cycle progression, but after much higher doses than were used in this 
study (>2Gy)342.  
An interesting theme involving metabolomics biomarkers has come through strongly 
from the data presented. Both SESN1 and FDXR were strongly expressed, and both are 
involved in the cellular maintenance of ROS production and/or peroxiredoxins. SESN1 
shows the most potential for radiosensitivity prediction as it is the most highly expressed 
in all cohorts within this work. This is not unusual as it is activated by p53 in response to 
ionizing radiation and evidence suggests that inhibition of protein synthesis in breast 
cancer cells results from inhibiting SESN1 activity343.  As the cell cycle in controlled by 
p53 and P21, PCNA and SESN1 are in turn regulated by p53, the genes are important for 
analysing the cellular response to irradiation. In addition, SESN1 has been found to 
regulate ROS through studies which inhibit SESN1 expression. Kopnin et al found that 
repression of SESN1 levels substantially increased levels of ROS in response to cellular 
stress340. 
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It was identified in microarray data of previous reports by Kabacik et al  who explain that 
FDXR is of major interest for bio dosimetry as they found a near 15 fold increase of 
expression at 2 and 24 hrs after irradiation331. This could be why much of a response was 
not observed as the samples used were processed at 1 hr after irradiation and this time 
point could have been too early to identify an appropriate response. Found solely within 
the mitochondria and interacting with TP53, it could be a good predictor of radio-response 
as it could be a marker of apoptosis. It is not evident from this data how beneficial it could 
be as a predictor of radiosensitivity, and further work is needed to investigate this. 
However, Hwang et al found that total destruction of FDXR showed that this gene is 
essential for cellular viability and oxidative stress regulation. Partial destruction showed 
that FDXR favoured cell death through p53 regulation of apoptosis341.  
For combined gene expression a slightly higher (but not significant) increase in general 
gene expression was observed for all genes in both HC and PCa donors at 0.5Gy 
compared to 0.05Gy. This is not unusual as the radio-responsive genes analysed were 
originally found to be activated at doses of >1Gy331, therefore the dose points used may 
not have been high enough to activate the selected genes completely. This is not surprising 
as a large number of radio-responsive genes require a “threshold” dose in order to change. 
The present study confirms work by El-Saghire et al  in 2013 who identified activation 
of chemokine signalling and activation (GNG11 and CCR4) at lower doses (<0.05Gy) 
and DNA damage and checkpoint related gene activation (p53 related) at doses of >1Gy 
using peripheral blood lymphocytes from healthy donors344. The expression of SESN1 is 
of interest as it showed the highest change in expression and highest variation between 
donors of each cohort. It is of note that donors with the most change in gene expression 
from 0.05Gy to 0.5Gy (HC3 and HC9) show much higher levels of SESN1 also. 
However, no correlation of gene expression with G2 radiosensitivity of these donors was 
found.  
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P21 in the PCa cohort showed the highest variation. As most PCa tumours are p53 
deficient and p21 regulates p53 in the response to ionizing radiation, this result is also not 
unusual. The highest variation for HC’s was observed for SESN1, which was also the 
gene expressed with the highest fold increase compared to non-irradiated controls. As 
SESN1 plays a key role in the cellular response to oxidative stress, this result is not 
unusual for healthy cells.  
Variation in gene expression is difficult to assess as it is altered between cell types, stage 
of the cell cycle and within different cohorts. For instance Whitney et al  investigated 
over 300 gene expression profiles in 75 healthy donors and found blood cellular subtype 
specific alterations in gene expression as well as gender, age and time of day which played 
a huge role in genetic variation345.  Finnon et al failed to correlate lymphocyte 
radiosensitivity with normal tissue response to radiotherapy using gene expression arrays 
despite finding changes in over 800 genes. Although it did not predict radiosensitivity, 
the technique showed potential for biodosimetry346.  
No significant regulation of gene expression was observed in AT cells. Given that ATM 
drives the expression or regulation of the genes analysed, this data is not unusual. There 
was a clear change between the two AT cell lines which represents the heterogeneity of 
LCL’s as they came from individual donors. From chapter 4 it is now known that both of 
these LCL’s show inter individual variation which could explain the differences in gene 
expression patterns shown here, but analysis such as denaturing High Performance Liquid 
Chromatography (dHPLC) would be needed to genetically determine these. AT2Bi shows 
more differences in time-points than AT3Bi, as there is a complete gene expression 
reversal in FDXR and P21 at 0.05Gy, SESN1 at 0.5Gy and PCNA and SESN1 at 2Gy. It 
is interesting that a complete change in FDXR was observed between the two AT cell 
lines, with upregulation in AT2Bi and downregulation in AT3Bi (not significant), and 
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SESN1 was the only gene which was significantly upregulated in AT2Bi at 24 hrs as 
FDXR and SESN1 are the only two genes studied that are known to be not directly 
regulated by ATM. Zhou et al  investigated changes in gene expression in 3 AT cell lines 
in response to 1.5Gy of irradiation and found that most genes were attenuated or delayed 
– therefore suggesting that longer time points and higher doses would need to be 
investigated to find a significant change in gene expression347. 
Interestingly, no change in gene expression for any of the genes was observed pre and 
post hormone therapy by dose. This would suggest that radiation dose does not make a 
huge difference to the expression of the genes analysed in combination with hormone 
treatment. This would be beneficial for predicting radiosensitivity of PCa patients, as their 
radiosensitivity could be monitored throughout their radiotherapy treatment regime 
knowing that hormone treatment would not cause variation of the result. However, further 
work is required to conclude this hypothesis. 
Using the panel of genes for donors of different radiosensitivity levels, combined analysis 
showed that HC could be significantly distinguished from PCa and AT cell types at 0.5Gy 
only. This has not been shown before with the given genes. The data shows potential for 
predicting radiosensitivity using a MQRT-PCR technique, and future work would include 
higher dose points (1Gy) as well as longer time points to determine the most sensitive 
dose/ gene expression for clinical radiosensitivity prediction. From the current work it is 
clear that SESN1 was highly responsive in all cohorts and doses and highly expressed in 
AT cells at 24 hrs post irradiation, therefore this family of genes would be of further 
interest to investigate. 
5.5 Chapter Conclusions 
The present data show that expression of the panel of genes p21, PCNA, SESN1 and 
FDXR in combination or alone show potential as biomarkers for predicting 
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radiosensitivity in patient cohorts. The analyses of these 4 genes also led to further 
understanding of the underlying genetic mechanisms of cellular radiosensitivity. 
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6. A PANEL OF EXOSOMAL MIRNA’S CAN DISTINGUISH EXTREME 
RADIOSENSITIVITY FROM NORMAL CONTROLS 
 
 
6.1 Introduction 
Exosomes are small (30 – 120nm) membrane derived endocytic vesicles involved in 
cellular trafficking and communication and they contain active components such as 
proteins, DNA, mRNA and miRNA348. Exosomes were first described by Trams et al 349 
as enzymatic vesicles. This work was developed further by Harding and Stahl who 
explained that exosomes could take up particles such as colloidal gold and release them 
in rat reticulocytes350.  Evidence suggests that exosomes may carry functional molecules 
from the endosomal sorting complex required for transport (ESCRT machinery) for their 
own biogenesis351. These include ESCRT components I-III and accessory proteins 
apoptosis-linked gene 2 interacting protein X (ALIX) and tumour susceptibility gene 101 
(TSG101) which are now used as markers for exosomal identification. It is now known 
almost all cells in the human body (including bacterial) are capable of excreting 
exosomes, such as red and white blood cells352, platelets353 and endothelial cells354. These 
have major research implications in pathogenic diseases as a blood sample can be taken 
with ease and numerous subcellular components can be analysed. Over the past decade, 
the role of exosomes has become more diverse. This was demonstrated by  Montecalvo 
et al  who found that exosomes contained and delivered functional microRNA (miRNA’s) 
between dendritic cells355. Therefore, exosomes play a role in delivering miRNA’s that 
can influence the expression of genes through interference with gene translation. As of 
June 2014, 28,645 entries have been made to the micro RNA database (miRBase) 
representing individual miRNA discoveries356. Each miRNA has more than one target, 
greatly increasing the influence of miRNA on gene expression.  
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MiRNA’s are small non coding RNA’s that can interfere with translation through 
degradation or inhibition of target mRNA’s357. For biogenesis of miRNA see figure 1.12 
in section 1.5 of this thesis. The role of miRNA’s influencing various cancer types has 
been under  intense investigation; a 5 miRNA panel has shown early success in non-small 
cell lung carcinoma as a biomarker for cancer identification across races358. Cohort 
studies on blood from breast cancer patients revealed the importance of two expressed 
miRNA’s (miR-195-5p and miR-495) as a potential molecular signature for early case 
breast cancer359. Differential expression of miRNA’s in colorectal cancer compared to 
healthy controls with an overall downregulation of miRNA in colorectal cancer further 
implies an anti-tumour role of miRNA’s360. Inhibition of proliferation of bladder cancer 
cells was found through the regulation of p21 by miR-370, miR-1180 and miR-1236334 
and the implications of miR541 for inhibiting cancer metastasis or invasion in prostate 
cancer has also been documented361,362 and reviewed by Cheng et al 363. As well as 
oncogenesis, miRNA’s transported via exosomes have also been implicated in the 
propagation of non-targeted bystander effects and their roles in influencing radiation 
sensitivity.  For example, Jella et al found an increasing quantity of exosomes in 
keratinocytes exposed to 0.005Gy up to 5Gy in a dose dependent manner, and when 
transferred to fresh media from non-irradiated samples, a radiation-induced bystander 
response was evident through reactive oxygen species and calcium imaging364. Al-Mayah 
reported that the manipulation of miR-26a could cause radiosensitivity or radioresistance 
through overexpression or knockout of the gene respectively, using human glioblastoma 
cell lines365.  
A number of additional reports have investigated how miRNA’s influence cellular 
radiosensitivity. Ye et al showed that miR-145 was consistently downregulated in 
cervical cancer tissue samples and was correlated with advanced cancer stage, poor 
differentiation and large tumour size. Further analysis showed that its target mRNA 
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HTLF was inversely correlated with miR-145 and was involved in chromatin remodelling 
which enhanced radiosensitivity overall366. Upregulation of miR-25 was found to act on 
the downregulation of BTG2 in radioresistant NSCLC patients, therefore modulation of 
this radiosensitive miRNA could have implications for radiotherapy patients367. 
Furthermore, Lee et al  found that increased expression of miR-7 attenuated EGFR and 
akt expression which radiosensitized larynx, breast, lung and glioma cancer cell lines368. 
Recently, miR-26a enhanced radiosensitivity in U87 cells by reducing the  repair capacity 
of DNA damage after 4Gy of Caesium137 irradiation369, and miR-223 has already been 
shown to act on ataxia telangiectasia mutated (ATM) through downregulation of the ATM 
gene causing radiosensitivity in U87 cells both in vitro and in vivo370.  
As miRNA’s excreted from exosomes have previously shown roles in affecting 
radiosensitivity, the purpose of this study was to isolate exosomes from cell culture media 
of the lymphoblastoid cell lines from chapter 4. Two normal (2145 and 2139) and two 
ataxia telangiectasia (AT) cell lines were used for this work. The isolated exosomes were 
then characterised using TEM and by a protein marker known as TSG101. Analysis was 
then done on differentially expressed miRNA’s to investigate if miRNA’s could be used 
as a biomarker to predict individual radiosensitivity and be applied to patient cohorts with 
future therapeutic implications 
6.2 Methods 
6.2.1 Cell Culture 
Lymphoblastoid cell lines (LCL’s) described in the previous chapter 4 and 5 were used 
and were maintained in standard RPMI medium (Sigma) supplemented with 10% Foetal 
bovine serum (FBS), L-Glutamine and incubated at 37°C with 5% CO2. The cells in 
suspension were sub cultured by 1:5 dilutions every 24-48hrs. 1x105 cells/ml were added 
to T25 flasks (5ml total) using cell culture media that was exosome depleted FBS (10%) 
 181 
 
in RPMI medium. Cells were cultured for 72 hrs before media harvesting for isolation of 
exosomes. 
6.2.2 Isolation of Exosomes 
Cells were pelleted by centrifugation at 300g for 5 mins and conditioned medium was 
removed. The conditioned medium was then centrifuged at 2000g for 10 mins at 4°C to 
remove debris, and then filtered through a 0.22μm pore filter. This was then 
ultracentrifuged at 110,000g for 75mins at 4°C to isolate the exosomes. Exosome pellets 
were then washed in PBS and ultracentrifuged at 110,000g for 75mins at 4°C to purify 
the exosome fractions. Half of the sample was stored in PBS and transported to the Centre 
for Microscopy and Analysis (CMA), Trinity College Dublin for characterisation by 
transmission electron microscopy (TEM) and half was resuspended in RIPA buffer 
(Sigma) for protein lysis and subsequent Western blot analysis. 
6.2.3 Characterisation by Transmission Electron Microscopy (TEM) 
TEM of exosome fractions was conducted by technical support staff at the CMA in 
Trinity College Dublin. The protocol  as previously published371 was applied. 
6.2.4 Protein extraction and analysis of Cell and Exosome Extracts 
1ml of RIPA buffer (Sigma) was added to each sample containing exosomes (approx. 
100μl), vortexed and stored on ice for 5 mins. Samples were then centrifuged at 8000g 
for 10 mins at 4°C to pellet cell debris, while the supernatant (protein) was transferred to 
an Eppendorf and frozen at -80°C until quantification. The Biorad DC protein estimation 
kit was used for protein quantification against protein standards which were previously 
made up from 2mg/ml up to 12mg/ml in 2mg/ml increments and frozen. Protein standards 
and protein samples for SDS-Polyacrylamide Gel Electrophoresis (the Westerns are just 
a mirror image of the separation on the gels) were pipetted into a 96 well plate in triplicate 
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wells. An appropriate volume of Solution A and S (from the Biorad DC assay, appendix 
3) were mixed in a 5:1 ratio and 25µl of this mix was added to each well. 200µl of reagent 
B was added to each well and the plate was incubated for 5mins with a gentle shake before 
spectrophotometric reading at a wavelength of 595nm.   An average was taken from each 
triplicate of each protein reading. The values for the standards were plotted and a line of 
best fit was calculated forming a standard curve. The unknown protein quantities were 
then calculated with reference to the standard curve. Protein loading quantities can be 
found in appendix 10.4, section for Chapter 6 Raw data on page 308. 
6.2.5 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
gel electrophoresis 
After protein quantification, 30μg of protein for each sample was resolved on 10% SDS-
PAGE gels in a Bio-Rad mini Protean system. These were made up by a separating gel 
and stacking gel and were composed as demonstrated in table 7.1. TEMED and APS were 
added to the gels at the last minute as they cause the gel to solidify. The separating gel 
was first poured into the gel rig and topped with isopropanol and left for 10-20minutes to 
allow solidification. After solidification, stacking gel was made up according to table 7.1 
and poured over the separating gel (with TEMED and APS last). The comb for protein 
wells was added quickly to the gel rig and it was left for 20mins. During this time, 30µg 
of protein from each sample was prepared with approximately 10µl of loading buffer 
(Laemelli) (dependent on amount in µl for each protein to make up to 20µl total sample 
volume for loading). The samples were boiled at 100°C for 3mins to linearize proteins 
before loading.  
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Table 6.1 Components and concentrations used for SDS-PAGE. Water (H20), 
TrisHydroxymethylaminomethane (Tris), Sodium Dodecyl Sulphate (SDS), Ammonium persulfate (APS), 
Tetramethylethylenediamine (TEMED). 
Separating Gel Stacking Gel 
PERCENTAGE SOLUTION 10% PERCENTAGE SOLUTION 4% 
Deionised H2O 4.1 Deionised H2O 3.6 
30% Acrylamide 3.2 30% Acrylamide 0.65 
1.5M Tris (pH8.8) 2.5 1M Tris (pH 6.8) 0.63 
10% SDS 0.1 10% SDS 0.05 
10% APS 0.1 10% APS 0.075 
TEMED 0.01 TEMED 0.007 
 
 
30µg of each protein sample (approximately 20ul volume) was loaded into relevant wells. 
10µl of prestained BenchMark protein ladder (Invitrogen) was loaded into the first 
well/lane. The SDS-PAGE gel loaded with the protein samples was placed into a BioRad 
electrophoresis tank and filled up with 1X SDS-PAGE running buffer (Tris base, acetic 
acid and Ethylenediaminetetraacetic acid, appendix 3). Gels were electrophoresed at 80-
100milliamps for 1.5hrs or until the protein dye was visible at the bottom of the gel.  
6.2.6 Western Blotting 
After electrophoresis, the SDS-PAGE gel was carefully transferred to a nitrocellulose 
membrane -with blotting paper sandwiched either side of the gel and membrane for 
western blotting transfer. Each ‘sandwich’ was placed in a BioRad transfer cassette and 
transfer tank. The tank was topped up with pre-cooled 1X High molecular weight (HMW) 
transfer buffer made using 100mls of 10X HMW transfer buffer (Tris, Glycine, SDS and 
H20, Appendix 3) with 200mls of methanol and topped up to 1liter with deionised H20. 
and run at 100volts for 1hr. The membrane was recovered from the BioRad apparatus 
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when finished and transferred to a dish for subsequent antibody probing. (Information for 
all buffers can be found in appendix 10.2).  
6.2.7 Antibody Probing 
Membranes were blocked in 5% low fat powdered milk in Tris buffered saline and tween 
(TBS-T) (appendix 3) for 1hr to limit unspecific binding of antibody. The membranes 
were incubated overnight with primary antibody TSG101 (Abcam) for detection of the 
presence of exosomes and it was prepared in 1:1000 in 3% low fat powered milk in TBST. 
Membranes were then washed 3 x 10mins in TBS-T. They were then incubated with 
secondary horseradish peroxidase (HRP) tagged antibody prepared in 1:5000 in 3% low 
fat powdered milk for 1hr. This was done to detect the antigen-antibody reaction on the 
membrane. After an additional 3 x 10min TBS-T washes the membranes were processed 
using chemiluminescent detection. 
6.2.8 Chemiluminescent Detection and Imaging 
Membranes were incubated with enhanced chemiluminescent (ECL) detection kit 
(Pierce).   This was done according to the kit specifications, with equal volumes of reagent 
1 (Peroxide solution) mixed with reagent 2 (Luminol enhancer). After 1 minute of 
incubation, Western blots were imaged on a Syngene g-Box Chemi XR5 system. 
6.2.9 Real Time PCR Panel Analysis (Exiqon) 
RNA was extracted, quantified and qualified as described in the protocol from 
section.5.2.2. RNA samples were then sent to Exiqon services in Denmark who 
collaborate with Companies, Research Institutes and Pharmaceutical Industries to deliver 
top quality, novel molecular diagnostics for early detection of disease.  They analysed 
samples for detection of a) 5 known miRNA’s ((miR-142, miR-451, miR-23a, miR-30c 
and miR-103a) and then to subsequently determine whether to proceed with b) profiling 
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a full miRNA panel of 752 miRNAs’. The following procedures were carried out by 
Exiqon in Denmark. 
6.2.9.1 Detection of 5 known miRNA’s in Cells and Exosomes 
For a) 10µl RNA was reverse transcribed in 50μl reactions using the miRCURY LNA™ 
Universal RT microRNA PCR, Polyadenylation and cDNA synthesis kit (Exiqon). Each 
RT was performed including an artificial RNA spike-in (UniSp6). cDNA was diluted 
100x and assayed in 10µl PCR reactions according to the protocol for miRCURY LNA™ 
Universal RT microRNA PCR; each microRNA was assayed once by qPCR using assays 
for miR-23a, miR-30c, miR-103, miR-142-3p, and miR-451. In addition to these miRNA 
assays, the RNA spike-ins were assayed. Negative controls excluding a template from the 
reverse transcription reaction was performed and profiled like the samples. Amplification 
was performed in a LightCycler® 480 Real-Time PCR System (Roche) in 384 well plates. 
The amplification curves were analysed using the Roche LC software, both for 
determination of Cp (by the 2nd derivative method) and for melting curve analysis. The 
raw data was extracted from the Lightcycler 480 software. An average Cp was calculated 
for the duplicate RT’s, and evaluation of expression levels was performed based on raw 
Cp-values.  
6.2.9.2 Full miRNA Panel analysis of Cell Extracts 
50ng RNA was reverse transcribed in 50μl reactions using the miRCURY LNA™ 
universal RT microRNA PCR, Polyadenylation and cDNA synthesis kit (Exiqon). cDNA 
was diluted 100 x and assayed in 10ul PCR reactions according to the protocol for 
miRCURY LNA™ Universal RT microRNA PCR; each microRNA was assayed once 
by qPCR on the microRNA Ready-to-Use PCR, Human panel I+II using ExiLENT 
SYBR® Green master mix. Negative controls excluding template from the reverse 
transcription reaction was performed and profiled like the samples. The amplification was 
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performed in a LightCycler® 480 Real Time PCR System (Roche) in 384 well plates. 
The amplification curves were analyzed using the Roche LC software, both for 
determination of Cq (by the 2nd derivative method) and for melting curve analysis. 
6.2.10 Data Analysis 
The amplification efficiency was calculated using algorithms similar to the LinReg 
software. All assays were inspected for distinct melting curves and the Tm was checked 
to be within known specifications for the assay. Furthermore, assays must be detected 
with 5Cqs less than the negative control, and with Cq<37 to be included in the data 
analysis. Data that did not pass these criteria were omitted from any further analysis. Cq 
was calculated as the 2nd derivative. Using NormFinder the best normalizer was found 
to be the average of assays detected in all samples. All data was normalized to the average 
of assays detected in all samples (average – assay Cq). 
Data is presented in two forms using a hierarchial clustering heat map and a principle 
component analysis plot. Hierarchial clustering is a form of data analysis which clusters 
data by individual means firstly, and gradually reduces the number of clusters based on 
similarities within the data. For example, each miRNA here begins in its own cluster 
based on its expression, then miRNA’s with similar expression become one cluster, and 
gradually until the heat map is generated to classify each of the cell lines based on miRNA 
expression profiles. Principal Component Analysis (PCA) is a method used to reduce the 
dimension of large data sets and thereby a useful way to explore the naturally arising 
sample classes based on the expression profile. The method is simply a way to identify 
any particular pattern that arises in the data by highlighting similarities or differences. It 
orders data on the basis of variance so here the cell lines can be classified on the plot 
based on variance of the miRNA data for each cell line.   
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Additionally, T-Tests were used to determine if miRNA profiling differed significantly 
between each cell line and between normal (2145 and 2139) and radiosensitivity AT cell 
lines (AT2Bi and AT3Bi).  
6.3 Results 
6.3.1 Characterisation 
Characterisation of exosomes was performed through transmission electron microscopy 
and protein Western blot analysis. The exosomal marker TSG101 was positively 
identified in exosomes isolated from all lymphoblastoid cell lines which consisted of 2 
normal (2145 and 2139) and 2 AT (AT2Bi and AT3Bi) cells (figure 6.1). A small band 
was observed at 43kDa were TSG101 is present.  
 
 
 
 
 
 
 
 
 
 
 
TSG101 – 43kDa 
Figure 6.1 Western Blot identification of exosomal 
marker TSG101 present at 43kDA (N=7). In the 
normal cell lines (2145 and 2139) and AT cell lines 
(AT2Bi and AT3Bi). 
 
     2139             2145        AT2Bi          AT3Bi 
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Exosomes were positively identified using TEM in all extracts from media filtered from 
all cell lines including the two normal (2145 and 2139) and two AT cell lines (AT2Bi and 
AT3Bi) (Figure 6.2). The exosomes were sized from 30nm-100nm. 
6.3.2 Detection of miRNA in Cell and Exosome samples 
Before full miRNA panel profiling, cell extracts and exosome extracts from two 
seemingly normal cell lines and two AT cell lines were sent to Exiqon in Denmark to 
detect the presence of 5 common miRNA’s which were miR-142, miR-451, miR-23a, 
Figure 6.2 Identification of exosomes in samples by 
transmission electron microscopy. This image was 
taken from AT2Bi from the marked example 
(arrowhead) the crystal type outer structure of the 
exosome can be observed which appears grainy 
here. 
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miR-30c and miR-103a (Figure 6.3). 4 of the 5 microRNAs (miR-142, miR-23a, miR-
30c and miR-103a) were detected in the cell samples, but only 1 of the 5 microRNAs 
(miR-451) were detected in 1 of the 4 exosome samples (AT2Bi). Figure 6.3 shows the 
quantity of total miRNA from each cell and exosome sample for each cell line. Only miR-
451 was detected in one exosome sample for AT2Bi (cell extract miRNA is represented 
to the left of the graph, which is highlighted in a red box). From the Exiqon preliminary 
report for detection of miRNA in cell and exosome extracted from each cell line, the 
expression levels of the detected microRNAs in the cell fraction were good quality and 
comparable with samples used within the company. The signal in the exosomes samples 
was extremely low for the detection of only one miRNA (miR-451) in AT2Bi, therefore 
company reports suggested the exosomes samples would not perform well in a profiling 
experiment. Therefore, full miRNA profiling was continued using cell fractions only, and 
not exosomes isolated from those fractions. miRCURY LNA™ Universal RT microRNA 
PCR Human panel I+II were used for each cell line 2145, 2139, AT2Bi and AT3Bi, which 
were commercially available due to their high sensitivity and specificity for profiling 
analysis. In general terms of miRNA content, of the 752 miRNA’s for each cell line, 106 
were detected in all cell samples and on average 216 miRNA’s were detected for each 
sample (Figure 6.4).  Figure 6.4 demonstrates a general quantity of miRNA’s detected in 
each cell line, with the lowest number of miRNA’s detected in the 2145 cell line. This 
cell line also performed poorly in previous work for cytogenetic analysis (chapter 4). 
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Figure 6.4 Graphical illustration of the microRNA content. The blue bars represent number of 
microRNAs detected and the red line shows the average Cq value for the commonly expressed 
microRNAs. On average, 216 microRNA were detected per sample 
 
 
 
 
Figure 6.3 Average Cp values of common miRNA’s in each sample. Steady cp of the cDNA 
synthesis control in blue (UniSp6) indicates that both cDNA synthesis and qPCR were successful. 
Little to no miRNA’s were detected in the exosomal extracts (depicted in the red box), but 4 out of 
5 miRNAs’ were detected in all of the cell extract samples. 
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6.3.3 Heat map and unsupervised clustering from Exiqon  
Exiqon in Denmark handle and represent large datasets with heat map analysis as it allows 
for an initial, immediate summary of the data. Exiqon prepared a heat map of the miRNA 
data obtained from the outsourced cell samples. Here, a two-way hierarchical clustering 
of miRNA’s is represented based on sample type (Figure 6.5). Hierarchial clustering is a 
method used with large datasets to cluster data based on similarities within the data. For 
this data, this is represented by similar levels of miRNA expression being clustered 
together. Figure 6.5 shows a representation of this using the top 50 expressed miRNAs 
within the data. Each row represents a miRNA while each column represents the sample 
type. The expression level of each miRNA is represented by a colour, green indicating an 
expression level below the mean, whereas red represents expression levels of miRNAs 
above the mean. From figure 6.5 it is clear that different expression profiles of miRNA 
can be observed between the cell lines which are represented by horizontal panels. The 
normal 2145 cell line looks to be completely different from the remaining three cell lines 
(2139, AT2Bi and AT3Bi). This indicates differences in miRNA expression based on cell 
line alone. From heat map clustering, normal cells could clearly be distinguished from 
radiosensitive cells based on the latest data about the 2139 lymphoblastoid cell lines 
(chapter 4) that the donor of these cells was shown to have Turners syndrome and is also 
considered to be radiosensitive.  
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6.3.4 Differential Expression of miRNA between Normal and Radiosensitive  
Exiqon carried out PCA analysis using the top 50 microRNA that have the largest 
variation across all samples, in which an overview of how the samples cluster based on 
this variance is obtained (Figure 6.6). Figure 6.6 shows a PCA plot of each cell line based 
on the variance of miRNA expression within each cell line using only the top 50 highest 
expressed miRNA’s. From the PCA it would seem that good classification was made 
between normal and radiosensitive LCLs. This is based on what was known from the 
Figure 6.5 Heat map and unsupervised hierarchical clustering. The clustering is performed on all samples, and on 
the top 50 microRNAs with highest standard deviation. The normalized (dCq) values have been used for the 
analysis. The horizontal bar shows how the data is clustered based on the mean of expression of each miRNA. 
Green represents expression of miRNA that fall below the mean whereas red represents expression of miRNA 
that fall above the mean.  
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“normal” 2139 at the time of sample processing, which was later discovered to have 
Turner’s syndrome and is considered radiosensitive (Chapter 4 findings). 
 
 
 
 
Figure 6.6 PCA plot of miRNAs from AT and normal cell lines. The principal component analysis is performed 
on all samples, and on the top 50 microRNAs with highest standard deviation. The normalized (dCq) values 
have been used for the analysis. No outliers were detected. 
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6.3.5 Differentially expressed miRNA’s 
A full list of 88 detected miRNAs’ in all four cell samples is presented in Table 6.2 in 
descending order of highest standard deviation between the samples. From Table 6.2, the 
majority of miRNA’s expressed seem to be higher in the normal cell line (2139) and lower 
in the two AT cell lines (AT2Bi and AT3Bi) and the 2139 cell line (Turners). This would 
imply that radiosensitivity may involve downregulation of certain miRNA’s. In Table 6.2 
a few miRNAs’ which have been shown to influence radiosensitivity are highlighted in 
pink. These are miR-21-5p, miR-26a-5p, miR-7-5p, miR-25-3p. Additionally, miR-125b 
was highly expressed in one of the AT cell lines, and was not expressed in the normal 
2145 cell line.  This miRNA has been shown to influence radiosensitivity and 
radioresistance372. This was not represented here as only the miRNA’s are shown which 
were expressed in all of the cell lines. See appendix 3 for full list of miRNA’s expressed 
in each cell line. 
From Table 6.2, miRNA’s involved with radiosensitivity and the let-7 family of miRNA’s 
are highlighted (The let-7 miRNA’s are highlighted in yellow). The let-7 family of 
miRNA’s were the first miRNA’s to be discovered. A lower let-7 miRNA expression has 
been previously linked to poor differentiation and development of aggressive carcinomas. 
Additionally, Let-7 (a, c, d, g, f and I) have been found to bind to and regulate CDKN1A 
(p21) and PCNA. It is interesting here that all of the mentioned let-7 miRNA’s involved 
with cell cycle and DNA synthesis control (p21 and PCNA) are expressed in the top 88 
of 752 miRNA’s analysed within these cell lines (2145, 2139, AT2Bi and AT3Bi) (Table 
6.2). It is interesting that a higher expression of let-7 miRNAs was found in the control 
cell line 2145 and reduced in the radiosensitive cell lines; 2139 with Turners and AT2bi 
and AT3Bi with AT. Therefore, the data suggests a reduction in overall miRNA 
expression is associated with disease.  
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Table 6.2 Differentially expressed miRNAs in each cell line. miRNAs are represented in an order from 
highest standard deviation between the cell lines to the lowest standard deviation. A few miRNAs’ which 
have been investigated for radiosensitivity analysis in the literature have been highlighted in pink and the 
let-7 miRNA’s are highlighted in yellow. 
Target miRNA AT3Bi 2139.00 AT2Bi 2145.00 Standard 
Dev.  
hsa-miR-138-5p 28.13 26.79 29.66 36.08 4.111835 
hsa-miR-210-3p 28.03 28.69 27.58 35.34 3.650165 
hsa-miR-142-5p 27.94 27.98 26.71 34.71 3.629733 
hsa-miR-29b-3p 28.88 28.90 27.79 35.53 3.543452 
hsa-miR-320b 29.02 29.29 29.42 36.15 3.459292 
hsa-miR-155-3p 30.52 30.06 29.17 36.68 3.427411 
hsa-miR-142-3p 23.86 23.89 22.55 30.10 3.390336 
hsa-miR-29c-3p 27.95 28.18 27.88 34.62 3.312354 
hsa-miR-106b-5p 28.13 27.90 27.71 34.48 3.286748 
hsa-miR-15b-5p 29.27 29.85 29.22 35.79 3.183962 
hsa-miR-19a-3p 26.85 26.15 25.53 32.43 3.17148 
hsa-miR-18b-5p 29.46 28.59 28.63 35.15 3.15468 
hsa-miR-30e-5p 29.81 29.21 29.11 35.62 3.140427 
hsa-let-7f-5p 27.75 27.30 27.04 33.48 3.074023 
hsa-miR-9-5p 29.75 32.05 31.45 36.90 3.066573 
hsa-miR-19b-3p 25.16 24.80 24.22 30.80 3.059394 
hsa-miR-185-5p 30.02 29.83 29.94 36.05 3.059229 
hsa-miR-16-2-3p 30.97 30.71 30.51 36.83 3.055473 
hsa-miR-29a-3p 26.46 27.53 26.16 32.67 3.0357 
hsa-miR-30b-5p 29.55 29.63 27.95 34.85 3.006985 
hsa-miR-874-3p 30.54 30.72 30.91 36.62 2.949477 
hsa-let-7c-5p 29.47 30.29 29.37 35.52 2.935857 
hsa-miR-21-5p 23.91 24.05 23.36 29.60 2.929886 
hsa-miR-20a-5p 25.60 25.04 24.81 30.94 2.914006 
hsa-miR-32-5p 31.52 29.84 29.66 35.91 2.910561 
hsa-miR-26a-5p 29.70 30.50 30.59 35.96 2.878848 
hsa-miR-30d-5p 30.89 30.55 29.51 35.95 2.874756 
hsa-let-7d-5p 28.28 28.24 28.20 33.98 2.873581 
hsa-let-7a-5p 26.07 26.78 26.13 31.94 2.827859 
hsa-miR-15a-5p 27.89 27.63 26.95 33.05 2.807802 
hsa-miR-484 31.52 31.49 30.72 36.70 2.755886 
hsa-miR-103a-3p 26.57 25.97 26.34 31.78 2.755582 
hsa-miR-101-3p 30.51 29.77 29.26 35.25 2.747172 
hsa-miR-16-5p 24.16 24.28 23.90 29.56 2.72668 
hsa-miR-22-3p 30.20 30.09 29.98 35.54 2.725949 
hsa-let-7g-5p 26.59 26.45 26.22 31.86 2.725185 
hsa-miR-155-5p 22.55 22.79 22.08 27.89 2.724615 
hsa-miR-151a-5p 30.46 31.65 31.90 36.62 2.717459 
hsa-let-7i-5p 27.87 27.99 27.72 33.27 2.705802 
hsa-miR-423-3p 28.02 27.80 27.95 33.32 2.700826 
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hsa-miR-331-3p 29.66 29.75 29.79 35.12 2.696144 
hsa-miR-24-3p 27.49 27.04 27.82 32.75 2.669208 
hsa-miR-107 27.95 27.98 27.93 33.28 2.662738 
hsa-miR-27b-3p 30.85 31.07 30.20 35.95 2.645943 
hsa-miR-27a-3p 30.33 30.50 30.57 35.75 2.644047 
hsa-miR-146a-5p 25.53 24.91 25.31 30.50 2.638056 
hsa-miR-320a 27.54 27.82 27.63 32.93 2.636105 
hsa-miR-17-3p 29.51 29.72 29.65 34.86 2.616154 
hsa-miR-342-3p 27.73 27.65 29.66 33.22 2.608903 
hsa-miR-454-3p 31.59 31.03 31.10 36.42 2.603605 
hsa-miR-106a-5p 26.01 25.54 25.58 30.89 2.59768 
hsa-miR-18a-5p 29.21 28.36 28.29 33.71 2.578466 
hsa-miR-140-3p 29.69 29.76 29.07 34.58 2.554523 
hsa-miR-34a-5p 26.89 26.54 26.72 31.80 2.547093 
hsa-miR-148a-3p 27.68 28.97 27.90 33.11 2.52892 
hsa-miR-1260a 26.78 26.81 26.47 31.68 2.501639 
hsa-miR-92a-3p 25.50 25.98 25.55 30.62 2.482241 
hsa-miR-361-3p 30.77 31.65 30.91 35.96 2.457265 
hsa-miR-365a-3p 27.70 27.30 27.70 32.45 2.451102 
hsa-miR-148b-3p 29.89 29.97 29.93 34.81 2.439152 
hsa-miR-339-5p 28.48 28.50 28.05 33.20 2.436424 
hsa-miR-30c-5p 27.49 27.51 27.36 32.29 2.416767 
hsa-miR-320c 31.09 30.86 31.03 35.79 2.401571 
hsa-miR-26b-5p 31.30 31.48 31.17 36.10 2.3938 
hsa-miR-132-3p 29.82 29.45 31.16 34.68 2.383593 
hsa-miR-193b-3p 26.05 25.56 26.13 30.65 2.383491 
hsa-miR-7-5p 32.32 31.54 31.43 36.45 2.379498 
hsa-miR-98-5p 31.79 30.65 31.06 35.83 2.379198 
hsa-miR-23a-3p 27.48 27.11 27.80 32.11 2.34128 
hsa-let-7i-3p 32.15 32.68 32.15 36.91 2.304812 
hsa-miR-23b-3p 29.53 29.47 29.62 34.14 2.301586 
hsa-miR-181b-5p 29.78 28.38 28.79 33.37 2.269711 
hsa-miR-191-5p 28.11 27.96 28.66 32.66 2.226295 
hsa-miR-222-3p 28.78 27.92 27.60 32.41 2.212354 
hsa-miR-181a-5p 27.07 26.06 26.44 30.87 2.210726 
hsa-miR-339-3p 31.83 31.27 31.20 35.80 2.205092 
mmu-miR-378a-3p 28.37 27.01 27.69 31.90 2.176159 
hsa-miR-93-5p 27.86 27.56 27.79 32.00 2.137058 
hsa-miR-146b-5p 31.08 31.03 31.15 35.34 2.127614 
hsa-miR-425-5p 28.67 29.07 29.01 33.15 2.1257 
hsa-miR-423-5p 29.49 29.54 29.64 33.77 2.107572 
hsa-miR-940 30.84 32.32 32.10 35.66 2.058938 
hsa-miR-197-3p 31.60 31.31 31.19 35.46 2.054514 
hsa-miR-25-3p 28.75 28.22 28.21 32.45 2.04617 
hsa-miR-660-5p 32.47 31.67 31.35 35.80 2.039174 
hsa-miR-128-3p 31.82 30.96 30.86 35.17 2.023652 
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hsa-miR-362-3p 33.11 31.84 31.93 36.05 1.965652 
hsa-miR-150-5p 33.30 33.88 32.06 36.53 1.886441 
 
 
 
Table 6.3 illustrates the function of the highlighted miRNAs from Table 6.2. The let-7 
family of miRNA’s (which include hsa-miR-98) are in the top 88 expressed miRNA’s in 
this work and have been found to regulate cell cycle control genes and DNA synthesis 
genes such as p21 and PCNA. Additional miRNAs of interest include miR-21, 26 and 
451 which have various roles in carcinogenesis and resistance to chemotherapeutic drugs. 
Additionally, two miRNAs were expressed in the normal 2145 cell lines and not the 
radiosensitive cell lines (miR-411-5p and miR545-3p). A few miRNAs were expressed 
in both AT cell lines (AT2Bi and AT3Bi) and not the normal control cell lines as shown 
in Table 6.4. None of the miRNA’s in table 6.4 has been detected in radiosensitivity 
cohorts from the literature but could be a novel signature for radiosensitivity prediction.  
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Table 6.3 Summary of the roles of miRNAs of interest. The chromosome number and examples of the roles 
of each miRNA are depicted. 
miRNA Name/cluster Chromosome location Functions Reference 
hsa-let-7a-5p Chromosome 9, 11 and 22  Let-7 family of miRNA's 
were first miRNA's 
discovered. Roles in 
embryogenesis, 
metabolism and 
oncogenesis, cell cycle 
control, proliferation and 
apoptosis. Found to bind 
to and regulate cell cycle 
control genes such as P21 
and DNA synthesis clamp 
PCNA. Interacts with 
oncogenes such as RAS 
and MYC. 
 
 
 
373  
hsa-let-7c Chromosome 21 
hsa-let-7d Chromosome 9 
hsa-let-7f Chromosome 9 and X 
hsa-let-7g Chromosome 3 
hsa-let-7i Chromosome 12 
hsa-miR-98    
hsa-miR-21-5p Chromosome 17 Encodes for a gene TMEM 
(a vacuole membrane 
protein). Most targets are 
tumour suppressors. High 
levels detected in B cell 
lymphoma & cervical 
cancer. Increased 
expression found in heart 
failure of humans and 
murine models 
 
 
 
 374,375 
    
    
    
    
hsa-miR-26a-5p Chromosome 3 Induced in response to 
hypoxia. Downregulated in 
hepatocellular, 
nasopharyngeal, lung and 
breast cancer. 
Upregulated in glioma, 
pituitary and bladder 
carcinoma 
 
 
 
376,377  
    
    
    
hsa-miR-451  Chromosome 17 Regulates drug transporter 
protein P-glycoprotein 
which could regulate 
resistance to chemo drug 
Paclitaxel 
 
 
 378,379 
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Table 6.4 Potential radiosensitivity miRNA's. The miRNA's presented here are highly expressed in both 
AT cell lines (AT2Bi and AT3Bi) but not expressed in controls (2145 and 2139). No expression is denoted 
as Not determined (ND)   
Target MiRNA AT3Bi AT2Bi 2139 2145 
hsa-miR-450a-5p 35.01261997 32.8176891 ND ND 
hsa-miR-99b-5p 33.7923948 35.76875706 ND ND 
hsa-miR-363-3p 31.6732785 30.29645028 ND ND 
hsa-miR-513c-5p 33.9027518 35.07598372 ND ND 
hsa-miR-542-5p 34.64203508 35.64230108 ND ND 
hsa-miR-708-5p 35.60798058 34.73660205 ND ND 
hsa-miR-20b-5p 34.90190879 34.03990372 ND ND 
hsa-miR-618 34.76197598 33.93939199 ND ND 
hsa-miR-320d 32.0163168 32.50126174 ND ND 
hsa-miR-10a-5p 36.01983424 35.60760192 ND ND 
hsa-miR-503-5p 33.59965861 33.71171554 ND ND 
hsa-miR-424-5p 31.93660052 32.02640131 ND ND 
hsa-miR-96-5p 35.07064865 35.15061287 ND ND 
hsa-miR-550a-3p 34.92316622 34.98927438 ND ND 
 
 
6.4 Discussion 
To date, much work has been done to date investigating the use of miRNA signatures for 
cancer detection and to enhance radiosensitivity by regulating genes which cause 
radioresistance for treatment purposes. To our knowledge, no study has investigated the 
potential of using a miRNA signature excreted from exosomes for radiosensitivity 
prediction. This chapter forms the basis of early stage experimental work for investigating 
radiosensitivity prediction using miRNA from exosomes from normal and radiosensitive 
cell lines but with implications for use in blood samples from cohorts of patients 
undergoing radiotherapy treatment 
Work by Mitchell et al investigated if exosome quantification from urine of prostate 
cancer patients could predict radiotherapy treatment response. The work reported a 2-fold 
increase in exosome quantities in the urine of prostate cancer patients post androgen 
deprivation therapy. No pattern was observed in the radiotherapy treatment time and large 
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variation in exosome amount and quality was observed between individuals294. The work 
here aimed to go a step further and investigate if by profiling the miRNAs could be used 
for use on prostate cancer blood samples in future work. Only one of the 5 routinely used 
miRNAs was detected in exosomes secreted from AT2Bi (miR-451). miR-451 has been 
found to increase radiosensitivity of nasopharyngeal carcinoma cells through inhibiting 
Ras-related protein 14 (RAB14)378.  Therefore, it was unfortunate that the exosome 
samples did not perform well for miRNA microarray analysis. This could be due to small 
numbers of exosomes detected in each of the exosome extract samples. For future work, 
a higher number of cells would be used and incubated for a longer period of time for 
harvesting of exosomes from culture media. 
However, the let-7 family of miRNAs were of interest in this study. Let-7 miRNA’s were 
the first discovered and are the most studied miRNA’s and therefore have been reported 
to have diverse roles in embryogenesis, carcinogenesis and metabolism. It is interesting 
that a distinct set of let-7 miRNA’s (hsa-let-7a/c/d/f/g/I and miR-98) were part of the top 
88 miRNA’s expressed and found to be downregulated in radiosensitive cells. Of further 
interest is that the same distinct set of let-7 miRNAs were reported to bind to and regulate 
Cyclin Dependent Kinase inhibitor 1a (CDKN1A or also known as p21) and proliferating 
cell nuclear antigen (PCNA) (expressed genes described in chapter 5). This is interesting 
as p21 is a crucial cell cycle inhibitor, which stops the progression of the cell cycle in 
response to irradiation. Therefore, the let-7 family of miRNAs could have crucial roles in 
cell cycle checkpoint response to cellular stress. More work is warranted in this area to 
investigate the functional effects of let-7 miRNAs on cell cycle response. PCNA acts as 
a clamp on DNA during replication. It has been found that DNA synthesis is also inhibited 
in response to cellular stress, which PCNA could have a role in335. Additionally, p21 
inhibits PCNA during DNA synthesis if Cyclin/CDK complexes are absent332.  It is 
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obvious why the roles of miRNAs are attractive targets for cancer therapies as they can 
be manipulated to control tumour suppressor genes or oncogenes for therapeutic gain.  
Heat map analysis is a current method used which allows for immediate visualisation of 
gene expression data. In this work, the use of a heat map shows a clear distinction of 
normal vs radiosensitive samples based on their gene expression pattern. Although only 
four samples were used, this work has been done previously to identify radioresponsive 
biomarkers in cells vs whole blood. Kabacik et al conducted a study in 2011 and found 
clear subsets of genes activated in response to different doses331. This was also used in a 
study in 2015 by Ghandhi et al who identified p53 pathway and immune cell activation 
using heat map plots of gene expression profiling to clearly outline the different subsets 
of genes activated in response to different doses of irradiation and different dose rates380.  
Of the top 5 expressed miRNA’s in each cell line, no particular miRNA’s of interest were 
observed except for miR-125b which has been shown to influence radiosensitivity. Shiiba 
et al  demonstrated that inhibition of miR-125b was found in oral squamous cell 
carcinoma cell lines and when those cells were transfected with miR-125 a decreased 
proliferation rate in combination with increased x-ray radiosensitivity was discovered372. 
Although miRNA expression has been investigated for their potential use for maximising 
radiosensitivity for therapeutic gain, no study has yet confirmed the use of a miRNA 
signature for radiosensitivity prediction. The current study shows a distinct set of 
miRNA’s found to be expressed in radiosensitive cells (AT) and not expressed in control 
cells.  
6.5 Chapter Summary and conclusions 
Overall, good classification was observed between normal cell lines and radiosensitive 
cell lines using the top 50 differentially expressed miRNAs from micro-array analysis. 
The present work forms a basis for progression of work on prostate cancer patient blood 
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samples. The current data also provides a basis for future work into investigating the 
potential of a miRNA signature for radiosensitivity prediction. The hsa-let-7 family of 
miRNAs are involved in a number of processes such as cell cycle control and 
progression and oncogenesis. The current study is beneficial for future work which is 
needed to investigate the use of a gene signature for predicting late tissue toxicity 
following radiotherapy.  
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7. GENERAL THESIS DISCUSSION 
 
The ultimate goal of this work was 2 fold (1) to identify an efficient reliable predictive 
assay of radiosensitivity (2) to identify novel biomarker/s of radiosensitivity which can 
potentially be brought to the clinic to measure individual radiosensitivity in patients at 
their radiotherapy treatment planning stage and/or throughout the course of their 
radiotherapy to predict response. In order to obtain this ultimate goal, in vitro translational 
research studies incorporating healthy donor, prostate cancer patient samples and Ataxia-
Telangiectasia radiosensitive cohorts were used to study varied radiosensitivity responses 
and their underlying molecular mechanisms of response. Cell cycle checkpoint control is 
well known to be central to the cellular DNA damage response (DDR) from ionising 
radiation exposure and this formed the basis of this thesis from a cellular to a molecular 
radiobiological level hence predictive assay to biomarker level respectively. 
Individual variation in radiosensitivity was observed among all samples and cohorts and 
is well documented in the literature. There have been many attempts to find a predictive 
assay of radiation response in vitro to report individual radiosensitivity. The underlying 
molecular mechanisms of individual variation in radiosensitivity is attributed to the DNA 
damage response (DDR) sensors (γH2AX, BRCA, 53BP1), major molecular signalling 
pathways involving Ataxia Telangiectasia Mutated (ATM) and P53, cell cycle 
checkpoints and inhibition of the cell cycle in response to ionising radiation such as 
CHK1 and CHK2, and the underlying miRNA’s which bind to and regulate the activity 
of the different molecular players in the DDR cascade. Chapter 1 provides a detailed 
review of the literature about these key concepts directly relevant to this thesis. 
Experimental Chapter 2 optimised and validated the well-known G2 chromosomal 
radiosensitivity assay with a healthy control cohort. This assay was chosen because it is 
a well-known to be a reliable in vitro predictive assay of radiosensitivity that can be 
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applied to blood samples directly from donors/patients and has potential clinical 
applications. Radiosensitivity cut off values and variation between donors was compared 
to other published studies for consistency.  Within this work it was investigated if 
radiation sources and doses played a major role in biological variation between healthy 
donors. This was done because the blood samples from the HC cohort were irradiated 
using photons from a 60Co which was decommissioned and replaced with a linear 
accelerator (Linac). As expected the most radiosensitive dose was 0.5Gy delivered from 
a linac source. The different radiation sources did not alter the response.  
In Experimental Chapter 3, PCa patients were recruited and the G2 chromosomal 
radiosensitivity assay applied at different time points during radiotherapy treatment (i.e. 
before and after hormone treatment, last day of radiotherapy and at the 2 and 8month 
follow up). This was done to determine if the G2 chromosomal radiosensitivity assay was 
not only a predictor of intrinsic radiosensitivity but also a method to monitor 
radiosensitivity response throughout a radiotherapy treatment regime. Chromosomal 
radiosensitivity and checkpoint response was a good indicator of bio dosimetry and good 
predictors of radiosensitivity with patterns based on time and dose.  
Therefore, in Experimental Chapter 4, an array of DNA damage based assays including 
cellular viability was applied to Lymphoblastoid Cell Lines (LCL’s) to two donors with 
confirmed Ataxia Telangiectasia (and compared to two healthy donors). Ataxia 
Telangiectasia cells were selected for this study as AT is a well-known radiosensitivity 
phenotype exhibiting extreme levels of cellular radiosensitivity. Further Cytogenetic 
techniques including G-Banding and FISH using cytogenetic markers were applied to 
these cells in a collaboration with Crumlin Genetics department. Interestingly, one of the 
healthy control cell lines was actually deemed to be radiosensitive with the cell based 
assays and was alter confirmed to be a sufferer of Turners syndrome which has been 
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reported to display radiosensitivity. This cytogenetic study also confirmed the major role 
of the signalling protein ATM and the roles of the cell cycle checkpoint proteins in 
response to the DDR. Without ATM (as represented in the AT cells), aberrant cell growth, 
cell cycle checkpoint responses and reduced signalling of γH2AX occurs as a result.  
This allowed for the progression of gene expression studies in Experimental Chapter 5 
which used genetic biomarkers obtained from bio dosimetry studies in Public Health 
England. The genes were cell cycle and DDR related genes (cyclin dependent kinase 
inhibitor 1a (CDKN1A also known as p21), proliferating cell nuclear antigen (PCNA), 
Sestrin 1 (SESN1) and ferredoxin reductase (FDXR)). Multiplex PCR was carried out as 
it was rapid and multiple patient’s/donors samples could be done simultaneously. 
Although no significant changes were found in gene expression, different patterns of 
expression between HC, PCa and AT cells were found using the four genes in 
combination. These genes are of interest as they are active in the inhibition of the cell 
cycle in response to DNA damage, specifically p21 which is a cell cycle inhibitor, and is 
under control of p53 which in turn is controlled by ATM. P53 also interacts with SESN1 
and p21 with PCNA so all of the genes studied except for FDXR interact with each other. 
FDXR was sensitive for bio dosimetry purposes from previous studies but is more 
involved in metabolism. This was promising, but longer time-points are needed to 
investigate this further. This study outlined the interesting changes in gene expression 
using Sestrin 1, which is modulated fully by p53 which could be an interesting family of 
genes to look at in future studies.  
Finally, in Experimental Chapter 6 the AT and normal LCL’s were used for the 
investigation of novel markers of radiosensitivity. 106 miRNA’s showed excellent 
classification between normal and radiosensitive cells, and even classified the 
radiosensitive ‘healthy’ donor 2139 correctly as radiosensitive. This work was promising 
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for finding a potential novel biomarker of radiosensitivity. Additionally, the let 7 family 
of miRNA’s were found to be upregulated and in the literature these miRNAs’ are known 
to regulate cell cycle checkpoint proteins such as p21 and also interact with proliferating 
cell nuclear antigen (PCNA) which plays a crucial role in the replication fork machinery 
and inhibits the progression of DNA synthesis in response to irradiation stress. 
Figure 7.1 summarises the progression of this research from predictive assays to 
biomarkers via cellular and cytogenetic to molecular research respectively. This also 
indicates that future molecular work would be required to find novel biomarkers of 
radiosensitivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypothesis of Intrinsic radiosensitivity 
By investigating the underlying molecular mechanisms of radiosensitivity for novel 
biomarkers of radiosensitivity, specific DNA damage and repair genes emerged. Figure 
8.2 below displays these genetic targets (in green) on a cellular level and nuclear level. In 
G2 Radiosensitivity ATM γH2AX  Cell Cycle Gene Expression MiRNA 
Optimisation/ validation  
 
Predictive assays 
Predictive Biomarkers 
4 Year PhD 
Future Work 
Figure 7.1 Progression of work and summary over 4 years of the PhD. G2 radiosensitivity studies were done 
firstly. Then more in depth, mechanistic work was done to investigate the role of the key molecular players 
involved in radiosensitivity including ATM, cell cycle checkpoint control, gene expression and finally 
progressing on to novel miRNA markers for radiosensitivity. 
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figure 7.2 (right hand side) the DDR in the nucleus demonstrates the interconnections of 
the genes with the genes directly studied highlighted in green.  
Additional extra-nuclear molecular targets also emerged as potential biomarkers of 
radiosensitivity and in figure 7.2 (left hand side). These included FDXR involved in 
metabolism, and miRNA’s which are transported out of the nucleus and are encapsulated 
within exosomes for exporting out of the cell into the microenvironment (for example, 
the blood stream) where they can release miRNA’s to regulate target genes. MiRNA’s 
are depicted in boxes which regulate ATM, SESN1, P53 and P21. These were found to 
be downregulated in AT cells in chapter 6.  
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Nucleus 
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γH2AX 
Damage 
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Repair 
miRN
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Nucleus 
Figure 7.2 Summary of interplay between the molecular markers of radiosensitivity. Directly investigated in this work (Green). The cell nucleus and cytoplasm is shown in brief on the left 
depicting where DNA damage sensing and repair takes place, as well as the exocytosis of exosomes and their contents and metabolic processes involving FDXR and apoptosis. To the right, a 
more detailed summary of the nucleus and interplay of molecular markers in response to DNA damage is shown, MiRNA’ which regulate PCNA, P21, SESN1 and ATM are shown in boxes. 
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8. LIMITATIONS AND FUTURE WORK 
 
Each chapter of work within this thesis yield information about the biological 
mechanisms of radiosensitivity for the development of a potential predictive biomarker 
or assay, but are not without limitations. For instance, in chapter 2 the main limitation 
outside the control of the research scientist is individual intrinsic variation. Although this 
falls within the ranges of previously published work, variation of radiosensitivity cannot 
be regulated but factors which affect it can be recorded. In chapter 2, these limitations are 
explored, finding more factors involved in variation of results.  
As chapter 3 was a preliminary, pilot study for radiosensitivity analysis using prostate 
cancer donors, the main limitation was lack of donor samples at each treatment visit, for 
e.g. although more than 25 donors were analysed for visit 1, only 5 donor’s samples had 
been obtained and analysed for this chapter. This work is currently ongoing.  
Use of immortalised cell lines in chapter 4 was the major limitation of this work. It is 
known that immortalised cell lines lack key factors from the cellular microenvironment 
which may play a role in the stress response, which will ultimately influence assay results. 
In addition, the normal cell lines were not cooperative, i.e. the 2145 cell line had been 
cultured over time and had reached its hayflick limit, and the 2139 cell line could also 
have been cultured to a degree where it had incorporated genomic instability and therefore 
produced false positive results. The 2139 cell line was also a normal, control cell line 
which after cytogenetic characterisation was found to be abnormal. If the study was 
repeated, whole blood from healthy donors would be used and if immortalised cell lines 
were needed, these would be made from freshly obtained whole blood.  
Again, the major limitations of chapter 5 were lack of donor samples and cell lines. This 
was primarily due to storage failure of some healthy control RNA extracted from whole 
blood which underwent defrosting in transit to England from Ireland. In addition, higher 
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dose points could be used to investigate gene expression profiles further, with particular 
attention on metabolomics pathways incorporating SESN1 and FDXR.  
Finally, chapter 6 was a primary study using the same immortalised cell lines from chapter 
4. Limitations associated with this batch of work involved the small number of exosomes 
secreted from each sample and failure of miRNA profiling using those exosome samples. 
If repeated in future work, a higher number of cells in a more concentrated volume of 
media would be used to improve exosomal yield. In addition, this method would benefit 
if whole blood lymphocytes were used instead of immortalised cell lines. 
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10. APPENDICES 
 
10.1 Inclusion/Exclusion Criteria for Prostate Cancer Donor Recruitment 
Inclusion Criteria: 
1. Patients undergoing a radical course of RT for high-risk disease (defined 
according to the National Comprehensive Cancer Network Practice Guidelines in 
Oncology v.1 as one or more of the NCCN high risk criteria > or equal to T3, > 
or equal to Gleason 8, PSA > 20ng/ml) 
2. Only patients requiring neo-adjuvant / adjuvant hormonal therapy will be included 
in this study 
3. Absence of distant metastases as demonstrated by history and physical 
examination, FBC, screening profile including liver function tests, PSA and bone 
scan 
4. All patients must have an MRI/CT of the prostate and pelvis to investigate the 
nodal status and precise T-stage. This MRI/CT scan must be performed prior to 
commencement of hormonal therapy. Suspicious nodes need to be histologically 
proven to be benign before the patient can be included in the study). M0 on 
staging. 
5. No previous surgery for urinary conditions except TURP or TRUS 
6. KPS > or equal to 60 
7. Age >18 years 
8. Provision of written informed consent in line with ICH-GCP guidelines 
Exclusion Criteria: 
1. Previous RT to the pelvic region 
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2. The patient has nodal involvement or it is decided to electively treat pelvic lymph 
nodes 
3. The patient has had a bilateral orchiectomy 
4. The patient has previously received a full course of hormonal treatment for his 
prostate cancer 
5. The patient has or has had other malignancies within the last 5 years (non-
melanoma skin cancer is permitted) 
6. Evidence of any other significant clinical disorder or laboratory finding that 
makes it undesirable for the patient to participate in the trial or if it is felt by the 
research/ medical team that the patient may not be able to comply with the 
protocol 
7. Patients who have had a prostatectomy 
8. The presence of hip prostheses 
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10.2 Reagents, Suppliers and Catalogue numbers 
 
Product Company Catalogue Number 
      
Blood, Lymphocyte extraction and Cell Culture 
Vacutainers Sarstedt 04.1921.100 
RPMI Sigma R8758 LOT# RNBC7450 
MEM-F12 Sigma M2279 
PHA PAA Laboratories J01-006 LOT# J00612-0914 
Dulbeco's PBS Sigma D8537 LOT#RNBC28878 
Histopaque - 1077 Sigma 10771 
L-Glutamine 
ThermoFisher 
Scientific 25030081 
Penicillen-Streptomycin Gibco 15070063  
      
G2 Chromosomal Radiosensitivity Assay  
Colcemid Gibco J01-003 LOT# J00312-0259 
Potassium Chloride Sigma P3911-500g 077K0024 
Methanol Sigma 
32213-2.5L LOT# 
5ZBC1035V 
Acetic Acid Merck Millipore K42840763141 
Gurr's pH 6.8 buffer VWR 331932D 111952 
Giemsa Sigma WG16-500ml 71M4343 
DPX VWR 360294H Batch#HX135994 
      
γH2AX Assay 
Paraformaldehyde Sigma F8775-500ML 
Triton - X Sigma T8787-50ML 
Anti-Phospho Histone H2AX Millipore 
Clone JBW301 CAT#05-
636 
Alexa Fluor 488 Invitrogen A11017 
Propidium Iodide Sigma P4864 
      
RNA/ DNA Extraction, Quantification and Qualitation 
Rnase Away Fisher Scientific 7002 
Tri Reagent BD Sigma 
T3809-200mls 
LOT#SLBC3837V 
Chloroform Sigma 
B9673-200mls 
LOT#MKBP2795V 
Isopropanol Sigma 
19516 - 500mls 
LOT#SHBB6114V 
Ethanol Merck Millipore K38656983 817 
Qiagen Blood and Tissue Kit Qiagen 69504 133218099 
Agarose Sigma A9539 - 50g 071M0551V 
Bionic Buffer Sigma B6185 - 1L 035k6143 
 239 
 
Gel Red Biotium 41003 
1kb plus RNA Ladder Invitrogen 10787-018 
0.5 - 10kb RNA Ladder Invitrogen 15623-200 
6 x DNA  Invitrogen  10787-017 
      
CDNA Synthesis, RT-PCR and MQRTPCR 
PerfeCTa ® MultiPlex qPCR 
SuperMix  Quanta Biosciences Cat# 95063-200 
3'6-Carboxyfluorescein (FAM) Eurogentec Ltd MD-FL001-03100 
6-Hexachlorofluorescein (HEX) Eurogentec Ltd MD-FL010-05100 
Texas Red Eurogentec Ltd AS-81130 
CY5 Eurogentec Ltd Cat#81255 
      
FlSH 
DAPI Stain Fisher Scientific 10374168 
IGH, Breakapart Probe Abbott 05J73-001 
ATM/TP53 Dual Colour Probe Abbott 08L53-020 
CEP X Probe Abbott 06N29-020 
      
      
Protein Extraction, Western Blotting 
RIPA Buffer Sigma R0278 
BioRad DC Protein Estimation 
Kit Biorad Cat#5000111 
SDS Sigma L3771-100G 
Acrylamide Biorad 1610180 
Tris Base Sigma 11814273001 
Ammonium Persulfate Sigma A3678-100G 
Temed Sigma T9281-25ML 
Prestained Protein Ladder 
ThermoFisher 
Scientific  10748010 
1% Low Fat Powdered Milk Marvel N/a 
Nitrocellulose Membrane Biorad 162-0115 
TSG101  Abcam AB83 
HRP BioLegend Cat#405306 
ECL Pierce Cat#32106 
Other 
ApoTox Kit Promega Cat#G6320 
   
 
 
 
 
 240 
 
10.3 Protocols used in this thesis 
 
Tissue Culture 
1.1. G2 Blood Culture 
a) 3x 2ml cultures are set up for different doses. 
b) Put 2mls of whole blood into each T25 flask.  
c) Add 18mls of prewarmed media.  
d) Add 200µl of PHA 
e) Wrap in tinfoil and incubate standing upright in incubator for 3 days.  
 
1.2. Separation of monocytes from lymphocytes by plastic adhesion for Raman 
 
a) Count cell/PBS suspension 
b) Plate at approx. 5×106 cells in 8 cm2 tissue culture dishes (Nunc) 
c) Incubate 2 h at 37ºC, 5% CO2. 
d) Non-adherent cells (lymphocytes) can be pelleted and resuspended in full media 
and further cultured. 
e) Wash adherent cells (monocytes) with pre-warmed PBS and further cultured in 
fresh full media. 
f) Set up 4 x 2ml cell cultures, (monocytes and lymphocytes) add 18mls of media, 
and 200µl of PHA. and Culture for 3 days. 
 
1.3. Histopaque Isolation of LCL’s for Raman Spectroscopy 
 
a) To a 15ml conical centrifuge tube, add 3ml of Histopaque – 1077 and bring to 
room temperature. 
b) Carefully layer 3ml of whole blood on to histopaque. 
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c) Centrifuge at 400g for exactly 30mins at room temperature. Centrifugation at 
lower temperatures results in cell clumping. 
d) After centrifugation, carefully aspirate the upper layer with a Pasteur pipette to 
within 0.5cm of the opaque interface containing mononuclear cells. Discard upper 
layer. 
e) Carefully transfer the opaque interface with a Pasteur pipette into a clean conical 
centrifuge tube. 
f) Wash the cells by adding 10mls of isotonic PBS or appropriate cell culture 
medium, and mix by gently drawing in and out of Pasteur pipette. 
g) Centrifuge at 250g for 10mins. 
h) Aspirate the supernatant and discard. 
i) Resuspend the cell pellet with 5ml of isotonic PBS or appropriate cell culture 
medium and mix. 
j) Centrifuge at 250g for 10mins 
k) Repeat steps for washing, discard supernatant and resuspend cell pellet in 0.5mls 
of PBS. 
1.4. Lymphoblastoid Cell Line Culture 
 
A. LCL’s were maintained in standard RPMI medium (Sigma) supplemented with 
10% Foetal bovine serum (FBS), L-Glutamine and incubated at 37°C with 5% 
CO2.  
B. 2139, AT2Bi and AT3Bi were sub cultured 3 times weekly 
C. 2145 was sub cultured weekly 
 
2. Irradiation Procedures 
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A. All Irradiations carried out in St. Luke’s Hospital, Rathgar, Dublin 
B. 60Co irradiations conducted using Teletherapy unit (Theratron 780 E, MDS Canada 
C. Linac Irradiations conducted using 6 MV photon beam and a 12 MeV electron 
beam on an Elekta Precise Linac.   
D. Doses of 0.05Gy, 0.5Gy, 2Gy and 5Gy were delivered to cells (explained 
throughout chapters) 
 
 
 
3. Cytogenetics 
3.1. G2 Chromosomal Radiosensitivity Assay 
A. Add 0.2ml colcemid (10µg/ml) 30mins post irradiation and leave for 60mins. 
B. Split the contents of each flask between 2 x 12.5ml plastic centrifuge tubes and 
plunge the tubes into a bucket of ice: agitate to cool rapidly. 
C. Spin at 1000rpm for 5 mins (Refrigerated centrifuge) 
D. Remove supernatant, add 5ml pre cooled 0.075M KCL and leave in the ice bucket 
for 20mins. 
E. Spin at 1000rpm for 5mins 
F. Remove supernatant to about 1ml above cell pellet, mix cells, add freshly made 
fixative (3:1 Methanol: Glacial acetic acid) and mix. 
G. Spin immediately at 1000rpm for 5mins, change fixative and leave in fridge 
overnight. (Can be left longer if necessary). 
H. Allow the cells to come to room temperature, wash in fresh fixative twice and make 
slides. 
I. Stain in 2% Giemsa (GURRS) in PH 6.8 buffer for 5mins. Rinse in tap water, clear 
in xylene and mount in DPX. 
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Scoring 
J. All aberrations are scored. These will be mainly chromatid gaps and breaks with a 
few isochromatid breaks and exchanges.  When calculating aberration yields we 
exclude exchanges because there is evidence that repair involving exchanges is 
different from that involving repair of breaks. 
K. Gaps are only counted if they are wider than the diameter of the chromatid. 
Inclusion of smaller gaps gives greater variability of results. 
L. Subtract spontaneous yields from yields observed in irradiated cells to obtain the 
yield of radiation-induced aberrations. 
 
 
3.2. G-Banding  
 
 
a) Age the slides for 1 minute in the UV box.   
 
b) Place the slide on the slide rack and cover with 30% hydrogen peroxide solution 
for one minute 
 
c) Using a plastic transfer pipette, rinse the slide with 0.9% NaCl solution 
 
d) Place the slide in the trypsin solution for the selected time. This time will vary 
depending on the conditions in the lab 
 
e) Start the timer 
 
f) Using 1ml plastic transfer pipettes, make up the stain solution (banding strength) 
in plastic Universal container; one part Leishmann stain and two parts Gurr buffer 
 
g) Stop the timer 
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h) Remove the slide from the trypsin solution and rinse with 0.9% NaCl solution 
 
i) Using a plastic transfer pipette, rinse with Gurr buffer and place the slide on the 
slide rack 
 
j) Flood the slide with the stain solution and set the timer for 1 minute 
 
k) After 1 minute, using a plastic transfer pipette, rinse the slide with Gurr buffer 
and immediately with distilled water 
 
l) Carefully drain the excess water from the slide on to tissue.  Dry the back of the 
slide and the frosted part of the slide using tissue taking care not touch the front 
of the slide 
 
m) Put the slide on to the slide dryer and allow the surface to dry completely 
 
n) Place the slide on some tissue and drop a small amount of DPX mountant on the 
surface of the slide 
 
o) Put a coverslip on the centre of the slide taking care to avoid all air bubbles 
 
p) Put the slide on to the slide dryer, which is located within a fume hood, until the 
DPX mountant is completely dry 
 
 Evaluate the slide under the microscope set up for bright-field use, noting conditions 
of under or over banding or staining 
 
Fix spacing here. No need for so much spacing 
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 Adjust the amount of time in trypsin and hydrogen peroxide as necessary (see 
troubleshooting notes) until a test slide produces acceptable banding results. 
 
 Run the remaining slide required for analysis through the banding protocol using the 
times determined by the test run(s) 
 
 
 
3.3. Fluorescent In Situ Hybridisation 
Harvesting Protocol 
PROCEDURE 
This method follows on from DOC249 Set-Up of Cultures from Postnatal Solid Tissue. 
 
a. Ensure the laminar flow hood is running efficiently DOC321 and wipe the 
working area with 1% Virkon 
 
 
b. Flasks are assessed for growth.  On the day of harvest, remove the samples 
from the incubator and place in the sample rack within the laminar flow 
hood 
 
c. Using a sterile 1ml pipette add 100ul of colcemid (CT) and return to the 
CO2 incubator for 1hrs.  Write ‘C’ on the flask with a water resistant felt 
tip pen indicating that colcemid has been added 
 
d. Following 1hr incubation, the flasks are returned to the hood.  Label sterile 
15ml centrifuge tubes with pre-printed patient laboratory labels, the 
corresponding unique letter and date and place in the hood 
 
e. The culture medium is removed and placed in the corresponding pre-
labelled tube.  
 
 
f. Using a 1ml pipette, transfer the media containing the suspended cells with 
colcemid from the flask into the appropriately labelled 15ml tube.   
 
g. Centrifuge tubes for 10 minutes at 1000 rpm  
 
h. Pour off supernatant into 1% Virkon, and resuspend the pellet by gently 
flicking the base of each tube 
 
i. Add excess (8-10ml) pre-warmed 0.075M KCl (KCl) to each tube.  Invert 
each tube to ensure proper mixing and return to the incubator for 20 
minutes 
 
j. After 20 minutes place the tubes in the centrifuge. Add any appropriate 
balances, seal buckets and spin for 10 minutes at 1000 rpm  
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k. Following centrifugation, return the tubes to the hood, remove the 
supernatant and resuspend the pellet by gently flicking the base of each 
tube.  At this point, remove tubes from the long term tissue culture 
laboratory.  The remainder of the procedure is carried out in cytogenetic 
laboratory 2 
 
l. Using a sterile 1ml pipette, add ~1ml of fresh 3:1 fixative to each tube in 
a drop-wise manner.  Mix continuously by gently flicking the base of each 
tube 
 
m. Top up the flask to 10ml using the fresh 3:1 fixative 
 
 
n. Place the tubes in the centrifuge.  Add any appropriate balances, seal 
buckets and spin for 10 minutes at 1000rpm  
 
o. Following centrifugation, remove the supernatant leaving approximately 
0.5ml in each tube.  Resuspend the pellet by gently flicking the base of 
each tube 
 
p. Top up the flask to 10ml using the fresh 3:1 fixative 
 
q. Repeat steps q) & r) for a total of 3 times 
 
r. Following centrifugation, remove the supernatant leaving approximately 
0.5-1ml in each tube depending on the size of the pellet 
 
s. Samples are now ready for slide making 
 
 
Slide Making Protocol 
 
PROCEDURE 
 
 
Notes 
 Only one sample should be open at any one time 
 
 Label slides in pencil by copying the patient name, lab number, your initials, and 
culture ID to the slide immediately after dropping the suspension 
 
 While slides are drying they should be placed to avoid any splashes etc. arising 
when slides from subsequent cultures are prepared 
 
 A maximum of 4 slides will be made on each culture unless otherwise specified 
 
 Any changes to the slide making protocol must be discussed with a senior staff 
member and documented prior to the change 
 
A. Place the tubes containing the cell suspensions in the centrifuge and spin at 1500rpm 
for 5 minutes (last stage of harvest, see appropriate procedure for specimen type) 
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B. Place a single sheet of clean tissue paper on the hotplate B set at 7.1 on the dial in the 
Down flow slide making hood 
 
C. Place 1-2 clean sheet(s) of tissue paper in front of you in the Down flow slide making 
hood for blotting slides 
 
D. Uncap one tube and remove the supernatant using a pipette and discard into a waste 
container taking care not to disturb the pellet 
 
E. If required, use a 3ml plastic pipette to add fresh Carnoy 3:1 fixative drop-wise until 
the suspension is slightly cloudy and discard pipette into waste container 
 
F. Using the forceps remove one slide from the beaker containing slides in fresh cold 
distilled water.  When taking the slide out of the beaker the water should be retained 
on the slide.   
 
G. Keeping the slide horizontal, holding a fresh 3ml pipette at approximately 2-3cm 
away from the slide add two drops of cell suspension towards the middle of the slide 
(see Fig 1) 
 
H. Place the slide on clean tissue paper 
 
I. Using the pencil, clearly copy the lab number, patient initial and surname; culture 
type, slide number and your initials to the frosted part of the slide 
 
J. Return the remaining supernatant to the open culture tube 
 
K. Discard the pipette into waste container 
 
 
 
 
Fig 1: Slide making technique 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Place the slide on the tissue on the hotplate to dry 
 
B. Once the slide has dried, assess its suitability under phase contrast microscope, see 
below 
 
 
2-3cm 
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C. If the metaphases look unsuitable for analysis and the slide-making may need 
modification 
 
D. Troubleshoot and repeat points g) to m) 
 
E. If the slide is suitable make the remaining 3 slides in the same way f)-j) 
 
F. Recap the tube 
 
G. Place slides from each patient on an individual slide tray, cover the tray and move it 
away from slide making area 
 
H. Repeat process for each sample 
 
I. Initial the set-up/harvest list and file in constitutional set-up/harvest list folder 
 
 
4. Molecular Extractions 
 
4.1. Protein Extraction 
Procedure for lysis of suspension cultured cells as per RIPA protocol (Sigma) 
A. Pellet the cells by centrifugation at 450 x g for 5 minutes. 
B. Carefully remove the medium from the cell pellet by decantation or aspiration. 
C. Wash the cells to remove residual medium. Add a volume of a physiological wash 
solution, such as DPBS, equal to the original medium volume. Mix or vortex 
briefly to resuspend the cells completely.  
D. Centrifuge for 5 minutes at 450 x g to pellet the cells and carefully remove wash 
solution supernatant. Repeat the wash once in order to remove any other minor 
contaminants. More washing steps can be done, but two is usually sufficient to 
remove nearly all of the contaminants. 
E. After removal of the final wash solution from the cells, add an appropriate volume 
of RIPA Buffer (1 ml per 0.5 to 5 x 107 cells) to the cell pellet, and mix or vortex 
briefly to resuspend the cells completely. Incubate on ice or in a refrigerator (2–8 
°C) for five minutes. Vortex briefly to resuspend and lyse residual cells. 
F. The lysate can either be used immediately or quick frozen in liquid nitrogen and 
stored at –70 °C for future use. 
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G. Clarify the lysate by centrifugation at 8,000 x g for 10 minutes at 4 °C to pellet 
the cell debris. 
H. Note: If a mucoid aggregate of denatured nucleic acids is present, carefully 
remove it with a micropipette before centrifugation. 
I. Carefully transfer the supernatant containing the soluble protein to a tube on ice 
for immunoprecipitation or other analysis.  
Protein estimation using the Bio Rad DC protein estimation kit 
Method 
A. Mix 500ul of solution A to 10ul of reagent S into a fresh Eppendorf and label it 
Mix/Reagent A. 
B. Pipette 2.5ul of each standard in descending order in the labelled wells in a 
micro-titre 96 well plate. 
C. Pipette 2.5ul of each sample in triplicate in three wells 
D. Pipette 25ul of the mix/reagent A solution to all of the wells used in the plate 
E. Pipette 200ul of Reagent B to all of the used wells also 
F. Mix gently 
G. Read on spec at 705nm 
Note: The standards are BSA made up in the protein lysis buffer at concentrations 
of 2mg/ml to 10mg/ml 
4.2. RNA Extraction 
Cell Lysis 
A. Add 200µl of blood to 1ml of Tri Reagent. Store in -80 At This Stage 
B. Shake well or vortex 
Phase Separation 
C. Store for 5mins @ RT 
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D. Add 200µl of chloroform 
E. Cover and shake for 15 seconds 
F. Store @ RT for 2-5mins 
G. Centrifuge @ 12000g for 15mins @4˚C 
H. Transfer aqueous (colourless) layer to new tube (RNA) 
RNA Precipitation 
I. Add 500µl of Isopropanol 
J. Store @ RT for 5-10mins 
K. Centrifuge @ 12000g for 10mins @4-25˚C 
L. Gel or white pellet forms 
RNA Wash 
M. Remove supernatant 
N. Mix RNA pellet in 1ml of 75% ethanol & vortex 
O. Centrifuge @12000g for 5mins @4 - 25˚C 
RNA Solubilisation 
P. Remove ethanol wash 
Q. Air dry RNA pellet for 5mins (do not let dry completely) 
 Dissolve RNA in 50µl of DEPC treated water or 0.5% SDS 
 
 
4.3. DNA Extraction (DNeasy Blood and Tissue DNA extraction Kit) 
Before Starting; 
A. Buffer AL may form precipitate in storage. If necessary, warm to 56˚C until fully 
dissolved 
B. For step 2, Buffer AL without added ethanol is needed 
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C. Buffer AW1 and AW2 are concentrates. Ensure appropriate amount of ethanol 
(96%-100%) has been added to make a working solution 
D. Preheat a thermomixer/shaking water bath/rocking platform to 56˚C for use in 
step 2 
 
Protocol 
A. Non nucleated blood – Pipette 20µl of proteinase k into a 1.5ml or 2ml micro 
centrifuge tube. Add 50-100µl of anti-coagulated blood. Adjust volume to 220µl 
with PBS. 
B. Add 200µl of Buffer AL without Ethanol. Mix by vortexing and incubate at 56˚C 
for 10mins 
C. Add 200µl of ethanol (96%-100%) to sample, mix by vortexing 
D. Pipette mix into DNeasy mini spin column placed in a 2ml collection tube 
(provided). Centrifuge at >6000xg for 1min. Discard flow through and collection 
tube 
E. Place DNeasy mini spin column in a new 2ml collection tube, add 500µl of Buffer 
AW1 and centrifuge for 1min at >6000xg. Discard flow through and collection 
tube. 
F. Place DNeasy mini spin column in a new 2ml tube, add 500µl of Buffer AW2 and 
centrifuge for 3mins at 20,000xg to dry the DNeasy membrane. Discard flow 
through and collection tube 
G. Place DNeasy mini spin column in a clean 1.5ml/2ml micro centrifuge tube (not 
provided) and pipette 200µl of buffer AE directly on to DNeasy membrane. 
Incubate at RT for 1min, then centrifuge for 1min at >6000xg to elute 
H. Repeat step 7 for maximum DNA yield 
Estimate: Protocol steps = 25mins, Preparation time = 15mins, Between steps = 15mins 
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Total Estimated Time = 55mins 1hr 
 
 
 
 
5. Assays for Radiobiological Studies 
5.1. Cell survival 
E. 1hr before irradiation, subculture cells (LCL’s) in concentrations of 1x105/ml 
(5mls total) 
F. Irradiate flasks at 0.05Gy, 0.5Gy, 2Gy and sham irradiate 0Gy control 
G. Incubate in incubator at 37°C in 5% Co2 for 72hrs 
H. Using coulter counter, do cell counts in triplicate on all cell lines and doses 
I. Repeat experiment x3 times 
 
5.2. γH2AX flow and confocal 
 
5.2.1. γH2AX Foci Induction by Confocal Microscopy 
 
A. Centrifuge samples 400g 5mins 
B. Resuspend in 500ul Triton X solution 
C. Incubate 5mins RT 
D. Spin 400g 5mins 
E. Resuspend in 200ul blocking solution 
F. Incubate 30mins RT 
G. Centrifuge 400g 5mins 
H. Resuspend in 150ul Primary AB solution 
I. Incubate 2hrs at RT (or overnight in fridge) 
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J. PBS Wash x 3 (500ul 400g 5mins) 
K. Resuspend in 150ul Secondary AB solution 
L. Incubate in dark 1hr 
M. PBS Wash x 3 (500ul 400g 5mins) 
N. Resuspend in 100ul PI Solution 
O. Incubate 10mins RT 
P. PBS Wash x 3 (500ul 400g 5mins) 
Q. Resuspend in 100ul of PBS 
R. Make cytospins – 800rpm 5mins 
S. Mount with vectashield and secure with nail varnish 
T. Store in fridge until use 
 
5.2.2. Confocal Microscope Parameters 
A. Machine is switched on and let to set up for 10-15 mins (noises are normal) 
B. Open LSM and click ‘Scan New Image’ and ‘Start Expert Mode’ 
C. To set up go to ‘File’ and ‘Acquire only’ 
D. Acquire laser 2  Argon (Standby first) then on 
E. Acquire laser  Hene1 (on) 
F. Go to micro – objective – change to low power for starting 
G. Transmitted light – configure – fitc/rhodamine  apply 
H. Made new database – filename is ‘Lisa’ under gammaH2AX 
I. If coming back, just load the file by ‘open database’ and click ‘Re-use’ 
J. Lasers are always first thing to configure. Check back and they should be ready, with 
Argon at 50% 
K. When beginning to scan slides, click micro and scan control. Multiple windows will 
remain open on the monitor for use back and fourth 
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L. Use objective x10 or x20 to begin and setting PH1 on the microscope 
M. Load slide face down and focus using ‘Vis’ on computer and make sure the 
transmission light is on 
N. Find cluster of cells and focus 
O. Take slide off, chose oil objective and change to setting PH3 on microscope 
P. Drop of oil on the slide and place face down on lens of microscope 
Q. Focus cells then click ‘LSM’ 
R. Click fast xy and split xy so channels can be observed and focused on the monitor 
S. Adjust palette by clicking ‘range detector.’ Here you can adjust gain, but record the 
numbers to use the same settings for one experiment throughout 
T. Adjust background by clicking ‘Amplifier offset’ 
U. Minimum of 100 cells per slide are recorded 
V. Turn lasers off (Argon goes on standby first until ready to switch off) 
W. Close all other windows 
X. Clean lens with Zeiss solution and clean slide 
Y. Wait for fan of the laser control to switch off before switching computer and machine 
off 
5.3. Flow cytometry parameters 
A. Samples up to step 14, part 5.2.1 were resuspended in 1ml of PI/ PBS solution per 
sample 
B. Measure total, median and mean fluorescence intensity of H2AX using a CyFlow 
(Partec) flow cytometer.  
C. Record a minimum of 10,000 events per sample 
D. On the monitor, exclude cell aggregates and debris by forward and side scatter 
discriminative characteristics 
5.4. Cell Viability/Cytotoxicity/Caspase Activation 
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These were measured using ApoTox kit (Promega) 
A. Thaw each assay component as follows:  
B.  Assay Buffer: 37°C water bath  
A. GF-AFC Substrate: 37°C water bath 
B. bis-AAF-R110 Substrate: 37°C water bath  
C. Caspase-Glo® 3/7 Buffer: Room temperature 
D. Caspase-Glo® 3/7 Substrate: Room temperature  
E. Transfer the contents of the GF-AFC Substrate and bis-AAF-R110 Substrate into 2.0 
or 2.5ml of Assay Buffer, depending on the plate format used.  
F. For 96-well plates, transfer 10µl of each substrate into 2ml of Assay Buffer.  
G. Mix the Assay Buffer containing substrates by vortexing the contents until the 
substrates are thoroughly dissolved. This mixture will be referred to as the 
Viability/Cytotoxicity Reagent. 
H. Transfer the contents of the Caspase-Glo® 3/7 Buffer bottle into the amber bottle 
containing Caspase-Glo® 3/7 Substrate.  
I. Mix by swirling or inverting the contents until the substrate is thoroughly dissolved 
to form the Caspase-Glo® 3/7 Reagent (~20 seconds).  
J. Set up 96-well assay plates containing cells in medium at the selected density 
K. Add test compounds and vehicle controls to appropriate wells for a final volume of 
100µl per well. 
L. Culture cells for the desired test exposure period. Note: When characterizing new 
compounds, it is important to use in multiple exposure periods to assess the full effect 
on cellular health 
M. Add 20µl of Viability/Cytotoxicity Reagent containing both GF-AFC Substrate and 
bis-AAF-R110 Substrate to all wells, and briefly mix by orbital shaking (300–500rpm 
for ~30 seconds) 
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N. Incubate for 30 minutes at 37°C 
O. Measure fluorescence at the following two wavelength sets: 400Ex/505Em (Viability) 
485Ex/520Em (Cytotoxicity)  
P. Add 100µl of Caspase-Glo® 3/7 Reagent to all wells, and briefly mix by orbital 
shaking (300–500rpm for ~30 seconds) Note: Incubation times longer than 30 minutes 
may improve assay sensitivity and dynamic range 
Q. Incubate for 30 minutes at room temperature 
R. Measure luminescence (caspase activation, a hallmark of apoptosis) 
 
6. Exosome Isolation and Characterisation  
6.1. Isolation Procedure 
A. Culture cells for 3 days in Medium replaced with DMEM containing 10% 
exosome-depleted-FBS 
B. Centrifuge samples at 2000 g for 10 min at 4°C  
C. Filter to eliminate cells and dead cells using 0.45 lm pore filters  
D. Ultracentrifuge at 110,000 g for 75 min at 4°C 
E. Wash Exosome pellets phosphate buffered solution (PBS)  
F. Repeat ultracentrifugation and resuspend in PBS 
6.2. SDS-PAGE, Western Blotting and Antigen Binding 
A. Set up Bio-rad rig as directed (by Orla) the evening before the gels will be done. 
Fill the rig up with deionised water or alcohol to ensure that there are no leaks. 
B. Set up the separating Gel first (% separating gel depends on size of desired 
protein).  The general rule is the smaller the protein the larger the % separating 
Gel.  In this case, 10% will be done.  Check the SDS-PAGE concs. 
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C. Add all of the solutions together accordingly.  Always remember to add the 
10% APS (aliquoted in the freezer) and temed last as they solidify the gel 
solution. 
D. Quickly mix and pipette approx. 4mls (2/3 the size of the whole area) into the gel 
rig.  Carefully add a layer of isopropanol over the gel to create a defined edge on 
the gel.  Allow to set for approx. 10 mins. 
E. Carefully pour off the isopropanol using tissue at the edge of the rig to clear off 
the excess. 
F. Add all of the solutions for the 4% stacking gel together (again remember APS 
and Temed last) 
G. Pipette carefully into the rig on top of the separating gel and carefully add in the 
comb (from sideways).  Allow to set for approx. 10 mins. 
H. Meanwhile prepare the lysed protein samples for SDS-PAGE by aliquoting the 
desired amount in µl into separate Eppendorf tubes.  Add the SDS-gel loading 
dye (approx. 10µl) and boil in a heating block (use PCR machine) for 3 mins at 
100ºC.  This is to linearize the proteins for the gel. 
I. Dry load or wet load the wells of the prepared Gel with the protein samples.   Do 
not forget the protein ladder. 
J. Fill the inside of the rig to the top with running buffer and place the lid on top.  
Set the electrophoresis power unit to 20mA per gel and run for approximately 1-
1.5hrs until the samples/blue dye front reaches the bottom of the gel. 
Step 3:  Western Blotting 
K. Undo the Gel rig as instructed (by Orla) and carefully take the spacers out from 
between the glass plates.  The plates usually separate and the gel remains on one 
plate.  Cut off the stacking layer of the gel. 
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L. The membrane is immersed with transfer buffer and placed on top of the gel.  
Two pieces of blotting paper (pre-cut to size) are also immersed in transfer buffer 
and placed over the membrane and the gel.  Two pieces of blotting paper are 
immersed in transfer buffer and placed on the other side of the gel.  Tease out all 
air bubbles by gently rolling a long pipette over the sandwich. 
M. The sandwich is placed in the Bio-Rad transfer cassette with the membrane to the 
black side.  The clamp is closed and placed into the transfer rig.  The general 
rule is the membrane to the positive side (red) and the gel to the negative 
side (black).  Thus, black side of cassette to the red side of the transfer rig.  Fill 
with cool transfer buffer (always keep 1X transfer buffer in the fridge). 
N. Set the power unit to 100 volts for 1 hr. Check the current also while it has started 
to run to ensure that it is running OK.  This is done by switching to Amps. 
 
Step 4: Antibody-Antigen binding 
O. Carefully remove the membrane from the cassette and peeling off the other 
layers.  Place the membrane into a large Petri dish or trough and add 20mls of 
5% (1g in 20mls tris buffer) milk solution for 1 hour at RT on the shaker. This is 
to block the membrane. 
P. Make up the primary antibody in 3% protein solution (0.3g in 10mls tris buffer). 
Q. Add the primary antibody to the membrane overnight and leave on the shaker. 
R. Wash off the solution from the membrane by doing 3 x 10 minute washes in Tris-
T. 
S. Add the secondary antibody (also made up in 3% protein solution) to the 
membrane for 1 hour on the shaker. 
T. Wash off the solution from the membrane by doing 3 x 10 minute washes in Tris-
T. 
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Step 5:  Visualisation of desired protein 
Chemilluminescence 
U. Using the homemade ECL chemiluminescent kit (solution A and B) place over 
the membrane for 1 minute. 
V. Carefully place the membrane into the exposure cassette. 
W. In a dark room, carefully open the X-ray film and place over the membrane and 
expose for 1 min and 5 mins.  Develop X-ray film and dry.  If there is not enough 
exposure, re-do the chemilluminescence step and expose for longer. 
Staining 
X. DAB can be used to stain the membrane for the specific protein.  Make up 10mls 
of DAB and add hydrogen peroxide to activate the chromogen. Add to membrane 
and the protein of interest can be visualised. 
 
6.3. Exosome identification by TEM 
A. To further eliminate contaminating proteins, resuspend the exosome enriched pellet 
in PBS and ultracentrifuge at 120 000 x g for 70 minutes at 4 °C to re-pellet the 
exosomes.  
B. Take a small aliquot of the sample for protein isolation and total protein measurement. 
Make sure that only a small part of the sample is lysed and used for the protein 
measurement and keep the intact exosomes, solved in PBS, separate on ice or at -80 
°C for further experiments.  
C. Place a drop, approximately 10 μg of exosomal protein of the intact exosomes 
resuspended in PBS, on a Parafilm. Then, with forceps, gently position a formvar 
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coated l grid on top of each drop for 30-60 minutes. Assure that the grid is positioned 
with the coating side facing the drop containing exosomes.  
D. Place three drops, each 30 μl, of PBS on the Parafilm and wash the grid by 
sequentially positioning the grid on top of the droplets of PBS, and use an absorbing 
paper in between. Use the absorbing paper gently just by holding it closely to the side 
of the grid, without making contact with the coated area.  
E. Fix the sample by deposit a drop of 2% paraformaldehyde on the Parafilm and place 
the grid on top of the drop for 10 minutes.  
F. Repeat the washing step in point 4, substituting ddH2O for PBS. 
G. Contrast the sample by adding a drop of 2% uranyl acetate to the Parafilm and 
incubate the grid on top of the drop for 15 minutes. Wick away the stain and allow to 
dry 
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10.4 Raw Data 
Chapter 2 Raw Data 
Code Irradiated Plasma G2/mitotic H2AX AGE SMOKER SEX 
HC1 0 1 0 0     M 
HC2 1 1 1 1 37   M 
HC3 1 1 1 1 23   M 
HC4 0 1 0 0     M 
HC5 1 1 1 1 26   M 
HC6 0 1 0 0     F 
HC7 1 1 1 0 23   M 
HC8 1 1 1 1 23   F 
HC9 1 1 1 1 22   F 
HC10 1 1 1 1 29   F 
HC11 1 1 1 1 26   F 
HC12 1 1 1 1 21   F 
HC13 1 1 1 1 30   F 
HC14 1 1 1 1 37 YES M 
HC15 1 1 1 1 40   F 
HC16 1 1 1 1 54   F 
HC17 1 1 1 1 56   M 
HC18 1 1 1 1 35   M 
HC19 1 1 1 1 48   F 
HC20 1 1 1 1 32 YES M 
HC21 1 1 1 1 31   M 
HC22 1 1 1 1 23   F 
HC23 1 1 1 1 24   F 
HC24 1 1 1 1 31 YES F 
HC25 1 1 1 1 33 YES M 
HC26 1 1 1 1 23 YES M 
HC27 1 1 1 1 31   F 
HC28 1 1 1 1 38   F 
HC29 1 1 1 1 38   M 
HC30 1 1 1 0 41   M 
HC31 1 1 1 0 33   F 
HC32 1 1 1 0 43   F 
HC33 1 1 1 0 42   F 
HC34 1 1 1 0 31   M 
HC35 1 1 1 0 24   M 
HC36 1 1 1 0 30   M 
HC37 1 1 1 0 29   F 
HC38 1 1 1 0 23 YES F 
HC39 1 1 1 0 23 YES M 
HC40 1 1 1 0 25   F 
HC41 1 1 1 0 29 YES M 
HC42 1 1 1 0 28   F 
HC43 1 1 1 0 22   F 
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HC44 1 1 1 1 25   F 
HC45 1 1 1 1 29   M 
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Patient ID Date Mitotic Index MIn G2 Score 
I.Induced G2 
Score 
    
0
Gy 
0.05
Gy 
0.5
Gy 
0.05
Gy 
0.5
Gy 
0
Gy 
0.05
gy 
0.5
gy 
0.05
Gy 
0.5G
y 
HC3 Whole 
Blood 
06/07/2
012 
1.
6 1.7 0.7 -0.1 0.9 4 40 116 36 112 
HC3 
Lymphocytes 
06/07/2
012 
1.
6 2.1 0.8 -0.5 0.8 4 40 96 36 92 
HC7 Whole 
Blood 
29/03/2
012 
1.
5 1.2 0.5 0.3 1 0 68 156 68 156 
HC7 
Lymphocytes 
29/03/2
012 
1.
1 0.6 0.7 0.5 0.4 4 36 83 32 79 
HC25 Whole 
Blood 
06/07/2
012 
0.
8 0.7 0.5 0.1 0.3 0 28 172 28 172 
HC25 
Lymphocytes 
06/07/2
012 
2.
5 1 1 1.5 1.5 4 32 132 28 128 
 
  Mitotic Index MIn G2 Score 
I. Induced G2 
Score 
Donor 0Gy 0.5Gy 2Gy 0.5Gy 2Gy 0Gy 0.5Gy 2Gy 0.5Gy 2Gy 
HC3 3.4 2 1.1 1.4 2.3 4 123 420 119 416 
HC5 3.6 1.2 1.3 2.4 2.3 0 148 424 148 424 
HC27 1 1.8 1.4 -0.8 -0.4 8 184 664 176 656 
 
Patient 
ID Date Mitotic Index MIn G2 Score 
I. Induced G2 
Score 
    
0G
y 
0.05
Gy 
0.5
Gy 
0.05
Gy 
0.5
Gy 
0G
y 
0.05
Gy 0.5Gy 
0.05G
y 0.5Gy 
HC3 1 
20/04/2
012 
2.
5 2 1.3 0.5 1.2 4 60 156 56 152 
HC3 2 
06/07/2
012 
1.
6 1.7 0.7 -0.1 0.9 4 40 116 36 112 
HC3 3 
13/07/2
012 
2.
7 1.9 0.4 0.8 2.3 4 32 132 28 128 
HC3 4 
20/07/2
012 2 1.1 1.1 0.9 0.9 4 32 134 28 130 
HC3 5 
27/07/2
012 
3.
6 2.7 1.6 0.9 2 0 32 126 32 126 
HC3 6 
16/01/2
014 
3.
6 2 0.7 1.6 2.9 4 36 124 32 120 
         Mean 
35.333
33 128 
         
St.DE
V 
10.557
78 
13.446
19 
         
Coeff. 
% 
29.880
5 
10.504
84 
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Patient 
ID Date Mitotic Index MIn G2 Score 
I. Induced G2 
Score 
    
0G
y 
0.05
Gy 
0.5
Gy 
0.05
Gy 
0.5
Gy 
0G
y 
0.05
Gy 0.5Gy 0.5Gy 0.5Gy 
HC8 1 
27/07/2
012 
2.
2 1.5 0.6 0.7 1.2 8 64 116 56 108 
HC8 2 
16/01/2
014 
2.
1 2.2 0.9 0.7 1.1 0 44 170 44 170 
HC8 3 
10/03/2
014 
1.
6 2.5 0.8 0.7 1.8 12 28 138 16 126 
HC8 4 
10/04/2
014 
2.
8 2.1 1 1.2 1.2 8 56 188 48 180 
HC8 5 
30/05/2
014 
1.
5 1.4 0.7 0.1 0.8 8 44 156 36 148 
         Mean 40 146.4 
         
St.DE
V 
15.231
55 
29.913
21 
         
Coeff. 
% 
38.078
87 
20.432
52 
 
Patient 
ID Date Mitotic Index MIn G2 Score 
I. Induced G2 
Score 
    
0G
y 
0.05
Gy 
0.5
Gy 
0.05
Gy 
0.5
Gy 
0G
y 
0.05
Gy 0.5Gy 0.5Gy 0.5Gy 
HC38 1  
16/01/2
014 
2.
5 0.4 1.4 2.1 1.1 4 36 116 32 114 
HC38 2 
10/03/2
014 
3.
6 1.7 0.6 1.9 3 4 32 122 28 118 
HC38 3 
30/05/2
014 
1.
7 1.5 0.8 0.2 0.9 16 44 208 28 192 
HC38 5 
08/12/2
014 4 4.4 2.2 -0.4 1.5 4 48 160 44 156 
HC38 6 
14/04/2
015 
3.
9 2.9 4.2 1 -0.3 4 28 128 24 124 
         Mean 31.2 140.8 
         
St.DE
V 
7.6941
54 
33.063
58 
         
Coeff. 
% 
24.660
75 
23.482
65 
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  Mitotic Index Mitotic Inhibition 
Donor 0Gy 0.05Gy 0.5Gy 0.05Gy 0.5Gy 
HC2  1.9 3.4 1.5 -1.5 0.4 
HC3  2.5 2 1.3 0.5 1.2 
HC5  3.9 3.1 1.3 0.8 2.6 
HC7  1.5 1.2 0.5 0.3 1 
HC8  2.1 1.4 0.9 0.7 1.2 
HC9  1.2 1.1 0.5 0.1 0.7 
HC10  3.6 2.6 1.1 1 2.5 
HC11  2.6 2.1 1.3 0.5 1.3 
HC12  3.5 2.8 1.2 0.7 2.3 
HC13  1.6 1.5 1 0.1 0.6 
HC14  2.2 1.9 0.9 0.3 1.3 
HC15  2.5 1.5 0.8 1 1.7 
HC16  1.8 1.6 1.1 0.2 0.7 
HC17  1.1 1.4 0.8 -0.3 0.3 
HC18 2.5 1.8 1.4 0.7 1.1 
HC19 2.8 1.4 0.6 1.4 2.2 
HC20 3.4 1.7 0.8 1.7 2.6 
HC21 3.2 1.4 0.7 1.8 2.5 
HC22 3.2 2 0.4 1.2 2.8 
HC23 1.7 0.8 1.1 0.9 0.6 
HC24 1.4 1.5 0.6 -0.1 0.8 
HC25 0.8 0.7 0.5 0.1 0.3 
HC26 3 1.3 0.4 1.7 2.6 
HC27 1.2 2.4 0.4 -1.2 0.8 
HC28 1.1 0.8 0.3 0.3 0.8 
HC29 1.4 1.1 0.9 0.3 0.5 
HC30 2.6 1.9 0.8 0.7 1.8 
HC31 0.9 0.5 0.7 0.4 0.2 
HC32 1.4 1.5 0.7 -0.1 0.7 
HC33 1.6 1.8 0.5 -0.2 1.1 
HC34 2.5 1.2 1.1 1.3 1.4 
HC35 3.3 2 2.2 1.3 1.1 
HC36 3.3 1.9 1.9 1.4 1.4 
HC37 1.5 0.6 0.1 0.9 1.4 
HC38 2.5 0.4 1.4 2.1 1.1 
HC39 2.8 1.6 1.8 1.2 1 
HC40 2.5 1.3 0.5 1.2 2 
HC41 3.4 4.4 1.5 -1 1.9 
HC42 4.4 2.4 2.9 2 1.5 
HC43 2.9 1.9 0.9 1 2 
HC44 3.1 3.3 1.6 -0.2 1.5 
HC45 4.3 2.8 1.3 1.5 3 
Mean 2.39762 1.7619 1.00476 0.63571 1.39286 
ST.DEV 0.95214 0.83226 0.55302 0.81923 0.76872 
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Coefficient of Variation (%) 39.7121 47.2365 55.0398 128.867 55.1898 
 
 
  Lisa G2 Scores I. Induced G2 Score 
Donor 0Gy 0.05Gy 0.5Gy 0.05Gy 0.5Gy 
HC 2 8 60 128 52 120 
HC 3 4 60 156 56 152 
HC 5 20 40 160 20 140 
HC 7 0 68 156 68 156 
HC 8 8 64 116 56 108 
HC 9 4 68 152 64 148 
HC 10 4 40 92 36 88 
HC 11 8 56 106 48 98 
HC 12 8 44 90 36 82 
HC 13 4 40 184 36 180 
HC 14 8 32 94 24 86 
HC 15 8 32 110 24 102 
HC 16 8 24 126 16 118 
HC 17 4 40 100 36 96 
HC 18 8 48 218 40 210 
HC 19 8 24 124 16 116 
HC 20 0 32 92 32 92 
HC 21 8 32 142 24 134 
HC 22 0 44 94 44 94 
HC 23 4 48 150 44 146 
HC 24 4 28 134 24 130 
HC 25 0 28 172 28 172 
HC 26 4 32 100 28 96 
HC 27 0 32 152 32 152 
HC 28 4 28 148 24 144 
HC 29 0 36 132 36 132 
HC 30 4 28 126 24 122 
HC 31 0 40 124 40 124 
HC 32 4 32 104 28 100 
HC 33 16 36 112 20 96 
HC 34 4 44 116 40 112 
HC 35 8 36 142 28 134 
HC 36 4 32 138 28 134 
HC 37 4 36 106 32 102 
HC 38 4 36 116 32 112 
HC 39 12 56 158 44 146 
HC 40 4 36 146 32 142 
HC 41 0 36 108 36 108 
HC 42 4 44 148 40 144 
HC 43 8 36 106 28 98 
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HC 44 4 40 134 36 130 
HC 45 20 64 132 44 112 
Mean 5.61905 40.7619 129.619 35.1429 124 
ST.DEV 4.76242 12.024 27.6326 12.0336 27.7304 
Coefficient of Variation (%) 84.7549 29.4981 21.3183 34.242 22.3632 
 
 
Donor 0Gy 0.05Gy 0.5Gy 
HC2  0 12 dicent + 4endo 0 
HC3  0 8 dicent 10 dicent + 4 cring 
HC5  0 8 cring 4 acentric 
HC7  0 16 dicent 0 
HC8  0 4 acentric + 4 dicent 0 
HC9  0 8 acentric 2 cring 
HC10  0 4 endo + 8 Dicent 6 dicent 
HC11  0 0 4 dicent 
HC12  0 0 0 
HC13  0 8 dicent 0 
HC14  4 dicent 8 dicent 0 
HC15  0 0 2 cring 
HC16  0 0 0 
HC17  0 0 4 dicent 
HC18 4 endo 4 cring 4 dicent 
HC19 4 dicent 8 dicent 0 
HC20 0 4 endo  0 
HC21 4 dicent 8 dicent 6 dicent 
HC22 0 0 0 
HC23 0 8 dicent 0 
HC24 0 12 dicent 0 
HC25 0 4 tetra 6 dicent 
HC26 0 0 0 
HC27 0 0 6 tetra 
HC28 0 0 0 
HC29 0 0 2 cring 
HC30 0 0 2 dicent 
HC31 0 0 0 
HC32 0 0 0 
HC33 0 0 0 
HC34 0 4 dicent 0 
HC35 0 4 dicent 2 tetra 
HC36 0 0 2 tetra 
HC37 0 0 2 tetra 
HC38 0 0 0 
HC39 0 8 dicent 0 
HC40 0 0 2 endo 
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HC41 0 4 tetra 2 dicent 
HC42 0 0 2 dicent + 2 Tetra 
HC43 0 4 tetra 0 
HC44 0 0 14 dicent 
HC45 4 dicent 20 dicent + 4 endo 6 dicent + 2 endo 
 
 
 Mitotic Index 
   
60Co 
Irradiati
on     
Linac 
Photon 
Irradiati
on     
Linac 
Electron 
Irradiati
on     
 
Dono
r 0 
0.05G
y 
0.5G
y 0 
0.05G
y 
0.5G
y 0 
0.05G
y 
0.5G
y 
1 HC2  2.9 1.5 1.2 2.9 0.6 0.5 2.9 2.4 1.4 
2 HC3 3.6 1.2 1.4 3.6 1.8 1.3 3.6 2.7 1.9 
3 HC7 2.4 2.3 1.7 2.4 1.3 1.8 2.4 1.5 2.5 
4 HC8 1.2 0.5 0.1 1.2 0.6 0.8 1.2 1.7 1.1 
5 HC21 2.1 1.4 2 3 2.6 2.4 N/A N/A N/A 
6 HC23 2.7 1.4 2 2.7 1.4 1.1 2.7 1.5 1.9 
7 HC30 2.6 1.9 0.8 2.6 1.9 1.1 2.6 1.7 1 
8 HC31 0.9 0.5 0.7 0.9 0.6 0.9 0.9 1.2 0.7 
9 HC32 1.4 1.5 0.7 1.4 0.8 1 1.4 1.7 1 
1
0 HC33 1.6 1.8 0.5 1.6 0.9 1.6 1.6 0.6 0.4 
1
1 HC34 2.5 1.2 1.1 2.5 1.5 0.8 2.5 1.7 1.7 
1
2 HC35 3.3 2 2.2 3.3 3.2 1.6 3.3 1.9 1.6 
1
3 HC36 3.3 1.9 1.9 3.3 1.5 1.8 3.3 2 2 
1
4 HC37 1.5 0.6 0.1 1.5 0.4 0.1 1.5 0.8 0.7 
1
5 HC38 2.5 0.4 1.4 2.5 0.9 0.5 2.5 2 1.1 
1
6 HC39 2.8 1.6 1.8 2.8 2.2 1.5 2.8 2.2 1 
1
7 HC40 2.5 1.3 0.5 2.5 1.4 0.7 2.5 2.2 0.6 
1
8 HC41 3.4 4.4 1.5 3.4 2.1 1.3 NONE NONE 
NON
E 
1
9 HC42 4.4 2.4 2.9 4.4 2.3 1.3 NONE NONE 
NON
E 
2
0 HC43 2.9 1.9 0.9 2.9 1.3 1.2 NONE NONE 
NON
E 
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 MIn 
   60Co Irradiation 
Linac Photon 
Irradiation Linac Electron Irradiation 
 Donor 0 0.05Gy 0.5Gy 0 0.05Gy 0.5Gy 0 0.05Gy 0.5Gy 
1 HC2    1.4 1.7   2.3 2.4   0.5 1.5 
2 HC3   2.4 2.2   1.8 2.3   0.9 1.7 
3 HC7   0.1 0.7   1.1 0.6   0.9 -0.1 
4 HC8   0.7 1.1   0.6 0.4   -0.5 0.1 
5 HC21   0.7 0.1   0.4 0.6   NONE NONE 
6 HC23   1.3 0.7   1.3 1.6   1.2 0.8 
7 HC30   0.7 1.8   0.7 1.5   0.9 1.6 
8 HC31   0.4 0.2   0.3 0   -0.3 0.2 
9 HC32   -0.1 0.7   0.6 0.4   -0.3 0.4 
10 HC33   -0.2 1.1   0.7 0   1 1.2 
11 HC34   1.3 1.4   1 1.7   0.8 0.8 
12 HC35   1.3 1.1   0.1 1.7   1.4 1.7 
13 HC36   1.4 1.4   1.8 1.5   1.3 1.3 
14 HC37   0.9 1.4   1.1 1.4   0.7 0.8 
15 HC38   2.1 1.1   1.6 2   0.5 1.4 
16 HC39   1.2 1   0.6 1.3   0.6 1.8 
17 HC40   1.2 2   1.1 1.8   0.3 1.9 
18 HC41   -1 1.9   1.3 2.1 NONE NONE NONE 
19 HC42   2 1.5   2.1 3.1 NONE NONE NONE 
20 HC43   1 2   1.6 1.7 NONE NONE NONE 
 
 
 G2 Score 
   60Co Irradiation 
Linac Photon 
Irradiation 
Linac Electron 
Irradiation 
 Donor 0 0.05Gy 0.5Gy 0 0.05Gy 0.5Gy 0 0.05Gy 0.5Gy 
1 HC2  12 48 142 12 32 100 12 32 102 
2 HC3 4 32 162 4 48 124 4 48 130 
3 HC7 8 40 154 8 36 116 8 48 126 
4 HC8 0 44 170 0 40 96 0 40 168 
5 HC21 12 44 100 4 48 120 N/a N/a N/a 
6 HC23 8 36 134 8 32 156 8 40 114 
7 HC30 4 28 126 4 40 128 4 32 88 
8 HC31 0 40 124 0 40 106 0 44 106 
9 HC32 4 32 104 4 36 98 4 36 90 
10 HC33 16 36 112 16 36 104 16 40 130 
11 HC34 4 44 116 4 36 102 4 44 154 
12 HC35 8 36 142 8 36 136 8 32 112 
13 HC36 4 32 138 4 28 118 4 44 104 
14 HC37 4 36 106 4 32 106 4 36 142 
15 HC38 4 36 116 4 36 110 4 40 122 
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16 HC39 12 56 158 12 48 132 12 48 142 
17 HC40 4 36 146 4 48 156 4 44 128 
18 HC41 0 36 108 0 36 130 N/a N/a N/a 
19 HC42 4 44 148 4 40 114 N/a N/a N/a 
20 HC43 8 36 106 8 40 126 N/a N/a N/a 
 
 
 Radiation induced G2 Score 
   60Co Irradiation 
Linac Photon 
Irradiation 
Linac Electron 
Irradiation 
 Donor 0 0.05Gy 0.5Gy 0 0.05Gy 0.5Gy 0 0.05Gy 0.5Gy 
1 HC2    36 130   20 88   20 90 
2 HC3   28 158   44 120   44 126 
3 HC7   32 146   28 108   40 118 
4 HC8   44 170   40 96   40 168 
5 HC21   32 88   44 116   N/a n/A 
6 HC23   28 126   24 148   32 106 
7 HC30   24 122   36 124   28 84 
8 HC31   40 124   40 106   44 106 
9 HC32   28 100   32 94   32 86 
10 HC33   20 96   20 88   24 114 
11 HC34   40 112   32 98   40 150 
12 HC35   28 134   28 128   24 104 
13 HC36   28 134   24 114   40 100 
14 HC37   32 102   28 102   32 138 
15 HC38   32 112   32 106   36 118 
16 HC39   44 146   36 120   36 130 
17 HC40   32 142   44 152   40 124 
18 HC41   36 108   36 130 N/a N/a N/a 
19 HC42   40 144   36 110 N/a N/a N/a 
20 HC43   28 98   32 118 N/a N/a N/a 
 
 
 
  Dose in mGy 0 5 50 500 5000 
              
200 kV 
Media 100 106.5 102.8 86.9 16.9 
std dev 11.3 10.2 16.3 19.1 0.7 
              
              
6 MV 
Media 100 93.4 88.7 84.6 15 
std dev 2.7 3.1 2.1 2.8 3.4 
              
              
10 MV Media 100 98 99.1 82.5 21.2 
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std dev 13.7 10.5 16.7 6.9 5.3 
              
              
15 MV 
Media 100 93.5 88.7 84.6 15 
std dev 2.7 3.1 2.1 2.8 3.4 
 
 
Chapter 3 Raw Data 
Donor 
Date of 
Exp. 
AG
E MITOTIC INDEX 
Mitotic 
Inhibition 
G2 
RADIOSENSITIVI
TY SCORE 
Radiation 
Induced G2 
Score 
      
0G
Y 
0.05
GY 
0.5
GY 
0.05
Gy 
0.5
Gy 
0G
Y 
0.05
GY 
0.5
GY 
0.05
Gy 
0.5
Gy 
PC001 
V1 
06/05/2
014 66 
3.
6 1.8 0.9 1.8 2.7 12 32 210 20 198 
PC002 
V1 
30/06/2
014 72 
2.
4 1 1.1 1.4 1.3 4 64 184 60 180 
PC003 
V1 
05/08/2
014 66 
0.
4 0.2 0.6 0.2 -0.2 0 44 192 44 192 
PC004 
V1 
22/09/2
014 85 
4.
8 2.9 1.7 1.9 3.1 8 80 218 72 210 
PC005 
V1 
20/10/2
014 60 
2.
5 1 1 1.5 1.5 12 44 190 32 178 
PC007 
V1 
16/12/2
014 58 
1.
3 0.6 1.3 0.7 0 52 48 170 -4 118 
PC009 
V1 
12/01/2
015   
1.
2 1.6 0.6 -0.4 0.6 20 52 186 32 166 
PC010 
V1 
19/01/2
015   
3.
4 1.5 1.3 1.9 2.1 12 52 200 40 188 
PC011 
V1 
20/01/2
015 67 2 1 0.4 1 1.6 24 52 138 28 114 
PC013 
V1 
09/02/2
015   
0.
3 0.7 0.2 -0.4 0.1 8 40 134 32 126 
PC014 
V1 
11/02/2
015   
2.
6 1.6 1.7 1 0.9 24 64 234 40 210 
PC015 
V1 
16/02/2
015 76 
0.
5 0.1 0.5 0.4 0 16 40 154 24 138 
PC016 
V1 
16/02/2
015 60 
0.
9 0.6 0.8 0.3 0.1 8 36 134 28 126 
PC017 
V1 
03/03/2
015   
2.
3 1.9 0.6 0.4 1.7 12 32 96 20 84 
PC018 
V1 
23/03/2
015 69 
1.
3 0.8 0.9 0.5 0.4 24 44 134 20 110 
PC019
V1 
26/03/2
015 76 2 1.3 1.1 0.7 0.9 16 32 174 16 158 
PC020
V1 
07/04/2
015 68 
2.
1 1.5 1.2 0.6 0.9 20 40 184 20 164 
PC021
V1 
13/04/2
015 68 
2.
3 2.3 2.3 0 0 16 40 216 24 200 
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PC022
V1 
19/05/2
015 62 
3.
8 3.4 1.5 0.4 2.3 12 40 144 28 132 
PC023
V1 
19/05/2
015 77 
1.
8 1.4 1 0.4 0.8 12 40 140 28 128 
PC024
V1 
25/05/2
015 72 
1.
2 0 0.1 1.2 1.1 12 43 150 31 138 
PC025
V1 
25/05/2
015   
0.
9 0.1 0.3 0.8 0.6 4 40 130 36 126 
 
 
      MITOTIC INDEX 
Mitotic 
Inhibition 
G2 
RADIOSENSITIVI
TY SCORE 
Radiation 
Induced G2 
Score 
Donor 
Date of 
Exp. 
AG
E 
0G
Y 
0.05
GY 
0.5
GY 
0.05
Gy 
0.5
Gy 
0G
Y 
0.05
GY 
0.5
GY 
0.05
Gy 
0.5
Gy 
PC001 
V2 
30/09/20
14 66 
0.
7 1 0.5 -0.3 0.2 0 44 202 44 202 
PC002 
V2 
07/08/20
14 72 2 2.5 0.9 -0.5 1.1 8 44 138 36 130 
PC003 
V2 
17/11/20
14 66 
1.
4 0.8 0.4 0.6 1 36 52 140 16 104 
PC004 
V2 
02/10/20
14 85 0 2.5 2.4 -2.5 -2.4 8 52 154 44 146 
PC005 
V2 
09/12/20
14 60 
1.
2 0.4 0.6 0.8 0.6 32 36 195 4 163 
PC006 
V2 
12/11/20
14 67 
2.
2 0.9 1.6 1.3 0.6 24 44 202 20 178 
PC008 
V2 
23/04/20
15   
0.
4 0.4 0.2 0 0.2 13 55 160 42 147 
PC009 
V2 
25/05/20
15   
1.
8 0 0.3 1.8 1.5 5 71 148 66 143 
PC010 
V2 
24/06/20
015   
2.
7 2.6 1.3 0.1 1.4 12 72 260 60 248 
PC011 
V2 
29/07/20
15 67 2 0.4 0.2 1.6 1.8 12 44 205 32 193 
PC012 
V2 
13/05/20
15   
2.
4 0.9 0.9 1.5 1.5 8 45 140 37 132 
PC013 
V2 
25/06/20
15   
4.
1 1.2 0.4 2.9 3.7 0 44 132 44 132 
PC014 
V2 
22/04/20
15   1 0 0 1 1 20 60 158 40 138 
PC015 
V2 
25/06/20
15 76 
1.
3 1.4 0.1 -0.1 1.2 16 60 220 44 204 
PC018 
V2 
22/04/20
15 69 
3.
7 1.4 1.6 2.3 2.1 12 48 160 36 148 
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      MITOTIC INDEX 
Mitotic 
Inhibition 
G2 
RADIOSENSITIVI
TY SCORE 
Radiation 
Induced G2 
Score 
Donor 
Date of 
Exp. 
AG
E 
0G
Y 
0.05
GY 
0.5
GY 
0.05
Gy 
0.5
Gy 
0G
Y 
0.05
GY 
0.5
GY 
0.05
Gy 
0.5
Gy 
PC001 
V3 
01/12/2
014 66 
3.
3 2.8 1.7 0.5 1.6 48 76 270 28 222 
PC002 
V3 
06/10/2
014 72 
2.
5 1.4 1.4 1.1 1.1 44 64 212 20 168 
PC003 
V3 
19/01/2
015 66 
0.
1 1.4 0 -1.3 0.1 12 92 190 80 178 
PC004 
V3 
09/12/2
014 85 
0.
6 0.6 0.4 0 0.2 24 40 188 16 164 
PC005 
V3 
09/02/2
015 60 
0.
6 0.5 0.7 0.1 -0.1 28 60 204 32 176 
PC006 
V3 
19/01/2
015 67 
0.
9 1 0.2 -0.1 0.7 20 56 268 36 248 
PC009 
V3 
28/07/2
015   
1.
9 1.4 0.5 0.5 1.4 8 72 160 64 152 
PC012 
V3 
15/07/2
015   
7.
3 6.3 3.9 1 3.4 0 40 140 40 140 
PC014 
V3 
25/06/2
015   
0.
4 0.1 0.1 0.3 0.3 12 50 100 38 88 
PC018 
V3 
25/06/2
015 69 
0.
9 0.5 0 0.4 0.9 8 64 140 56 132 
 
      MITOTIC INDEX 
Mitotic 
Inhibition 
G2 
RADIOSENSITIVI
TY SCORE 
Radiation 
Induced G2 
Score 
Donor 
Date of 
Exp. 
AG
E 
0G
Y 
0.05
GY 
0.5
GY 
0.05
Gy 
0.5
Gy 
0G
Y 
0.05
GY 
0.5
GY 
0.05
Gy 
0.5
Gy 
PC001 
V4 
16/02/2
015 66 1 0.7 0.7 0.3 0.3 16 72 172 56 156 
PC002 
V4 
08/12/2
014 72 
2.
1 2.5 2 -0.4 0.1 60 76 202 16 142 
PC003 
V4 
24/03/2
015 66 
1.
4 1.3 0.7 0.1 0.7 12 72 206 60 194 
PC004 
V4 
24/02/2
014 85 
0.
5 0.3 0.1 0.2 0.4 50 50 170 0 120 
PC005 
V4 
13/04/2
015 60 
0.
9 0.9 0.3 0 0.6 12 56 104 44 92 
PC006 
V4 
24/03/2
015 67 1 0.6 0.2 0.4 0.8 16 44 170 28 154 
PC014 
V4     
0.
8 0.4 0.6 0.4 0.2 20 52 176 32 156 
 
      MITOTIC INDEX 
Mitotic 
Inhibition 
G2 
RADIOSENSITIVI
TY SCORE 
Radiation 
Induced G2 
Score 
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Donor 
Date of 
Exp. 
AG
E 
0G
Y 
0.05
GY 
0.5
GY 
0.05
Gy 
0.5
Gy 
0G
Y 
0.05
GY 
0.5
GY 
0.05
Gy 
0.5
Gy 
PC001 
V5 
15/06/2
015 66 
1.
3 0.9 1.2 0.4 0.1 8 48 196 40 188 
PC002 
V5   72 
4.
7 2 1.8 2.7 2.9 16 64 212 48 196 
PC004 
V5   85 2 1.6 0.9 0.4 1.1 16 36 200 20 184 
 
Dicentrics 
Donor 0GY 0.05GY 0.5GY 
PC001 V1 0 4 6 
PC002 V1 0 8 10 
PC003 V1 0 0 0 
PC004 V1 0 12 16 
PC005 V1 4 8 12 
PC007 V1 8 16 12 
PC009 V1 4 4 8 
PC010 V1 4 12 0 
PC011 V1 4 0 0 
PC013 V1 0 0 16 
PC014 V1 4 4 6 
PC015 V1 4 0 8 
PC016 V1 0 4 6 
PC017 V1 0 4 10 
PC018 V1 8 4 6 
PC019V1 4 0 4 
PC020V1 0 4 8 
PC021V1 4 4 8 
PC022V1 4 4 8 
PC023V1 4 0 12 
PC024V1 4 0 30 
PC025V1 0 5 5 
 
Donor 0GY 0.05GY 0.5GY 
PC001 V2 0 0 2 
PC002 V2 0 8 8 
PC003 V2 12 0 0 
PC004 V2 0 12 28 
PC005 V2 4 0 6 
PC006 V2 8 4 20 
PC008 V2 0 8 0 
PC009 V2 4 14 4 
PC010 V2 0 12 0 
PC011 V2 0 0 4 
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PC012 V2 0 12 21 
PC013 V2 0 0 8 
PC014 V2 8 0 14 
PC015 V2 4 4 0 
PC018 V2 0 0 12 
 
 
 
Donor 0GY 0.05GY 0.5GY 
PC001 V3 12 20 10 
PC002 V3 16 16 16 
PC003 V3 4 12 10 
PC004 V3 8 12 20 
PC005 V3 12 4 16 
PC006 V3 4 4 8 
PC009 V3 8 0 4 
PC012 V3 0 12 4 
PC014 V3 0 0 0 
PC018 V3 8 12 0 
 
Donor 0GY 0.05GY 0.5GY 
PC001 V4 8 4 0 
PC002 V4 20 28 24 
PC003 V4 0 16 12 
PC004 V4 0 0 0 
PC005 V4 8 16 4 
PC006 V4 4 4 10 
PC014 V4 12 0 0 
 
Donor 0GY 0.05GY 0.5GY 
PC001 V5 0 0 12 
PC002 V5 4 4 4 
PC004 V5 0 0 4 
 
 
Donor 0GY 0.05GY 0.5GY 
SPC001 8 20 14 
SPC003 4 4 8 
SPC004 4 4 8 
 
 
 276 
 
Chapter 4 Raw Data
0Gy 1hr 72hr 
 
21
39 0 
48
77
4 0 
97
88
5 
21
45 
14
24 
20
27
0 
51
06
9 
88
31
6 
A
T2
Bi 0 
60
16
4 0 
86
60
1 
A
T3
Bi 
10
76
20 
73
68
7 
24
39
6 
44
66
5 
     
0.05G
y 1hr 72hr 
21
39 
20
87
7 0 0 0 
21
45 
10
56
88 
46
13
9 
41
48
8 0 
A
T2
Bi   
44
63
8 0 
22
86
5 
A
T3
Bi 0 
70
03
0 
75
34
8 
94
57
7 
     
0.5Gy 1hr 72hr 
21
39 
10
01
29 
72
91
9 0 
58
55 
21
45 
92
08
9 
78
49
3 0 
11
31
66 
A
T2
Bi   
99
77
5 0 0 
A
T3
Bi 
58
46
0 
64
54
7 0 0 
     
2Gy 1hr 72hr 
21
39 
13
61
39 
13
22
26 0 0 
21
45 0 
16
59
06 0 
15
89
03 
A
T2
Bi 
11
25
82 
58
10
0 0 0 
A
T3
Bi 0 
16
59
06 0 
15
89
03 
     
0Gy 1hr 72hr 
213
9 
1
0
5 
1
7
8 0 0 
214
5 
1
1
0 
1
7
0 
1
6
7 
4
2
0 
AT2
Bi 
1
6
4 
1
1
3 0 0 
AT3
Bi 
1
7
1 6 0 0 
     
0.05
Gy 1hr 72hr 
213
9 0 
1
8
2 
2
4
9 
9
6 
214
5 
1
5
6 
5
1 0 0 
AT2
Bi   
1
7
3 0 0 
AT3
Bi 
5
0 
1
3
2 
4
3
6 0 
     
0.5
Gy 1hr 72hr 
213
9 0 
2
6
9 
5
7 
9
8
4 
214
5 
8
6 
4
3
7 7 0 
AT2
Bi   
1
9
5 
9
7 0 
AT3
Bi 
1
0
7 0 
2
2
2 0 
     
2Gy 1hr 72hr 
213
9 
1
6
8 
2
7
6 
5
6
5 
3
9
9 
214
5 
5
3 
1
3
9 0 
1
4
8 
AT2
Bi 
5
6 8 
1
4
6 0 
AT3
Bi 0 
5
7
3 
2
6 
4
4
2 
0Gy 1hr 72hr 
213
9 
0.
5 
5.
1 
1.
8 
3.
6 
214
5 
3.
8 
4.
8 
12
.8 
9.
3 
AT2
Bi 
2.
1 5 
4.
5 4 
AT3
Bi 
3.
9 
1.
3 
3.
1 
2.
2 
     
0.0
5Gy 1hr 72hr 
213
9 
2.
4 
5.
5 
2.
7 
2.
6 
214
5 
6.
3 
4.
4 
6.
7 0 
AT2
Bi   
3.
4 
1.
1 
1.
4 
AT3
Bi 2 
4.
7 
12
.3 4 
     
0.5
Gy 1hr 72hr 
213
9 
0.
6 
7.
7 
5.
6 
5.
2 
214
5 4 
9.
1 
6.
4 6 
AT2
Bi   
5.
2 
5.
9 
0.
4 
AT3
Bi 
4.
5 
1.
1 
2.
4 0 
     
2Gy 1hr 72hr 
213
9 
5.
4 
9.
5 
11
.1 
3.
3 
214
5 
1.
9 
3.
2 
7.
9 
10
.3 
AT2
Bi 
3.
6 
2.
2 
7.
4 
1.
5 
AT3
Bi 
1.
3 
10
.4 
2.
5 
6.
8 
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yH2AX Foci 72hr Data 
  2139 2145 AT2Bi AT3Bi 
0Gy 0.25 0.43 0.46 0.94 0.78 0.68 0.53 0.30 0.30 0.78 0.36 0.60 
0.05Gy 0.21 0.22 0.24 0.57 0.59 0.65 0.58 0.50 0.47 0.62 0.79 0.63 
0.5Gy 0.49 0.48 0.46 0.68 0.83 0.90 1.15 1.13 1.18 1.20 1.13 1.09 
2Gy 0.89 0.71 0.79 0.84 0.68 0.76 0.57 1.05 0.96 1.40 1.18 1.19 
 
ApoTox Viability % of Control 
  JHP 2139 2145 AT2Bi AT3Bi 
0 Gy 1h 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
0.05 Gy 
1h 89.90 96.61 
110.9
4 
112.7
9 96.15 82.89 97.61 91.23 89.07 97.99 
0.5 Gy 1h 95.20 91.49 
104.9
3 
106.6
8 
103.8
8 91.54 
110.9
8 79.74 98.86 95.22 
2 Gy 1h 
100.0
7 94.45 
123.1
2 
112.6
1 
102.0
4 92.21 
112.6
7 86.31 
112.5
3 
110.1
1 
0Gy 24h 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
0.05 Gy 
24h 95.82 89.55 86.67 94.31 84.26 93.73 
231.3
4 88.95 50.16 93.91 
0.5 Gy 
24h 95.76 87.53 86.67 
100.4
1 
102.6
8 92.70 
227.8
9 76.04 47.06 88.80 
2 Gy 24h 
100.1
2 90.30 80.00 95.05 92.56 87.19 
220.4
9 81.80 51.00 86.10 
 
Apotox Viability 1- 24hrs 
  JHP 2139 2145 AT2Bi AT3Bi 
0Gy 
2.137
48 
1.399
927 
2.728
215 
2.271
17 
2.334
138 
1.472
293 
1.043
216 
1.706
539 
4.815
922 
1.596
269 
0.05
Gy 
2.278
27 
1.297
65 
2.131
217 
1.899
106 
2.045
422 
1.664
845 
2.472
36 
1.663
899 
2.711
961 
1.529
798 
0.5G
y 
2.150
024 
1.339
393 
2.253
306 
2.137
668 
2.306
967 
1.490
846 
2.142
143 
1.627
26 
2.292
654 
1.488
669 
2Gy 
2.138
636 
1.338
539 
1.772
735 
1.917
125 
2.117
241 
1.392
173 
2.041
501 
1.617
481 
2.182
676 
1.248
202 
Apotox Cytotoxicity % of Control 
  JHP 2139 2145 AT2Bi AT3Bi 
0 Gy 1h 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
0.05 Gy 
1h 87.97 42.03 
101.7
2 99.95 
102.4
1 96.32 90.95 96.45 
311.6
7 
100.2
1 
0.5 Gy 1h 92.40 39.02 
148.2
8 
100.1
1 
135.2
7 99.06 
116.6
3 88.74 
271.0
1 94.48 
2 Gy 1h 93.28 41.35 
111.2
3 
105.8
3 
124.4
6 
104.7
9 
109.0
9 93.20 
264.7
7 
105.8
7 
0Gy 24h 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
0.05 Gy 
24h 84.07 87.38 92.31 88.62 
106.1
9 82.51 
422.2
0 86.43 46.10 84.48 
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0.5 Gy 
24h 84.85 84.58 
107.6
9 97.13 82.91 88.32 
416.0
8 79.93 66.04 82.85 
2 Gy 24h 92.37 88.00 
100.0
0 
195.2
6 94.26 87.79 
441.0
9 97.23 58.64 83.71 
 
Apotox Cytotoxicity 1- 24hrs 
  JHP 2139 2145 AT2Bi AT3Bi 
0Gy 2.16 0.55 2.25 1.71 1.79 1.46 0.40 1.67 6.96 1.39 
0.05Gy 2.07 1.14 2.04 1.51 1.86 1.25 1.84 1.49 1.03 1.17 
0.5Gy 1.99 1.18 1.64 1.66 1.10 1.30 1.42 1.50 1.70 1.22 
2Gy 2.14 1.16 2.02 3.15 1.36 1.22 1.60 1.74 1.54 1.10 
 
Apotox Caspase Activity % of Control 
  JHP 2139 2145 AT2Bi AT3Bi 
0 Gy 1h 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
0.05 Gy 
1h 61.05 32.25 98.76 35.73 
114.2
1 41.80 
102.3
0 
109.4
3 
101.7
2 
126.8
3 
0.5 Gy 1h 48.07 78.45 
101.3
9 
102.8
8 
102.4
9 
111.2
5 
115.1
0 99.58 96.77 
116.9
3 
2 Gy 1h 61.21 74.31 85.85 87.20 
104.0
0 
123.4
9 
104.2
8 
106.3
5 99.02 
106.1
9 
0Gy 24h 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
100.0
0 
0.05 Gy 
24h 86.40 
113.6
4 92.20 
106.1
4 93.78 
103.6
9 0.00 88.32 48.32 
108.7
5 
0.5 Gy 
24h 
115.7
6 
177.2
7 
101.6
9 
120.9
6 
104.7
1 90.08 0.00 98.65 56.76 95.78 
2 Gy 24h 
101.4
5 
126.8
2 
118.5
7 94.59 
107.2
3 90.74 0.00 93.74 72.64 
100.4
7 
 
ApoTox Caspase Activity 1-24hrs 
  JHP 2139 2145 AT2Bi AT3Bi 
0Gy 0.93 0.36 1.48 1.31 1.77 1.34 0.00 1.47 4.91 1.24 
0.05Gy 1.32 1.28 1.38 3.89 1.45 3.34 1.82 1.19 2.33 1.07 
0.5Gy 2.24 0.82 1.49 1.54 1.81 1.09 1.62 1.46 2.88 1.02 
2Gy 1.54 0.62 2.05 1.42 1.83 0.99 2.05 1.30 3.60 1.18 
 
Cell Counts 72hrs post irradiation 
  0Gy 0.05Gy 0.5Gy 2Gy 
214
5 
236
46 
2826
6 
3771
6 
2683
8 
3175
2 
2780
4 
242
76 
264
60 
371
70 
283
50 
274
26 
295
26 
213
9 
800
94 
1037
84 
1002
12 
8719
2 
9370
2 
9823
8 
861
00 
866
04 
774
90 
617
82 
575
82 
490
98 
AT2
Bi 
395
22 
1008
42 
1579
20 
1177
26 
8933
4 
1173
90 
860
58 
795
48 
844
62 
777
42 
696
78 
541
80 
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AT3
Bi 
795
90 
1189
86 
1025
64 
1100
82 
1015
56 
8353
8 
740
04 
470
40 
649
32 
434
28 
360
36 
378
84 
 
Mitotic Index (MI) and Mitotic Inhibition (MIn) 
MI 2139 2145 AT2Bi AT3Bi 
0Gy 2.3 1.5 0 2.1 1.4 1.4 2.3 1 1.1 1.9 0.8 0.2 
0.05Gy 1.7 1.5 0 1 1.1 1.1 1.8 2.1 0.8 2.7 0.6 0.4 
0.5Gy 1.1 0.6 0 0.3 0.3 0.3 2.6 1.3 0.2 1.2 1.2 0.2 
2Gy 0.4 0.8 0.2 0.5 0.4 0.4 1 1.2 0.2 1 0.7 0.6 
             
MIN 2139 2145 AT2Bi AT3Bi 
0.05Gy 0.6 0 0 1.1 0.3 0.3 0.5 -1.1 0.3 -0.8 0.2 -0.2 
0.5Gy 1.2 0.9 0 1.8 1.1 1.1 -0.3 -0.3 0.9 0.7 -0.4 0 
2Gy 1.9 0.7 -0.2 1.6 1 1 1.3 -0.2 0.9 0.9 0.1 -0.4 
 
G2 Scoring and Radiation Induced G2 Scores (RIG2) 
G2 Score 2139 2145 AT2Bi AT3Bi 
0Gy 16 4 20 8 20 8 28 28 35 52 20 30 
0.05Gy 32 36 30 32 64 32 56 36 65 60 62 50 
0.5Gy 160 228 260 112 148 112 124 220 150 252 208 190 
2Gy 428 616 380 348 388 348 352 732 140 372 708 310 
             
RIG2 2139 2145 AT2Bi AT3Bi 
0.05Gy 16 32 10 24 44 24 28 8 30 8 42 20 
0.5Gy 144 224 240 104 128 104 96 192 115 200 188 160 
2Gy 412 612 360 340 368 340 324 704 105 320 688 280 
 
 
Chapter 5 Raw Data 
MQRT –PCR  - Normalised Data (Fold Change) 
 
Sample PCNA FDXR P21 SESN1 
AT2Bi 0.05Gy 1hr 0.919177 1.110493 1.032746 1.11577 
AT2Bi 0.5Gy 1hr 0.754587 1.270328 1.016582 0.880653 
AT2Bi 2Gy 1hr 0.745508 1.287842 1.029392 0.967804 
AT3Bi 0.05Gy 1hr 0.902605 0.911643 1.030412 1.122742 
AT3Bi 0.5Gy 1hr 0.888705 0.781666 0.895406 1.008241 
AT3Bi 2Gy 1hr 0.949094 0.89301 0.980568 1.324691 
AT2Bi 0.05Gy 24hr 0.868377 0.86088 0.934733 1.086126 
AT2Bi 0.5Gy 24hr 0.918508 1.245308 1.174283 1.624216 
AT2Bi 2Gy 24hr 1.241255 1.830222 1.672011 2.189475 
AT3Bi 0.05Gy 24hr 0.784252 0.349404 0.804571 0.702519 
AT3Bi 0.5Gy 24hr 0.841185 0.780811 1.131008 1.132107 
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AT3Bi 2Gy 24hr 0.842179 0.815155 1.549165 1.209027 
 
Healthy Controls - Normalised Data (fold change) 
Sample PCNA FDXR P21 SESN1 
HC2 0.05Gy 1.110126 0.877863 1.281174 1.322508 
HC2 0.5Gy 1.119646 1.578781 2.058172 3.278546 
HC3 0.05Gy 1.397979 0.662263 1.948526 1.177761 
HC3 0.5Gy 1.521833 2.164034 3.280928 4.46511 
HC5 0.05Gy 0.860438 1.624883 0.847281 1.076097 
HC5 0.5Gy 0.890608 1.559131 1.974453 1.911292 
HC8 0.05Gy 0.952913 1.07103 0.499578 0.738732 
HC8 0.5Gy 1.786761 1.518046 0.944732 1.940352 
HC9 0.05Gy 0.991377 1.318096 0.826383 0.832364 
HC9 0.5Gy 1.302731 2.523767 1.779014 3.627248 
HC14 0.05Gy 0.962132 1.025735 1.230263 0.734703 
HC14 0.5Gy 1.355342 0.877589 1.665457 1.247238 
HC16 0.05Gy 1.322959 2.391783 0.816146 3.545202 
HC19 0.05Gy 0.988173 1.404782 1.755273 1.287977 
HC19 0.5Gy 0.879663 2.31001 1.983739 1.715043 
HC20 0.05Gy 0.868947 0.953691 2.597556 1.192586 
HC21 0.05Gy 1.052153 0.841791 0.954154 1.049787 
HC22 0.05Gy 0.879997 0.817977 0.790888 1.1716 
HC22 0.5Gy 0.912996 2.612916 2.064115 2.844642 
HC26 0.05Gy 1.255739 1.208948 0.879326 0.639961 
HC27 0.05Gy 0.861952 0.922499 0.84357 1.054141 
HC27 0.5Gy 1.265653 0.945579 1.07601 2.26491 
HC44 0.05Gy 1.069835 1.016579 1.114588 1.307459 
HC44 0.5Gy 1.040415 1.215458 0.624157 1.340188 
HC45 0.05Gy 0.909927 0.774047 0.989748 0.689184 
HC45 0.5Gy 0.917717 1.082442 1.261589 1.190184 
HC46 0.05Gy 0.834676 1.66211 0.729044 0.623268 
HC46 0.5Gy 0.963741 1.53199 0.909161 0.825911 
HC47 0.05Gy 0.961919 1.760766 1.414731 1.465533 
HC47 0.5Gy 1.04936 1.274469 1.790858 1.75134 
HC48 0.05Gy 1.033921 1.003336 1.010927 0.915691 
HC48 0.5Gy 1.041853 0.950855 1.076004 1.194177 
HC50 0.05Gy 1.080487 1.250464 2.05233 1.345692 
HC50 0.5Gy 1.119204 1.010686 1.545948 0.826563 
     
Healthy Controls Just 0.05Gy 
Sample PCNA FDXR P21 SESN1 
HC2 0.05Gy 1.110126 0.877863 1.281174 1.322508 
HC3 0.05Gy 1.397979 0.662263 1.948526 1.177761 
HC5 0.05Gy 0.860438 1.624883 0.847281 1.076097 
HC8 0.05Gy 0.952913 1.07103 0.499578 0.738732 
 281 
 
HC9 0.05Gy 0.991377 1.318096 0.826383 0.832364 
HC14 0.05Gy 0.962132 1.025735 1.230263 0.734703 
HC16 0.05Gy 1.322959 2.391783 0.816146 3.545202 
HC19 0.05Gy 0.988173 1.404782 1.755273 1.287977 
HC20 0.05Gy 0.868947 0.953691 2.597556 1.192586 
HC21 0.05Gy 1.052153 0.841791 0.954154 1.049787 
HC22 0.05Gy 0.879997 0.817977 0.790888 1.1716 
HC26 0.05Gy 1.255739 1.208948 0.879326 0.639961 
HC27 0.05Gy 0.861952 0.922499 0.84357 1.054141 
HC44 0.05Gy 1.069835 1.016579 1.114588 1.307459 
HC45 0.05Gy 0.909927 0.774047 0.989748 0.689184 
HC46 0.05Gy 0.834676 1.66211 0.729044 0.623268 
HC47 0.05Gy 0.961919 1.760766 1.414731 1.465533 
HC48 0.05Gy 1.033921 1.003336 1.010927 0.915691 
HC50 0.05Gy 1.080487 1.250464 2.05233 1.345692 
Mean 1.020824 1.188876 1.188499 1.166855 
St.DEV 0.159527 0.427568 0.540988 0.633251 
          
 
     
     
Healthy Controls Just 0.5Gy 
Sample PCNA FDXR P21 SESN1 
HC2 0.5Gy 1.119646 1.578781 2.058172 3.278546 
HC3 0.5Gy 1.521833 2.164034 3.280928 4.46511 
HC5 0.5Gy 0.890608 1.559131 1.974453 1.911292 
HC8 0.5Gy 1.786761 1.518046 0.944732 1.940352 
HC9 0.5Gy 1.302731 2.523767 1.779014 3.627248 
HC14 0.5Gy 1.355342 0.877589 1.665457 1.247238 
HC19 0.5Gy 0.879663 2.31001 1.983739 1.715043 
HC22 0.5Gy 0.912996 2.612916 2.064115 2.844642 
HC27 0.5Gy 1.265653 0.945579 1.07601 2.26491 
HC44 0.5Gy 1.040415 1.215458 0.624157 1.340188 
HC45 0.5Gy 0.917717 1.082442 1.261589 1.190184 
HC46 0.5Gy 0.963741 1.53199 0.909161 0.825911 
HC47 0.5Gy 1.04936 1.274469 1.790858 1.75134 
HC48 0.5Gy 1.041853 0.950855 1.076004 1.194177 
HC50 0.5Gy 1.119204 1.010686 1.545948 0.826563 
Mean 1.144502 1.543717 1.602289 2.028183 
St.DEV 0.259536 0.592095 0.662057 1.080612 
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Prostate Cancer - Normalised Data (Fold Change) 
Sample PCNA FDXR P21 SESN1 
PC001 V1 0.05Gy 1.063391 1.03777 1.402611 0.967529 
PC001 V1 0.5Gy 0.893782 1.381058 1.90267 1.86981 
PC002 V4 0.05Gy 0.994958 0.882049 1.304527 0.9542 
PC002 V4 0.5Gy 1.111059 0.841627 1.947614 1.709929 
PC003 V1 0.05Gy 1.033709 0.728164 0.734806 0.613978 
PC003 V1 0.5Gy 1.039751 0.493734 0.380631 0.365461 
PC005 V1 0.05Gy 0.946253 1.077003 1.867887 1.290449 
PC005 V1 0.5Gy 0.815879 2.475847 2.14395 1.740451 
PC005 V2 0.05Gy 1.334633 0.952007 0.298479 0.523459 
PC005 V2 0.5Gy 1.505957 0.625373 0.443468 0.487382 
PC007 V2 0.05Gy 1.035384 0.720189 0.830568 0.981592 
PC007 V2 0.5Gy 1.041125 0.975453 1.425653 2.061837 
PC009 V1 0.05Gy 0.817622 1.697529 1.09141 1.627669 
PC009 V1 0.5Gy 1.021685 0.990841 0.795585 1.925674 
PC012 V2 0.05Gy 0.876305 0.786333 1.211596 0.930966 
PC012 V2 0.5Gy 0.81104 0.601146 0.957512 0.747135 
PC017 V1 0.05Gy 1.068953 1.072219 1.014133 1.034365 
PC017 V1 0.5Gy 1.044253 1.448709 1.335709 1.584734 
PC018 V1 0.05Gy 0.934593 1.272675 0.704984 0.897611 
PC018 V1 0.5Gy 0.848493 0.979243 0.565337 1.314584 
PC018 V2 0.05Gy 1.081918 0.975362 1.766153 1.361897 
PC018 V2 0.5Gy 0.999578 1.178319 1.358757 1.62562 
 
 
 
 
 
     
 
     
Prostate Cancer Just 0.05Gy 
Sample PCNA FDXR P21 SESN1 
PC001 V1 0.05Gy 1.063391 1.03777 1.402611 0.967529 
PC002 V4 0.05Gy 0.994958 0.882049 1.304527 0.9542 
PC003 V1 0.05Gy 1.033709 0.728164 0.734806 0.613978 
PC005 V1 0.05Gy 0.946253 1.077003 1.867887 1.290449 
PC005 V2 0.05Gy 1.334633 0.952007 0.298479 0.523459 
PC007 V2 0.05Gy 1.035384 0.720189 0.830568 0.981592 
PC009 V1 0.05Gy 0.817622 1.697529 1.09141 1.627669 
PC012 V2 0.05Gy 0.876305 0.786333 1.211596 0.930966 
PC017 V1 0.05Gy 1.068953 1.072219 1.014133 1.034365 
PC018 V1 0.05Gy 0.934593 1.272675 0.704984 0.897611 
PC018 V2 0.05Gy 1.081918 0.975362 1.766153 1.361897 
     
Prostate Cancer Just 0.5Gy 
Sample PCNA FDXR P21 SESN1 
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PC001 V1 0.5Gy 0.893782 1.381058 1.90267 1.86981 
PC002 V4 0.5Gy 1.111059 0.841627 1.947614 1.709929 
PC003 V1 0.5Gy 1.039751 0.493734 0.380631 0.365461 
PC005 V1 0.5Gy 0.815879 2.475847 2.14395 1.740451 
PC005 V2 0.5Gy 1.505957 0.625373 0.443468 0.487382 
PC007 V2 0.5Gy 1.041125 0.975453 1.425653 2.061837 
PC009 V1 0.5Gy 1.021685 0.990841 0.795585 1.925674 
PC012 V2 0.5Gy 0.81104 0.601146 0.957512 0.747135 
PC017 V1 0.5Gy 1.044253 1.448709 1.335709 1.584734 
PC018 V1 0.5Gy 0.848493 0.979243 0.565337 1.314584 
PC018 V2 0.5Gy 0.999578 1.178319 1.358757 1.62562 
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MQRT-PCR Efficiency Graphs 
PC 100 WELL ROTOR PLATE 1 
 
HPRT 0.01908 (9) 
 
PCNA 0.01908 (9) 
 
P21 0.03962 (9) 
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SESN1 0.0223 (9) 
 
FDXR 0.16541 (9) 
PC Plate 2 (72 well ROTOR) 
 
HPRT 0.02655 (1,8,9) 
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PCNA 0.01908 (1,8,9) 
 
 
P21 0.03962 (1,8,9) 
 
SESN1 0.0223 (1,8,9) 
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FDXR 0.01908 (1,8,9) 
HC PLATE 1 
 
HPRT 0.02655 (3,4,9) 
 
PCNA 0.01908 (3,4,9) 
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P21 0.03962 (3,4,9) 
 
SESN1 0.0223 (3,4,9) 
 
FDXR 0.16541 (3,4,9) 
 
HC PLATE 2 
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HPRT 0.02655 (1,2,9) 
 
PCNA 0.01908 (1,2,9) 
 
P21 0.03962 (1,2,9) 
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SESN1 0.0223 (1,2,9) 
 
FDXR 0.16541 (1,2,9) 
HC PLATE 3 
 
HPRT 0.02655  
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PCNA 0.01908 
 
P21 0.03962 
 
SESN1 0.0223 
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FDXR 0.16541 
PC 72 WELL ROTOR PLATE 1 
 
HPRT 0.02655 
 
PCNA 0.01908 
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P21 0.03962 
 
SESN1 0.0223 
 
FDXR 0.16541 
PC 72 WELL ROTOR PLATE 2 
 
CELL LINE PLATE 1 
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HPRT 0.02655 (2,5,9) 
 
PCNA 0.01908 (2,5,9) 
 
P21 0.03962 (2,5,9) 
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SESN1 0.0223 (2,5,9) 
 
FDXR 0.16541 (2,5,9) 
 
 
Chapter 6 Raw Data 
Protein Loading from Cells 
1.4 0.2204 0.2561  0.2999 0.2588 0.050667   
1.2 0.2133 0.2845  0.238 0.245266667 0.054467   
1 0.1712 0.1904  0.1893 0.183633333 0.073367   
0.8 0.2179 0.2194  0.2133 0.216866667 0.083067   
0.6 0.1759 0.1421  0.151 0.156333333 0.124133   
0.4 0.1291 0.1136  0.1297 0.124133333 0.156333   
0.2 0.0856 0.0841  0.0795 0.083066667 0.183633   
0.1 0.0732 0.0719  0.075 0.073366667 0.216867   
0.5 0.0553 0.0543  0.0538 0.054466667 0.245267   
0.01 0.0511 0.051  0.0499 0.050666667 0.2588   
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2139     Average µg/µl µl needed for 50µg 
0Gy 0.1938 0.1909  0.2247 0.203133333 7.768734 6.436055214 
0.05Gy 0.2466 0.2098  0.2596 0.238666667 9.145995 5.466873852 
0.5Gy 0.1852 0.2245  0.2135 0.207733333 7.947028 6.291659893 
2Gy 0.2113 0.1603  0.2442 0.205266667 7.851421 6.368273819 
             
2145          
0Gy 0.1758 0.2308  0.204 0.203533333 7.784238 6.423236515 
0.05Gy 0.1916 0.1729  0.1768 0.180433333 6.888889 7.258064516 
0.5Gy 0.2131 0.1751  0.1674 0.1852 7.073643 7.068493151 
2Gy 0.2288 0.2207  0.1735 0.207666667 7.944444 6.293706294 
             
AT2Bi          
0Gy 0.2107 0.2189  0.2302 0.219933333 8.419897 5.938315176 
0.05Gy 0.2184 0.2451  0.2303 0.231266667 8.859173 5.643867581 
0.5Gy 0.2195 0.2019  0.2034 0.208266667 7.9677 6.275336468 
2Gy 0.3004 0.3065  0.3402 0.3157 12.13178 4.121405751 
             
AT3Bi          
0Gy 0.2196 0.2518  0.2429 0.2381 9.124031 5.480033985 
0.05Gy 0.2695 0.2414  0.2137 0.241533333 9.257106 5.401256106 
0.5Gy 0.2262 0.1919  0.1889 0.202333333 7.737726 6.461846719 
2Gy 0.2096 0.1809  0.1864 0.1923 7.348837 6.803797468 
 
 
 
 
y = 0.0258x + 0.0027
R² = 0.9771
0
0.05
0.1
0.15
0.2
0.25
0.3
0 5 10 15
Series1
Linear (Series1)
 297 
 
 
Protein Loading from Exosomes 
2139       Average µg/µl µl needed for 50µg 
0Gy 0.0792 0.0793 0.0821 0.0802 3.003876 16.64516129 
0.05Gy 0.0958 0.0924 0.0741 0.087433 3.284238 15.22423289 
0.5Gy 0.0791 0.0724 0.0693 0.0736 2.748062 18.19464034 
2Gy 0.0874 0.0803 0.0715 0.079733 2.985788 16.7459974 
              
2145             
0Gy 0.0752 0.0836 0.0641 0.0743 2.775194 18.01675978 
0.05Gy 0.0743 0.0777 0.0662 0.072733 2.71447 18.4198001 
0.5Gy 0.1049 0.0642 0.0691 0.0794 2.972868 16.81877445 
2Gy 0.0724 0.0717 0.0632 0.0691 2.573643 19.42771084 
              
AT2Bi             
0Gy 0.0763 0.073 0.0754 0.0749 2.79845 17.86703601 
0.05Gy 0.0726 0.0805 0.0709 0.074667 2.789406 17.92496526 
0.5Gy 0.0855 0.0874 0.0798 0.084233 3.160207 15.8217498 
2Gy 0.0845 0.0741 0.0778 0.0788 2.949612 16.95137976 
              
AT3Bi             
0Gy 0.0966 0.093 0.0864 0.092 3.46124 14.44568869 
0.05Gy 0.0789 0.1427 0.1019 0.107833 4.074935 12.27013316 
0.5Gy 0.1209 0.1033 0.1434 0.122533 4.644703 10.76495132 
2Gy 0.1018 0.0853 0.0848 0.090633 3.408269 14.6702047 
 
 
y = 0.0258x + 0.0027
R² = 0.9771
0
0.05
0.1
0.15
0.2
0.25
0.3
0 2 4 6 8 10 12
Series1
Linear (Series1)
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Sample ID UniSp6 
miR-
142  
miR-
451 
miR-
23a 
miR-
30c 
miR-
103a 
2145 Exo 17.7 0  0 0 0 0 
AT3Bi Exo 17.8 0  0 0 0 0 
AT2Bi Exo 17.9 0  36.8 0 0 0 
2139 Exo 17.8 0  0 0 0 0 
AT3Bi Cell 17.8 23.2  37.8 27 27.5 25.9 
2139 Cell 17.8 23.3  36.8 26.7 27.2 25.6 
AT2Bi Cell 17.9 22.2  0 27.7 27.6 25.8 
2145 Cell 17.8 29.6  37.9 32.5 32.8 30.7 
Blank 17.8 0  0 0 0 0 
design_target_na
me 
42070.0
0 
42071.0
0 
42072.0
0 
42073.0
0   Count St. dev 
  
AT3Bi 
Cell 
2139 
Cell 
AT2Bi 
Cell 
2145 
Cell       
hsa-miR-138-5p 28.13 26.79 29.66 36.08   4.00 4.11 
hsa-miR-210-3p 28.03 28.69 27.58 35.34   4.00 3.65 
hsa-miR-142-5p 27.94 27.98 26.71 34.71   4.00 3.63 
hsa-miR-29b-3p 28.88 28.90 27.79 35.53   4.00 3.54 
hsa-miR-320b 29.02 29.29 29.42 36.15   4.00 3.46 
hsa-miR-155-3p 30.52 30.06 29.17 36.68   4.00 3.43 
hsa-miR-142-3p 23.86 23.89 22.55 30.10   4.00 3.39 
hsa-miR-29c-3p 27.95 28.18 27.88 34.62   4.00 3.31 
hsa-miR-106b-5p 28.13 27.90 27.71 34.48   4.00 3.29 
hsa-miR-15b-5p 29.27 29.85 29.22 35.79   4.00 3.18 
hsa-miR-19a-3p 26.85 26.15 25.53 32.43   4.00 3.17 
hsa-miR-18b-5p 29.46 28.59 28.63 35.15   4.00 3.15 
hsa-miR-30e-5p 29.81 29.21 29.11 35.62   4.00 3.14 
hsa-let-7f-5p 27.75 27.30 27.04 33.48   4.00 3.07 
hsa-miR-9-5p 29.75 32.05 31.45 36.90   4.00 3.07 
hsa-miR-19b-3p 25.16 24.80 24.22 30.80   4.00 3.06 
hsa-miR-185-5p 30.02 29.83 29.94 36.05   4.00 3.06 
hsa-miR-16-2-3p 30.97 30.71 30.51 36.83   4.00 3.06 
hsa-miR-29a-3p 26.46 27.53 26.16 32.67   4.00 3.04 
hsa-miR-30b-5p 29.55 29.63 27.95 34.85   4.00 3.01 
hsa-miR-874-3p 30.54 30.72 30.91 36.62   4.00 2.95 
hsa-let-7c-5p 29.47 30.29 29.37 35.52   4.00 2.94 
hsa-miR-21-5p 23.91 24.05 23.36 29.60   4.00 2.93 
hsa-miR-20a-5p 25.60 25.04 24.81 30.94   4.00 2.91 
hsa-miR-32-5p 31.52 29.84 29.66 35.91   4.00 2.91 
hsa-miR-26a-5p 29.70 30.50 30.59 35.96   4.00 2.88 
hsa-miR-30d-5p 30.89 30.55 29.51 35.95   4.00 2.87 
hsa-let-7d-5p 28.28 28.24 28.20 33.98   4.00 2.87 
hsa-let-7a-5p 26.07 26.78 26.13 31.94   4.00 2.83 
hsa-miR-15a-5p 27.89 27.63 26.95 33.05   4.00 2.81 
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hsa-miR-484 31.52 31.49 30.72 36.70   4.00 2.76 
hsa-miR-103a-3p 26.57 25.97 26.34 31.78   4.00 2.76 
hsa-miR-101-3p 30.51 29.77 29.26 35.25   4.00 2.75 
hsa-miR-16-5p 24.16 24.28 23.90 29.56   4.00 2.73 
hsa-miR-22-3p 30.20 30.09 29.98 35.54   4.00 2.73 
hsa-let-7g-5p 26.59 26.45 26.22 31.86   4.00 2.73 
hsa-miR-155-5p 22.55 22.79 22.08 27.89   4.00 2.72 
hsa-miR-151a-5p 30.46 31.65 31.90 36.62   4.00 2.72 
hsa-let-7i-5p 27.87 27.99 27.72 33.27   4.00 2.71 
hsa-miR-423-3p 28.02 27.80 27.95 33.32   4.00 2.70 
hsa-miR-331-3p 29.66 29.75 29.79 35.12   4.00 2.70 
hsa-miR-24-3p 27.49 27.04 27.82 32.75   4.00 2.67 
hsa-miR-107 27.95 27.98 27.93 33.28   4.00 2.66 
hsa-miR-27b-3p 30.85 31.07 30.20 35.95   4.00 2.65 
hsa-miR-27a-3p 30.33 30.50 30.57 35.75   4.00 2.64 
hsa-miR-146a-5p 25.53 24.91 25.31 30.50   4.00 2.64 
hsa-miR-320a 27.54 27.82 27.63 32.93   4.00 2.64 
hsa-miR-17-3p 29.51 29.72 29.65 34.86   4.00 2.62 
hsa-miR-342-3p 27.73 27.65 29.66 33.22   4.00 2.61 
hsa-miR-454-3p 31.59 31.03 31.10 36.42   4.00 2.60 
hsa-miR-106a-5p 26.01 25.54 25.58 30.89   4.00 2.60 
hsa-miR-18a-5p 29.21 28.36 28.29 33.71   4.00 2.58 
hsa-miR-140-3p 29.69 29.76 29.07 34.58   4.00 2.55 
hsa-miR-34a-5p 26.89 26.54 26.72 31.80   4.00 2.55 
hsa-miR-148a-3p 27.68 28.97 27.90 33.11   4.00 2.53 
hsa-miR-1260a 26.78 26.81 26.47 31.68   4.00 2.50 
hsa-miR-92a-3p 25.50 25.98 25.55 30.62   4.00 2.48 
hsa-miR-361-3p 30.77 31.65 30.91 35.96   4.00 2.46 
hsa-miR-365a-3p 27.70 27.30 27.70 32.45   4.00 2.45 
hsa-miR-148b-3p 29.89 29.97 29.93 34.81   4.00 2.44 
hsa-miR-339-5p 28.48 28.50 28.05 33.20   4.00 2.44 
hsa-miR-30c-5p 27.49 27.51 27.36 32.29   4.00 2.42 
hsa-miR-320c 31.09 30.86 31.03 35.79   4.00 2.40 
hsa-miR-26b-5p 31.30 31.48 31.17 36.10   4.00 2.39 
hsa-miR-132-3p 29.82 29.45 31.16 34.68   4.00 2.38 
hsa-miR-193b-3p 26.05 25.56 26.13 30.65   4.00 2.38 
hsa-miR-7-5p 32.32 31.54 31.43 36.45   4.00 2.38 
hsa-miR-98-5p 31.79 30.65 31.06 35.83   4.00 2.38 
hsa-miR-23a-3p 27.48 27.11 27.80 32.11   4.00 2.34 
hsa-let-7i-3p 32.15 32.68 32.15 36.91   4.00 2.30 
hsa-miR-23b-3p 29.53 29.47 29.62 34.14   4.00 2.30 
hsa-miR-181b-5p 29.78 28.38 28.79 33.37   4.00 2.27 
hsa-miR-191-5p 28.11 27.96 28.66 32.66   4.00 2.23 
hsa-miR-222-3p 28.78 27.92 27.60 32.41   4.00 2.21 
hsa-miR-181a-5p 27.07 26.06 26.44 30.87   4.00 2.21 
hsa-miR-339-3p 31.83 31.27 31.20 35.80   4.00 2.21 
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mmu-miR-378a-
3p 28.37 27.01 27.69 31.90   4.00 2.18 
hsa-miR-93-5p 27.86 27.56 27.79 32.00   4.00 2.14 
hsa-miR-146b-5p 31.08 31.03 31.15 35.34   4.00 2.13 
hsa-miR-425-5p 28.67 29.07 29.01 33.15   4.00 2.13 
hsa-miR-423-5p 29.49 29.54 29.64 33.77   4.00 2.11 
hsa-miR-940 30.84 32.32 32.10 35.66   4.00 2.06 
hsa-miR-197-3p 31.60 31.31 31.19 35.46   4.00 2.05 
hsa-miR-25-3p 28.75 28.22 28.21 32.45   4.00 2.05 
hsa-miR-660-5p 32.47 31.67 31.35 35.80   4.00 2.04 
hsa-miR-128-3p 31.82 30.96 30.86 35.17   4.00 2.02 
hsa-miR-362-3p 33.11 31.84 31.93 36.05   4.00 1.97 
hsa-miR-150-5p 33.30 33.88 32.06 36.53   4.00 1.89 
hsa-miR-152-3p 32.90 34.36 31.87 36.17   4.00 1.87 
hsa-miR-551b-3p 30.35 31.02 28.72 33.20   4.00 1.86 
hsa-miR-532-3p 32.17 31.65 32.67 35.62   4.00 1.78 
hsa-miR-664a-3p 32.61 32.98 32.22 36.09   4.00 1.77 
hsa-miR-590-5p 33.05 31.79 31.52 35.37   4.00 1.75 
hsa-miR-192-5p 33.91 33.23 31.95 36.08   4.00 1.73 
hsa-miR-221-3p 31.35 30.12 30.23 33.44   4.00 1.54 
hsa-miR-181a-2-
3p 33.27 32.73 32.38 35.68   4.00 1.49 
hsa-miR-301b 33.72 34.15 34.12 36.89   4.00 1.46 
hsa-miR-93-3p 32.75 31.53 31.38 34.49   4.00 1.44 
hsa-miR-200c-3p 32.57 31.65 32.30 34.94   4.00 1.43 
hsa-miR-15b-3p 32.74 31.96 32.30 35.08   4.00 1.41 
hsa-miR-26b-3p 34.61 34.61 33.58 36.72   4.00 1.32 
hsa-miR-181d-5p 35.49 33.78 36.31 36.65   4.00 1.28 
hsa-miR-186-5p 33.49 32.92 33.06 35.49   4.00 1.19 
hsa-miR-188-5p 36.65 35.93 34.74 36.82   4.00 0.95 
hsa-miR-421 36.42 35.80 36.04 36.46   4.00 0.31 
hsa-miR-329-3p 35.05 35.48 35.35 35.48   4.00 0.20 
hsa-miR-335-3p BF 32.05 36.52 36.63   3.00 2.61 
hsa-miR-455-3p 34.97 36.01 31.48 ND   3.00 2.37 
hsa-miR-138-1-3p 32.33 31.66 35.51 ND   3.00 2.06 
hsa-let-7d-3p 32.71 32.76 35.82 ND   3.00 1.78 
hsa-miR-501-3p 36.81 33.50 35.68 ND   3.00 1.69 
hsa-miR-143-3p 31.51 31.36 34.34 ND   3.00 1.68 
hsa-miR-19a-5p 35.84 36.98 33.71 ND   3.00 1.66 
hsa-miR-582-5p 32.64 30.65 33.80 ND   3.00 1.59 
hsa-miR-125b-5p 31.54 34.59 33.46 ND   3.00 1.55 
hsa-miR-497-5p 36.29 33.99 36.76 ND   3.00 1.48 
hsa-miR-135a-5p 34.21 36.51 33.87 ND   3.00 1.43 
hsa-miR-223-3p 30.64 33.48 31.81 ND   3.00 1.43 
hsa-miR-651-5p 36.99 34.89 34.30 ND   3.00 1.41 
hsa-miR-205-5p 31.88 ND 31.94 34.24   3.00 1.35 
hsa-let-7e-5p 33.90 36.59 35.20 BF   3.00 1.34 
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hsa-miR-513a-3p 34.39 35.63 36.98 ND   3.00 1.30 
hsa-miR-99a-5p 31.73 34.25 32.78 ND   3.00 1.27 
hsa-miR-424-3p 34.52 ND 32.98 35.44   3.00 1.24 
hsa-miR-501-5p 34.12 35.29 36.50 ND   3.00 1.19 
hsa-miR-34b-5p 34.23 34.11 36.18 ND   3.00 1.16 
hsa-miR-629-5p 35.30 34.67 33.11 ND   3.00 1.13 
hsa-miR-328-3p 33.02 35.13 34.00 ND   3.00 1.06 
hsa-miR-146a-3p 33.84 33.45 31.84 ND   3.00 1.06 
hsa-miR-330-3p 33.54 35.62 34.49 BF   3.00 1.04 
hsa-miR-24-2-5p 34.11 34.96 36.16 ND   3.00 1.03 
hsa-miR-29c-5p 33.14 33.32 34.99 ND   3.00 1.02 
hsa-miR-146b-3p 34.08 36.11 35.09 ND   3.00 1.01 
hsa-miR-769-5p 33.75 33.27 35.16 ND   3.00 0.98 
hsa-miR-92a-1-5p 31.36 33.00 31.33 ND   3.00 0.96 
hsa-miR-215-5p 33.51 34.69 32.82 ND   3.00 0.94 
hsa-miR-195-5p 35.53 33.65 34.77 ND   3.00 0.94 
hsa-miR-16-1-3p 34.45 34.73 32.97 ND   3.00 0.94 
hsa-miR-141-3p 33.95 32.10 33.29 ND   3.00 0.94 
hsa-miR-9-3p 32.90 34.20 34.71 ND   3.00 0.93 
hsa-miR-324-5p 32.05 30.95 32.74 ND   3.00 0.90 
hsa-miR-194-5p 34.09 34.69 32.93 ND   3.00 0.90 
hsa-miR-19b-1-5p 34.15 32.79 32.47 ND   3.00 0.89 
hsa-miR-191-3p 34.14 35.60 35.69 ND   3.00 0.87 
hsa-miR-671-3p 34.33 34.12 32.73 ND   3.00 0.87 
hsa-miR-342-5p 33.47 33.69 35.02 ND   3.00 0.84 
hsa-miR-181a-3p 34.36 33.28 32.93 ND   3.00 0.74 
hsa-miR-33a-5p 32.48 32.56 31.24 BF   3.00 0.74 
hsa-miR-28-5p 35.28 35.56 ND 36.68   3.00 0.74 
hsa-miR-378a-5p 32.55 31.17 32.26 BF   3.00 0.73 
hsa-let-7f-1-3p 34.45 34.55 35.71 ND   3.00 0.70 
hsa-miR-576-5p 35.81 34.97 34.47 BF   3.00 0.68 
hsa-miR-301a-3p 32.58 31.57 31.34 ND   3.00 0.66 
hsa-miR-671-5p 36.30 35.04 35.32 ND   3.00 0.66 
hsa-miR-219a-5p 35.54 35.01 34.24 ND   3.00 0.65 
hsa-miR-135b-5p 35.37 36.59 35.61 ND   3.00 0.65 
hsa-miR-132-5p 33.03 34.23 33.94 BF   3.00 0.63 
hsa-miR-106b-3p 33.27 32.98 32.10 ND   3.00 0.61 
hsa-miR-589-3p 35.27 36.08 36.43 ND   3.00 0.60 
hsa-miR-30e-3p 32.48 32.03 31.30 BF   3.00 0.60 
hsa-miR-574-3p 32.47 33.39 33.57 ND   3.00 0.59 
hsa-miR-21-3p 32.78 32.17 31.62 BF   3.00 0.58 
hsa-miR-25-5p 33.60 34.72 33.98 ND   3.00 0.57 
hsa-miR-22-5p 31.77 32.66 32.76 ND   3.00 0.54 
hsa-miR-642a-5p 34.15 35.03 34.06 ND   3.00 0.54 
hsa-miR-942-5p 34.49 33.63 34.61 ND   3.00 0.54 
hsa-miR-361-5p 31.16 30.50 30.18 BF   3.00 0.50 
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hsa-miR-486-5p 33.65 33.17 32.66 BF   3.00 0.50 
hsa-miR-590-3p 35.71 35.44 34.78 ND   3.00 0.48 
hsa-miR-505-3p 33.80 33.06 33.94 ND   3.00 0.47 
hsa-miR-532-5p 33.17 32.34 32.37 ND   3.00 0.47 
hsa-miR-28-3p 34.18 35.06 34.91 ND   3.00 0.47 
hsa-miR-941 33.35 34.28 33.84 ND   3.00 0.47 
hsa-miR-181c-5p 33.77 33.63 34.50 ND   3.00 0.46 
hsa-miR-877-5p 33.15 33.14 33.92 BF   3.00 0.45 
hsa-miR-17-5p 32.32 32.19 31.49 ND   3.00 0.45 
hsa-miR-545-3p BF 36.65 35.81 36.01   3.00 0.44 
hsa-miR-502-3p 32.87 33.73 33.28 ND   3.00 0.43 
hsa-miR-29a-5p 31.79 31.22 30.96 ND   3.00 0.43 
hsa-miR-625-3p 32.81 33.58 33.52 ND   3.00 0.43 
hsa-miR-188-3p 35.43 34.61 34.95 ND   3.00 0.42 
hsa-miR-130a-3p 33.65 34.32 33.58 BF   3.00 0.41 
hsa-let-7f-2-3p 34.64 34.72 35.36 ND   3.00 0.40 
hsa-miR-130b-5p 33.19 33.66 32.88 ND   3.00 0.39 
hsa-miR-500a-5p 34.56 35.26 35.18 ND   3.00 0.38 
hsa-miR-425-3p 31.88 32.59 32.07 ND   3.00 0.37 
hsa-miR-374b-5p 31.34 30.86 31.54 BF   3.00 0.35 
hsa-miR-148b-5p 36.21 36.27 36.83 ND   3.00 0.34 
hsa-miR-140-5p 31.62 30.97 31.13 ND   3.00 0.34 
hsa-miR-20a-3p 31.53 30.97 30.93 ND   3.00 0.34 
hsa-miR-362-5p 36.28 35.70 36.27 BF   3.00 0.33 
hsa-miR-491-5p 32.32 32.29 32.86 BF   3.00 0.32 
hsa-miR-27b-5p 36.13 36.65 36.12 ND   3.00 0.31 
hsa-miR-296-5p 31.36 31.20 31.78 ND   3.00 0.30 
hsa-miR-652-3p 31.66 31.25 31.09 BF   3.00 0.29 
hsa-miR-29b-2-5p 33.00 32.76 33.31 ND   3.00 0.27 
hsa-miR-7-1-3p 31.62 32.04 31.52 ND   3.00 0.27 
hsa-miR-374a-5p 32.91 32.48 32.96 BF   3.00 0.27 
hsa-miR-330-5p 34.23 34.02 34.54 ND   3.00 0.26 
hsa-miR-151a-3p 33.97 34.40 34.37 ND   3.00 0.24 
hsa-miR-1248 35.26 34.80 35.14 ND   3.00 0.24 
hsa-miR-624-5p 36.12 36.07 36.48 ND   3.00 0.23 
hsa-miR-766-3p 31.28 31.21 31.61 BF   3.00 0.21 
hsa-miR-193b-5p 31.62 31.98 31.64 ND   3.00 0.20 
hsa-let-7g-3p 32.53 32.79 32.87 ND   3.00 0.18 
hsa-miR-130b-3p 32.58 32.44 32.35 BF   3.00 0.11 
hsa-miR-18a-3p 31.90 31.85 31.80 BF   3.00 0.05 
hsa-let-7b-5p 30.64 34.47 ND ND   2.00 2.71 
hsa-miR-335-5p 36.72 33.08 ND ND   2.00 2.58 
hsa-miR-663a 33.29 ND ND 36.74   2.00 2.44 
hsa-miR-450a-5p 35.01 ND 32.82 ND   2.00 1.55 
hsa-miR-181c-3p 35.31 33.31 BF ND   2.00 1.42 
hsa-miR-99b-5p 33.79 ND 35.77 ND   2.00 1.40 
 303 
 
hsa-miR-33b-5p 35.14 BF 36.73 ND   2.00 1.13 
hsa-miR-363-3p 31.67 ND 30.30 ND   2.00 0.97 
hsa-miR-374b-3p ND 34.91 36.26 ND   2.00 0.95 
hsa-miR-33a-3p BF 35.42 36.74 ND   2.00 0.93 
hsa-miR-505-5p 35.52 36.78 BF ND   2.00 0.89 
hsa-miR-629-3p 34.88 36.08 ND ND   2.00 0.84 
hsa-miR-33b-3p 34.83 36.01 ND ND   2.00 0.83 
hsa-miR-513c-5p 33.90 ND 35.08 ND   2.00 0.83 
hsa-miR-199a-3p ND 35.55 36.72 ND   2.00 0.83 
hsa-miR-542-5p 34.64 ND 35.64 BF   2.00 0.71 
hsa-miR-708-5p 35.61 ND 34.74 ND   2.00 0.62 
hsa-miR-20b-5p 34.90 ND 34.04 ND   2.00 0.61 
hsa-miR-92b-3p BF 36.68 35.83 ND   2.00 0.60 
hsa-miR-618 34.76 BF 33.94 BF   2.00 0.58 
hsa-miR-744-3p BF 34.86 35.62 ND   2.00 0.54 
hsa-miR-15a-3p BF 34.89 35.61 ND   2.00 0.50 
hsa-miR-1271-5p ND 35.66 34.96 ND   2.00 0.49 
hsa-miR-744-5p 35.02 34.47 ND ND   2.00 0.39 
hsa-miR-320d 32.02 ND 32.50 BF   2.00 0.34 
hsa-miR-30d-3p ND 35.50 35.02 ND   2.00 0.34 
hsa-miR-10a-5p 36.02 ND 35.61 ND   2.00 0.29 
hsa-miR-200b-3p 35.57 35.97 BF ND   2.00 0.29 
hsa-miR-212-3p 33.29 33.60 ND ND   2.00 0.22 
hsa-miR-34b-3p 35.99 36.26 ND ND   2.00 0.19 
hsa-miR-145-5p 32.70 32.49 ND ND   2.00 0.15 
hsa-miR-34c-5p 36.64 36.46 ND ND   2.00 0.13 
hsa-miR-324-3p 30.66 30.49 BF BF   2.00 0.12 
hsa-miR-24-1-5p 36.63 36.46 ND ND   2.00 0.12 
hsa-miR-221-5p BF 34.64 34.77 ND   2.00 0.09 
hsa-miR-503-5p 33.60 ND 33.71 ND   2.00 0.08 
hsa-miR-424-5p 31.94 BF 32.03 BF   2.00 0.06 
hsa-miR-96-5p 35.07 ND 35.15 ND   2.00 0.06 
hsa-miR-346 35.64 35.72 ND ND   2.00 0.05 
hsa-miR-550a-3p 34.92 ND 34.99 ND   2.00 0.05 
hsa-miR-331-5p 35.63 35.65 ND ND   2.00 0.01 
hsa-miR-99b-3p ND 36.58 ND ND   1.00 ND 
hsa-miR-99a-3p ND ND 35.89 ND   1.00 ND 
hsa-miR-92a-2-5p ND BF 35.81 ND   1.00 ND 
hsa-miR-877-3p ND ND 36.21 ND   1.00 ND 
hsa-miR-769-3p ND ND 36.70 ND   1.00 ND 
hsa-miR-7-2-3p ND ND 36.80 ND   1.00 ND 
hsa-miR-649 ND ND 36.18 ND   1.00 ND 
hsa-miR-628-3p ND ND 36.89 ND   1.00 ND 
hsa-miR-627-5p 36.90 BF BF ND   1.00 ND 
hsa-miR-616-5p ND 36.00 ND ND   1.00 ND 
hsa-miR-604 BF ND 36.75 ND   1.00 ND 
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hsa-miR-584-5p ND 36.89 ND ND   1.00 ND 
hsa-miR-579-3p BF 36.25 ND ND   1.00 ND 
hsa-miR-571 ND ND 34.88 ND   1.00 ND 
hsa-miR-566 ND ND 36.94 ND   1.00 ND 
hsa-miR-562 ND ND 36.95 ND   1.00 ND 
hsa-miR-543 36.93 ND ND ND   1.00 ND 
hsa-miR-455-5p ND ND 34.78 ND   1.00 ND 
hsa-miR-454-5p 35.75 BF ND ND   1.00 ND 
hsa-miR-411-5p ND ND ND 36.02   1.00 ND 
hsa-miR-345-5p 31.50 BF BF BF   1.00 ND 
hsa-miR-340-5p ND 35.76 ND ND   1.00 ND 
hsa-miR-340-3p ND 36.48 ND ND   1.00 ND 
hsa-miR-32-3p BF 36.16 ND ND   1.00 ND 
hsa-miR-30c-1-3p ND BF 36.71 ND   1.00 ND 
hsa-miR-30b-3p 36.67 ND BF ND   1.00 ND 
hsa-miR-300 BF BF 34.50 ND   1.00 ND 
hsa-miR-23b-5p 35.24 ND ND ND   1.00 ND 
hsa-miR-23a-5p ND BF 34.70 ND   1.00 ND 
hsa-miR-218-5p ND ND 35.61 ND   1.00 ND 
hsa-miR-200a-3p ND ND 36.63 ND   1.00 ND 
hsa-miR-199b-5p 36.59 ND BF ND   1.00 ND 
hsa-miR-1972 BF 33.13 BF BF   1.00 ND 
hsa-miR-196a-5p 36.82 ND ND ND   1.00 ND 
hsa-miR-192-3p ND 36.19 ND ND   1.00 ND 
hsa-miR-190a-5p BF 36.15 ND ND   1.00 ND 
hsa-miR-1908-5p 35.69 ND ND ND   1.00 ND 
hsa-miR-18b-3p BF ND 35.89 ND   1.00 ND 
hsa-miR-182-5p 35.08 ND ND ND   1.00 ND 
hsa-miR-147b ND ND 36.58 ND   1.00 ND 
hsa-miR-143-5p 36.65 ND ND ND   1.00 ND 
hsa-miR-139-5p 36.52 ND ND ND   1.00 ND 
hsa-miR-134-5p ND ND 36.44 ND   1.00 ND 
hsa-miR-133b ND ND 35.97 ND   1.00 ND 
hsa-miR-1296-5p ND 35.60 ND ND   1.00 ND 
hsa-miR-1272 36.14 BF ND ND   1.00 ND 
hsa-miR-1270 ND BF 36.57 ND   1.00 ND 
hsa-miR-125b-2-
3p ND BF 36.85 ND   1.00 ND 
hsa-miR-1256 ND 36.11 ND ND   1.00 ND 
hsa-miR-1255b-
5p ND 36.57 ND ND   1.00 ND 
hsa-miR-1244 ND ND 36.61 ND   1.00 ND 
hsa-miR-1224-3p 35.53 BF ND ND   1.00 ND 
hsa-miR-10b-3p ND 36.79 ND BF   1.00 ND 
hsa-let-7b-3p 36.50 ND ND ND   1.00 ND 
hsa-miR-95-3p BF ND BF ND   0.00 ND 
hsa-miR-944 ND ND BF ND   0.00 ND 
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hsa-miR-937-3p ND ND BF BF   0.00 ND 
hsa-miR-922 BF ND ND ND   0.00 ND 
hsa-miR-887-3p BF ND BF ND   0.00 ND 
hsa-miR-885-3p BF ND BF ND   0.00 ND 
hsa-miR-875-3p ND ND ND BF   0.00 ND 
hsa-miR-765 ND ND BF ND   0.00 ND 
hsa-miR-760 BF ND BF ND   0.00 ND 
hsa-miR-708-3p ND BF BF ND   0.00 ND 
hsa-miR-663b BF BF BF BF   0.00 ND 
hsa-miR-654-5p ND ND ND BF   0.00 ND 
hsa-miR-645 ND ND ND BF   0.00 ND 
hsa-miR-632 ND ND BF ND   0.00 ND 
hsa-miR-628-5p ND ND BF ND   0.00 ND 
hsa-miR-615-3p BF ND ND ND   0.00 ND 
hsa-miR-603 ND ND ND BF   0.00 ND 
hsa-miR-598-3p BF BF BF BF   0.00 ND 
hsa-miR-595 BF ND ND ND   0.00 ND 
hsa-miR-589-5p ND ND BF ND   0.00 ND 
hsa-miR-580-3p ND ND BF ND   0.00 ND 
hsa-miR-577 BF ND ND ND   0.00 ND 
hsa-miR-576-3p ND BF BF ND   0.00 ND 
hsa-miR-570-3p ND ND BF ND   0.00 ND 
hsa-miR-564 ND ND BF ND   0.00 ND 
hsa-miR-551b-5p BF ND ND ND   0.00 ND 
hsa-miR-548i BF ND ND ND   0.00 ND 
hsa-miR-548d-5p ND BF BF ND   0.00 ND 
hsa-miR-548c-5p BF BF BF BF   0.00 ND 
hsa-miR-548a-5p BF ND ND ND   0.00 ND 
hsa-miR-548a-3p BF BF BF ND   0.00 ND 
hsa-miR-524-5p ND ND ND ND   0.00 ND 
hsa-miR-520h ND ND ND ND   0.00 ND 
hsa-miR-518f-5p BF ND ND ND   0.00 ND 
hsa-miR-518d-5p ND ND ND ND   0.00 ND 
hsa-miR-513b-5p BF ND BF ND   0.00 ND 
hsa-miR-507 BF ND ND ND   0.00 ND 
hsa-miR-499a-5p ND BF ND ND   0.00 ND 
hsa-miR-496 ND BF ND ND   0.00 ND 
hsa-miR-491-3p BF ND BF ND   0.00 ND 
hsa-miR-485-3p BF ND ND ND   0.00 ND 
hsa-miR-483-5p ND BF ND BF   0.00 ND 
hsa-miR-451a ND BF ND ND   0.00 ND 
hsa-miR-410-3p BF ND ND ND   0.00 ND 
hsa-miR-382-3p ND BF BF ND   0.00 ND 
hsa-miR-380-5p ND ND ND ND   0.00 ND 
hsa-miR-379-5p ND ND ND ND   0.00 ND 
hsa-miR-376c-3p BF ND BF BF   0.00 ND 
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hsa-miR-373-3p ND ND ND ND   0.00 ND 
hsa-miR-34a-3p BF BF BF BF   0.00 ND 
hsa-miR-326 ND BF BF BF   0.00 ND 
hsa-miR-30a-3p ND BF BF ND   0.00 ND 
hsa-miR-27a-5p ND ND ND BF   0.00 ND 
hsa-miR-222-5p ND ND BF ND   0.00 ND 
hsa-miR-219a-1-
3p ND BF ND ND   0.00 ND 
hsa-miR-216a-5p ND BF ND ND   0.00 ND 
hsa-miR-212-5p BF ND ND ND   0.00 ND 
hsa-miR-211-5p BF ND ND ND   0.00 ND 
hsa-miR-2110 BF BF BF BF   0.00 ND 
hsa-miR-20b-3p ND ND BF ND   0.00 ND 
hsa-miR-208a-3p ND ND BF ND   0.00 ND 
hsa-miR-206 ND ND ND ND   0.00 ND 
hsa-miR-199a-5p ND BF BF ND   0.00 ND 
hsa-miR-1913 ND ND ND ND   0.00 ND 
hsa-miR-187-5p BF ND ND ND   0.00 ND 
hsa-miR-183-5p ND ND BF ND   0.00 ND 
hsa-miR-1539 ND ND BF BF   0.00 ND 
hsa-miR-1471 ND ND BF ND   0.00 ND 
hsa-miR-139-3p ND BF ND ND   0.00 ND 
hsa-miR-138-2-3p ND BF BF ND   0.00 ND 
hsa-miR-137 BF ND BF ND   0.00 ND 
hsa-miR-127-3p ND ND BF ND   0.00 ND 
hsa-miR-125a-5p BF BF BF BF   0.00 ND 
hsa-miR-125a-3p BF ND ND ND   0.00 ND 
hsa-miR-1249 ND BF ND ND   0.00 ND 
hsa-miR-1205 ND BF ND ND   0.00 ND 
hsa-miR-1203 ND BF ND ND   0.00 ND 
hsa-miR-1184 ND BF ND ND   0.00 ND 
hsa-miR-1183 BF ND ND ND   0.00 ND 
hsa-miR-10b-5p ND ND BF ND   0.00 ND 
hsa-miR-101-5p BF ND ND ND   0.00 ND 
hsa-let-7a-3p BF ND ND ND   0.00 ND 
                
Count 252.00 244.00 254.00 113.00       
Global mean 29.64 29.47 29.29 34.27       
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Patient code:
Slide code: MI normal MI low
Metaphases 
clear
Metaphases 
unclear Abbs clear
Abbs 
unclear G2 Score:     /25
Date: Total:
Slide Comments:
No of Interphase 
cells in field
No of mitosis in 
field Ct gap Ct break Ct fragment Ct Minute
Terminal 
deletion
Inter-arm 
exchange
Other Abb 
type
Total no 
of Abbs Vernier reading
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
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21
22
23
24
25
Vernier readings of Endoreduplication events: Vernier readings of Tetraploidy events:
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